
<html lang="en"     class="pb-page"  data-request-id="07968dda-210f-4754-8e98-993db629f1e5"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;article:article:10.1021/jm501254d;ctype:string:Journal Content;wgroup:string:ACHS website Group;issue:issue:10.1021/jmcmar.2015.58.issue-2;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Synthesis and Pharmacological Evaluation of Dual Acting Ligands Targeting the Adenosine A2A and Dopamine D2 Receptors for the Potential Treatment of Parkinson’s Disease" /></meta><meta name="dc.Creator" content="Manuela  Jörg" /></meta><meta name="dc.Creator" content="Lauren T.  May" /></meta><meta name="dc.Creator" content="Frankie S.  Mak" /></meta><meta name="dc.Creator" content="Kiew Ching K.  Lee" /></meta><meta name="dc.Creator" content="Neil D.  Miller" /></meta><meta name="dc.Creator" content="Peter J.  Scammells" /></meta><meta name="dc.Creator" content="Ben  Capuano" /></meta><meta name="dc.Description" content="A relatively new strategy in drug discovery is the development of dual acting ligands. These molecules are potentially able to interact at two orthosteric binding sites of a heterodimer simultaneou..." /></meta><meta name="Description" content="A relatively new strategy in drug discovery is the development of dual acting ligands. These molecules are potentially able to interact at two orthosteric binding sites of a heterodimer simultaneou..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="December 24, 2014" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm501254d" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2014 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm501254d" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm501254d" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm501254d" /></link>
        
    
    

<title>Synthesis and Pharmacological Evaluation of Dual Acting Ligands Targeting the Adenosine A2A and Dopamine D2 Receptors for the Potential Treatment of Parkinson’s Disease | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm501254d" /></meta><meta property="og:title" content="Synthesis and Pharmacological Evaluation of Dual Acting Ligands Targeting the Adenosine A2A and Dopamine D2 Receptors for the Potential Treatment of Parkinson’s Disease" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-2/jm501254d/20150115/images/large/jm-2014-01254d_0011.jpeg" /></meta><meta property="og:description" content="A relatively new strategy in drug discovery is the development of dual acting ligands. These molecules are potentially able to interact at two orthosteric binding sites of a heterodimer simultaneously, possibly resulting in enhanced subtype selectivity, higher affinity, enhanced or modified physiological response, and reduced reliance on multiple drug administration regimens. In this study, we have successfully synthesized a series of classical heterobivalent ligands as well as a series of more integrated and “drug-like” dual acting molecules, incorporating ropinirole as a dopamine D2 receptor agonist and ZM 241385 as an adenosine A2A receptor antagonist. The best compounds of our series maintained the potency of the original pharmacophores at both receptors (adenosine A2A and dopamine D2). In addition, the integrated dual acting ligands also showed promising results in preliminary blood–brain barrier permeability tests, whereas the classical heterobivalent ligands are potentially more suited as pharmacological tools." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm501254d"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm501254d">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm501254d&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm501254d&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm501254d&amp;href=/doi/10.1021/jm501254d" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2015</span><span class="cit-fg-volume">, 58</span><span class="cit-fg-issue">, 2</span><span class="cit-fg-pageRange">, 718-738</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/58/2" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm501224x" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm501285x" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Synthesis and Pharmacological Evaluation of Dual Acting Ligands Targeting the Adenosine A<sub>2A</sub> and Dopamine D<sub>2</sub> Receptors for the Potential Treatment of Parkinson’s Disease</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Manuela++J%C3%B6rg">Manuela Jörg</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lauren+T.++May">Lauren T. May</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Frankie+S.++Mak">Frankie S. Mak</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kiew+Ching+K.++Lee">Kiew Ching K. Lee</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Neil+D.++Miller">Neil D. Miller</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Peter+J.++Scammells">Peter J. Scammells</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ben++Capuano">Ben Capuano</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text"><sup>†</sup>Medicinal Chemistry and <sup>‡</sup>Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, 381 Royal Parade, Parkville, Victoria 3052, Australia</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">§</span> <span class="aff-text">Neural Pathways DPU, Neurosciences TAU, GSK R&D, 11 Biopolis Way, Helios Bldg #03-01/02, Singapore 138667, Singapore</span></div><div class="corresp-info"><strong>*</strong>For B.C.: phone, +61 3 9903 9556; E-mail, <a href="/cdn-cgi/l/email-protection#8bc9eee5a5c8eafbfeeae5e4cbe6e4e5eaf8e3a5eeeffe"><span class="__cf_email__" data-cfemail="e9ab8c87c7aa88999c888786a9848687889a81c78c8d9c">[email protected]</span></a></div><div class="corresp-info"><strong>*</strong>For P.J.S.: phone. +61 3 9903 9542; E-mail, <a href="/cdn-cgi/l/email-protection#91c1f4e5f4e3bfc2f2f0fcfcf4fdfde2d1fcfefff0e2f9bff4f5e4"><span class="__cf_email__" data-cfemail="ca9aafbeafb8e499a9aba7a7afa6a6b98aa7a5a4abb9a2e4afaebf">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm501254d&amp;href=/doi/10.1021%2Fjm501254d" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2015</span></span><span class="cit-volume">, 58</span><span class="cit-issue">, 2</span><span class="cit-pageRange">, 718–738</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">December 9, 2014</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>15 August 2014</li><li><span class="item_label"><b>Published</b> online</span>24 December 2014</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 22 January 2015</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm501254d" title="DOI URL">https://doi.org/10.1021/jm501254d</a></div><div class="article_header-article-copyright"><strong>Copyright © 2014 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D718%26pageCount%3D21%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DManuela%2BJ%25C3%25B6rg%252C%2BLauren%2BT.%2BMay%252C%2BFrankie%2BS.%2BMak%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D58%26issueNum%3D2%26contentID%3Djm501254d%26title%3DSynthesis%2Band%2BPharmacological%2BEvaluation%2Bof%2BDual%2BActing%2BLigands%2BTargeting%2Bthe%2BAdenosine%2BA2A%2Band%2BDopamine%2BD2%2BReceptors%2Bfor%2Bthe%2BPotential%2BTreatment%2Bof%2BParkinson%25E2%2580%2599s%2BDisease%26numPages%3D21%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D738%26publicationDate%3DJanuary%2B2015">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm501254d"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2606</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">32</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm501254d" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Synthesis and Pharmacological Evaluation of Dual Acting Ligands Targeting the Adenosine A2A and Dopamine D2 Receptors for the Potential Treatment of Parkinson’s Disease&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Manuela&quot;,&quot;last_name&quot;:&quot;Jörg&quot;},{&quot;first_name&quot;:&quot;Lauren&quot;,&quot;last_name&quot;:&quot;T. May&quot;},{&quot;first_name&quot;:&quot;Frankie&quot;,&quot;last_name&quot;:&quot;S. Mak&quot;},{&quot;first_name&quot;:&quot;Kiew&quot;,&quot;last_name&quot;:&quot;Ching K. Lee&quot;},{&quot;first_name&quot;:&quot;Neil&quot;,&quot;last_name&quot;:&quot;D. Miller&quot;},{&quot;first_name&quot;:&quot;Peter&quot;,&quot;last_name&quot;:&quot;J. Scammells&quot;},{&quot;first_name&quot;:&quot;Ben&quot;,&quot;last_name&quot;:&quot;Capuano&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2014&quot;,&quot;month&quot;:&quot;12&quot;,&quot;day&quot;:&quot;24&quot;,&quot;issue&quot;:&quot;2&quot;,&quot;volume&quot;:&quot;58&quot;,&quot;pages&quot;:&quot;718-738&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm501254d&quot;},&quot;abstract&quot;:&quot;A relatively new strategy in drug discovery is the development of dual acting ligands. These molecules are potentially able to interact at two orthosteric binding sites of a heterodimer simultaneously, possibly resulting in enhanced subtype selectivity, higher affinity, enhanced or modified physiological response, and reduced reliance on multiple drug administration regimens. In this study, we have successfully synthesized a series of classical heterobivalent ligands as well as a series of more integrated and “drug-like” dual acting molecules, incorporating ropinirole as a dopamine D2 receptor agonist and ZM 241385 as an adenosine A2A receptor antagonist. The best compounds of our series maintained the potency of the original pharmacophores at both receptors (adenosine A2A and dopamine D2). In addition, the integrated dual acting ligands also showed promising results in preliminary blood–brain barrier permeability tests, whereas the classical heterobivalent ligands are potentially more suited as pharmacologic&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm501254d&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm501254d" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm501254d&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm501254d" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm501254d&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm501254d" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm501254d&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm501254d&amp;href=/doi/10.1021/jm501254d" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm501254d" /></input><a href="/doi/pdf/10.1021/jm501254d" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (1 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm501254d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm501254d%26sid%3Dliteratum%253Aachs%26pmid%3D25490054%26genre%3Darticle%26aulast%3DJ%25C3%25B6rg%26date%3D2015%26atitle%3DSynthesis%2Band%2BPharmacological%2BEvaluation%2Bof%2BDual%2BActing%2BLigands%2BTargeting%2Bthe%2BAdenosine%2BA2A%2Band%2BDopamine%2BD2%2BReceptors%2Bfor%2Bthe%2BPotential%2BTreatment%2Bof%2BParkinson%25E2%2580%2599s%2BDisease%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D58%26issue%3D2%26spage%3D718%26epage%3D738%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291181" title="Amines">Amines</a>,</li><li><a href="/action/doSearch?ConceptID=292589" title="Agonists">Agonists</a>,</li><li><a href="/action/doSearch?ConceptID=292366" title="Ligands">Ligands</a>,</li><li><a href="/action/doSearch?ConceptID=291754" title="Molecules">Molecules</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/58/2" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-2/jmcmar.2015.58.issue-2/20150122/jmcmar.2015.58.issue-2.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-2/jm501254d/20150115/images/medium/jm-2014-01254d_0011.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-2/jm501254d/20150115/images/large/jm-2014-01254d_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501254d&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">A relatively new strategy in drug discovery is the development of dual acting ligands. These molecules are potentially able to interact at two orthosteric binding sites of a heterodimer simultaneously, possibly resulting in enhanced subtype selectivity, higher affinity, enhanced or modified physiological response, and reduced reliance on multiple drug administration regimens. In this study, we have successfully synthesized a series of classical heterobivalent ligands as well as a series of more integrated and “drug-like” dual acting molecules, incorporating ropinirole as a dopamine D<sub>2</sub> receptor agonist and ZM 241385 as an adenosine A<sub>2A</sub> receptor antagonist. The best compounds of our series maintained the potency of the original pharmacophores at both receptors (adenosine A<sub>2A</sub> and dopamine D<sub>2</sub>). In addition, the integrated dual acting ligands also showed promising results in preliminary blood–brain barrier permeability tests, whereas the classical heterobivalent ligands are potentially more suited as pharmacological tools.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48721" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48721" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Parkinson’s disease is a progressive neurodegenerative disorder affecting about 1% of the world population over 60 years of age.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1, 2)</a> Mechanistically, current clinical therapeutics almost exclusively focus on the deficiency in dopamine production in specific parts of the brain which is associated with the primary symptoms observed in patients with Parkinson’s disease.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3, 4)</a> Dopamine replacement therapies such as the pro-drug levodopa or dopamine D<sub>2</sub> receptor (D<sub>2</sub>R) agonists are able to improve the quality of life enormously, but are insufficient due to side effects and their inability to alter or delay the progression of the disease.<a onclick="showRef(event, 'ref5 ref6 ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref5 ref6 ref7 ref8">(5-8)</a> Hence, there is an urgent need for a better understanding of the disease and more effective drugs.</div><div class="NLM_p">Animal models as well as clinical studies have given evidence that adenosine A<sub>2A</sub> receptor (A<sub>2A</sub>R) antagonists, as monotherapy and in conjunction with levodopa or D<sub>2</sub>R agonists, are able to amplify the therapeutic effects of levodopa or D<sub>2</sub>R agonists, respectively, and reduce motor complications such as dyskinesia, on–off oscillation, and wearing-off effects in patients with Parkinson’s disease.<a onclick="showRef(event, 'ref9 ref10 ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref9 ref10 ref11 ref12">(9-12)</a> Another potential benefit of A<sub>2A</sub>R antagonists in contrast to current drugs on the market is their proposed capability of slowing down the degeneration of dopaminergic neurons, thereby delaying the onset and progression of the disease.<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13, 14)</a> Therefore, A<sub>2A</sub>R antagonists are considered a promising new drug class that could potentially complement the dopaminergic drugs currently available for patients suffering from Parkinson’s disease.</div><div class="NLM_p">Consequently, scientists have investigated the possibility of designing a single molecule which is able to target the A<sub>2A</sub>R and D<sub>2</sub>R. A strategy which gained greater attention after the discovery of A<sub>2A</sub>R–D<sub>2</sub>R heterodimers is the development of heterobivalent ligands; a molecule consisting of two different pharmacophores separated by a spacer which is linked to each individual drug entity (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>).<a onclick="showRef(event, 'ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref15 ref16">(15, 16)</a> The simultaneous interactions of these molecules with both orthosteric binding sites of a D<sub>2</sub>R–A<sub>2A</sub>R heterodimer has the potential to result in enhanced subtype selectivity, higher affinity, enhanced or modified physiological response, and reduced reliance on multiple drug administration regimens. Furthermore, these heterobivalent systems can be used as pharmacological tools, permitting estimations of the distance between the targets and their spatial distribution. Soriano et al.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> published a series of heterobivalent ligands (XCC-PPHT-NH<sub>2</sub>) ranging from 26 to 118 atoms spacer length to target A<sub>2A</sub>R–D<sub>2</sub>R heterodimers. The molecules are constructed of a functionalized xanthine-based adenosine A<sub>2A</sub>R antagonist (XCC) and a 2-amino-5-hydroxytetralin-based dopamine D<sub>2</sub>R agonist (PPHT-NH<sub>2</sub>) component. In this study, higher affinity was observed for the heterobivalent ligands compared to the monovalent analogue in brain striatum and cells coexpressing both receptors, whereas in cells expressing just one receptor type no change in affinity was reported. These findings were explained by the existence of A<sub>2A</sub>R–D<sub>2</sub>R heterodimers in brain striatum and simultaneous binding of the heterobivalent ligands to both receptors. Even though such molecules are interesting pharmacological tools, their use as drugs is potentially limited due to their size.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-2/jm501254d/20150115/images/medium/jm-2014-01254d_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-2/jm501254d/20150115/images/large/jm-2014-01254d_0002.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (left) Schematic representation of a heterobivalent ligand and integrated dual acting ligand consisting of a D<sub>2</sub>R agonist and an A<sub>2A</sub>R antagonist. (right) Schematic examples of a heterobivalent ligand binding to a heterodimer and an integrated dual acting ligand acting at the two orthosteric sites of two different types of receptor monomers.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-2/jm501254d/20150115/images/large/jm-2014-01254d_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501254d&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Consequently, the design of integrated dual acting ligands (also referred to as merged or fused designed multiple ligands or twin ligands) is a more promising approach for the development of drugs for the treatment of CNS drugs such as Parkinson’s disease (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>).<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> The advantages of integrated dual acting ligands over heterobivalent ligands are the reduction in molecular mass, topological polar surface area, and clogP, which is equivalent to the enhancement of the “drug-like” properties including their ability to cross the blood–brain barrier. Dual acting ligands for the treatment of Parkinson’s disease have been reported with the aim to target the A<sub>2A</sub> receptor while inhibiting MAO-B.<a onclick="showRef(event, 'ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref19 ref20">(19, 20)</a> To the best of our knowledge, comparatively small “drug-like” molecules targeting the A<sub>2A</sub> and D<sub>2</sub> receptors simultaneously have not formerly been reported. A related concept is the design of dual acting pro-drugs as exemplified by Gogoi et al.;<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> in this instance, a molecule consisting of two pharmacophores is required to cross the blood–brain barrier before it dissociates into two entities able to interact at the A<sub>2A</sub>R and D<sub>2</sub>R individually.</div><div class="NLM_p">In summary, both of these concepts provide interesting aspects that are worthwhile investigating. Heterobivalent ligands are potentially more suited as pharmacological tools to further investigate the properties of the A<sub>2A</sub>R–D<sub>2</sub>R heterodimers, whereas integrated dual acting ligands may find their application in drug discovery as novel drugs for the treatment of Parkinson’s disease.</div><div class="NLM_p">In this project, the A<sub>2A</sub>R antagonist of choice was ZM 241385 (<b>1</b>) (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>),<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22, 23)</a> the first A<sub>2A</sub>R antagonist where an X-ray structure of an A<sub>2A</sub>R antagonist in complex with the A<sub>2A</sub> receptor existed,<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> which allowed good predictions of the binding mode of triazolotriazine-based analogues. The D<sub>2</sub>R agonist of choice was the established antiparkinsonian drug ropinirole (<b>2</b>) (trade name: Requip) (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>) due to its simple structure compared to other D<sub>2</sub>R agonists on the market.<a onclick="showRef(event, 'ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref25 ref26">(25, 26)</a> Furthermore, its low molecular weight is beneficial for the design of dual acting ligands with more “drug-like” properties. Notably, ropinirole (<b>2</b>) is a nonergot derived D<sub>2</sub>R agonist which has been shown to be superior to ergot derived first-generation drugs due to reduced side effects.<a onclick="showRef(event, 'ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref27 ref28">(27, 28)</a> The drug is also available as an extended-release formulation permitting once-daily administration. Our group has previously published the successful development of functionalized congeners of each pharmacophore (<b>3</b>–<b>5</b>), allowing further extension into the extracellular space while maintaining comparable activity to the parent molecules.<a onclick="showRef(event, 'ref29 ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref29 ref30 ref31">(29-31)</a> For the design of the heterobivalent ligands, we have used the functionalized congeners TCAC (<b>3</b>) and OAC (<b>5</b>) as our starting point (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>) before moving onto more “drug-like” analogues with reduced molecular mass. The synthesized dual acting ligands were tested in cell-based assays to determine their inhibitory potency at the A<sub>2A</sub> receptor, and functional potency as well as the maximum response at the D<sub>2</sub> receptor. In addition, preliminary permeability testing was performed on selected analogues to predict their ability to cross the blood–brain barrier, which is an essential attribute for a potential CNS drug.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-2/jm501254d/20150115/images/medium/jm-2014-01254d_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-2/jm501254d/20150115/images/large/jm-2014-01254d_0003.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Chemical structures of the A<sub>2A</sub>R antagonist ZM 241385 (<b>1</b>) and D<sub>2</sub>R agonist ropinirole (<b>2</b>) and their respective functionalized carboxylic acid congeners TCAC (<b>3</b>) and OCAC (<b>4</b>), as well as the functionalized amine congener OAC (<b>5</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-2/jm501254d/20150115/images/large/jm-2014-01254d_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501254d&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Synthesis of the Dual Acting Ligands</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30888" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30888" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">We first investigated classical heterobivalent ligands, consisting of the fully furnished pharmacophores ZM 241385 (<b>1</b>) and ropinirole (<b>2</b>), separated with various lengths and types of linkers or/and spacers spanning the two moieties (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>). Second, we focused on more structurally integrated dual acting ligands with desirable physical properties (molecular mass, polar surface area, and clogP) for the development of potential CNS drugs (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>). This was achieved by the elimination of the spacer and tyramine moiety, which according to structure–activity relationship studies<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> and the receptor bound X-ray structure<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> are nonessential for the activity of the A<sub>2A</sub>R antagonist ZM 241385 (<b>1</b>).</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-2/jm501254d/20150115/images/medium/jm-2014-01254d_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-2/jm501254d/20150115/images/large/jm-2014-01254d_0004.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. An example of the design principle of the “classical” heterobivalent ligands incorporating the fully furnished pharmacophores ZM 241385 (<b>1</b>) and ropinirole (<b>2</b>) and the integrated dual acting ligands without the tyramine moiety of the A<sub>2A</sub>R antagonist ZM 241385 (<b>1</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-2/jm501254d/20150115/images/large/jm-2014-01254d_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501254d&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Heterobivalent Ligands</h3><div class="NLM_p">We first investigated ester linked heterobivalent ligands (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>) due to their simplicity and facile synthetic accessibility. The OAC (<b>5</b>) was added to succinic anhydride (<b>6</b>) in toluene and stirred at reflux. LC-MS indicated the formation of the carboxylic acid intermediate <b>7</b>, but this compound was not sufficiently stable and readily converted to the pyrrolidine-2,5-dione byproduct <b>7a</b>. The addition of ZM 241385 (<b>1</b>) and the appropriate coupling reagents to the in situ formed intermediate <b>7</b> also afforded mainly the pyrrolidine-2,5-dione byproduct <b>7a</b> and not the desired heterobivalent ligand. To avoid this ring closure, the order of the reaction steps was reversed. Consequently, the cyclic anhydride was first added to the A<sub>2A</sub>R antagonist ZM 241385 (<b>1</b>) followed by OAC (<b>5</b>). Therefore, ZM 241385 (<b>1</b>) was reacted with succinic anhydride (<b>6</b>) or glutaric anhydride (<b>9</b>) in the presence of triethylamine in toluene at room temperature. In the case of succinic anhydride (<b>6</b>), the reaction failed, whereas glutaric anhydride (<b>9</b>) furnished the desired compound <b>10</b> albeit in modest yields (28%). The carboxylic acid <b>10</b> was then converted under standard peptide coupling conditions to the heterobivalent ligand <b>11</b>. The disadvantage of this approach is the limited range of linker lengths available (larger cyclic anhydrides are not stable or commercially available) as well as the metabolic instability of ester bonds. However, this approach provided a relatively straightforward synthetic route to obtain a first dual acting ligand for preliminary in vitro testing as a proof-of-concept system to evaluate the overall approach.</div><figure id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-2/jm501254d/20150115/images/medium/jm-2014-01254d_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-2/jm501254d/20150115/images/large/jm-2014-01254d_0006.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of the Ester-Linked Heterobivalent Ligand <b>11</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-2/jm501254d/20150115/images/large/jm-2014-01254d_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501254d&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) toluene, 24 h, reflux, 13% (<b>7a</b>); (b) TEA, toluene, 29 h, rt, no product observed (<b>8</b>), 28% (<b>10</b>); (c) DIPEA, HCTU, DMF, 3 h, rt, 10%.</p></p></figure><div class="NLM_p">Next, we designed and synthesized heterobivalent ligands where the two pharmacophores were connected via a more hydrolytically and metabolically stable amide and ether linkage (Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>). Consequently, molecules of this type provide pharmacological tools that are potentially able to interact simultaneously at both orthosteric binding sites of a D<sub>2</sub>R–A<sub>2A</sub>R heterodimer. Therefore, the functionalized congeners OAC (<b>5</b>) and TCAC (<b>3</b>) as well as a shorter version of the latter (compound <b>16</b>) were either connected directly to afford compounds <b>17a</b> and <b>17b</b> or incorporated amino acid spacers of varying lengths to afford compounds <b>18a</b>–<b>c</b>. The formation of the amide bonds was performed using standard coupling reagents and conditions. It was important to protect the amino acids <b>12a</b>–<b>c</b> to avoid undesired side products, which simplified the purification step and drastically increased the yield. Initially, benzotriazole-based coupling reagents such as BOP and HCTU were used, but the byproducts of these coupling reagents were challenging to remove in the final step. The use of COMU as a coupling reagent furnished higher conversion and simplified the purification process to remove undesired byproducts associated with the coupling reagent.</div><figure id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-2/jm501254d/20150115/images/medium/jm-2014-01254d_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-2/jm501254d/20150115/images/large/jm-2014-01254d_0007.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Heterobivalent Ligands <b>17a</b>, <b>17b</b>, and <b>18a</b>–<b>c</b> Incorporating Amide Bonds and the Chemical Structure of the Triazolotriazine Monovalent Ligand <b>19</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-2/jm501254d/20150115/images/large/jm-2014-01254d_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501254d&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Boc anhydride, 1 M NaOH, THF, 3 h, rt, 66% (<b>13a</b>), Boc anhydride, TEA, methanol, 2 h, 60 °C, 81% (<b>13b</b>) and 68% (<b>13c</b>); (b) COMU, DIPEA, DMF, 1 h, 0 °C followed by 2 h, rt, 31% (<b>14a</b>), 23% (<b>14b</b>), and 41% (<b>14c</b>); (c) TFA, DCM, 2.5–9 h, rt, 69% (<b>15a</b>), 99% (<b>15b</b>), and 39% (<b>15c</b>); (d) BOP, DIPEA, DMF, 5 h, rt, 7% (<b>17a</b>), HCTU, DIPEA, DMF, 3 h, rt, 24% (<b>17b</b>); (e) COMU, DIPEA, DMF, 1 h, 0 °C followed by 2–9 h, rt, 17% (<b>18a</b>), 17% (<b>18b</b>), and 8% (<b>18c</b>).</p></p></figure><div class="NLM_p">In addition to the heterobivalent ligands (<b>17a</b>, <b>17b</b>, and <b>18a</b>–<b>c</b>), the monovalent analogues with the protected 12-carbon spacer attached to either the oxindole (<b>14c</b>) or triazolotriazine (<b>19</b>) congener were synthesized and tested as additional reference compounds.</div><div class="NLM_p">Next, we investigated the possibility of incorporating a triazine spacer, which was further functionalized with a morpholine group to potentially improve the overall solubility of the heterobivalent ligand <b>24</b> (Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>). The triazine linker unit has been incorporated into the heterobivalent ligands because it is a commonly used motif in drug discovery (i.e., PI3K inhibitors, dendrimers).<a onclick="showRef(event, 'ref33 ref34 ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref33 ref34 ref35 ref36">(33-36)</a> The starting material cyanuric chloride (<b>20</b>) is an inexpensive and commercially available compound with diverse reactivity of the three chlorine atoms, allowing selective substitution. Therefore, cyanuric chloride (<b>20</b>) in acetone was added dropwise to a solution of morpholine (<b>21</b>) and triethylamine in acetone at −20 °C to afford intermediate <b>22</b> in 75% yield, which was used in the next step without further purification. ZM 241385 (<b>1</b>) was deprotonated with sodium hydride, treated with the triazine spacer <b>22</b>, and the reaction mixture stirred at room temperature for 2 days to obtain compound <b>23</b> in 53% yield. Intermediate <b>23</b> was then further reacted with OAC (<b>5</b>) in a sealed microwave tube to furnish the heterobivalent ligand <b>24</b> in 67% yield.</div><figure id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-2/jm501254d/20150115/images/medium/jm-2014-01254d_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-2/jm501254d/20150115/images/large/jm-2014-01254d_0008.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Triazine Spacer Containing Heterobivalent Ligand <b>24</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-2/jm501254d/20150115/images/large/jm-2014-01254d_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501254d&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) TEA, acetone, 15 min, −20 °C, 75%; (b) NaH 60%, THF, 2 days, rt, 53%; (c) K<sub>2</sub>CO<sub>3</sub>, DMF, microwave, 15 min, 100 °C, 67%.</p></p></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Integrated Dual Acting Ligands</h3><div class="NLM_p">Unlike the synthesis of the heterobivalent ligands, the more integrated molecules did not consist of the fully furnished pharmacohore ZM 241385 (<b>1</b>). Therefore, the sulfone intermediate <b>28</b> (which does not contain the tyramine moiety of ZM 241385 (<b>1</b>)) was key to facilitate the introduction of the 2-(furan-2-yl)-5-(methylsulfonyl)-[1,2,4]triazolo[1,5-<i>a</i>][1,3,5]triazin-7-amine portion of the A<sub>2A</sub>R antagonist instead of the TCACs <b>3</b> or <b>16</b>. The synthesis of the integrated molecules <b>32a</b>–<b>c</b> and <b>29</b> (Scheme <a class="ref internalNav" href="#sch4" aria-label="4">4</a>) started with commercially available 4-(2-hydroxyethyl)indolin-2-one (<b>25</b>), which was activated by conversion into the tosylated intermediate <b>26</b>, thereby allowing substitution with either methylamine or propylamine at reflux to furnish the secondary amines <b>27a</b> and <b>27b</b>. Our dual acting ligand <b>29</b> was formed by stirring intermediate <b>27b</b> and sulfone <b>28</b> in acetonitrile at room temperature for 2.5 days. In the design of compound <b>29</b>, the linker between the two pharmacophores was fully removed to further reduce the molecular weight. This approach is associated with the loss of the ionizable nitrogen; as a consequence the pharmacological evaluation of this molecule will further validate the vitality of this feature for activity at the D<sub>2</sub> receptor. Intermediates <b>27a</b> and <b>27b</b> were also utilized for the synthesis of the target compounds <b>32a</b>–<b>c</b>. Boc-protected amine linkers of different lengths were incorporated into the secondary amine moieties of compound <b>27a</b> and <b>27b</b> to afford analogues <b>30a</b>–<b>c</b> which, after cleavage of the Boc protecting group, furnished the oxindole amine congeners <b>31a</b>, <b>31c</b>, and <b>5</b>. The final step involved stirring the newly formed congeners <b>31a</b>, <b>31c</b>, and <b>5</b> with sulfone <b>28</b> in acetonitrile at room temperature to afford the target compounds <b>32a</b>–<b>c</b> in yields of 23–65%. The dual acting ligands <b>32a</b>–<b>c</b> and <b>29</b> represent a small set of compounds with varying linker lengths between the two pharmacophores as well as in the length of the side chain attached to the ionizable tertiary amine of the ropinirole portion of the molecule.</div><figure id="sch4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-2/jm501254d/20150115/images/medium/jm-2014-01254d_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-2/jm501254d/20150115/images/large/jm-2014-01254d_0009.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Integrated Dual Acting Ligands Based on ZM 241385 (<b>1</b>) and Ropinirole (<b>2</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-2/jm501254d/20150115/images/large/jm-2014-01254d_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501254d&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <i>p</i>-toluenesulfonyl chloride, DCM, pyridine, 5–10 °C, 4 h, 80%; (b) 40% aq methylamine solution or neat <i>n</i>-propylamine, reflux, 1.5 h, 57% and 74%, respectively; (c) 1 M NaOH, ethyl acetate or DCM, rt, 15–20 min, 54% (<b>27a</b>) and 92% (<b>27b</b>); (d) <b>28</b>, acetonitrile, rt, 2.5 days, 8%; (e) Br(CH<sub>2</sub>)<sub>n+2</sub>NHBoc, K<sub>2</sub>CO<sub>3</sub>, acetonitrile, reflux, 3–19 h, 46% (<b>30a</b>), 38% (<b>30b</b>), and 48% (<b>30c</b>); (f) TFA, DCM, rt, 1 h, 43% (<b>31a</b>), 84% (<b>5</b>), and 87% (<b>31c</b>); (g) <b>28</b>, acetonitrile, toluene, rt, 5–60 h, 23% (<b>32a</b>), 65% (<b>32b</b>), and 63% (<b>32c</b>).</p></p></figure><div class="NLM_p">Next, we looked at molecules with a cyclic linker unit between the two pharmacophores, which increases the rigidity of the molecule without interfering with the original triazolotriazine and oxindole scaffolds of ZM 241385 (<b>1</b>) and ropinirole (<b>2</b>), respectively. The idea behind this research was based on the fact that molecules with a reduced number of rotatable bonds tend to show improved penetration of the BBB compared to highly flexible and branched compounds.<a onclick="showRef(event, 'ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref37 ref38">(37, 38)</a> Synthesized were three variations thereof: the aminopiperidine <b>37</b>, piperazine <b>40a</b>, and homopiperazine <b>40b</b> analogue (Scheme <a class="ref internalNav" href="#sch5" aria-label="5">5</a>). The first pathway for the synthesis of the dual acting ligand <b>37</b> commenced with sulfone <b>28</b>, which was treated with <i>tert</i>-butyl piperidin-4-ylcarbamate in acetonitrile to afford intermediate <b>33</b> in 63% yield. The Boc protecting group was removed using trifluoroacetic acid followed by alkaline treatment to furnish intermediate <b>34</b> in form of the free base. The aminopiperidine functionalized triazolotriazine analogues <b>34</b> was then further reacted under alkaline conditions with tosylate <b>26</b> in acetonitrile at reflux, however, no conversion to molecule <b>37</b> was observed and mainly starting material was recovered. Therefore, an alternative pathway starting from tosylate <b>26</b> was investigated. Compound <b>26</b> was reacted with <i>tert</i>-butyl piperidin-4-ylcarbamate under alkaline conditions at reflux, affording intermediate <b>35</b> in 34% yield. Cleavage of the Boc protecting group with TFA and treatment with 1 M aqueous sodium hydroxide furnished intermediate <b>36</b>, which was subsequently converted to the desired dual acting ligand <b>37</b> in 75% yield by adding sulfone <b>28</b> in acetonitrile at room temperature.</div><figure id="sch5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-2/jm501254d/20150115/images/medium/jm-2014-01254d_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-2/jm501254d/20150115/images/large/jm-2014-01254d_0010.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Cyclic Integrated Dual Acting Ligands Based on ZM 241385 (<b>1</b>) and Ropinirole (<b>2</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-2/jm501254d/20150115/images/large/jm-2014-01254d_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501254d&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <i>tert</i>-butyl 4-aminopiperidine-1-carboxylate, acetonitrile, rt, 3 h, 63%; (b) TFA, DCM, rt, 3.5 h; (c) <b>26</b>, DIPEA, DBU, acetonitrile, 85 °C, 2 days, no product; (d) <i>tert</i>-butyl piperidin-4-ylcarbamate, DIPEA, acetonitrile, reflux 6 h, 34%; (e) TFA, DCM, rt, 2 h, 46%; (f) <b>28</b>, acetonitrile, DMF, rt, 22 h, 49%; (g) Boc-piperazine, DIPEA, acetonitrile, reflux, 22 h, 75% (<b>38a</b>), <b>26</b>, Boc-homopiperazine, DIPEA, acetonitrile, 23 h, reflux, 74% (<b>38b</b>); (h) TFA, DCM, rt, 5 h, followed 1 M NaOH, 71% (<b>39a</b>), TFA, DCM, rt, 3.5 h (<b>39b</b>); (i) <b>28</b>, acetonitrile, toluene, rt, 18 h, 66% (<b>40a</b>); DBU, acetonitrile, rt, 23 h, 5% (<b>40b</b>).</p></p></figure><div class="NLM_p last">The second synthetic pathway was used to obtain the dual acting ligands <b>40a</b> and <b>40b</b>. The tosylate <b>26</b> was stirred under alkaline conditions with either Boc-piperazine or Boc-homopiperazine to afford intermediate <b>38a</b> and <b>38b</b>, respectively. The Boc group of compound <b>38a</b> was removed with trifluoroacetic acid followed by an alkaline treatment to afford the free amine <b>39a</b>, which was further reacted with sulfone <b>28</b> to furnish the target compound <b>40a</b> in 66% yield. Intermediate <b>39a</b> was extracted into the aqueous layer after washing with 1 M sodium hydroxide solution, therefore intermediate <b>39b</b> was isolated as the trifluoroacetate salt after the cleavage of Boc protecting group by simply evaporating the residual under reduced pressure. Consequently, the non-nucleophilic base 1,8-diazabicycloundec-7-ene (DBU) was added to intermediate <b>39b</b> and sulfone <b>28</b> in acetonitrile at room temperature to afford the target compound <b>40b</b> in low yield (5%).</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">Pharmacological Results</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01374" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01374" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> A<sub>2A</sub>R Inhibitory Potency and D<sub>2</sub>R Functional Potency</h3><div class="NLM_p">The adenosine A<sub>2A</sub>R inhibitory potency (IC<sub>50</sub>) of the dual acting ligands and some selected monovalent ligands was determined in a cyclic adenosine monophosphate (cAMP) assay, whereas the dopamine D<sub>2</sub>R functional activity (EC<sub>50</sub>) and efficacy (<i>E</i><sub>max</sub>) were determined in a [<sup>35</sup>S]GTPγS assay (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). The functional assays were used to compare the activity (IC<sub>50</sub> and EC<sub>50</sub>) of the synthesized molecules to each other as well as the parent pharmacophores ZM 241385 (<b>1</b>) and ropinirole (<b>2</b>).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Reported are the Calculated Molecular Weight (MW), Topological Polar Surface Area (tPSA), and Partition Coefficient (clogP) as well as the Inhibitory Potency at the Adenosine A<sub>2A</sub> Receptor and the Functional Potency and Efficacy at the Dopamine D<sub>2</sub> Receptor of the Reference Compounds, Selected Monovalent Ligands as well as Dual Acting Molecules<a class="ref internalNav" href="#tbl1-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="center" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="rowsep1 colsep0" colspan="2" align="center">A<sub>2A</sub>R inhibitory potency</th><th class="rowsep1 colsep0" colspan="3" align="center">D<sub>2</sub>R functional potency and efficacy</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd no.</th><th class="colsep0 rowsep0" align="center" char=".">MW<a class="ref internalNav" href="#t1fn1" aria-label="b">b</a> [g/mol]</th><th class="colsep0 rowsep0" align="center" char=".">tPSA<a class="ref internalNav" href="#t1fn1" aria-label="b">b</a> [Å<sup>2</sup>]</th><th class="colsep0 rowsep0" align="center" char=".">clogP<a class="ref internalNav" href="#t1fn1" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">pIC<sub>50</sub>  ± SEM</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> [nM]</th><th class="colsep0 rowsep0" align="center">pEC<sub>50</sub>  ± SEM</th><th class="colsep0 rowsep0" align="center">EC<sub>50</sub> [nM]</th><th class="colsep0 rowsep0" align="center"><i>E</i><sub>max</sub> [%]</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">ZM 241385 (<b>1</b>)</td><td class="colsep0 rowsep0" align="char" char=".">337.34</td><td class="colsep0 rowsep0" align="char" char=".">127</td><td class="colsep0 rowsep0" align="char" char=".">2.82</td><td class="colsep0 rowsep0" align="center">7.48 ± 0.14<a class="ref internalNav" href="#t1fn2" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="center">33</td><td class="colsep0 rowsep0" align="center"><4<a class="ref internalNav" href="#t1fn4" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="center">>100000</td><td class="colsep0 rowsep0" align="center">nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">ropinirole (<b>2</b>)</td><td class="colsep0 rowsep0" align="char" char=".">260.38</td><td class="colsep0 rowsep0" align="char" char=".">32</td><td class="colsep0 rowsep0" align="char" char=".">2.49</td><td class="colsep0 rowsep0" align="center">nd</td><td class="colsep0 rowsep0" align="center">nd</td><td class="colsep0 rowsep0" align="center">6.52 ± 0.02<a class="ref internalNav" href="#t1fn5" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="center">304</td><td class="colsep0 rowsep0" align="center">74 ± 1<a class="ref internalNav" href="#t1fn4" aria-label="e">e</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>11</b></td><td class="colsep0 rowsep0" align="char" char=".">708.82</td><td class="colsep0 rowsep0" align="char" char=".">195</td><td class="colsep0 rowsep0" align="char" char=".">3.76</td><td class="colsep0 rowsep0" align="center">7.45 ± 0.06<a class="ref internalNav" href="#t1fn3" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="center">35</td><td class="colsep0 rowsep0" align="center">6.32 ± 0.25<a class="ref internalNav" href="#t1fn4" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="center">484</td><td class="colsep0 rowsep0" align="center">79 ± 5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>14c</b></td><td class="colsep0 rowsep0" align="char" char=".">572.84</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="char" char=".">5.83</td><td class="colsep0 rowsep0" align="center"><4<a class="ref internalNav" href="#t1fn4" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="center">>100000</td><td class="colsep0 rowsep0" align="center">6.95 ± 0.22<a class="ref internalNav" href="#t1fn4" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="center">114</td><td class="colsep0 rowsep0" align="center">66 ± 0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>17a</b></td><td class="colsep0 rowsep0" align="char" char=".">652.75</td><td class="colsep0 rowsep0" align="char" char=".">178</td><td class="colsep0 rowsep0" align="char" char=".">3.91</td><td class="colsep0 rowsep0" align="center">7.20 ± 0.10<a class="ref internalNav" href="#t1fn3" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="center">63</td><td class="colsep0 rowsep0" align="center">6.83 ± 0.01<a class="ref internalNav" href="#t1fn4" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="center">148</td><td class="colsep0 rowsep0" align="center">88 ± 0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>17b</b></td><td class="colsep0 rowsep0" align="char" char=".">680.80</td><td class="colsep0 rowsep0" align="char" char=".">178</td><td class="colsep0 rowsep0" align="char" char=".">4.23</td><td class="colsep0 rowsep0" align="center">7.74 ± 0.10<a class="ref internalNav" href="#t1fn3" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="center">18</td><td class="colsep0 rowsep0" align="center">6.69 ± 0.10<a class="ref internalNav" href="#t1fn4" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="center">204</td><td class="colsep0 rowsep0" align="center">95 ± 1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>18a</b></td><td class="colsep0 rowsep0" align="char" char=".">765.92</td><td class="colsep0 rowsep0" align="char" char=".">207</td><td class="colsep0 rowsep0" align="char" char=".">3.73</td><td class="colsep0 rowsep0" align="center">6.96 ± 0.18<a class="ref internalNav" href="#t1fn2" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="center">110</td><td class="colsep0 rowsep0" align="center">6.11 ± 0.02<a class="ref internalNav" href="#t1fn4" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="center">785</td><td class="colsep0 rowsep0" align="center">68 ± 0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>18b</b></td><td class="colsep0 rowsep0" align="char" char=".">822.03</td><td class="colsep0 rowsep0" align="char" char=".">207</td><td class="colsep0 rowsep0" align="char" char=".">5.37</td><td class="colsep0 rowsep0" align="center">7.39 ± 0.13<a class="ref internalNav" href="#t1fn2" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="center">41</td><td class="colsep0 rowsep0" align="center">6.30 ± 0.08<a class="ref internalNav" href="#t1fn4" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="center">501</td><td class="colsep0 rowsep0" align="center">77 ± 1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>18c</b></td><td class="colsep0 rowsep0" align="char" char=".">878.14</td><td class="colsep0 rowsep0" align="char" char=".">207</td><td class="colsep0 rowsep0" align="char" char=".">7.41</td><td class="colsep0 rowsep0" align="center">5.97 ± 0.15<a class="ref internalNav" href="#t1fn4" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="center">1072</td><td class="colsep0 rowsep0" align="center">5.86 ± 0.11<a class="ref internalNav" href="#t1fn4" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="center">1396</td><td class="colsep0 rowsep0" align="center">38 ± 5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>19</b></td><td class="colsep0 rowsep0" align="char" char=".">634.78</td><td class="colsep0 rowsep0" align="char" char=".">172</td><td class="colsep0 rowsep0" align="char" char=".">6.87</td><td class="colsep0 rowsep0" align="center">6.36 ± 0.30<a class="ref internalNav" href="#t1fn4" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="center">437</td><td class="colsep0 rowsep0" align="center"><4<a class="ref internalNav" href="#t1fn4" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="center">>100000</td><td class="colsep0 rowsep0" align="center">nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>23</b></td><td class="colsep0 rowsep0" align="char" char=".">535.95</td><td class="colsep0 rowsep0" align="char" char=".">168</td><td class="colsep0 rowsep0" align="char" char=".">3.71</td><td class="colsep0 rowsep0" align="center">6.87 ± 0.07<a class="ref internalNav" href="#t1fn2" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="center">135</td><td class="colsep0 rowsep0" align="center"><4<a class="ref internalNav" href="#t1fn4" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="center">>100000</td><td class="colsep0 rowsep0" align="center">nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>24</b></td><td class="colsep0 rowsep0" align="char" char=".">774.87</td><td class="colsep0 rowsep0" align="char" char=".">212</td><td class="colsep0 rowsep0" align="char" char=".">4.87</td><td class="colsep0 rowsep0" align="center">6.92 ± 0.16<a class="ref internalNav" href="#t1fn2" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="center">120</td><td class="colsep0 rowsep0" align="center">6.51 ± 0.14<a class="ref internalNav" href="#t1fn4" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="center">311</td><td class="colsep0 rowsep0" align="center">65 ± 3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>29</b></td><td class="colsep0 rowsep0" align="char" char=".">418.46</td><td class="colsep0 rowsep0" align="char" char=".">127</td><td class="colsep0 rowsep0" align="char" char=".">3.04</td><td class="colsep0 rowsep0" align="center">7.49 ± 0.16<a class="ref internalNav" href="#t1fn4" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="center">32</td><td class="colsep0 rowsep0" align="center"><4<a class="ref internalNav" href="#t1fn4" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="center">>100000</td><td class="colsep0 rowsep0" align="center">nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>32a</b></td><td class="colsep0 rowsep0" align="char" char=".">447.50</td><td class="colsep0 rowsep0" align="char" char=".">140</td><td class="colsep0 rowsep0" align="char" char=".">2.02</td><td class="colsep0 rowsep0" align="center">5.95 ± 0.04<a class="ref internalNav" href="#t1fn4" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="center">1122</td><td class="colsep0 rowsep0" align="center">6.41 ± 0.22<a class="ref internalNav" href="#t1fn4" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="center">389</td><td class="colsep0 rowsep0" align="center">77 ± 2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>32b</b></td><td class="colsep0 rowsep0" align="char" char=".">475.55</td><td class="colsep0 rowsep0" align="char" char=".">140</td><td class="colsep0 rowsep0" align="char" char=".">3.04</td><td class="colsep0 rowsep0" align="center">6.04 ± 0.08<a class="ref internalNav" href="#t1fn3" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="center">912</td><td class="colsep0 rowsep0" align="center">7.06 ± 0.09<a class="ref internalNav" href="#t1fn6" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="center">88</td><td class="colsep0 rowsep0" align="center">89 ± 4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>32c</b></td><td class="colsep0 rowsep0" align="char" char=".">517.64</td><td class="colsep0 rowsep0" align="char" char=".">140</td><td class="colsep0 rowsep0" align="char" char=".">4.19</td><td class="colsep0 rowsep0" align="center">5.75 ± 0.04<a class="ref internalNav" href="#t1fn4" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="center">1778</td><td class="colsep0 rowsep0" align="center">7.43 ± 0.09<a class="ref internalNav" href="#t1fn4" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="center">38</td><td class="colsep0 rowsep0" align="center">77 ± 0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>33</b></td><td class="colsep0 rowsep0" align="char" char=".">400.44</td><td class="colsep0 rowsep0" align="char" char=".">137</td><td class="colsep0 rowsep0" align="char" char=".">3.00</td><td class="colsep0 rowsep0" align="center">5.76 ± 0.07<a class="ref internalNav" href="#t1fn3" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="center">1738</td><td class="colsep0 rowsep0" align="center">nd</td><td class="colsep0 rowsep0" align="center">nd</td><td class="colsep0 rowsep0" align="center">nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>34</b></td><td class="colsep0 rowsep0" align="char" char=".">300.33</td><td class="colsep0 rowsep0" align="char" char=".">119</td><td class="colsep0 rowsep0" align="char" char=".">1.53</td><td class="colsep0 rowsep0" align="center">5.07 ± 0.07<a class="ref internalNav" href="#t1fn3" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="center">8511</td><td class="colsep0 rowsep0" align="center">nd</td><td class="colsep0 rowsep0" align="center">nd</td><td class="colsep0 rowsep0" align="center">nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>35</b></td><td class="colsep0 rowsep0" align="char" char=".">359.47</td><td class="colsep0 rowsep0" align="char" char=".">71</td><td class="colsep0 rowsep0" align="char" char=".">1.90</td><td class="colsep0 rowsep0" align="center">nd</td><td class="colsep0 rowsep0" align="center">nd</td><td class="colsep0 rowsep0" align="center"><4<a class="ref internalNav" href="#t1fn4" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="center">>100000</td><td class="colsep0 rowsep0" align="center">nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>36</b></td><td class="colsep0 rowsep0" align="char" char=".">259.35</td><td class="colsep0 rowsep0" align="char" char=".">58</td><td class="colsep0 rowsep0" align="char" char=".">1.10</td><td class="colsep0 rowsep0" align="center">nd</td><td class="colsep0 rowsep0" align="center">nd</td><td class="colsep0 rowsep0" align="center"><4<a class="ref internalNav" href="#t1fn4" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="center">>100000</td><td class="colsep0 rowsep0" align="center">nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>37</b></td><td class="colsep0 rowsep0" align="char" char=".">459.51</td><td class="colsep0 rowsep0" align="char" char=".">140</td><td class="colsep0 rowsep0" align="char" char=".">2.27</td><td class="colsep0 rowsep0" align="center">5.82 ± 0.15<a class="ref internalNav" href="#t1fn4" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="center">1514</td><td class="colsep0 rowsep0" align="center"><4<a class="ref internalNav" href="#t1fn4" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="center">>100000</td><td class="colsep0 rowsep0" align="center">nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>38a</b></td><td class="colsep0 rowsep0" align="char" char=".">345.44</td><td class="colsep0 rowsep0" align="char" char=".">62</td><td class="colsep0 rowsep0" align="char" char=".">1.62</td><td class="colsep0 rowsep0" align="center">nd</td><td class="colsep0 rowsep0" align="center">nd</td><td class="colsep0 rowsep0" align="center"><4<a class="ref internalNav" href="#t1fn4" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="center">>100000</td><td class="colsep0 rowsep0" align="center">nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>38b</b></td><td class="colsep0 rowsep0" align="char" char=".">359.46</td><td class="colsep0 rowsep0" align="char" char=".">62</td><td class="colsep0 rowsep0" align="char" char=".">1.95</td><td class="colsep0 rowsep0" align="center">nd</td><td class="colsep0 rowsep0" align="center">nd</td><td class="colsep0 rowsep0" align="center"><4<a class="ref internalNav" href="#t1fn4" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="center">>100000</td><td class="colsep0 rowsep0" align="center">nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>39a</b></td><td class="colsep0 rowsep0" align="char" char=".">245.32</td><td class="colsep0 rowsep0" align="char" char=".">44</td><td class="colsep0 rowsep0" align="char" char=".">–0.19</td><td class="colsep0 rowsep0" align="center">nd</td><td class="colsep0 rowsep0" align="center">nd</td><td class="colsep0 rowsep0" align="center"><4<a class="ref internalNav" href="#t1fn4" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="center">>100000</td><td class="colsep0 rowsep0" align="center">nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>39b</b></td><td class="colsep0 rowsep0" align="char" char=".">259.35</td><td class="colsep0 rowsep0" align="char" char=".">44</td><td class="colsep0 rowsep0" align="char" char=".">0.09</td><td class="colsep0 rowsep0" align="center">nd</td><td class="colsep0 rowsep0" align="center">nd</td><td class="colsep0 rowsep0" align="center"><4<a class="ref internalNav" href="#t1fn4" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="center">>100000</td><td class="colsep0 rowsep0" align="center">nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>40a</b></td><td class="colsep0 rowsep0" align="char" char=".">445.48</td><td class="colsep0 rowsep0" align="char" char=".">131</td><td class="colsep0 rowsep0" align="char" char=".">1.65</td><td class="colsep0 rowsep0" align="center">7.23 ± 0.12<a class="ref internalNav" href="#t1fn3" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="center">59</td><td class="colsep0 rowsep0" align="center"><4<a class="ref internalNav" href="#t1fn4" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="center">>100000</td><td class="colsep0 rowsep0" align="center">nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>40b</b></td><td class="colsep0 rowsep0" align="char" char=".">459.51</td><td class="colsep0 rowsep0" align="char" char=".">131</td><td class="colsep0 rowsep0" align="char" char=".">1.98</td><td class="colsep0 rowsep0" align="center">5.83 ± 0.13<a class="ref internalNav" href="#t1fn4" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="center">1479</td><td class="colsep0 rowsep0" align="center"><4<a class="ref internalNav" href="#t1fn4" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="center">>100000</td><td class="colsep0 rowsep0" align="center">nd</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl1-fn1"><div class="footnote" id="tbl1-fn1"><sup>a</sup><p class="last"><i>E</i><sub>max</sub> values were referenced to quinelorane at 100 μM. All the active compounds showed full inhibition in the cAMP assay. Compounds with <i>E</i><sub>max</sub> less than 20% were considered as inactive (pXC<sub>50</sub> <4).</p></div><div class="footnote" id="t1fn1"><sup>b</sup><p class="last">The physical properties were calculated with the software ChemSketch from ACD Lab.</p></div><div class="footnote" id="t1fn2"><sup>c</sup><p class="last">Data represent the mean ± SEM of three experiments performed in duplicate.</p></div><div class="footnote" id="t1fn3"><sup>d</sup><p class="last">Data represent the mean ± SEM of four separate experiments performed in duplicate.</p></div><div class="footnote" id="t1fn4"><sup>e</sup><p class="last">Data represent the mean ± SEM of two experiments performed in duplicate.</p></div><div class="footnote" id="t1fn5"><sup>f</sup><p class="last">Literature value (Ghosh et al.),<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> ropinirole (<b>2</b>) was not tested in this assay, but the potency of the reference compound quinelorane (pEC<sub>50</sub> of 7.35 ± 0.14 (EC<sub>50</sub> = 45 nM)) is consistent with the literature,<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> thereby permitting subsequent comparisons of test compounds to ropinirole (<b>2</b>)</p></div><div class="footnote" id="t1fn6"><sup>g</sup><p class="last">Data represent the mean ± SEM of five separate experiments performed in duplicate; nd = not determined.</p></div></div></div><div class="NLM_p">The reference and parent compound ZM 241385 (<b>1</b>) inhibited 5′-<i>N</i>-ethylcarboxamidoadenosine (NECA) (500 nM) mediated cAMP accumulation with a pIC<sub>50</sub> value of 7.48 ± 0.14. The attachment of the longest spacer to the triazolotriazine scaffold (compound <b>19</b>) showed a 13-fold decrease in inhibitory potency at the A<sub>2A</sub> receptor; this result is in accordance with a study from our group focusing on the biological impact of extensions of selected literature A<sub>2A</sub>R antagonists.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> The reference and parent compound ropinirole (<b>2</b>) has a literature pEC<sub>50</sub> value of 6.52 ± 0.02 in a [<sup>35</sup>S]GTPγS assay.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Attachment of the 12-carbon spacer to the OAC (<b>5</b>) lead to a 3-fold increase of the functional activity at the D<sub>2</sub>R, which again is in accordance with work published earlier.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> The triazolotriazine-based monovalent <b>1</b> and <b>19</b> ligands did not exhibit any detectable activity at the D<sub>2</sub> receptor, likewise the oxindole-based monovalent ligand <b>14c</b> did not show any detectable activity at the A<sub>2A</sub> receptor, as expected.</div><div class="NLM_p">The fused heterobivalent ligands <b>11</b>, <b>17a</b>, and <b>17b</b> (without the incorporation of an amino acid spacer) showed very comparable activity to the initial pharmacophores. In this small group of analogues, only small changes in D<sub>2</sub> functional potency were observed; analogue <b>11</b> exhibited the lowest functional potency, being about 1.5-fold less potent than ropinirole (<b>2</b>), whereas <b>17b</b> was the most potent analogue with 1.5-fold improved functional potency. Similar variations of inhibitory potency were observed at the A<sub>2A</sub> receptor ranging from 18 nM for molecules <b>17b</b> to 63 nM for <b>17a</b> in comparison to 33 nM for the parent compound <b>1</b>. The “classical” heterobivalent ligands <b>18a</b>–<b>c</b> in general showed reduced potencies at both receptors in comparison to analogues <b>11</b>, <b>17a</b>, and <b>17b</b>, with <b>18b</b> being the exception exhibiting an IC<sub>50</sub> value of 41 nM. There is no obvious correlation between linker length and the observed potency values. However, analogue <b>18c</b> (molecule with the longest spacer) not only showed the lowest potency at both receptors but also exhibited a significant drop in efficacy of the dopamine response, possibly indicating steric clashes with the receptor.</div><div class="NLM_p">The triazine-based analogue <b>24</b> exhibited a 4-fold decrease in A<sub>2A</sub>R inhibitory potency compared to the A<sub>2A</sub>R antagonist ZM 241385 (<b>1</b>) while maintaining equipotent activity compared to the D<sub>2</sub>R agonist ropiniole (<b>2</b>). Intermediate <b>23</b> showed comparable A<sub>2A</sub>R inhibitory potency to final compound <b>24</b>, however, it failed to exhibit any functional potency at the D<sub>2</sub> receptor. This result was expected as the ligand lacked the D<sub>2</sub> pharmacophore, therefore confirming that the introduction of the oxindole scaffold is responsible for D<sub>2</sub> agonism of molecule <b>24</b>.</div><div class="NLM_p last">The noncyclic integrated dual acting ligands (compounds <b>32a</b>–<b>c</b> and <b>29</b>) in general showed a significant drop (28 to 54-fold) in inhibitory potency at the A<sub>2A</sub> receptor, with the exception of compound <b>29</b> that was equipotent to ZM 241385 (<b>1</b>). The decrease in antagonism of analogues <b>32a</b>–<b>c</b> can potentially be explained by the introduction of an ionizable nitrogen atom at physiological pH, whereas compound <b>29</b> does not contain this feature and therefore maintained antagonism. Conversely, compound <b>29</b> did not exhibit any detectable activity at the D<sub>2</sub> receptor, which may be related to the lack of the ionizable nitrogen atom, whereas dual acting ligands <b>32a</b>–<b>c</b> exhibited D<sub>2</sub>R functional potencies ranging from 38 to 389 nM. Compounds <b>32b</b> and <b>32c</b> showed a respectable 3- and 8-fold gain in D<sub>2</sub>R functional potency, respectively, compared to the parent compound <b>2</b>. The exchange of the propyl chain of molecule <b>32b</b> with the methyl group in analogue <b>32a</b> caused a decrease in functional potency at the D<sub>2</sub> receptor (note <b>32a</b> was equipotent to ropinirole (<b>2</b>)), which is not unexpected as literature shows that incorporation of a propyl chain in commonly used D<sub>2</sub> agonist on the market improves their D<sub>2</sub> affinity.<a onclick="showRef(event, 'ref40 ref41 ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref40 ref41 ref42 ref43">(40-43)</a> The cyclic monovalent (<b>35</b>, <b>36</b>, <b>38a</b>, <b>38b</b>, <b>39a</b>, and <b>39b</b>) as well as the dual acting ligands (<b>37</b>, <b>40a</b>, and <b>40b</b>) did not exhibit any detectable activity at the D<sub>2</sub> receptor, which is possibly due to the introduction of a constrained ring system not allowing sufficient flexibility for the molecule to interact with the D<sub>2</sub> receptor in a favorable pose. The inhibitory potencies at the A<sub>2A</sub> receptor of monovalent compounds <b>33</b> and <b>34</b> as well as the dual acting ligands <b>37</b>, <b>40a</b>, and <b>40b</b> were comparable to the noncyclic analogues <b>32a</b>–<b>c</b>, with compound <b>40a</b> being the stand out. It is noteworthy that the physical properties of the integrated dual acting ligands (<b>29</b>, <b>32a</b>–<b>c</b>, <b>37</b>, <b>40a</b>, and <b>40b</b>) with topological polar surface areas and clogPs ranging from 127 to 140 Å<sup>2</sup> and 1.65–4.19, respectively, are very respectable considering that ZM 241385 (<b>1</b>) has a polar surface area of 127 Å<sup>2</sup> and clogP of 2.82.</div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Prediction of in Vivo CNS Penetration</h3><div class="NLM_p">Selected analogues were tested in a brain:blood partition ratio (<i>K</i><sub>bb</sub>) assay using blood and brain tissue from a Winstar Han Rat. Selection criteria were based on the inclusion of analogues with different levels of integration (MW ranging from 775 to 445 g/mol), structural diversity (cyclic and noncyclic analogue), the availability of sufficient quantities for testing (>5 mg), and the requirement of being in solid form. The percent fraction unbound in blood and brain tissue was determined, which indicates the percentage amount of unbound drug available to reach the site of action (results Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). Compounds that exhibited <1% fraction unbound were considered to be very highly protein bound. Further determined was the in vitro brain:blood partition ratio (<i>K</i><sub>bb</sub>), which is a prediction of in vivo CNS penetration (results Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>).<a onclick="showRef(event, 'ref45 ref46 ref47'); return false;" href="javascript:void(0);" class="ref ref45 ref46 ref47">(45-47)</a> As a general rule, compounds with a <i>K</i><sub>bb</sub> value >1 have a greater likelihood to be CNS penetrant due to their higher affinity for binding to brain tissue over blood components provided the compounds have a high level of membrane permeability and is not a substrate of an active efflux transporter.<a onclick="showRef(event, 'ref45 ref46 ref47'); return false;" href="javascript:void(0);" class="ref ref45 ref46 ref47">(45-47)</a></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Percent Fraction Unbound (<i>f</i><sub>u</sub>) in Blood and Brain Tissue and the in Vitro Brain:Blood Partition Ratio (<i>K</i><sub>bb</sub>) of Selected Analogues</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="center" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd no.</th><th class="colsep0 rowsep0" align="center">species/matrix</th><th class="colsep0 rowsep0" align="center" char="±">% undiluted <i>f</i><sub>u</sub> mean value ± SD<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char="."><i>K</i><sub>bb</sub><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">ZM 241385 (<b>1</b>)</td><td class="colsep0 rowsep0" align="left">Wistar Han rat blood</td><td class="colsep0 rowsep0" align="char" char="±">6.47 ± 0.45</td><td class="colsep0 rowsep0" align="char" char=".">0.76</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="left">Wistar Han rat brain tissues</td><td class="colsep0 rowsep0" align="char" char="±">8.49 ± 0.23</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>24</b></td><td class="colsep0 rowsep0" align="left">Wistar Han rat blood</td><td class="colsep0 rowsep0" align="char" char="±">2.22 ± 0.086</td><td class="colsep0 rowsep0" align="char" char=".">3.64</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="left">Wistar Han rat brain tissues</td><td class="colsep0 rowsep0" align="char" char="±">0.61 ± 0.034</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>32b</b></td><td class="colsep0 rowsep0" align="left">Wistar Han rat blood</td><td class="colsep0 rowsep0" align="char" char="±">19.76 ± 3.16</td><td class="colsep0 rowsep0" align="char" char=".">1.29</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="left">Wistar Han rat brain tissues</td><td class="colsep0 rowsep0" align="char" char="±">15.33 ± 1.01</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>40a</b></td><td class="colsep0 rowsep0" align="left">Wistar Han rat blood</td><td class="colsep0 rowsep0" align="char" char="±">6.05 ± 0.18</td><td class="colsep0 rowsep0" align="char" char=".">1.07</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="left">Wistar Han rat brain tissues</td><td class="colsep0 rowsep0" align="char" char="±">5.63 ± 0.22</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">The experiments have been performed in triplicate.</p></div></div></div><div class="NLM_p last">The literature A<sub>2A</sub>R antagonist ZM 241385 (<b>1</b>) showed a <i>K</i><sub>bb</sub> value of 0.76 and moderate protein binding. The D<sub>2</sub>R agonist ropinirole (<b>2</b>) was not included in the testing, but given it is an established D<sub>2</sub>R agonist for the treatment of Parkinson’s disease permits that the molecule is able to cross the blood–brain barrier. Dual acting ligand <b>24</b>, although having unfavorable physical properties (MW, 775 g/mol; tPSA, 212 Å<sup>2</sup>; clogP, 4.87), exhibited a <i>K</i><sub>bb</sub> value of 3.65; this value potentially is driving a higher level of CNS penetrance based on the protein binding equilibrium. Clinically used CNS drugs, for example diazepam, exhibit similar <i>K</i><sub>bb</sub> values to compound <b>24</b>, therefore indicating a realistic chance of compound <b>24</b> being CNS accessible.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> Unfortunately, compound <b>24</b> is highly protein bound, implying that only a limited amount of the free drug would reach the site of action when orally administered. The higher integrated “drug-like” dual acting ligands <b>32b</b> exhibited a <i>K</i><sub>bb</sub> value of 1.29, which corresponds to higher affinity for binding to brain tissue than blood components. Compound <b>32b</b> also exhibited low protein binding, suggesting a sufficient amount of unbound drug is able to reach the site of action in an in vivo model. The cyclic integrated dual acting ligand <b>40a</b> exhibited promising <i>K</i><sub>bb</sub> data, but its low potency at the D<sub>2</sub> receptor makes it an undesirable compound for further investigations. In summary, all the designed dual acting ligands that were tested (<b>24</b>, <b>32b</b>, and <b>40a</b>) exhibited promising <i>K</i><sub>bb</sub> values even though their physical properties are at the upper limit (or above for compound <b>24</b>) considering common guidelines for the design of CNS drugs. Additional studies, for example a Madin–Darby canine kidney–MDR1 gene assay, will be necessary to further assess both membrane permeability and P-glycoprotein (P-gp) liability of the presented compounds. Furthermore, the initial in vitro permeability data will need to be confirmed by in vivo brain uptake studies in rodents.</div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05475" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05475" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Herein, we report the successful synthesis of a series of compounds ranging from classical heterobivalent ligands to integrated dual acting molecules based on the chemical structure of the D<sub>2</sub>R agonist ropinirole (<b>1</b>) and the A<sub>2A</sub>R antagonist ZM 241385 (<b>2</b>) (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>). The most promising dual acting ligands maintained the potencies of the original pharmacophores at both receptors (adenosine A<sub>2A</sub> and dopamine D<sub>2</sub>). The results presented in this study for a set of dual acting ligands able to act at two distinct GPCRs represents a remarkable achievement considering the challenges associated with designing and synthesizing compounds to act at just one receptor system.</div><figure id="fig4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-2/jm501254d/20150115/images/medium/jm-2014-01254d_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-2/jm501254d/20150115/images/large/jm-2014-01254d_0005.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Overview of some of the most promising dual acting ligands including chemical structures, physical structures as well as the inhibitory and functional potencies at the adenosine A<sub>2A</sub> and dopamine D<sub>2</sub> receptors, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-2/jm501254d/20150115/images/large/jm-2014-01254d_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501254d&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The “classical” heterobivalent ligands (<b>18a</b>–<b>c</b>) exhibited very respectable potencies at both receptors and therefore are useful pharmacological tools to probe the aforementioned receptor systems as monomers or potentially heterodimers, however, they are labor intensive to synthesize and have unfavorable physical properties for a potential CNS drug. Heterobivalent ligand <b>18c</b>, containing the longest spacer in our series, exhibited a substantial drop in the inhibitory potency at the A<sub>2A</sub> receptor and efficacy at the D<sub>2</sub> receptor. It remains open if heterobivalent ligands incorporating longer spacers would continue this trend or potentially recover the inhibitory potency at the A<sub>2A</sub> receptor and efficacy at the D<sub>2</sub> receptor. The removal of the spacer reduced the number of synthetic steps and the molecular weight slightly while improving the functional potency at both receptors to some extent. Unlike the classical heterobivalent ligands (<b>18a</b>–<b>c</b>), the analogues without a spacer (<b>11</b>, <b>17a</b>, and <b>17b</b>) not only maintained the equivalent inhibitory potency of ZM 241385 (<b>1</b>) at the A<sub>2A</sub> receptor but also the functional activity of ropinirole (<b>2</b>) at the D<sub>2</sub> receptor. The active noncyclic integrated dual acting ligands (<b>32a</b>–<b>c</b>) were relatively more straightforward to synthesize from commercially available starting materials, mainly due to the fact that the triazolotriazine portion was introduced via the sulfone intermediate <b>28</b>. As a result, the more labor intensive synthesis of a TCAC (compound <b>3</b> or <b>16</b>) compared to sulfone <b>28</b> was circumvented. Compounds <b>32a</b>–<b>c</b> exhibited EC<sub>50</sub> values at the D<sub>2</sub> receptor ranging from equivalent to a 8-fold increased functional potency in comparison to ropinirole while the inhibitory potency at the A<sub>2A</sub> receptor was still respectable but approximately 1.5 orders of magnitude weaker than ZM 241385 (<b>1</b>). Compounds <b>32a</b>–<b>c</b> have significantly improved physical properties but are admittedly still at the upper limit for a potential CNS drug. Nevertheless, it should be pointed out that there are CNS drugs with similar properties on the market.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> More importantly, initial permeability testing of selected analogues exhibited promising <i>K</i><sub>bb</sub> values, indicating that these molecules might be able to cross the blood–brain barrier. Compound <b>24</b> is a very interesting molecule because it is highly potent at the A<sub>2A</sub> and D<sub>2</sub> receptors (pIC<sub>50</sub> 6.92 and pEC<sub>50</sub> 6.51, respectively). It should be noted that, with a molecular weight of 775 g/mol, topological polar surface area of 212 Å<sup>2</sup>, and a partition coefficient of 4.87, compound <b>24</b> does not display ideal physical properties, however, exhibited a promising <i>K</i><sub>bb</sub> value of 3.65.</div><div class="NLM_p last">To our knowledge, these are the first “drug-like” dual acting ligands successfully targeting the adenosine A<sub>2A</sub> and dopamine D<sub>2</sub> receptors.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> These dual acting ligands with relatively low molecular weight are potential lead compounds in drug discovery. An important question that remains is if these dual acting molecules provide a benefit to patients with Parkinson’s disease over the single administration of D<sub>2</sub>R agonists in the clinic. Therefore, it would be interesting to compare the dual acting ligands <b>11</b>, <b>24</b>, <b>32a</b>, and the D<sub>2</sub>R agonist ropinirole (<b>2</b>), which all exhibit comparable functional potency and efficacy at the D<sub>2</sub> receptor, but differ in their inhibitory potency at the adenosine A<sub>2A</sub> receptor, in an appropriate animal model. A study of this type would also provide an insight into what inhibitory potency is needed at the A<sub>2A</sub> receptor to observe a beneficial therapeutic effect in an animal model. Consequently, the integrated analogues that exhibit a lower pIC<sub>50</sub> value compared to ZM 241385 (<b>1</b>) are potentially as beneficial for the treatment of Parkinson’s disease as molecules that have better inhibitory potency at the A<sub>2A</sub> receptor (compound <b>24</b> and <b>11</b>). Future studies would include the determination of the subtype selectivity for the different adenosine and dopamine receptors, allowing a comparison of the selectivity profile of the presented dual acting ligands with the monovalent pharmacophores. This information can potentially lead to a better understanding of the properties of the different subtypes as well as improve the design of more selective D<sub>2</sub>R and A<sub>2A</sub>R agonists and antagonists, respectively.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72257" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72257" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> General Information</h3><div class="NLM_p">All reactions were stirred magnetically in oven-dried glassware. Anhydrous solvents were transferred via oven-dried syringe or cannula. Technical grade solvents used for extraction, and column chromatography were distilled prior to use. Absolute solvents were used without further purification. The ropinirole hydrochloride salt was purchased from Betapharma Shanghai Co., Ltd. and 4-(2-hydroxyethyl)indolin-2-one was purchased from China Langchem Inc. and <i>tert</i>-butyl (6-bromohexyl)carbamate from Astatech Inc. All the other reagents were purchased from Merck, TCI Chemicals, Aldrich, or AK Scientific in the highest available grade and used without further purification. Analytical thin layer chromatography (TLC) plates from Merck were used for reaction control (silica gel 60 on aluminum sheets). Silica gel 60 (Fluka) was used for silica gel flash chromatography. Proton nuclear magnetic resonance (<sup>1</sup>H NMR) spectra and carbon-13 nuclear magnetic resonance (<sup>13</sup>C NMR) spectra were recorded on Bruker spectrometers Avance 400 (400 MHz for <sup>1</sup>H NMR and 101 MHz for <sup>13</sup>C NMR) at ambient temperature in the solvents indicated and referenced to tetramethylsilane (TMS). <sup>13</sup>C NMR spectra were routinely run with broadband decoupling. Distortionless enhancement by polarization transfer (DEPT) experiments were routinely used for <sup>13</sup>C NMR spectra. Chemical shifts (δ) are reported in parts per million (ppm). Coupling constants (<i>J</i>) are reported in Hertz (Hz). The following abbreviations are used: s (singlet), br s (broad singlet), d (doublet), t (triplet), q (quartet), and m (multiplet). Characterization of known compounds has been in accordance with literature, and references have been provided for relevant compounds in the <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a> and <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>. High resolution mass spectra (HRMS) were obtained on a Waters LCT Premier XE (TOF) spectrometer fitted with an electrospray ion source. Mass signals are given in mass units per charge (<i>m</i>/<i>z</i>). The fragments and intensities are written in brackets. Liquid chromatography mass spectra (LCMS) were measured on either two instruments an Agilent 6100 series single quad LC/MS or Agilent 1200 Series HPLC (pump, 1200 series G1311A quaternary pump; autosampler, 1200 series G1329A thermostated autosampler; detector, 1200 series G1314B variable wavelength detector). Gradient takes 4 min to get to 100% acetonitrile, maintain for 3 min, and a further 3 min to get back to the original 5% acetonitrile. An Agilent 1290 Infinity (Agilent, Palo Alto, CA) ionization mode electrospray ionization was used. Chromatographic separation was performed using an Agilent Zorbax SB-C18 rapid resolution HT 2.1 mm × 50 mm, 1.8 μm column (Agilent Technologies, Palo Alto, CA) using an acetonitrile gradient (5–100%) over 3.5 min at 0.5 mL/min. Solvent A = aqueous 0.1% formic acid; solvent B = acetonitrile/0.1% formic acid. Preparative HPLC was performed on a Agilent 1260 infinity coupled with binary prep pump and Agilent 1260 FC-PS fraction collector. It operated on Agilent OpenLAB CDS Rev C.01.04 software. The column was an Alltima C85 μ 22 mm × 250 mm. Analytical HPLC was performed on an Agilent 1260 Infinity. It was operated on Agilent OpenLAB CDS Rev C.01.04 software. The column used was a Poroshell 120 SB-C18 4.6 mm × 100 mm, 2.7 μm. All the final compounds showed a single peak at the designated retention time and are at least 95% pure.</div><div class="NLM_p">All studies were conducted in accordance with the GSK Policy on the Care, Welfare, and Treatment of Laboratory Animals and were reviewed the Institutional Animal Care and Use Committee either at GSK or by the ethical review process at the institution where the work was performed.</div><div class="NLM_p last">NMR analysis: Compound which include a triazolotriazine moiety show doubling of some signals in the <sup>1</sup>H and <sup>13</sup>C NMR spectra due to dimer formation and/or hindered rotation. For details, refer to the extensive NMR study of the adenosine A<sub>2A</sub>R antagonist ZM 241385 (<b>1</b>) by our group that was previously published.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a></div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Synthesis</h3><div id="sec5_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> 5-(4-(2-((7-Amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-<i>a</i>][1,3,5]triazin-5-yl)amino)ethyl) phenoxy)-5-oxopentanoic Acid (<b>10</b>)</h4><div class="NLM_p last">4-(2-((7-Amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-<i>a</i>][1,3,5]triazin-5-yl)amino)ethyl)phenol (ZM 241385) (<b>1</b>) (50.0 mg, 148 μmol) and glutaric anhydride (<b>9</b>) (18.6 mg, 163 μmol) was suspended in toluene (4 mL). The reaction mixture was stirred at reflux for 18 h before TEA (100 μL, 717 μmol) was added. Another 5 equiv of glutaric anhydride were added in portions, while the reaction mixture was stirred for another 29 h at rt. The reaction mixture was then partitioned between ethyl acetate, toluene, and brine. The organic layer was washed with water and dried with anhydrous sodium sulfate, filtered, and the solvent removed under reduced pressure. The crude material was purified by column chromatography (CH<sub>2</sub>Cl<sub>2</sub> → CH<sub>2</sub>Cl<sub>2</sub>:CH<sub>3</sub>OH 9:1) to afford the title compound <b>10</b> (19 mg, 28%) as a white solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 12.17 (br s, 1H), 8.30 (2 × br s, ratio 1:6, 2H), 7.87 (m, 1H), 7.52 (2 × br t, <i>J</i> = 5.6 Hz, 1H), 7.29 (m, 2H), 7.11–6.99 (m, 3H), 6.68 (m, 1H), 3.49 (m, 2H), 2.87 (m, 2H), 2.61 (t, <i>J</i> = 7.4 Hz, 2H), 2.34 (t, <i>J</i> = 7.2 Hz, 2H), 1.85 (m, 2H). Some of the <sup>13</sup>C signal show up twice, the signal with lower intensity is marked with an asterisk (*). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ 174.0 (C), 171.5 (C), 161.1 (C), 159.2 (C), 155.8 (C), 150.0 (C), 148.7 (C), 146.2 (C), 144.6 (CH), 137.1 (C), 129.6 (CH), 121.6 (CH), 111.9 (CH), 111.6 (CH), 42.7 (CH<sub>2</sub>*), 42.1 (CH<sub>2</sub>), 34.5 (CH<sub>2</sub>*), 34.0 (CH<sub>2</sub>), 32.7 (CH<sub>2</sub>), 32.6 (CH<sub>2</sub>), 19.8 (CH<sub>2</sub>). LCMS: <i>m</i>/<i>z</i> (ESI 20 V) 452.2 (MH<sup>+</sup>, 100).</div></div><div id="sec5_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> 4-(2-((7-Amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-<i>a</i>][1,3,5]triazin-5-yl)amino)ethyl)phenyl 5-Oxo-5-((3-((2-(2-oxoindolin-4-yl)ethyl)(propyl)amino)propyl)amino)pentanoate (<b>11</b>)</h4><div class="NLM_p last">4-(2-((3-Aminopropyl)(propyl)amino)ethyl)indolin-2-one (<b>5</b>) (12.2 mg, 44.3 μmol) and 5-(4-(2-((7-amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-<i>a</i>][1,3,5]triazin-5-yl)amino)ethyl)phenoxy)-5-oxopentanoic acid (<b>10</b>) (20.0 mg, 44.3 μmol) were dissolved DMF (4 mL) and DIPEA (11.6 μL, 66.5 μmol) and 1-(bis(dimethylamino)methylene)-5-chloro-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazole-1-ium 3-oxide hexafluorophosphate (V) (HCTU) (18.3 mg, 44.3 μmol) were added and the reaction mixture was stirred at rt for 3 h. The volatile components were removed under reduced pressure. The residue was redissolved in ethyl acetate and washed with 1 M aqueous potassium carbonate solution. The organic layer was dried with anhydrous sodium sulfate, filtered, and evaporated to dryness. The crude material was purified by column chromatography (ethyl acetate → ethyl acetate:CH<sub>3</sub>OH 1:1) to afford the title compound <b>11</b> (3 mg, 10%) as a purple oil. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 10.35 (br s, 1H), 8.60–7.95 (2 × br s, ratio 1:6, 2H), 7.85 (m, 1H), 7.83 (t, <i>J</i> = 5.5 Hz, 1H), 7.62 (2 × br t, ratio 1:2, <i>J</i> = 5.7 Hz, 1H), 7.27 (m, 2H), 7.11–7.01 (m, 4H), 6.76 (m, 1H), 6.68 (m, 1H), 6.64 (m, 1H), 3.49 (m, 2H), 3.43 (s, 2H), 3.06 (m, 2H), 2.86 (m, 2H), 2.58 (s, 4H), 2.54 (m, 2H), 2.44 (m, 2H), 2.37 (m, 2H), 2.16 (t, <i>J</i> = 7.3 Hz, 2H), 1.84 (m, 2H), 1.52 (m, 2H), 1.37 (m, 2H), 0.82 (t, <i>J</i> = 7.4 Hz, 3H). LCMS: <i>m</i>/<i>z</i> (ESI 20 V) 707.4 (MH<sup>–</sup>, 100). HPLC: <i>t</i><sub>R</sub> 7.83 min, >95% (214 nm), >97% (254 nm). HRMS (C<sub>37</sub>H<sub>44</sub>N<sub>10</sub>O<sub>5</sub>): calcd, 709.3574 [M + H]<sup>+</sup>; found 709.3558.</div></div><div id="sec5_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> 4-((<i>tert</i>-Butoxycarbonyl)amino)butanoic Acid (<b>13a</b>)</h4><div class="NLM_p last">4-Aminobutanoic acid (<b>12a</b>) (1.00 g, 9.70 mmol) was dissolved in THF (15 mL) and 1 M aqueous sodium hydroxide solution (10 mL) and di-<i>tert</i>-butyl dicarbonate (2.75 g, 12.61 mmol) were added at 0 °C before the reaction mixture was allowed to warm up to rt and stirred for another 3 h. The solvent was then evaporated under reduced pressure. The residue was taken up in water and extracted with diethyl ether. The aqueous phase was acidified with 1 M aqueous hydrochloric acid solution and quickly extracted with diethyl ether. The combined organic layers were dried with anhydrous sodium sulfate, filtered, and the solvent removed under reduced pressure. Purification by column chromatography (CH<sub>2</sub>Cl<sub>2</sub> → CH<sub>2</sub>Cl<sub>2</sub>:CH<sub>3</sub>OH 95:5) gave the title compound <b>13a</b> (1.30 g, 66%) as a colorless oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 10.00 (br s, 1H), 4.75 (br s, 1H), 3.19 (m, 2H), 2.40 (t, <i>J</i> = 7.2 Hz, 2H), 1.83 (p, <i>J</i> = 7.0 Hz, 2H), 1.45 (s, 9H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 178.4 (C), 156.6 (C), 79.7 (C), 40.0 (CH<sub>2</sub>), 31.3 (CH<sub>2</sub>), 28.3 (CH<sub>3</sub>), 25.1 (CH<sub>2</sub>).</div></div><div id="sec5_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> 8-((<i>tert</i>-Butoxycarbonyl)amino)octanoic Acid (<b>13b</b>)</h4><div class="NLM_p last">8-Aminooctanoic acid (<b>12b</b>) (292 mg, 1.83 mmol) was suspended in CH<sub>3</sub>OH (25 mL). TEA (365 μL, 2.75 mmol) and a solution of di-<i>tert</i>-butyl dicarbonate (800 mg, 3.67 mmol) in CH<sub>3</sub>OH (5 mL) were added, and the reaction mixture was heated up to 60 °C and stirred for 2 h before the solvent was removed under reduced pressure. The residue was taken up in CHCl<sub>3</sub> and washed quickly with 1 M aqueous hydrochloric acid solution. The organic phase was dried with anhydrous sodium sulfate, filtered, and the solvent removed under reduced pressure. Purification by column chromatography (CH<sub>2</sub>Cl<sub>2</sub> → CH<sub>2</sub>Cl<sub>2</sub>:CH<sub>3</sub>OH 9:1) gave the title compound <b>13b</b> (383 mg, 81%) as a white solid; mp 82–85 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 4.56 (s, 1H), 3.10 (m, 2H), 2.34 (t, <i>J</i> = 7.5 Hz, 2H), 1.62 (m, 2H), 1.46 (m, 11H), 1.32 (m, 6H).</div></div><div id="sec5_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> 12-((<i>tert</i>-Butoxycarbonyl)amino)dodecanoic Acid (<b>13c</b>)</h4><div class="NLM_p last">12-Aminododecanoic acid (<b>12c</b>) (860 mg, 4.00 mmol) was suspended in CH<sub>3</sub>OH (40 mL). TEA (796 μL, 5.99 mmol) and a solution of di-<i>tert</i>-butyl dicarbonate (1.74 g, 7.99 mmol) in CH<sub>3</sub>OH (10 mL) were added. The reaction mixture was heated up to 60 °C and stirred for 1.5 h before the solvent was removed under reduced pressure. The residue was taken up in CHCl<sub>3</sub> and extracted quickly with 1 M aqueous hydrochloric acid solution. The organic phase was dried with anhydrous sodium sulfate, filtered, and the solvent removed under reduced pressure. Purification by column chromatography (CH<sub>2</sub>Cl<sub>2</sub> → CH<sub>2</sub>Cl<sub>2</sub>:CH<sub>3</sub>OH 95:5) gave the title compound <b>13c</b> (860 mg, 68%) as a white solid; mp 59–61 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 4.53 (s, 1H), 3.10 (m, 2H), 2.34 (t, <i>J</i> = 7.4 Hz, 2H), 1.68–1.56 (m, 2H), 1.44 (m, 11H), 1.27 (m, 14H).</div></div><div id="sec5_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> <i>tert</i>-Butyl (4-Oxo-4-((3-((2-(2-oxoindolin-4-yl)ethyl)(propyl)amino)propyl)amino)butyl)carbamate (<b>14a</b>)</h4><div class="NLM_p last">(1-Cyano-2-ethoxy-2-oxoethylidenaminooxy)dimethylamino-morpholino-carbenium hexafluorophosphate (COMU) (299 mg, 699 μmol) was added to a mixture of 4-(2-((3-aminopropyl)(propyl)amino)ethyl)indolin-2-one (<b>5</b>) (192 mg, 699 μmol), 8-((<i>tert</i>-butoxycarbonyl)amino)butanoic acid (<b>13a</b>) (142 mg, 699 μmol), and DIPEA (51.1 mg, 699 μmol) in DMF (2 mL) at 0 °C. The reaction mixture was stirred at 0 °C for 1 h then for another 2 h at rt. The reaction mixture was diluted with ethyl acetate and washed with 1 M aqueous hydrochloric acid solution, saturated aqueous sodium hydrogen carbonate solution, and brine. The organic layer was dried with anhydrous sodium sulfate, filtered, and the solvent removed under reduced pressure. Purification by column chromatography (CH<sub>2</sub>Cl<sub>2</sub> → CH<sub>2</sub>Cl<sub>2</sub>:CH<sub>3</sub>OH 8:2) gave the title compound <b>14a</b> (10 mg, 3%) as a yellow oil. The water layer was evaporated to dryness. The residue was suspended in CH<sub>3</sub>OH and filtered. The filtrate was evaporated to dryness, and purification column chromatography (CH<sub>2</sub>Cl<sub>2</sub> → CH<sub>2</sub>Cl<sub>2</sub>:CH<sub>3</sub>OH 8:1) gave the title compound <b>14a</b> (101 mg, 31%) as a yellow solid. <sup>1</sup>H NMR (acetone-<i>d</i><sub>6</sub>) δ 9.44 (br s, 1H), 7.85 (br s, 1H), 7.19 (t, <i>J</i> = 7.8 Hz, 1H), 6.96 (d, <i>J</i> = 7.7 Hz, 1H), 6.83 (d, <i>J</i> = 7.7 Hz, 1H), 6.10 (br s, 1H), 3.56 (s, 2H), 3.49 (m, 2H), 3.43–3.30 (m, 6H), 3.17–3.08 (m, 4H), 2.34 (t, <i>J</i> = 7.2 Hz, 2H), 2.14–2.04 (m, 2H), 1.95–1.85 (m, 2H), 1.85–1.73 (m, 2H), 1.47–1.33 (m, 9H), 1.05 (t, <i>J</i> = 7.4 Hz, 3H). LCMS: <i>m</i>/<i>z</i> (ESI 20 V) 461.4 (MH<sup>+</sup>, 100).</div></div><div id="sec5_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> <i>tert</i>-Butyl (8-Oxo-8-((3-((2-(2-oxoindolin-4-yl)ethyl)(propyl)amino)propyl)amino)octyl)carbamate (<b>14b</b>)</h4><div class="NLM_p last">(1-Cyano-2-ethoxy-2-oxoethylidenaminooxy)dimethylamino-morpholino-carbenium hexafluorophosphate (COMU) (301 mg, 702 μmol) was added to a mixture of 4-(2-((3-aminopropyl)(propyl)amino)ethyl)indolin-2-one (<b>5</b>) (193 mg, 702 μmol), 8-((<i>tert</i>-butoxycarbonyl)amino)octanoic acid (<b>13b</b>) (182 mg, 702 μmol), and DIPEA (51.3 mg, 702 μmol) in DMF (2 mL) at 0 °C. The reaction mixture was stirred at 0 °C for 1 h then for another 2 h at rt. The reaction mixture was diluted with ethyl acetate and washed with 1 M aqueous hydrochloric acid solution, saturated aqueous sodium hydrogen carbonate solution, and brine. The organic layer was dried with anhydrous sodium sulfate, filtered, and the solvent removed under reduced pressure. Purification by column chromatography (CH<sub>2</sub>Cl<sub>2</sub> → CH<sub>2</sub>Cl<sub>2</sub>:CH<sub>3</sub>OH 8:2) gave the title compound <b>14b</b> (82 mg, 23%) as a yellow oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.56 (br s, 1H), 7.11 (t, <i>J</i> = 7.6 Hz, 1H), 6.87 (br s, 1H), 6.82 (d, <i>J</i> = 7.7 Hz, 1H), 6.75 (d, <i>J</i> = 7.6 Hz, 1H), 4.89 (br s, 1H), 3.47 (s, 2H), 3.27 (m, 2H), 3.10–2.60 (m, 10H), 2.15 (m, 2H), 1.81 (m, 2H), 1.68–1.50 (m, 4H), 1.43 (m, 11H), 1.33–1.51 (m, 6H), 0.95 (t, <i>J</i> = 7.1 Hz, 3H). LCMS: <i>m</i>/<i>z</i> (ESI 20 V) 517.4 (MH<sup>+</sup>, 100).</div></div><div id="sec5_2_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> <i>tert</i>-Butyl (12-Oxo-12-((3-((2-(2-oxoindolin-4-yl)ethyl)(propyl)amino)propyl)amino)dodecyl)carbamate (<b>14c</b>)</h4><div class="NLM_p last">(1-Cyano-2-ethoxy-2-oxoethylidenaminooxy)dimethylamino-morpholino-carbenium hexafluorophosphate (COMU) (260 mg, 609 μmol) was added to a mixture of 4-(2-((3-aminopropyl)(propyl)amino)ethyl)indolin-2-one (<b>5</b>) (192 mg, 609 μmol), 12-((<i>tert</i>-butoxycarbonyl)amino)dodecanoic acid (<b>13c</b>) (168 mg, 609 μmol), and DIPEA (44.5 mg, 609 μmol) in DMF (4 mL) at 0 °C. The reaction mixture was stirred at 0 °C for 1 h then for another 2 h at rt. The reaction mixture was diluted with ethyl acetate and washed with 1 M aqueous hydrochloric acid solution, saturated aqueous sodium hydrogen carbonate solution, and brine. The organic layer was dried with anhydrous sodium sulfate, filtered, and the solvent removed under reduced pressure. Purification by column chromatography (CH<sub>2</sub>Cl<sub>2</sub> → CH<sub>2</sub>Cl<sub>2</sub>:CH<sub>3</sub>OH 8:2) gave the title compound <b>14c</b> (144 mg, 41%) as a yellow oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.83 (br s, 1H), 7.12 (t, <i>J</i> = 7.8 Hz, 1H), 6.88 (br s, 1H), 6.82 (d, <i>J</i> = 7.8 Hz, 1H), 6.75 (d, <i>J</i> = 7.7 Hz, 1H), 4.61 (br s, 1H), 3.47 (s, 2H), 3.30 (m, 2H), 3.08 (m, 2H), 2.82 (m, 2H), 2.75 (m, 4H), 2.62 (m, 2H), 2.13 (t, <i>J</i> = 7.6 Hz, 2H), 1.73 (m, 2H), 1.63–1.51 (m, 4H), 1.44 (m, 11H), 1.33–1.51 (m, 14H), 0.93 (t, <i>J</i> = 7.3 Hz, 3H). LCMS: <i>m</i>/<i>z</i> (ESI 20 V) 573.5 (MH<sup>+</sup>, 100). HPLC: <i>t</i><sub>R</sub> 7.36 min, >99% (254 nm). HRMS (C<sub>33</sub>H<sub>56</sub>N<sub>4</sub>O<sub>4</sub>): calcd, 573.4380 [M + H]<sup>+</sup>; found, 573.4389.</div></div><div id="sec5_2_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> 4-Amino-<i>N</i>-(3-((2-(2-oxoindolin-4-yl)ethyl)(propyl)amino)propyl)butanamide (<b>15a</b>)</h4><div class="NLM_p last">Trifluoroacetic acid (1 mL) was added to solution of <i>tert</i>-butyl (4-oxo-4-((3-((2-(2-oxoindolin-4-yl)ethyl)(propyl)amino)propyl)amino)butyl)carbamate (<b>14a</b>) (101 mg, 217 μmol) in CH<sub>2</sub>Cl<sub>2</sub> (5 mL). The reaction mixture was stirred at rt for 9 h before the solvent was removed under reduced pressure. The residue was diluted with CH<sub>2</sub>Cl<sub>2</sub>, and 1 M aqueous sodium hydroxide solution was added until pH 14. The aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub>, then the combined organic layers were dried with anhydrous sodium sulfate, filtered, and the solvent removed under reduced pressure. The titled compound <b>15a</b> (53.9 mg, 69%) was obtained as a yellow oil. The compound <b>15a</b> was suspected to be labile and therefore immediately reacted further to furnish analogue <b>18a</b> to avoid potential degradation. LCMS: <i>m</i>/<i>z</i> (ESI 20 V) 361.3 (MH<sup>+</sup>, 80).</div></div><div id="sec5_2_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> 8-Amino-<i>N</i>-(3-((2-(2-oxoindolin-4-yl)ethyl)(propyl)amino)propyl)octanamide (<b>15b</b>)</h4><div class="NLM_p last">Trifluoroacetic acid (1 mL) was added to solution of <i>tert</i>-butyl (8-oxo-8-((3-((2-(2-oxoindolin-4-yl)ethyl)(propyl)amino)propyl)amino)octyl)carbamate (<b>14b</b>) (85 mg, 165 μmol) in CH<sub>2</sub>Cl<sub>2</sub> (5 mL). The reaction mixture was stirred at rt for 2.5 h before the solvent was removed under reduced pressure. The residue was diluted with CH<sub>2</sub>Cl<sub>2</sub>, and 1 M aqueous sodium hydroxide solution was added until pH 14. The aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub>, then the combined organic layers were dried with anhydrous sodium sulfate, filtered, and the solvent removed under reduced pressure. The title compound <b>15b</b> (68.0 mg, 99%) was obtained as a yellow oil. The compound <b>15b</b> was suspected to be labile and therefore immediately reacted further to furnish analogue <b>18b</b> to avoid potential degradation. LCMS: <i>m</i>/<i>z</i> (ESI 20 V) 417.4 (MH<sup>+</sup>, 40).</div></div><div id="sec5_2_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> 12-Amino-<i>N</i>-(3-((2-(2-oxoindolin-4-yl)ethyl)(propyl)amino)propyl)dodecanamide (<b>15c</b>)</h4><div class="NLM_p last">Trifluoroacetic acid (1 mL) was added to solution of <i>tert</i>-butyl (12-oxo-12-((3-((2-(2-oxoindolin-4-yl)ethyl)(propyl)amino)propyl)amino)dodecyl) carbamate (<b>14c</b>) (117 mg, 204 μmol) in CH<sub>2</sub>Cl<sub>2</sub> (5 mL). The reaction mixture was stirred at rt for 2.5 h before the solvent was removed under reduced pressure. The residue was diluted with CH<sub>2</sub>Cl<sub>2</sub>, and 1 M aqueous sodium hydroxide solution was added until pH 14. The aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub>, then the combined organic layers were dried with anhydrous sodium sulfate, filtered, and the solvent removed under reduced pressure. The title compound <b>15c</b> (37.6 mg, 39%) was obtained as a yellow oil. The compound <b>15c</b> was suspected to be labile and therefore immediately reacted further to furnish analogue <b>18c</b> to avoid potential degradation. LCMS: <i>m</i>/<i>z</i> (ESI 20 V) 473.4 (MH<sup>+</sup>, 30).</div></div><div id="sec5_2_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> 2-(4-(2-((7-Amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-<i>a</i>][1,3,5]triazin-5-yl)amino)ethyl)phenoxy)-<i>N</i>-(3-((2-(2-oxoindolin-4-yl)ethyl)(propyl)amino)propyl)acetamide (<b>17a</b>)</h4><div class="NLM_p last">4-(2-((3-Aminopropyl)(propyl)amino)ethyl)indolin-2-one (<b>5</b>) (48.8 mg, 177 μmol) and 2-(4-(2-((7-amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-<i>a</i>][1,3,5]triazin-5-yl)amino)ethyl)phenoxy)acetic acid (<b>16</b>) (70.0 mg, 177 μmol) were dissolved DMF (4 mL) and DIPEA (46.3 μL, 266 μmol) and ((1<i>H</i>-benzo[<i>d</i>][1,2,3]triazol-1-yl)oxy)tris(dimethylamino)phosphonium hexafluorophosphate (V) (BOP) (78.3 mg, 177 μmol) were added and the reaction mixture was stirred at rt for 5 h. The volatile compounds were removed under reduced pressure. The residue was dissolved in ethyl acetate and washed with 1 M aqueous potassium carbonate solution. The organic layer was dried with anhydrous sodium sulfate, filtered, and the solvent removed under reduced pressure. The crude material was purified by column chromatography (ethyl acetate → ethyl acetate:CH<sub>3</sub>OH 7:3). The title compound <b>17a</b> (8.3 mg, 7%) was obtained as a purple oil. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 10.32 (s, 1H), 8.50–7.95 (2 × br s, ratio 1:6, 2H), 8.09 (t, <i>J</i> = 5.6 Hz, 1H), 7.87 (m, 1H), 7.55–7.40 (2 × br t, ratio 1:2, <i>J</i> = 5.7 Hz, 1H), 7.17 (m, <i>J</i> = 8.4 Hz, 2H), 7.10–7.03 (m, 2H), 6.89 (m, 2H), 6.76 (d, <i>J</i> = 7.7 Hz, 1H), 6.68 (m, 1H), 6.62 (d, <i>J</i> = 5.7 Hz, 1H), 4.42 (s, 2H), 3.50–3.38 (m, 4H), 3.16 (q, <i>J</i> = 6.6 Hz, 2H), 2.78 (m, 2H), 2.57 (m, 4H), 2.44 (t, <i>J</i> = 6.9 Hz, 2H), 2.34 (m, 2H), 1.57 (m, 2H), 1.38 (m, 2H), 0.82 (t, <i>J</i> = 7.3 Hz, 3H). Some of the <sup>13</sup>C signal show up twice, and the signal with lower intensity is marked with an asterisk (*). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ 176.2 (C), 167.5 (C), 161.1 (C), 159.2 (C), 156.1 (C), 155.8 (C), 150.0 (C), 146.2 (C), 144.6 (CH), 143.3 (C), 134.0 (C), 132.2 (C), 129.6 (CH), 127.4 (CH), 124.4 (C), 121.7 (CH), 114.6 (CH), 111.9 (CH), 111.6 (CH), 106.8 (CH), 67.1 (CH<sub>2</sub>), 55.3 (CH<sub>2</sub>), 53.5 (CH<sub>2</sub>), 51.1 (CH<sub>2</sub>), 42.9 (CH<sub>2</sub>*), 42.3 (CH<sub>2</sub>), 37.1 (CH<sub>2</sub>), 34.5 (CH<sub>2</sub>), 34.3 (CH<sub>2</sub>*), 33.9 (CH<sub>2</sub>), 29.8 (CH<sub>2</sub>), 26.6 (CH<sub>2</sub>), 19.9 (CH<sub>2</sub>), 11.8 (CH<sub>3</sub>). LCMS: <i>m</i>/<i>z</i> (ESI 20 V) 651.4 (MH<sup>–</sup>, 100). HPLC: <i>t</i><sub>R</sub> 7.41 min, >99% (214 nm), >99% (254 nm). HRMS (C<sub>34</sub>H<sub>40</sub>N<sub>10</sub>O<sub>4</sub>): calcd, 653.3312 [M + H]<sup>+</sup>; found, 653.3294.</div></div><div id="sec5_2_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 3-(4-(4-(2-((7-Amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-<i>a</i>][1,3,5]triazin-5-yl)amino)ethyl)phenoxy)butanamido)-<i>N</i>-(2-(2-oxoindolin-4-yl)ethyl)-<i>N</i>-propylpropan-1-aminium 2,2,2-trifluoroacetate (<b>17b</b>)</h4><div class="NLM_p last">4-(2-((3-Aminopropyl)(propyl)amino)ethyl)indolin-2-one (<b>5</b>) (50.1 mg, 182 μmol) and 4-(4-(2-((7-amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-<i>a</i>][1,3,5]triazin-5-yl)amino)ethyl)phenoxy)butanoic acid (<b>3</b>) (77.0 mg, 182 μmol) were dissolved DMF (4 mL) and DIPEA (47.5 μL, 273 μmol) and 1-(bis(dimethylamino)methylene)-5-chloro-1<i>H</i>-benzo[<i>d</i>][1,2,3]triazole-1-ium 3-oxide hexafluorophosphate (V) (HCTU) (75.2 mg, 182 μmol) was added and the reaction mixture was stirred at rt for 3 h. The volatile compounds were removed under reduced pressure. The residue was purified by column chromatography (ethyl acetate → ethyl acetate:CH<sub>3</sub>OH 35:65). The combined collected fractions were dried under reduced pressure, and the residue was redissolved in ethyl acetate and washed with 1 M aqueous potassium carbonate solution. The organic layer was dried with anhydrous sodium sulfate, filtered, and evaporated to dryness. Preparative HPLC was used to afford the title compound <b>17b</b> (30 mg, 24%) as a yellowish foam. Quoted NMRs are from the free base after column chromatography and washing with base. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 10.3 (s, 1H), 8.50–7.95 (2 × br s, ratio 1:6, 2H), 7.87 (m, 1H), 7.82 (t, <i>J</i> = 5.4 Hz, 1H), 7.57–7.42 (2 × br t, ratio 1:2, <i>J</i> = 5.7 Hz, 1H), 7.14 (m, 2H), 7.10–7.03 (m, 2H), 6.84 (m, 2H), 6.76 (d, <i>J</i> = 7.2 Hz, 1H), 6.67 (m, 1H), 6.64 (d, <i>J</i> = 7.6 Hz, 1H), 3.92 (t, <i>J</i> = 6.4 Hz, 2H), 3.50–3.37 (m, 4H), 3.06 (q, <i>J</i> = 6.7 Hz, 2H), 2.78 (m, 2H), 2.57 (m, 4H), 2.43 (t, <i>J</i> = 7.1 Hz, 2H), 2.36 (t, <i>J</i> = 7.8 Hz, 2H), 2.22 (t, <i>J</i> = 7.4 Hz, 2H), 1.92 (m, 2H), 1.53 (m, 2H), 1.38 (m, 2H), 0.81 (t, <i>J</i> = 7.3 Hz, 3H). Some of the <sup>13</sup>C signal show up twice, and the signal with lower intensity is marked with an asterisk (*). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ 176.2 (C), 171.3 (C), 161.1 (C), 159.2 (C), 156.9 (C), 155.8 (C), 150.0 (C), 146.2 (C), 144.6 (CH), 143.4 (C), 136.6 (C), 131.4 (C), 129.5 (CH), 127.4 (CH), 124.4 (C), 121.7 (CH), 114.3 (CH), 111.9 (CH), 111.6 (CH), 106.8 (CH), 66.8 (CH<sub>2</sub>), 55.3 (CH<sub>2</sub>), 53.6 (CH<sub>2</sub>), 50.9 (CH<sub>2</sub>), 42.9 (CH<sub>2</sub>*), 42.4 (CH<sub>2</sub>), 36.9 (CH<sub>2</sub>), 34.5 (CH<sub>2</sub>), 34.3 (CH<sub>2</sub>*), 33.8 (CH<sub>2</sub>), 31.8 (CH<sub>2</sub>), 29.9 (CH<sub>2</sub>), 26.9 (CH<sub>2</sub>), 25.0 (CH<sub>2</sub>), 20.0 (CH<sub>2</sub>), 11.8 (CH<sub>3</sub>). LCMS: <i>m</i>/<i>z</i> (ESI 20 V) 681.5 (MH<sup>+</sup>, 100), 679.5 (MH<sup>–</sup>, 100). HPLC: <i>t</i><sub>R</sub> 7.79 min, >99% (214 nm), >99% (254 nm). HRMS (C<sub>36</sub>H<sub>44</sub>N<sub>10</sub>O<sub>4</sub>): calcd, 681.3625 [M + H]<sup>+</sup>; found, 681.3627.</div></div><div id="sec5_2_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 4-(4-(2-((7-Amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-<i>a</i>][1,3,5]triazin-5-yl)amino)ethyl)phenoxy)-<i>N</i>-(4-oxo-4-((3-((2-(2-oxoindolin-4-yl)ethyl)(propyl)amino)propyl)amino)butyl)butanamide (<b>18a</b>)</h4><div class="NLM_p last">(1-Cyano-2-ethoxy-2-oxoethylidenaminooxy)dimethylamino-morpholino-carbenium hexafluorophosphate (COMU) (45.0 mg, 133 μmol) was added to a mixture of 4-amino-<i>N</i>-(3-((2-(2-oxoindolin-4-yl)ethyl)(propyl)amino)propyl)butanamide (<b>15a</b>) (47.9 mg, 133 μmol), 4-(4-(2-((7-amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-<i>a</i>][1,3,5]triazin-5-yl)amino)ethyl)phenoxy)butanoic acid (<b>3</b>) (45.0 mg, 106 μmol), and DIPEA (9.71 mg, 133 μmol) in DMF (2 mL) at 0 °C. The reaction mixture was stirred at 0 °C for 1 h then for another 9 h at rt. The reaction mixture was diluted with ethyl acetate and washed with 1 M aqueous hydrochloric acid solution, saturated aqueous sodium hydrogen carbonate solution, and brine. The water layer was evaporated to dryness. The residue was taken up in CH<sub>3</sub>OH, and the suspension was filtered. The filtrate was evaporated to dryness, and purification by column chromatography (CH<sub>2</sub>Cl<sub>2</sub> → CH<sub>2</sub>Cl<sub>2</sub>:CH<sub>3</sub>OH 8:2) gave the title compound <b>18a</b> (22.3 mg, 17%) as a white resin. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 10.46 (s, 1H), 8.51–7.95 (m, 4H), 7.87 (m, 1H), 7.57–7.44 (2 × br t, ratio 1:2, <i>J</i> = 5.7 Hz, 1H), 7.14 (m, 2H), 7.70 (m, 1H), 7.05 (m, 1H), 6.86–6.78 (m, 3H), 6.70 (m, 1H), 6.67 (m, 1H), 3.90 (t, <i>J</i> = 6.4 Hz, 2H), 3.51 (s, 2H), 3.44 (m, 2H), 3.21–2.56 (m, 14H), 2.22 (t, <i>J</i> = 7.4 Hz, 2H), 2.09 (t, <i>J</i> = 7.4 Hz, 2H), 1.90 (m, 2H), 1.83–1.44 (m, 6H), 0.87 (t, <i>J</i> = 7.1 Hz, 3H). LCMS: <i>m</i>/<i>z</i> (ESI 20 V) 766.5 (MH<sup>+</sup>, 5). HPLC: <i>t</i><sub>R</sub> 5.25 min, 99% (214 nm), 99% (254 nm). HRMS (C<sub>10</sub>H<sub>51</sub>N<sub>11</sub>O<sub>5</sub>): calcd, 383.7116 [M + 2H]<sup>2+</sup>; found, 383.7121; calcd, 766.4153 [M + H]<sup>+</sup>; found, 766.4141.</div></div><div id="sec5_2_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 8-(4-(4-(2-((7-Amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-<i>a</i>][1,3,5]triazin-5-yl)amino)ethyl)phenoxy)butanamido)-<i>N</i>-(3-((2-(2-oxoindolin-4-yl)ethyl)(propyl)amino)propyl)octanamide (<b>18b</b>)</h4><div class="NLM_p last">(1-Cyano-2-ethoxy-2-oxoethylidenaminooxy)dimethylamino-morpholino-carbenium hexafluorophosphate (COMU) (69.5 mg, 162 μmol) was added to a mixture of 8-amino-<i>N</i>-(3-((2-(2-oxoindolin-4-yl)ethyl)(propyl)amino)propyl)octanamide (<b>15b</b>) (67.7 mg, 162 μmol), 4-(4-(2-((7-amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-<i>a</i>][1,3,5]triazin-5-yl)amino)ethyl)phenoxy)butanoic acid (55.0 mg, 130 μmol), and DIPEA (11.9 mg, 162 μmol) in DMF (2 mL) at 0 °C. The reaction mixture was stirred at 0 °C for 1 h then for another 4 h at rt. The reaction mixture was diluted with ethyl acetate and washed with 1 M aqueous hydrochloric acid solution, saturated aqueous sodium hydrogen carbonate solution, and brine. The water layer was evaporated to dryness. The residue was taken up in CH<sub>3</sub>OH, and the suspension was filtered. The filtrate was evaporated to dryness and purification by column chromatography (CH<sub>2</sub>Cl<sub>2</sub> → CH<sub>2</sub>Cl<sub>2</sub>:CH<sub>3</sub>OH 8:2) gave the title compound <b>18b</b> (22.3 mg, 17%) as a white resin. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 10.34 (s, 1H), 8.50–7.95 (2 × br s, ratio 1:6, 2H), 7.87 (m, 1H), 7.82 (t, <i>J</i> = 5.5 Hz, 1H), 7.76 (br s, 1H), 7.47 (2 × br t, ratio 1:2, <i>J</i> = 5.6 Hz, 1H), 7.15 (m, 2H), 7.11–7.03 (m, 2H), 6.84 (m, 2H), 6.77 (m, 1H), 6.69–6.62 (m, 2H), 3.91 (t, <i>J</i> = 6.3 Hz, 2H), 3.45 (m, 4H), 3.10–2.96 (m, 4H), 2.78 (m, 2H), 2.67–2.29 (m, 8H), 2.21 (t, <i>J</i> = 7.4 Hz, 2H), 2.03 (t, <i>J</i> = 7.3 Hz, 2H), 1.96–1.83 (m, 2H), 1.61–1.30 (m, 8H), 1.22 (m, 6H), 0.83 (t, <i>J</i> = 7.2 Hz, 3H). LCMS: <i>m</i>/<i>z</i> (ESI 20 V) 822.6 (MH<sup>+</sup>, 5). HPLC: <i>t</i><sub>R</sub> 5.71 min, 99% (214 nm), 99% (254 nm). HRMS (C<sub>44</sub>H<sub>59</sub>N<sub>11</sub>O<sub>5</sub>): calcd, 411.7439 [M+2H]<sup>2+</sup>; found, 411.7438; calcd, 822.4779 [M + H]<sup>+</sup>; found, 822.4774.</div></div><div id="sec5_2_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 3-(12-(4-(4-(2-((7-Amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-<i>a</i>][1,3,5]triazin-5-yl)amino)ethyl)phenoxy)butanamido)dodecanamido)-<i>N</i>-(2-(2-oxoindolin-4-yl)ethyl)-<i>N</i>-propylpropan-1-aminium 2,2,2-trifluoroacetate (<b>18c</b>)</h4><div class="NLM_p last">(1-Cyano-2-ethoxy-2-oxoethylidenaminooxy)dimethylamino-morpholino-carbenium hexafluorophosphate (COMU) (40.5 mg, 94.5 μmol) was added to a mixture of 12-amino-<i>N</i>-(3-((2-(2-oxoindolin-4-yl)ethyl)(propyl)amino)propyl)dodecanamide (<b>15c</b>) (44.7 mg, 94.5 μmol), 4-(4-(2-((7-amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-<i>a</i>][1,3,5]triazin-5-yl)amino)ethyl)phenoxy)butanoic acid (<b>3</b>) (40.0 mg, 94.5 μmol), and DIPEA (6.9 mg, 94.5 μmol) in DMF (2 mL) at 0 °C. The reaction mixture was stirred at 0 °C for 1 h then for another 2 h at rt. The reaction mixture was diluted with ethyl acetate and washed with 1 M aqueous hydrochloric acid solution, saturated aqueous sodium hydrogen carbonate solution, and brine. The organic layer was dried with anhydrous sodium sulfate, filtered, and the solvent removed under reduced pressure. Purification by preparative column chromatography gave the title compound <b>18c</b> (7 mg, 8%) as a white solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 10.43 (s, 1H), 9.29 (br s, 1H), 8.50–8.00 (2 × br s, ratio 1:6, 2H), 7.96 (t, <i>J</i> = 5.8 Hz, 1H), 7.87 (m, 1H), 7.80 (t, <i>J</i> = 5.6 Hz, 1H), 7.51 (2 × br t, ratio 1:2, <i>J</i> = 5.6 Hz, 1H), 7.19–7.12 (m, 3H), 7.06 (m, 1H), 6.87–6.84 (m, 3H), 6.73 (m, 1H), 6.68 (m, 1H), 3.91 (t, <i>J</i> = 5.6 Hz, 2H), 3.55 (m, 2H), 3.40 (m, 2H), 3.25 (m, 2H), 3.16–3.07 (m, 6H), 3.02 (m, 2H), 2.86 (m, 2H), 2.78 (m, 2H), 2.21 (t, <i>J</i> = 7.5 Hz, 2H), 2.07 (t, <i>J</i> = 7.4 Hz, 2H), 1.91 (m, 2H), 1.79 (m, 2H), 1.66 (m, 2H), 1.48 (m, 2H), 1.36 (m, 2H), 1.23 (m, 14H), 0.93 (t, <i>J</i> = 7.3 Hz, 3H). LCMS: <i>m</i>/<i>z</i> (ESI 20 V) 878.8 (MH<sup>+</sup>, 5). HPLC: <i>t</i><sub>R</sub> 6.50 min, >99% (214 nm), >99% (254 nm). HRMS (C<sub>48</sub>H<sub>67</sub>N<sub>11</sub>O<sub>5</sub>): calcd, 439.7742 [M+2H]<sup>2+</sup>; found, 439.7734; calcd, 878.5405 [M + H]<sup>+</sup>; found, 878.5363.</div></div><div id="sec5_2_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> Methyl 12-Aminododecanoate</h4><div class="NLM_p last">Conc H<sub>2</sub>SO<sub>4</sub> (0.5 mL) was added to a suspension of 12-aminododecanoic acid (1.00 g, 4.64 mmol) in CH<sub>3</sub>OH (20 mL). The reaction mixture was stirred at reflux for 24 h before the solvent was removed under reduced pressure. The residue was dissolved in CH<sub>2</sub>Cl<sub>2</sub> and water was added, and the white precipitate was filtered off and washed with water. The filter cake was dried under high vacuum. The title compound was obtained (750 mg, 70%) as a white solid; mp 96–98 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 3.58 (s, 3H), 2.52–2.48 (m, 2H), 2.29 (t, <i>J</i> = 7.4 Hz, 2H), 1.51 (m, 2H), 1.31 (m, 2H) 1.37–1.16 (m, 14H).</div></div><div id="sec5_2_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> Methyl 12-(4-(4-(2-((7-Amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-<i>a</i>][1,3,5]triazin-5-yl)amino)ethyl)phenoxy)butanamido)dodecanoate (<b>19</b>)</h4><div class="NLM_p last">(1-Cyano-2-ethoxy-2-oxoethylidenaminooxy)dimethylamino-morpholino-carbenium hexafluorophosphate (COMU) (101 mg, 236 μmol) was added to a mixture of 4-(4-(2-((7-amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-<i>a</i>][1,3,5]triazin-5-yl)amino)ethyl)phenoxy)butanoic acid (<b>3</b>) (100 mg, 236 μmol), 12-((<i>tert</i>-butoxycarbonyl)amino)dodecanoic acid (54.2 mg, 236 μmol), and DIPEA (22.7 μL, 236 μmol) in DMF (2 mL) at 0 °C. The reaction mixture was stirred at 0 °C for 1 h then another 7 h at rt. The reaction mixture was diluted with ethyl acetate and washed with brine. The organic layer was dried with anhydrous sodium sulfate, filtered, and the solvent removed under reduced pressure. Purification by column chromatography (ethyl acetate 100%) and preparative HPLC gave the title compound <b>19</b> (6 mg, 4%) as a white solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 8.50–7.95 (2 × br s, ratio 1:6, 2H), 7.87 (m, 1H), 7.80 (t, <i>J</i> = 5.5 Hz, 1H), 7.58–7.40 (2 × br t, <i>J</i> = 5.5 Hz, ratio 1:2, 1H), 7.15 (m, 2H), 7.06 (m, 1H), 6.84 (m, 2H), 6.68 (m, 1H), 3.91 (t, <i>J</i> = 6.4 Hz, 2H), 3.57 (s, 3H), 3.44 (m, 2H), 3.02 (dd, <i>J</i> = 12.7, 6.7 Hz, 2H), 2.78 (m, 2H), 2.27 (t, <i>J</i> = 7.4 Hz, 2H), 2.21 (t, <i>J</i> = 7.4 Hz, 2H), 1.91 (m, 2H), 1.41 (m, 2H), 1.28 (m, 2H), 1.22 (m, 14H). LCMS: <i>m</i>/<i>z</i> (ESI 20 V) 635.5 (MH<sup>+</sup>, 100). HPLC: <i>t</i><sub>R</sub> 8.06 min, >99% (254 nm), >99% (214 nm). HRMS (C<sub>33</sub>H<sub>46</sub>N<sub>8</sub>O<sub>5</sub>): calcd, 635.3669 [M + H]<sup>+</sup>; found, 635.3650.</div></div><div id="sec5_2_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 2-Morpholino-4,6-dichloro-1,3,5-triazine (<b>22</b>)</h4><div class="NLM_p last">To a solution of cyanuric chloride (<b>20</b>) (5.0 g, 27 mmol) in dry acetone (50 mL) was added dropwise to a cooled solution of morpholine (<b>21</b>) (1.7 g, 19 mmol) and TEA (1.9 g, 19 mmol) in dry acetone (50 mL) at −20 °C. The resulting mixture was poured onto water and stirred for 15 min before being filtered, washed with water and cold CH<sub>3</sub>OH, then dried to yield the title compound <b>22</b> as a white solid (3.4 g, 75%). <sup>1</sup>H NMR (CD<sub>3</sub>OD) δ 3.90–3.88 (m, 4H), 3.77–3.74 (m, 4H). LCMS: <i>m</i>/<i>z</i> (ESI 20 V) 235.0 (MH<sup>+</sup>, 100).</div></div><div id="sec5_2_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> <i>N</i><sup>5</sup>-(4-((4-Chloro-6-morpholino-1,3,5-triazin-2-yl)oxy)phenethyl)-2-(furan-2-yl)-[1,2,4]triazolo[1,5-<i>a</i>][1,3,5]triazine-5,7-diamine (<b>23</b>)</h4><div class="NLM_p last">4-(2-((7-Amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-<i>a</i>][1,3,5]triazin-5-yl)amino)ethyl)phenol (ZM 241385) (<b>1</b>) (200 mg, 596 μmol) was dissolved in THF (100 mL). Sodium hydride (60% suspension in mineral oil) (23.8 mg, 596 μmol) was added, and the reaction mixture was stirred at rt for 30 min. Then the reaction mixture was cooled down to −78 °C, and 2-morpholino-4,6-dichloro-1,3,5-triazine was added. The reaction mixture was allowed to warm up to rt, and after 21 h another portion of sodium hydride (60% suspension in mineral oil) (23.8 mg, 596 μmol) was added and the reaction mixture was stirred for an additional 26 h before ethyl acetate was added. The reaction mixture was washed with an aqueous ammonium chloride solution. The organic layer was dried with anhydrous sodium sulfate, filtered, and the solvent removed under reduced pressure. The crude material was purified twice by column chromatography (CH<sub>2</sub>Cl<sub>2</sub> → CH<sub>2</sub>Cl<sub>2</sub>:CH<sub>3</sub>OH 94:4) and (ethyl acetate:CHCl<sub>3</sub> 1:1). The title compound <b>23</b> (169 mg, 53%) was obtained as a white solid; mp 180–183 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 8.61–7.94 (2 × br s, ratio 1:6, 2H), 7.87 (m, 1H), 7.65–7.47 (2 × br t, ratio 1:2, <i>J</i> = 5.7 Hz, 1H), 7.32 (m, 2H), 7.16 (m, 2H), 7.06 (m, 1H), 6.68 (m, 1H), 3.74 (m, 2H), 3.63 (m, 2H), 3.60 (m, 4H), 3.52 (m, 2H), 2.90 (m, 2H). Some of the <sup>13</sup>C signal show up twice, and the signal with lower intensity is marked with an asterisk (*). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ 170.2 (C), 164.9 (C), 161.5 (C), 161.1 (C), 159.2 (C), 155.8 (C), 150.0 (C), 149.7 (C), 146.2 (C), 144.6 (CH), 137.2 (C), 129.7 (CH), 121.3 (CH), 111.9 (CH), 111.6 (CH), 65.6 (CH<sub>2</sub>), 65.4 (CH<sub>2</sub>), 44.0 (CH<sub>2</sub>), 43.8 (CH<sub>2</sub>), 42.6 (CH<sub>2</sub>*), 42.0 (CH<sub>2</sub>), 34.5 (CH<sub>2</sub>*), 34.0 (CH<sub>2</sub>). LCMS: <i>m</i>/<i>z</i> (ESI 20 V) 536.2 (MH<sup>+</sup>, 100). HPLC: <i>t</i><sub>R</sub> 9.38 min, 97% (214 nm), 95% (254 nm). HRMS (C<sub>23</sub>H<sub>22</sub>ClN<sub>11</sub>O<sub>3</sub>): calcd, 536.1674 [M + H]<sup>+</sup>; found, 536.1671.</div></div><div id="sec5_2_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 4-(2-((3-((4-(4-(2-((7-Amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-<i>a</i>][1,3,5]triazin-5-yl)amino)ethyl)phenoxy)-6-morpholino-1,3,5-triazin-2-yl)amino)propyl)(propyl)amino)ethyl)indolin-2-one diformic Acid Salt (<b>24</b>)</h4><div class="NLM_p last"><i>N</i><sup>5</sup>-(4-((4-Chloro-6-morpholino-1,3,5-triazin-2-yl)oxy)phenethyl)-2-(furan-2-yl)-[1,2,4]triazolo[1,5-<i>a</i>][1,3,5]triazine-5,7-diamine (<b>23</b>) (25.9 mg, 48.1 μmol), 4-(2-((3-aminopropyl)(propyl)amino)ethyl)indolin-2-one (<b>5</b>) (13.3 mg, 48.1 μmol), and potassium carbonate (6.7 mg, 48.1 μmol) were suspended in DMF (1.5 mL) in a microwave tube. The tube was sealed, and the reaction mixture was stirred at 100 °C for 15 min. The solvent was removed under reduced pressure. Purification by preparative column chromatography gave the title compound <b>24</b> (25 mg, 67%) as a white solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 10.33 (s, 1H), 8.53–8.03 (m, 4H), 7.86 (m, 1H), 7.58–7.39 (m, 2H), 7.25 (m, 2H), 7.10–7.02 (m, 4H), 6.76 (m, 1H), 6.66 (m, 2H), 3.73–3.46 (m, 10H), 3.43 (s, 2H), 3.30–3.08 (m, 2H), 2.86 (m, 2H), 2.75–2.45 (m, 8H), 1.72–1.54 (m, 2H), 1.43 (m, 2H), 0.83 (t, <i>J</i> = 7.3 Hz, 3H). Some of the <sup>13</sup>C signal show up twice, and the signal with lower intensity is marked with an asterisk (*). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ 176.6 (C), 170.9 (C*), 170.8 (C), 167.4 (C*), 167.0 (C), 166.3 (C), 165.9 (C*), 164.1 (CH, formic acid), 162.0 (C*), 161.6 (C), 159.7 (C), 156.6 (C*), 156.3 (C), 151.1 (C), 151.0 (C), 150.5 (C), 146.7 (C), 145.1 (CH), 143.9 (C), 136.6 (C*), 136.3 (C), 129.8 (CH), 129.6 (CH*), 128.0 (CH), 125.0 (C), 122.2 (CH), 122.1 (CH), 121.9 (CH*), 112.4 (CH), 112.1 (CH), 107.5 (CH), 66.3 (CH<sub>2</sub>), 55.3 (CH<sub>2</sub>), 53.5 (CH<sub>2</sub>), 53.4 (CH<sub>2</sub>), 51.1 (CH<sub>2</sub>), 43.8 (CH<sub>2</sub>), 43.2 (CH<sub>2</sub>*), 42.6 (CH<sub>2</sub>), 39.0 (CH<sub>2</sub>), 38.9 (CH<sub>2</sub>*), 34.9 (CH<sub>2</sub>), 34.6 (CH<sub>2</sub>*), 34.5 (CH<sub>2</sub>), 29.7 (CH<sub>2</sub>), 26.5 (CH<sub>2</sub>), 26.2 (CH<sub>2</sub>), 19.7 (CH<sub>2</sub>), 12.1 (CH<sub>3</sub>). LCMS: <i>m</i>/<i>z</i> (ESI 20 V) 775.5 (MH<sup>+</sup>, 100). LCMS: <i>m</i>/<i>z</i> (ESI 20 V) 773.9 (MH<sup>–</sup>, 100); (basic) <i>t</i><sub>R</sub> 1.17 min, 97%; (acidic) <i>t</i><sub>R</sub> 0.87 min, 98%. HRMS (C<sub>39</sub>H<sub>46</sub>N<sub>14</sub>O<sub>4</sub>): calcd, 775.3905 [M + H]<sup>+</sup>; found, 775.3894.</div></div><div id="sec5_2_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 2-(2-Oxoindolin-4-yl)ethyl 4-Methylbenzenesulfonate (<b>26</b>)<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a></h4><div class="NLM_p last">To a cooled (5–10 °C) suspension of 4-(2-hydroxyethyl)indolin-2-one (<b>25</b>) (6.30 g, 35.6 mmol) and pyridine (14.1 g, 177.8 mmol), a solution of <i>p</i>-toluenesulfonyl chloride (8.13 g, 42.7 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (32 mL) was added portionwise over 30 min. The reaction mixture was stirred at 5–10 °C for 4 h. Aqueous hydrochloric acid solution (6 M, 35 mL) was added so that the temperature was maintained below 15 °C. CH<sub>2</sub>Cl<sub>2</sub> was added, and the layers were separated. The aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub>. The combined organic layers were washed with water, then dried with anhydrous sodium sulfate, filtered, and the solvent removed under reduced pressure. The organic layer was concentrated under reduced pressure until a residual volume of about 50 mL was obtained. Petroleum spirits (about 50 mL) was added to induce the product to crystallize. The suspension was filtered, and the filter cake was washed with CH<sub>2</sub>Cl<sub>2</sub>:petroleum spirits 1:1. The filter cake was dried on the high vacuum overnight to give the title compound <b>26</b> (9.39 g, 80%) as a yellowish-white solid; mp 128–130 °C (lit.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> 130–131 °C). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 9.05 (s, 1H), 7.68–7.60 (m, 2H), 7.30–7.22 (m, 2H), 7.13 (app t, <i>J</i> = 7.8 Hz, 1H), 6.78 (d, <i>J</i> = 8.2 Hz, 1H), 6.76 (d, <i>J</i> = 8.2 Hz, 1H), 4.23 (t, <i>J</i> = 6.7 Hz, 2H), 3.33 (s, 2H), 2.89 (t, <i>J</i> = 6.7 Hz, 2H), 2.43 (s, 3H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 177.4 (C), 144.9 (C), 142.6 (C), 132.8 (C), 132.6 (C), 129.8 (CH), 128.4 (CH), 127.7 (CH), 124.5 (C), 122.9 (CH), 108.5 (CH), 69.3 (CH<sub>2</sub>), 34.9 (CH<sub>2</sub>), 32.6 (CH<sub>2</sub>), 21.6 (CH<sub>3</sub>). LCMS: <i>m</i>/<i>z</i> (ESI 20 V) 332.2 (MH<sup>+</sup>, 65), 663.3 (2M – H<sup>+</sup>, 100).</div></div><div id="sec5_2_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> <i>N</i>-Methyl-2-(2-oxoindolin-4-yl)ethan-1-aminium Chloride</h4><div class="NLM_p last">2-(2-Oxoindolin-4-yl)ethyl 4-methylbenzenesulfonate (<b>26</b>) (1.00 g, 3.02 mmol) was suspended in 40% aqueous methylamine solution (10 mL) and stirred at 50 °C for 1.5 h before the reaction mixture was cooled down to rt and ethyl acetate was added. The solution was extracted twice with 1 M aqueous potassium carbonate solution. The organic layer was then twice extracted with 1 M aqueous hydrochloric acid solution. The water layer was evaporated, and the residue was suspended in CH<sub>3</sub>OH, filtered, and the filter cake dried on the high vacuum. The title compound (393 mg, 57%) was obtained as a yellow solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 10.43 (s, 1H), 9.08 (br s, 2H), 7.14 (t, <i>J</i> = 7.8 Hz, 1H), 6.82 (d, <i>J</i> = 7.4 Hz, 1H), 6.73 (d, <i>J</i> = 7.4 Hz, 1H), 3.52 (s, 2H), 3.08 (m, 2H), 2.87 (m, 2H), 2.54 (t, <i>J</i> = 5.4 Hz, 3H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ 176.6 (C), 144.2 (C), 133.6 (C), 128.3 (CH), 125.5 (C), 122.0 (CH), 108.2 (CH), 48.3 (CH<sub>2</sub>), 35.1 (CH<sub>2</sub>), 32.7 (CH<sub>3</sub>), 29.4 (CH<sub>2</sub>). LCMS: <i>m</i>/<i>z</i> (ESI 20 V) 191.2 (MH<sup>+</sup>, 100).</div></div><div id="sec5_2_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 4-(2-(Propylamino)ethyl)indolin-2-one Hydrochloride</h4><div class="NLM_p last">2-(2-Oxoindolin-4-yl)ethyl 4-methylbenzenesulfonate (<b>26</b>) (2.00 g, 60.4 mmol) was dissolved in propylamine (3.57 g, 60.4 mmol). The reaction mixture was stirred at reflux for 1.5 h then partitioned between ethyl acetate and 1 M aqueous potassium carbonate solution. The aqueous layer was removed, and the organic layer was extracted with 1 M aqueous hydrochloric acid solution. The aqueous layer was concentrated under reduced pressure, and the resultant residue suspended in CH<sub>3</sub>OH, then filtered and washed with additional CH<sub>3</sub>OH. The filter cake was dried on high vacuum overnight, affording the title compound (1.13 g, 74%) as a yellow solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 10.43 (s, 1H), 9.05 (br s, 2H), 7.14 (t, <i>J</i> = 7.7 Hz, 1H), 6.82 (d, <i>J</i> = 7.7 Hz, 1H), 6.73 (d, <i>J</i> = 7.7 Hz, 1H), 3.52 (s, 2H), 3.07 (m, 2H), 2.97–2.80 (m, 4H), 1.65 (m, 2H), 0.92 (t, <i>J</i> = 7.4 Hz, 3H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>): δ 176.1 (C), 143.7 (C), 133.2 (C), 127.8 (CH), 124.9 (C), 121.4 (CH), 107.7 (CH), 48.2 (CH<sub>2</sub>), 46.3 (CH<sub>2</sub>), 34.6 (CH<sub>2</sub>), 29.0 (CH<sub>2</sub>), 18.9 (CH<sub>2</sub>), 11.0 (CH<sub>3</sub>). LCMS: <i>m</i>/<i>z</i> (ESI 20 V) 219.2 (MH<sup>+</sup>, 100). HRMS (C<sub>13</sub>H<sub>18</sub>N<sub>2</sub>O): calcd, 219.1492 [M + H]<sup>+</sup>; found, 219.1497. HPLC: <i>t</i><sub>R</sub> 7.34 min, 98% (214 nm), 97% (254 nm).</div></div><div id="sec5_2_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 4-(2-(Methylamino)ethyl)indolin-2-one (<b>27a</b>)</h4><div class="NLM_p last"><i>N</i>-Methyl-2-(2-oxoindolin-4-yl)ethan-1-aminium chloride (380 mg, 1.68 mmol) was dissolved in 1 M aqueous sodium hydroxide solution (50 mL) and ethyl acetate (50 mL) and stirred at rt for 15 min. The layers were separated, and the water layer was extracted with ethyl acetate. The combined organic layers were dried with anhydrous sodium sulfate, filtered, and the solvent removed under reduced pressure. The title compound <b>27a</b> (172 mg, 54%) was obtained as a purple oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.13 (t, <i>J</i> = 7.8 Hz, 1H), 6.85 (d, <i>J</i> = 7.7 Hz, 1H), 6.73 (d, <i>J</i> = 7.7 Hz, 1H), 3.67 (s, 2H), 2.86 (m, 2H), 2.76 (m, 2H), 2.45 (s, 3H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 178.0 (C), 143.0 (C), 136.2 (C), 128.1 (CH), 124.3 (C), 122.5 (CH), 107.9 (CH), 51.5 (CH<sub>2</sub>), 36.2 (CH<sub>3</sub>), 35.2 (CH<sub>2</sub>), 33.2 (CH<sub>2</sub>). LCMS: <i>m</i>/<i>z</i> (ESI 20 V) 191.2 (MH<sup>+</sup>, 100).</div></div><div id="sec5_2_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 4-(2-(Propylamino)ethyl)indolin-2-one (<b>27b</b>)</h4><div class="NLM_p last">4-(2-(Propylamino)ethyl)indolin-2-one hydrochloride (1.00 g, 3.93 mmol) was dissolved in 1 M aqueous sodium hydroxide solution (100 mL) and stirred for 5 min. CH<sub>2</sub>Cl<sub>2</sub> (100 mL) was added, and the reaction mixture was stirred for another 15 min. The layers were separated, and the aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 × 50 mL). The combined organic layers were washed with water, dried with a phase separating funnel, and the solvent removed under reduced pressure to afford the title compound <b>27b</b> (788 mg, 92%) as a yellowish oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 9.08 (br s, 1H), 7.16 (t, <i>J</i> = 7.6 Hz, 1H), 6.87 (d, <i>J</i> = 8.0 Hz, 1H), 6.74 (d, <i>J</i> = 7.6 Hz, 1H), 3.49 (s, 2H), 2.89 (t, <i>J =</i> 7.2 Hz, 2H), 2.76 (t, <i>J</i> = 7.2 Hz, 2H), 2.61 (t, <i>J</i> = 7.2 Hz, 2H), 1.65 (br s, 1H), 1.49 (m, 2H), 0.90 (t, <i>J</i> = 7.6 Hz, 3H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 177.1 (C), 142.3 (C), 136.6 (C), 128.1 (CH), 124.2 (C), 122.7 (CH), 107.6 (CH), 51.8 (CH<sub>2</sub>), 49.6 (CH<sub>2</sub>), 35.1 (CH<sub>2</sub>), 33.7 (CH<sub>2</sub>), 23.2 (CH<sub>2</sub>), 12.0 (CH<sub>3</sub>). LCMS: <i>m</i>/<i>z</i> (ESI 20 V) 219.2 (MH<sup>+</sup>, 100).</div></div><div id="sec5_2_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 4-(2-((7-Amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-<i>a</i>][1,3,5]triazin-5 yl)(propyl)amino)ethyl)indolin-2-one (<b>29</b>)</h4><div class="NLM_p last">4-(2-(Propylamino)ethyl)indolin-2-one (<b>27b</b>) (95 mg, 435 μmol) was added to a suspension of 2-(furan-2-yl)-5-(methylsulfonyl)-[1,2,4]triazolo[1,5-<i>a</i>][1,3,5]triazin-7-amine (<b>28</b>) (61 mg, 218 μmol) in acetonitrile (4 mL). The reaction mixture was stirred at rt for 2.5 days before the solvent was removed under reduced pressure. Purification by column chromatography (ethyl acetate:petroleum spirits 8:2 → ethyl acetate) and preparative HPLC gave the title compound <b>29</b> (8 mg, 8%) as a white solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 10.35 (d, <i>J</i> = 7.6 Hz, 1H), 8.50–8.20 (2 × br s, ratio 1:1, 2H), 7.88 (m, 1H), 7.10 (m, 1H), 7.06 (m, 1H), 6.88 (dd, <i>J</i> = 18.8, 7.7 Hz, 1H), 6.72–6.64 (m, 2H), 3.71 (m, 2H), 3.53 (d, <i>J</i> = 4.4 Hz, 2H), 3.45 (m, 2H), 2.81 (m, 2H), 1.59 (m, 2H), 0.87 (q, <i>J</i> = 7.5 Hz, 3H). Some of the carbon atoms showed up twice due to rotameric forms. <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ 176.9 (C), 176.8 (C), 160.5 (2 × C), 156.6 (C), 156.5 (C), 150.5 (C), 146.7 (C), 145.1 (CH), 143.9 (C), 144.0 (C), 143.9 (C), 135.8 (C), 135.6 (C), 128.1 (CH), 127.9 (CH), 125.4 (C), 125.3 (C), 122.4 (CH), 122.2 (CH), 112.4 (CH), 112.2 (CH), 107.7 (CH), 107.6 (CH), 49.8 (CH<sub>2</sub>), 49.4 (CH<sub>2</sub>), 48.5 (CH<sub>2</sub>), 48.1 (CH<sub>2</sub>), 35.0 (CH<sub>2</sub>), 34.9 (CH<sub>2</sub>), 31.6 (CH<sub>2</sub>), 31.1 (CH<sub>2</sub>), 21.4 (CH<sub>2</sub>), 21.0 (CH<sub>2</sub>), 11.7 (CH<sub>3</sub>). LCMS: <i>m</i>/<i>z</i> (ESI 20 V) 419.3 (MH<sup>+</sup>, 100), 417.2 (MH<sup>–</sup>, 100). HPLC: <i>t</i><sub>R</sub> 6.22 min, 99% (214 nm), >99% (254 nm). HRMS (C<sub>21</sub>H<sub>22</sub>N<sub>8</sub>O<sub>2</sub>): calcd, 419.1944 [M + H]<sup>+</sup>; found, 419.1935; calcd, 441.1763 [M + Na]<sup>+</sup>; found, 441.1755.</div></div><div id="sec5_2_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> <i>tert</i>-Butyl (3-(Methyl(2-(2-oxoindolin-4-yl)ethyl)amino)propyl)carbamate (<b>30a</b>)</h4><div class="NLM_p last">4-(2-(Methylamino)ethyl)indolin-2-one (<b>27a</b>) (577 mg, 3.03 mmol), <i>tert</i>-butyl (3-bromopropyl)carbamate (722 mg, 3.03 mmol), and potassium carbonate (461 mg, 3.34 mmol) were dissolved in acetonitrile (25 mL). The reaction mixture was heated up to reflux and stirred for 3 h before it was cooled down to rt and the solvent was removed under reduced pressure. Purification by column chromatography (CH<sub>2</sub>Cl<sub>2</sub> → CH<sub>2</sub>Cl<sub>2</sub>:CH<sub>3</sub>OH 9:2) gave the title compound <b>30a</b> (482 mg, 46%) as a purple oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 9.67 (br s, 1H), 7.11 (t, <i>J</i> = 7.8 Hz, 1H), 6.81 (d, <i>J</i> = 7.7 Hz, 1H), 6.74 (d, <i>J</i> = 7.7 Hz, 1H), 5.29 (br s, 1H), 3.44 (s, 2H), 3.14 (m, 2H), 2.71 (m, 2H), 2.61 (m, 2H), 2.49 (t, <i>J</i> = 6.9 Hz, 2H), 2.31 (s, 3H), 1.66 (m, 2H), 1.42 (s, 9H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 177.9 (C), 156.2 (C), 142.9 (C), 136.3 (C), 128.0 (CH), 124.1 (C), 122.5 (CH), 107.9 (CH), 79.0 (C), 57.6 (CH<sub>2</sub>), 55.5 (CH<sub>2</sub>), 41.9 (CH<sub>3</sub>), 39.4 (CH<sub>2</sub>), 35.1 (CH<sub>2</sub>), 30.7 (CH<sub>2</sub>), 28.4 (CH<sub>3</sub>), 27.0 (CH<sub>2</sub>). LCMS: <i>m</i>/<i>z</i> (ESI 20 V) 348.3 (MH<sup>+</sup>, 100).</div></div><div id="sec5_2_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> <i>tert</i>-Butyl (3-((2-(2-Oxoindolin-4-yl)ethyl)(propyl)amino)propyl)carbamate (<b>30b</b>)</h4><div class="NLM_p last">4-(2-(Propylamino)ethyl)indolin-2-one (<b>27b</b>) (788 g, 3.61 mmol), <i>tert</i>-butyl (3-bromopropyl)carbamate (860 mg, 3.61 mmol), and potassium carbonate (549 mg, 3.97 mmol) were dissolved in acetonitrile (35 mL). The reaction mixture was heated to reflux and stirred for 19 h, cooled down to rt, and the solvent removed under reduced pressure. Purification by column chromatography (CH<sub>2</sub>Cl<sub>2</sub> → CH<sub>2</sub>Cl<sub>2</sub>:CH<sub>3</sub>OH 9:1) gave the title compound <b>30b</b> (522 mg, 38%) as a purple oil, which was immediately stored under N<sub>2</sub> to minimize decomposition. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 10.32 (s, 1H), 7.07 (t, <i>J</i> = 7.7 Hz, 1H), 6.77 (d, <i>J</i> = 7.1 Hz, 2H), 6.64 (d, <i>J</i> = 7.3 Hz, 1H), 3.44 (s, 2H), 2.93 (m, 2H), 2.59 (m, 4H), 2.45 (m, 2H), 2.40 (m, 2H), 1.50 (m, 2H), 1.41 (m, 2H), 1.37 (s, 9H), 0.83 (t, <i>J</i> = 7.3 Hz, 3H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ 176.2 (C), 155.5 (C), 143.4 (C), 136.5 (C), 127.4 (CH), 124.40 (C), 121.7 (CH), 106.8 (CH), 77.3 (C), 55.2 (CH<sub>2</sub>), 53.5 (CH<sub>2</sub>), 50.8 (CH<sub>2</sub>), 38.3 (CH<sub>2</sub>), 34.5 (CH<sub>2</sub>), 29.7 (CH<sub>2</sub>), 28.2 (CH<sub>3</sub>), 26.9 (CH<sub>2</sub>), 19.9 (CH<sub>2</sub>), 11.7 (CH<sub>3</sub>). LCMS: <i>m</i>/<i>z</i> (ESI 20 V) 376.5 (MH<sup>+</sup>, 100). HRMS (C<sub>21</sub>H<sub>33</sub>N<sub>3</sub>O<sub>3</sub>): calcd, 376.2595 [M + H]<sup>+</sup>; found, 376.2612. HPLC: <i>t</i><sub>R</sub> 4.88 min, 97% (214 nm), 97% (254 nm).</div></div><div id="sec5_2_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> <i>tert</i>-Butyl (6-((2-(2-Oxoindolin-4-yl)ethyl)(propyl)amino)hexyl)carbamate (<b>30c</b>)</h4><div class="NLM_p last">4-(2-(Propylamino)ethyl)indolin-2-one (<b>27b</b>) (405 mg, 1.86 mmol), <i>tert</i>-butyl (6-bromohexyl)carbamate (520 mg, 1.86 mmol), and potassium carbonate (282 mg, 2.04 mmol) were dissolved in acetonitrile (20 mL). The reaction mixture was heated up to reflux and stirred for 18 h before it was cooled down to rt and the solvent removed under reduced pressure. Purification by column chromatography (CH<sub>2</sub>Cl<sub>2</sub> → CH<sub>2</sub>Cl<sub>2</sub>:CH<sub>3</sub>OH 9:1) gave the title compound <b>30c</b> (371 mg, 48%) as a purple oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.85 (br s, 1H), 7.16 (t, <i>J</i> = 7.8 Hz, 1H), 6.85 (d, <i>J</i> = 7.8 Hz, 1H), 6.78 (d, <i>J</i> = 7.7 Hz, 1H), 4.62 (br s, 1H), 3.50 (s, 2H), 3.11 (m, 2H), 2.82 (m, 4H), 2.62 (m, 4H), 1.65–1.45 (m, 6H), 1.48 (s, 9H), 1.38–1.24 (m, 4H), 0.93 (t, <i>J</i> = 7.4 Hz, 3H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 177.7 (C), 156.1 (C), 142.9 (C), 136.2 (C), 128.0 (CH), 124.1 (C), 122.5 (CH), 107.9 (CH), 78.9 (C), 55.7 (CH<sub>2</sub>), 53.9 (CH<sub>2</sub>), 53.7 (CH<sub>2</sub>), 40.4 (CH<sub>2</sub>), 35.2 (CH<sub>2</sub>), 30.1 (CH<sub>2</sub>), 30.0 (CH<sub>2</sub>), 28.4 (CH<sub>3</sub>), 27.03 (CH<sub>2</sub>), 26.6 (CH<sub>2</sub>), 26.3 (CH<sub>2</sub>), 19.60 (CH<sub>2</sub>), 11.8 (CH<sub>3</sub>). LCMS: <i>m</i>/<i>z</i> (ESI 20 V) 418.4 (MH<sup>+</sup>, 100).</div></div><div id="sec5_2_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 4-(2-((3-Aminopropyl)(methyl)amino)ethyl)indolin-2-one (<b>31a</b>)</h4><div class="NLM_p last">Trifluoroacetic acid (3 mL) was added to solution of <i>tert</i>-butyl (3-(methyl(2-(2-oxoindolin-4-yl)ethyl)amino)propyl)carbamate (<b>30a</b>) (450 mg, 1.3 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (20 mL). The reaction mixture was stirred at rt for 1 h before the solvent was removed under reduced pressure. The residue was diluted with CH<sub>2</sub>Cl<sub>2</sub>, and 1 M aqueous sodium hydroxide solution was added until pH 14. The water layer was extracted with CH<sub>2</sub>Cl<sub>2</sub>, then the combined organic layers were dried with anhydrous sodium sulfate, filtered, and the solvent removed under reduced pressure. The title compound <b>31a</b> (138 mg, 43%) was obtained as a yellow oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.15 (t, <i>J</i> = 7.8 Hz, 1H), 6.84 (d, <i>J</i> = 7.8 Hz, 1H), 6.77 (d, <i>J</i> = 7.7 Hz, 1H), 3.50 (s, 2H), 2.84 (t, <i>J</i> = 6.3 Hz, 2H), 2.72 (m, 2H), 2.63 (m, 2H), 2.54 (t, <i>J</i> = 6.6 Hz, 2H), 2.34 (s, 3H), 1.69 (m, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 177.7 (C), 142.8 (C), 136.5 (C), 128.1 (CH), 124.2 (C), 122.6 (CH), 108.0 (CH), 57.5 (CH<sub>2</sub>), 56.6 (CH<sub>2</sub>), 41.9 (CH<sub>3</sub>), 40.7 (CH<sub>2</sub>), 35.2 (CH<sub>2</sub>), 30.9 (CH<sub>2</sub>), 27.9 (CH<sub>2</sub>). LCMS: <i>m</i>/<i>z</i> (ESI 20 V) 248.2 (MH<sup>+</sup>, 100).</div></div><div id="sec5_2_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> 4-(2-((3-Aminopropyl)(propyl)amino)ethyl)indolin-2-one (<b>5</b>)</h4><div class="NLM_p last">To a stirred solution of <i>tert</i>-butyl (3-((2-(2-oxoindolin-4-yl)ethyl)(propyl)amino)propyl) carbamate (<b>30b</b>) (250 mg, 666 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (20 mL). The reaction mixture was stirred at rt for 1 h before the solvent was removed under reduced pressure. The residue was diluted with CH<sub>2</sub>Cl<sub>2</sub>, and 1 M aqueous sodium hydroxide solution was added until pH 14. The water layer was extracted with CH<sub>2</sub>Cl<sub>2</sub>, then the combined organic layers were dried with anhydrous sodium sulfate, filtered, and the solvent removed under reduced pressure. The title compound <b>5</b> (154 mg, 84%) was obtained as a yellow oil. Because of instability, the title compound <b>5</b> was stored in the fridge. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 9.50–7.80 (br s, 1H), 7.14 (t, <i>J</i> = 7.7 Hz, 1H), 6.84 (d, <i>J</i> = 7.7 Hz, 1H), 6.71 (d, <i>J</i> = 7.7 Hz, 1H), 3.48 (s, 2H), 2.72 (t, <i>J</i> = 6.8 Hz, 2H), 2.56, (m, 4H), 2.54 (m, 2H), 2.43 (m, 2H), 1.20–2.20 (br s, 2H), 1.60 (m, 2H), 1.45 (m, 2H), 0.88 (t, <i>J</i> = 7.6 Hz, 3H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 177.8 (C), 142.6 (C), 136.9 (C), 128.0 (CH), 124.1 (C), 122.8 (CH), 107.7 (CH), 56.0 (CH<sub>2</sub>), 54.0 (CH<sub>2</sub>), 52.3 (CH<sub>2</sub>), 40.7 (CH<sub>2</sub>), 35.1 (CH<sub>2</sub>), 30.6 (CH<sub>2</sub>), 29.7 (CH<sub>2</sub>), 20.2 (CH<sub>2</sub>), 11.9 (CH<sub>3</sub>). LCMS: <i>m</i>/<i>z</i> (ESI 20 V) 276.3 (MH<sup>+</sup>, 100). HRMS (C<sub>16</sub>H<sub>25</sub>N<sub>3</sub>O): calcd, 276.2070 [M + H]<sup>+</sup>; found, 276.2080. HPLC: <i>t</i><sub>R</sub> 4.52 min, 95% (214 nm), 98% (254 nm).</div></div><div id="sec5_2_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> 4-(2-((6-Aminohexyl)(propyl)amino)ethyl)indolin-2-one (<b>31c</b>)</h4><div class="NLM_p last">Trifluoroacetic acid (3 mL) was added to solution of <i>tert</i>-butyl (6-((2-(2-oxoindolin-4-yl)ethyl)(propyl)amino)hexyl)carbamate (<b>30c</b>) (371 mg, 888 μmol) in CH<sub>2</sub>Cl<sub>2</sub> (20 mL). The reaction mixture was stirred at rt for 1 h before the solvent was removed under reduced pressure. The residue was diluted with CH<sub>2</sub>Cl<sub>2</sub>, and 1 M aqueous sodium hydroxide solution was added until pH 14. The water layer was extracted with CH<sub>2</sub>Cl<sub>2</sub>, then the combined organic layers were dried with anhydrous sodium sulfate, filtered, and the solvent removed under reduced pressure. The title compound <b>31c</b> (245 mg, 87%) was obtained as a yellow oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.14 (t, <i>J</i> = 7.8 Hz, 1H), 6.84 (d, <i>J</i> = 7.8 Hz, 1H), 6.76 (d, <i>J</i> = 7.6 Hz, 1H), 3.49 (s, 2H), 2.75 (m, 2H), 2.66 (m, 4H), 2.49–2.38 (m, 4H), 1.54–1.17 (m, 10H), 0.89 (t, <i>J</i> = 7.4 Hz, 3H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 178.0 (C), 143.0 (C), 137.1 (C), 127.9 (CH), 124.2 (C), 122.6 (CH), 107.6 (CH), 56.1 (CH<sub>2</sub>), 54.2 (CH<sub>2</sub>), 54.1 (CH<sub>2</sub>), 41.8 (CH<sub>2</sub>), 35.3 (CH<sub>2</sub>), 33.3 (CH<sub>2</sub>), 30.8 (CH<sub>2</sub>), 27.4 (CH<sub>2</sub>), 27.1 (CH<sub>2</sub>), 26.8 (CH<sub>2</sub>), 20.2 (CH<sub>2</sub>), 12.0 (CH<sub>3</sub>). LCMS: <i>m</i>/<i>z</i> (ESI 20 V) 318.3 (MH<sup>+</sup>, 100).</div></div><div id="sec5_2_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> 4-(2-((3-((7-Amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-<i>a</i>][1,3,5]triazin-5-yl)amino)propyl)(methyl)amino) ethyl)indolin-2-one (<b>32a</b>)</h4><div class="NLM_p last">4-(2-((3-Aminopropyl)(methyl)amino)ethyl)indolin-2-one (<b>31a</b>) (138 mg, 558 μmol) was added to a suspension of 2-(furan-2-yl)-5-(methylsulfonyl)-[1,2,4]triazolo[1,5-<i>a</i>][1,3,5]triazin-7-amine (<b>28</b>) (78 mg, 279 μmol) in acetonitrile (2 mL) and toluene (2 mL). The reaction mixture was stirred at rt for 1.5 h before another portion of 2-(furan-2-yl)-5-(methylsulfonyl)-[1,2,4]triazolo[1,5-<i>a</i>][1,3,5]triazin-7-amine (<b>28</b>) (20 mg, 71 μmol) was added. The reaction mixture was stirred for another 16.5 h before the solvent was removed under reduced pressure. Purification by column chromatography (CH<sub>2</sub>Cl<sub>2</sub>:CH<sub>3</sub>OH 8:2 → CH<sub>2</sub>Cl<sub>2</sub>:CH<sub>3</sub>OH 8:4). Then the product was taken up in ethyl acetate and washed with 1 M aqueous potassium carbonate solution. The organic layer was dried with anhydrous sodium sulfate, filtered, and the solvent removed under reduced pressure. The title compound <b>32a</b> (29 mg, 23%) was obtained as a white foam. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 10.30 (br s, 1H), 8. 50–7.9 (2 × br s, ratio 1:6, 2H), 7.86 (m, 1H), 7.52–7.37 (2 × br t, ratio 1:2, <i>J</i> = 5.6 Hz, 1H), 7.10–7.00 (m, 2H), 6.79 (d, <i>J</i> = 7.7 Hz, 1H), 6.68 (m, 1H), 6.63 (d, <i>J</i> = 7.5 Hz, 1H), 3.43 (s, 2H), 3.28 (m, 2H), 2.63 (m, 2H), 2.53 (m, 2H), 2.42 (m, 2H), 2.23 (s, 3H), 1.66 (m, 2H). Some of the <sup>13</sup>C signal show up twice, and the signal with lower intensity is marked with an asterisk (*). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ 176.8 (C), 161.6 (C), 159.7 (C), 156.3 (C), 151.1 (C*),150.4 (C), 146.7 (C), 145.1 (CH), 143.9 (C), 136.9 (C), 127.9 (CH), 125.0 (C), 122.2 (CH), 112.4 (CH), 112.0 (CH), 107.4 (CH), 57.6 (CH<sub>2</sub>), 55.4 (CH<sub>2</sub>*), 55.0 (CH<sub>2</sub>), 42.1 (CH<sub>3</sub>), 39.5 (CH<sub>2</sub>), 35.0 (CH<sub>2</sub>), 30.5 (CH<sub>2</sub>), 27.3 (CH<sub>2</sub>*), 26.9 (CH<sub>2</sub>). LCMS: <i>m</i>/<i>z</i> (ESI 20 V) 448.3 (MH<sup>+</sup>, 100). HPLC: <i>t</i><sub>R</sub> 4.31 min, 95% (214 nm), 95% (254 nm). HRMS (C<sub>22</sub>H<sub>25</sub>N<sub>9</sub>O<sub>2</sub>): calcd, 448.2209 [M + H]<sup>+</sup>; found, 448.2214.</div></div><div id="sec5_2_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> 4-(2-((3-((7-Amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-<i>a</i>][1,3,5]triazin-5-yl)amino)propyl)(propyl)amino)ethyl)indolin-2-one (<b>32b</b>)</h4><div class="NLM_p last">4-(2-((3-Aminopropyl)(propyl)amino)ethyl)indolin-2-one (<b>5</b>) (50 mg, 182 μmol) was added to a suspension of 2-(furan-2-yl)-5-(methylsulfonyl)-[1,2,4]triazolo[1,5-<i>a</i>][1,3,5]triazin-7-amine (<b>28</b>) (25.4 mg, 90.8 μmol) in acetonitrile (2 mL) and toluene (2 mL). The reaction mixture was stirred at rt for 5 h before the solvent was removed under reduced pressure. Purification by column chromatography (CH<sub>2</sub>Cl<sub>2</sub> → CH<sub>2</sub>Cl<sub>2</sub>:CH<sub>3</sub>OH 7:3) gave the title compound <b>32b</b> (28 mg, 65%) as a purplish-white solid, mp 148–150 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 10.32 (s, 1H), 8.5–7.90 (2 × br s, ratio 1:6, 2H), 7.86 (m, 1H), 7.54–7.39 (2 × br t, ratio 1:2, <i>J</i> = 5.4 Hz, 1H), 7.10–7.03 (m, 2H), 6.77 (m, 1H), 6.67 (m, 1H), 6.63 (m, 1H), 3.46 (s, 2H), 3.30 (m, 2H), 2.61 (s, 4H), 2.53 (m, 2H), 2.41 (m, 2H), 1.68 (m, 2H), 1.41 (m, 2H), 0.84 (t, <i>J</i> = 7.3 Hz, 3H). Some of the <sup>13</sup>C signal show up twice, and the signal with lower intensity is marked with an asterisk (*). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ 176.2 (C), 161.1 (C), 159.2 (C), 155.8 (C), 149.9 (C), 146.2 (C), 144.5 (CH), 143.4 (C), 136.6 (C), 127.4 (C), 124.4 (CH), 121.8 (CH), 111.9 (CH), 111.5 (CH), 106.8 (CH), 55.3 (CH<sub>2</sub>), 53.6 (CH<sub>2</sub>), 51.1 (CH<sub>2</sub>), 39.1 (CH<sub>2</sub>), 34.5 (CH<sub>2</sub>), 29.9 (CH<sub>2</sub>), 26.8 (CH<sub>2</sub>*), 26.4 (CH<sub>2</sub>), 20.0 (CH<sub>2</sub>), 11.8 (CH<sub>3</sub>). LCMS: <i>m</i>/<i>z</i> (ESI 20 V) 476.3 (MH<sup>+</sup>, 100). HPLC: <i>t</i><sub>R</sub> 6.72 min, >99% (214 nm), >99% (254 nm). HRMS (C<sub>24</sub>H<sub>29</sub>N<sub>9</sub>O<sub>2</sub>): calcd, 476.2522 [M + H]<sup>+</sup>; found, 476.2518.</div></div><div id="sec5_2_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 4-(2-((6-((7-Amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-<i>a</i>][1,3,5]triazin-5-yl)amino)hexyl)(propyl)amino)ethyl)indolin-2-one (<b>32c</b>)</h4><div class="NLM_p last">4-(2-((6-Aminohexyl)(propyl)amino)ethyl)indolin-2-one (<b>31c</b>) (245 mg, 772 μmol) was added to a suspension of 2-(furan-2-yl)-5-(methylsulfonyl)-[1,2,4]triazolo[1,5-<i>a</i>][1,3,5]triazin-7-amine (<b>28</b>) (108 mg, 386 μmol) in acetonitrile (2 mL) and toluene (2 mL). The reaction mixture was stirred at rt for 1.5 h before another portion of 2-(furan-2-yl)-5-(methylsulfonyl)-[1,2,4]triazolo[1,5-<i>a</i>][1,3,5]triazin-7-amine (<b>28</b>) (20 mg, 71 μmol) was added. The reaction mixture was stirred for another 2.5 days before the solvent was removed under reduced pressure. Purification by column chromatography (CH<sub>2</sub>Cl<sub>2</sub> → CH<sub>2</sub>Cl<sub>2</sub>:CH<sub>3</sub>OH 8:2) gave the title compound <b>32c</b> (126 mg, 63%) as a beige foam. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 10.32 (s, 1H), 8.50–7.9 (2 × br s, ratio 1:6, 2H), 7.86 (m, 1H), 7.52–7.38 (2 × br t, <i>J</i> = 5.7 Hz, 1H), 7.07 (t, <i>J</i> = 7.8 Hz, 1H), 7.03 (d, <i>J</i> = 3.3 Hz, 1H), 6.77 (d, <i>J</i> = 7.7 Hz, 1H), 6.67 (dd, <i>J</i> = 3.2, 1.7 Hz, 1H), 6.64 (d, <i>J</i> = 7.7 Hz, 1H), 3.45 (s, 2H), 3.25 (m, 2H), 2.61 (m, 4H), 2.45 (m, 4H), 1.51 (m, 2H), 1.40 (m, 4H), 1.28 (m, 4H), 0.82 (t, <i>J</i> = 7.3 Hz, 3H). Some of the <sup>13</sup>C signal show up twice, and the signal with lower intensity is marked with an asterisk (*). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ 176.7 (C), 162.0 (C*), 161.6 (C), 159.7 (C), 156.6 (C*), 156.3 (C), 151.1 (C), 150.4 (C), 146.7 (C), 145.1 (CH), 143.9 (C), 125.0 (C), 127.9 (CH), 122.3 (CH), 112.4 (CH), 122.0 (CH), 107.4 (CH), 55.6 (CH<sub>2</sub>), 54.0 (CH<sub>2</sub>), 53.5 (CH<sub>2</sub>), 41.4 (CH<sub>2</sub>), 41.0 (CH<sub>2</sub>), 35.0 (CH<sub>2</sub>), 30.2 (CH<sub>2</sub>), 29.7 (CH<sub>2</sub>*), 29.3 (CH<sub>2</sub>), 27.1 (CH<sub>2</sub>), 26.8 (CH<sub>2</sub>), 20.2 (CH<sub>2</sub>), 12.2 (CH<sub>3</sub>). LCMS: <i>m</i>/<i>z</i> (ESI 20 V) 518.3 (MH<sup>+</sup>, 100). HPLC: <i>t</i><sub>R</sub> 5.08 min, 98% (214 nm), 98% (254 nm). HRMS (C<sub>27</sub>H<sub>35</sub>N<sub>9</sub>O<sub>2</sub>): calcd, 518.2992 [M + H]<sup>+</sup>; found, 518.2980.</div></div><div id="sec5_2_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> <i>tert</i>-Butyl 4-((7-Amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-<i>a</i>][1,3,5]triazin-5-yl)amino)piperidine-1-carboxylate (<b>33</b>)</h4><div class="NLM_p last"><i>tert</i>-Butyl 4-aminopiperidine-1-carboxylate (750 mg, 3.74 mmol) was added to a suspension of 2-(furan-2-yl)-5-(methylsulfonyl)-[1,2,4]triazolo[1,5-<i>a</i>][1,3,5]triazin-7-amine (<b>28</b>) (350 mg, 1.25 μmol) in acetonitrile (10 mL). The reaction mixture was stirred at rt for 3 h before the solvent was removed under reduced pressure. Purification by column chromatography (ethyl acetate 100%) gave the title compound <b>33</b> (316 mg, 63%) as a beige solid, mp 220–223 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 8.60–7.90 (2 × br s, ratio 1:5, 2H), 7.87 (m, 1H), 7.55–7.38 (2 × d, ratio 1:2, <i>J</i> = 8.0 Hz, 1H), 7.05 (m, 1H), 6.68 (m, 1H), 3.93 (m, 3H), 2.84 (m, 2H), 1.83 (m, 2H), 1.41 (s, 9H), 1.36 (m, 2H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ 160.9 (C), 159.6 (C), 156.3 (C), 154.3 (C), 150.5 (C), 146.6 (C), 145.1 (CH), 112.4 (CH), 112.1 (CH), 79.1 (C), 48.1 (CH), 42.7 (CH<sub>2</sub>), 31.6 (CH<sub>2</sub>), 28.6 (CH<sub>3</sub>). LCMS: <i>m</i>/<i>z</i> (ESI 20 V) 401.3 (MH<sup>+</sup>, 100), 399.2 (MH<sup>–</sup>, 100). HPLC: <i>t</i><sub>R</sub> 6.09 min, 97% (214 nm), 97% (254 nm). HRMS (C<sub>18</sub>H<sub>24</sub>N<sub>8</sub>O<sub>3</sub>): calcd, 401.2050 [M + H]<sup>+</sup>; found, 401.2050.</div></div><div id="sec5_2_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> 2-(Furan-2-yl)-<i>N</i><sup>5</sup>-(piperidin-4-yl)-[1,2,4]triazolo[1,5-<i>a</i>][1,3,5]triazine-5,7-diamine (<b>34</b>)</h4><div class="NLM_p last"><i>tert</i>-Butyl 4-((7-amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-<i>a</i>][1,3,5]triazin-5-yl)amino)piperidine-1-carboxylate (<b>33</b>) (325 mg, 812 μmol) was dissolved in trifluoroacetic acid (1 mL) and CH<sub>2</sub>Cl<sub>2</sub> (5 mL) and was stirred for 2 h at rt. The reaction mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub> (50 mL), and then 1 M aqueous sodium hydroxide solution was added until pH 14. 2-Propanol was added to get the product into the organic layer. The layers were separated, and the organic layer was dried with anhydrous sodium sulfate, filtered, and the solvent removed under reduced pressure. The title compound <b>34</b> (114 mg, 47%) was obtained as a white solid, mp 208 °C dec. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 8.26 (2 × br s, ratio 1:6, 2H), 7.87 (m, 1H), 7.44 (2 × d, ratio 1:2, <i>J</i> = 8.0 Hz, 1H), 7.04 (m, 1H), 6.68 (m, 1H), 3.77 (m, 1H), 2.96 (m, 2H), 2.50 (m, 2H), 1.78 (m, 2H), 1.34 (m, 2H). Some of the <sup>13</sup>C signal show up twice, and the signal with lower intensity is marked with an asterisk (*). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ 160.8 (C), 159.7 (C), 156.3 (C), 150.5 (C), 146.7 (C), 145.1 (CH), 112.4 (CH), 112.1 (CH), 49.0 (CH*), 48.8 (CH), 45.6 (CH<sub>2</sub>), 33.5 (CH<sub>2</sub>*), 33.0 (CH<sub>2</sub>). LCMS: <i>m</i>/<i>z</i> (ESI 20 V) 301.2 (MH<sup>+</sup>, 100), 299.2 (MH<sup>–</sup>, 100).</div></div><div id="sec5_2_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> <i>tert</i>-Butyl (1-(2-(2-Oxoindolin-4-yl)ethyl)piperidin-4-yl)carbamate (<b>35</b>)</h4><div class="NLM_p last"><i>tert</i>-Butyl piperidin-4-ylcarbamate (755 mg, 3.77 mmol) and diisopropylethylamine (770 μL, 4.53 mmol) was added to a solution of 2-(2-oxoindolin-4-yl)ethyl 4-methylbenzenesulfonate (<b>26</b>) (500 mg, 1.51 mmol) in acetonitrile (20 mL). The reaction mixture was stirred at reflux for 6 h before the solvent was removed under reduced pressure. The residue was taken up in CH<sub>2</sub>Cl<sub>2</sub> and washed with water. The organic layer was dried with anhydrous sodium sulfate, filtered, and the solvent removed under reduced pressure. The crude material was purified by column chromatography (ethyl acetate 100% → ethyl acetate:CH<sub>3</sub>OH 8:2). The title compound <b>35</b> (183 mg, 34%) was obtained as a yellow solid, mp 192–194 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.67 (br s, 1H), 7.15 (t, <i>J</i> = 7.8 Hz, 1H), 6.85 (d, <i>J</i> = 7.7 Hz, 1H), 6.73 (d, <i>J</i> = 7.6 Hz, 1H), 4.50 (d, <i>J</i> = 7.9 Hz, 1H), 3.48 (m, 3H), 2.92 (m, 2H), 2.74 (m, 2H), 2.57 (m, 2H), 2.16 (t, <i>J</i> = 10.9 Hz, 2H), 1.97 (m, 2H), 1.48 (m, 2H), 1.45 (s, 9H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 177.3 (C), 155.2 (C), 142.4 (C), 136.7 (C), 128.1 (CH), 124.1 (C), 122.7 (CH), 107.6 (CH), 79.3 (C), 58.6 (CH<sub>2</sub>), 52.5 (CH<sub>2</sub>), 47.7 (CH), 35.1 (CH<sub>2</sub>), 32.5 (CH<sub>2</sub>), 30.9 (CH<sub>2</sub>), 28.4 (CH<sub>3</sub>). LCMS: <i>m</i>/<i>z</i> (ESI 20 V) 360.3 (MH<sup>+</sup>, 100). HPLC: <i>t</i><sub>R</sub> 4.92 min, 96% (214 nm), 99% (254 nm). HRMS (C<sub>20</sub>H<sub>29</sub>N<sub>3</sub>O<sub>3</sub>): calcd 360.2287 [M + H]<sup>+</sup>; found, 360.2277.</div></div><div id="sec5_2_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> 4-(2-(4-Aminopiperidin-1-yl)ethyl)indolin-2-one (<b>36</b>)</h4><div class="NLM_p last"><i>tert</i>-Butyl (1-(2-(2-oxoindolin-4-yl)ethyl)piperidin-4-yl)carbamate (<b>36</b>) (170 mg, 473 μmol) was dissolved in trifluoroacetic acid (3 mL) and CH<sub>2</sub>Cl<sub>2</sub> (10 mL) and stirred at rt for 2 h. The reaction mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub> (20 mL), and then 1 M aqueous sodium hydroxide solution was added until pH 14. The layers were separated, and the water layer was dried under reduced pressure. The residue was taken up in CH<sub>2</sub>Cl<sub>2</sub> and CH<sub>3</sub>OH and purified by column chromatography (CH<sub>2</sub>Cl<sub>2</sub> 100% → CH<sub>3</sub>OH 100%). The title compound <b>36</b> (57 mg, 46%) was obtained a as purple oil. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 10.39 (s, 1H), 7.07 (t, <i>J</i> = 7.7 Hz, 1H), 6.77 (d, <i>J</i> = 7.8 Hz, 1H), 6.64 (d, <i>J</i> = 7.7 Hz, 1H), 4.70–4.40 (br s, 2H), 3.43 (s, 2H), 3.17 (m, 1H), 2.82 (m, 2H), 2.62 (m, 2H), 2.44 (m, 2H), 1.95 (m, 2H), 1.68 (m, 2H), 1.22 (m, 2H). LCMS: <i>m</i>/<i>z</i> (ESI 20 V) 260.2 (MH<sup>+</sup>, 100). HPLC: <i>t</i><sub>R</sub> 2.78 min, 83% (214 nm), >93% (254 nm). HRMS (C<sub>15</sub>H<sub>21</sub>N<sub>3</sub>O): calcd, 260.1763 [M + H]<sup>+</sup>; found, 260.1754.</div></div><div id="sec5_2_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> 4-(2-(4-((7-Amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-<i>a</i>][1,3,5]triazin-5-yl)amino)piperidin-1-yl)ethyl)indolin-2-one (<b>37</b>)</h4><div class="NLM_p last">4-(2-(4-Aminopiperidin-1-yl)ethyl)indolin-2-one (<b>36</b>) (50 mg, 193 μmol) was added to a suspension of 2-(furan-2-yl)-5-(methylsulfonyl)-[1,2,4]triazolo[1,5-<i>a</i>][1,3,5]triazin-7-amine (<b>29</b>) (45 mg, 161 μmol) in acetonitrile (3 mL) and DMF (3 mL). The reaction mixture was stirred at rt for 22 h before the solvent was removed under reduced pressure. Purification by column chromatography (CH<sub>2</sub>Cl<sub>2</sub> → CH<sub>2</sub>Cl<sub>2</sub>:CH<sub>3</sub>OH 8:2) gave the title compound <b>37</b> (36 mg, 49%) as a white solid, mp 267–276 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 10.36 (s, 1H), 8.55–7.95 (2 × br s, ratio 1:5, 2H), 7.87 (m, 1H), 7.52–7.35 (2 × d, ratio 1:2, <i>J</i> = 7.4 Hz, 1H), 7.10 (t, <i>J</i> = 7.7 Hz, 1H), 7.05 (m, 1H), 6.80 (d, <i>J</i> = 7.7 Hz, 1H), 6.70–6.64 (m, 2H), 3.79 (m, 1H), 3.48 (s, 2H), 3.02 (m, 2H), 2.71 (m, 2H), 2.60 (m, 2H), 2.30–1.98 (m, 2H), 1.89 (m, 2H), 1.57 (m, 2H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ 176.8 (C), 161.4 (C), 161.0 (C), 159.6 (C), 156.3 (C), 150.5 (C), 146.7 (C), 145.1 (CH), 143.9 (C), 128.0 (CH), 125.09 (C), 122.1 (CH), 112.4 (CH), 112.1 (CH), 107.5 (CH), 58.0 (CH<sub>2</sub>), 52.3 (CH<sub>2</sub>), 48.0 (CH), 34.9 (CH<sub>2</sub>), 31.4 (CH<sub>2</sub>), 30.2 (CH<sub>2</sub>). LCMS: <i>m</i>/<i>z</i> (ESI 20 V) 460.3 (MH<sup>+</sup>, 100). HPLC: <i>t</i><sub>R</sub> 4.43 min, 98% (214 nm), 97% (254 nm). HRMS (C<sub>23</sub>H<sub>26</sub>N<sub>9</sub>O<sub>2</sub>): calcd, 460.2209 [M + H]<sup>+</sup>; found, 460.2195.</div></div><div id="sec5_2_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> <i>tert</i>-Butyl 4-(2-(2-Oxoindolin-4-yl)ethyl)piperazine-1-carboxylate (<b>38a</b>)</h4><div class="NLM_p last">Boc-piperazine (674 mg, 3.62 mmol) and diisopropylethylamine (1.54 mL, 9.05 mmol) were added to a solution of 2-(2-oxoindolin-4-yl)ethyl 4-methylbenzenesulfonate (<b>26</b>) ((1.00 g, 3.02 mmol) in acetonitrile (40 mL). The reaction mixture was stirred at reflux for 5 h before another 1.2 equiv of Boc-piperazine (674 mg, 3.62 mmol) was added. The reaction mixture was stirred for an additional 17 h, then solvent was removed under reduced pressure. The residue was taken up in CH<sub>2</sub>Cl<sub>2</sub> and washed with water. The organic layer was dried with anhydrous sodium sulfate, filtered, and the solvent removed under reduced pressure. The crude material was purified by column chromatography (ethyl acetate 100% → ethyl acetate:CH<sub>3</sub>OH 8:2) to give the title compound <b>38a</b> (778 mg, 75%) as an orange foam. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.74 (br s, 1H), 7.16 (t, <i>J</i> = 7.8 Hz, 1H), 6.86 (d, <i>J</i> = 7.7 Hz, 1H), 6.75 (d, <i>J</i> = 7.7 Hz, 1H), 3.50–3.42 (m, 6H), 2.75 (m, 2H), 2.60 (m, 2H), 2.48 (m, 4H), 1.47 (s, 9H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ 176.8 (C), 143.9 (C), 137.1 (C), 127.9 (CH), 125.0 (C), 122.2 (CH), 59.3 (CH<sub>2</sub>), 54.6 (CH<sub>2</sub>), 46.1 (CH<sub>2</sub>), 35.0 (CH<sub>2</sub>), 30.3 (CH<sub>2</sub>). LCMS: <i>m</i>/<i>z</i> (ESI 20 V) 346.2 (MH<sup>+</sup>, 100), 344.2 (MH<sup>–</sup>, 100). HPLC: <i>t</i><sub>R</sub> 6.40 min, 97% (214 nm), 98% (254 nm). HRMS (C<sub>19</sub>H<sub>27</sub>N<sub>3</sub>O<sub>3</sub>): calcd, 346.2131 [M + H]<sup>+</sup>; found, 346.2129.</div></div><div id="sec5_2_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> <i>tert</i>-Butyl 4-(2-(2-Oxoindolin-4-yl)ethyl)-1,4-diazepane-1-carboxylate (<b>38b</b>)</h4><div class="NLM_p last">Boc-homopiperazine (1.45 mg, 7.24 mmol) and DIPEA (1.54 mL, 9.05 mmol) were added to a solution of 2-(2-oxoindolin-4-yl)ethyl 4-methylbenzenesulfonate (<b>26</b>) (1.00 g, 3.02 mmol) in acetonitrile (40 mL). The reaction mixture was stirred at reflux for 23 h before solvent was removed under reduced pressure. The residue was taken up in CH<sub>2</sub>Cl<sub>2</sub> and washed with water, then the organic layer was dried with anhydrous sodium sulfate, filtered, and the solvent removed under reduced pressure. The crude material was purified by column chromatography (ethyl acetate 100% → ethyl acetate:CH<sub>3</sub>OH 8:2) to give the title compound <b>38b</b> (799 mg, 74%) as an orange foam. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.95 (br d, <i>J</i> = 8.3 Hz, 1H), 7.15 (t, <i>J</i> = 7.7 Hz, 1H), 6.85 (d, <i>J</i> = 7.8 Hz, 1H), 6.75 (dd, <i>J</i> = 7.7, 2.1 Hz, 1H), 3.57–3.40 (m, 6H), 2.80–2.65 (m, 8H), 1.86 (m, 2H), 1.47 (s, 9H). Some of the carbon atoms showed up twice due to rotameric forms. <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 177.51 (C), 155.7 (C), 155.5 (C), 142.5 (C), 136.7 (C), 128.1 (CH), 124.0 (C), 122.8 (CH), 107.7 (CH), 107.6 (CH), 79.4 (C), 57.9 (CH<sub>2</sub>), 56.0 (CH<sub>2</sub>), 55.9 (CH<sub>2</sub>), 54.8 (CH<sub>2</sub>), 54.6 (CH<sub>2</sub>), 46.7 (CH<sub>2</sub>), 46.0 (CH<sub>2</sub>), 45.9 (CH<sub>2</sub>), 45.0 (CH<sub>2</sub>), 35.1 (CH<sub>2</sub>), 31.2 (CH<sub>2</sub>), 31.1 (CH<sub>2</sub>), 28.5 (CH<sub>3</sub>), 27.8 (CH<sub>2</sub>), 27.7 (CH<sub>2</sub>). LCMS: <i>m</i>/<i>z</i> (ESI 20 V) 360.3 (MH<sup>+</sup>, 100). HPLC: <i>t</i><sub>R</sub> 6.67 min, 95% (214 nm), >99% (254 nm). HRMS (C<sub>20</sub>H<sub>29</sub>N<sub>3</sub>O<sub>3</sub>): calcd, 360.2287 [M + H]<sup>+</sup>; found, 360.2283.</div></div><div id="sec5_2_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> 4-(2-(Piperazin-1-yl)ethyl)indolin-2-one (<b>39a</b>)</h4><div class="NLM_p last"><i>tert</i>-Butyl 4-(2-(2-oxoindolin-4-yl)ethyl)piperazine-1-carboxylate (<b>38a</b>) (740 mg, 2.14 mmol) was dissolved in trifluoroacetic acid (5 mL) and CH<sub>2</sub>Cl<sub>2</sub> (10 mL) and was stirred at rt for 5 h. The reaction mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub> (50 mL), and then 1 M aqueous sodium hydroxide solution was added until pH 14. The layers were separated, and the water layer was dried under reduced pressure. The residue was taken up in ethyl acetate and purified by column chromatography (ethyl acetate 100% → CH<sub>3</sub>OH 100%). The title compound <b>39a</b> (375 mg, 71%) was obtained as an orange-yellowish solid, mp 150–156 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 10.38 (s, 1H), 7.08 (t, <i>J</i> = 7.7 Hz, 1H), 6.77 (d, <i>J</i> = 7.5 Hz, 1H), 6.65 (d, <i>J</i> = 7.5 Hz, 1H), 3.44 (s, 2H), 2.67 (m, 4H), 2.63 (m, 2H), 2.43 (m, 2H), 2.34 (m, 4H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ 176.8 (C), 143.9 (C), 137.1 (C), 127.9 (CH), 125.0 (C), 122.2 (CH), 107.4 (CH), 59.3 (CH<sub>2</sub>), 54.6 (CH<sub>2</sub>), 46.1 (CH<sub>2</sub>), 35.0 (CH<sub>2</sub>), 30.3 (CH<sub>2</sub>). LCMS: <i>m</i>/<i>z</i> (ESI 20 V) 246.2 (MH<sup>+</sup>, 100). HPLC: <i>t</i><sub>R</sub> 1.94 min, 95% (214 nm), >99% (254 nm). HRMS (C<sub>14</sub>H<sub>19</sub>N<sub>3</sub>O): calcd, 246.1606 [M + H]<sup>+</sup>; found, 246.1604.</div></div><div id="sec5_2_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> 4-(2-(2-Oxoindolin-4-yl)ethyl)-1,4-diazepan-1-ium 2,2,2-trifluoroacetate (<b>39b</b>)</h4><div class="NLM_p last">Trifluoroacetic acid (5 mL) was added to a solution of <i>tert</i>-butyl 4-(2-(2-oxoindolin-4-yl)ethyl)-1,4-diazepane-1-carboxylate (<b>38b</b>) (750 mg, 2.09 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (5 mL). The reaction was stirred at rt for 3.5 h before the solvents were removed under reduced pressure. The title compound <b>39b</b> (1.39 g) was obtained as a brownish oil containing residual trifluoroacetic acid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 10.45 (s, 1H), 9.22 (br s, 2H), 7.16 (t, <i>J</i> = 7.8 Hz, 1H), 6.85 (d, <i>J</i> = 7.7 Hz, 1H), 6.74 (d, <i>J</i> = 7.6 Hz, 1H), 3.41–3.20 (m, 12H), 2.93 (m, 2H), 2.17 (m, 2H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ 176.6 (C), 159.1 (q, CF<sub>3</sub><u class="uu">C</u>OO<sup>–</sup>, <i>J</i> = 37 Hz), 144.3 (C), 132.9 (C), 128.4 (CH), 125.5 (C), 122.1 (CH), 116.1 (q, <i>J</i> = 292 Hz, <u class="uu">C</u>F<sub>3</sub>COO<sup>–</sup>), 108.4 (CH), 55.8 (CH<sub>2</sub>), 53.2 (CH<sub>2</sub>), 49.9 (CH<sub>2</sub>), 44.7 (CH<sub>2</sub>), 40.6 (CH<sub>2</sub>), 34.9 (CH<sub>2</sub>), 27.8 (CH<sub>2</sub>), 21.1 (CH<sub>2</sub>). LCMS: <i>m</i>/<i>z</i> (ESI 20 V) 260.2 (MH<sup>+</sup>, 100). HPLC: <i>t</i><sub>R</sub> 3.03 min, 98% (214 nm), 98% (254 nm). HRMS (C<sub>15</sub>H<sub>21</sub>N<sub>3</sub>O): calcd, 260.1763 [M + H]<sup>+</sup>; found, 260.1760.</div></div><div id="sec5_2_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> 4-(2-(4-(7-Amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-<i>a</i>][1,3,5]triazin-5-yl)piperazin-1-yl)ethyl)indolin-2-one (<b>40a</b>)</h4><div class="NLM_p last">4-(2-(Piperazin-1-yl)ethyl)indolin-2-one (<b>39a</b>) (325 mg, 1.32 mmol) was added to a suspension of 2-(furan-2-yl)-5-(methylsulfonyl)-[1,2,4]triazolo[1,5-<i>a</i>][1,3,5]triazin-7-amine (<b>28</b>) (124 mg, 442 μmol) in acetonitrile (7 mL) and toluene (7 mL). The reaction mixture was stirred at rt for 18 h before the solvent was removed under reduced pressure. Purification by column chromatography (CH<sub>2</sub>Cl<sub>2</sub> → CH<sub>2</sub>Cl<sub>2</sub>:CH<sub>3</sub>OH 9:1) gave the title compound <b>40a</b> (130 mg, 66%) as a beige solid, mp 280–285 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 10.35 (s, 1H), 8.50–8.20 (2 × br s, ratio 1:1, 2H), 7.88 (dd, <i>J</i> = 1.7, 0.8 Hz, 1H), 7.09 (t, <i>J</i> = 7.8 Hz, 1H), 7.06 (dd, <i>J</i> = 3.4, 0.7 Hz, 1H), 6.81 (d, <i>J</i> = 7.5 Hz, 1H), 6.68 (dd, <i>J</i> = 3.4, 1.8 Hz, 1H), 6.66 (d, <i>J</i> = 7.6 Hz, 1H), 3.78 (m, 4H), 3.48 (s, 2H), 2.70 (m, 2H), 2.58–2.47 (m, 6H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ 176.8 (C), 160.3 (C), 159.6 (C), 156.7 (C), 150.7 (C), 146.6 (C), 145.2 (CH), 143.9 (C), 136.8 (C), 128.0 (CH), 125.1 (C), 122.2 (CH), 112.4 (CH), 112.2 (CH), 107.4 (CH), 58.3 (CH<sub>2</sub>), 52.8 (CH<sub>2</sub>), 43.9 (CH<sub>2</sub>), 35.0 (CH<sub>2</sub>), 30.4 (CH<sub>2</sub>). LCMS: <i>m</i>/<i>z</i> (ESI 20 V) 446.3 (MH<sup>+</sup>, 100). HPLC: <i>t</i><sub>R</sub> 6.18 min, 96% (214 nm), 99% (254 nm). HRMS (C<sub>22</sub>H<sub>23</sub>N<sub>9</sub>O<sub>2</sub>): calcd, 446.2053 [M + H]<sup>+</sup>; found, 446.2048.</div></div><div id="sec5_2_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> 4-(7-Amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-<i>a</i>][1,3,5]triazin-5-yl)-1-(2-(2-oxoindolin-4-yl)ethyl)-1,4-diazepan-1-ium 2,2,2-trifluoroacetate (<b>40b</b>)</h4><div class="NLM_p last">1,8-Diazabicycloundec-7-ene (408 mg, 2.68 mmol) was added to a reaction mixture of 4-(2-(2-oxoindolin-4-yl)ethyl)-1,4-diazepan-1-ium 2,2,2-trifluoroacetate (<b>39b</b>) (500 mg, 1.34 mmol) and 2-(furan-2-yl)-5-(methylsulfonyl)-[1,2,4]triazolo[1,5-<i>a</i>][1,3,5]triazin-7-amine (<b>28</b>) (125 mg, 446 μmol) in acetonitrile (10 mL). The reaction mixture was stirred at rt for 23 h before the solvent was removed under reduced pressure. Purification by column chromatography twice (CH<sub>2</sub>Cl<sub>2</sub> 100% → CH<sub>2</sub>Cl<sub>2</sub>:CH<sub>3</sub>OH 9:1) and (CHCl<sub>3</sub> 100% → CHCl<sub>3</sub>:CH<sub>3</sub>OH 9:1) as well as preparative HPLC gave the title compound <b>40b</b> (10 mg, 5%) as a colorless oil. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 10.43 (s, 1H), 9.84–9.67 (2 × br s, ratio 1:1, 1H), 8.65–8.25 (2 × br s, ratio 1:1, 2H), 7.89 (dd, <i>J</i> = 1.7, 0.8 Hz, 1H), 7.14 (t, <i>J</i> = 7.7 Hz, 1H), 7.08 (dd, <i>J</i> = 3.4, 0.8 Hz, 1H), 6.83 (d, <i>J</i> = 7.6 Hz, 1H), 6.73 (d, <i>J</i> = 7.7 Hz, 1H), 6.69 (dd, <i>J</i> = 3.4, 1.8 Hz, 1H), 4.28 (m, 2H), 3.90–3.55 (m, 4H), 3.55 (s, 2H), 3.32 (m, 4H), 2.93 (m, 2H), 2.18 (m, 2H). Some of the <sup>13</sup>C signal show up twice, and the signal with lower intensity is marked with an asterisk (*). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ 176.6 (C), 160.6 (C), 158.5 (C), 156.6 (C), 150.8 (C), 146.4 (C), 145.3 (CH), 144.3 (C), 133.1 (C), 128.4 (CH), 125.5 (C), 122.2 (CH), 112.5 (CH), 112.4 (CH), 108.4 (CH), 56.0 (CH<sub>2</sub>), 54.1 (CH<sub>2</sub>), 53.5 (CH<sub>2</sub>), 53.2 (CH<sub>2</sub>*), 45.2 (CH<sub>2</sub>), 44.9 (CH<sub>2</sub>*), 42.2 (CH<sub>2</sub>*), 41.9 (CH<sub>2</sub>), 34.9 (CH<sub>2</sub>), 27.9 (CH<sub>2</sub>), 24.4 (CH<sub>2</sub>), 24.0 (CH<sub>2</sub>*). The signals for trifluoroacetate CF<sub>3</sub>COO<sup>–</sup> were not observed due to the low concentration. LCMS: <i>m</i>/<i>z</i> (ESI 20 V) 460.3 (MH<sup>+</sup>, 100), 458.3 (MH<sup>–</sup>, 100). HPLC: <i>t</i><sub>R</sub> 4.48 min, 98% (214 nm), 98% (254 nm). HRMS (C<sub>23</sub>H<sub>25</sub>N<sub>9</sub>O<sub>2</sub>): calcd, 460.2209 [M + H]<sup>+</sup>; found, 460.2202.</div></div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> Adenosine A<sub>2A</sub> Assay</h3><div id="sec5_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> Cell Culture</h4><div class="NLM_p last">Chinese hamster ovary FlpIn (FlpIn-CHO) cells stably transfected with the human adenosine A<sub>2A</sub> receptor were maintained in DMEM containing 10% FBS and 500 μg/mL hygromycin-B at 37 °C in a humidified incubator containing 5% CO<sub>2</sub>:95% O<sub>2</sub>.</div></div><div id="sec5_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> cAMP Assay</h4><div class="NLM_p last">Cells were seeded in 96-well cell culture plates at 2 × 10<sup>4</sup> cells per well and grown until 90% confluent. Cell were then washed with 100 μL of phosphate buffered saline solution and incubated at 37 °C for 45 min in 80 μL of stimulation buffer (140 mM NaCl, 5 mM KCl, 0.8 mM MgSO<sub>4</sub>·7 H<sub>2</sub>O, 0.2 mM Na<sub>2</sub>HPO<sub>4</sub>·2 H<sub>2</sub>O, 0.44 mM KH<sub>2</sub>PO<sub>4</sub>, 1.3 mM CaCl<sub>2</sub>·2 H<sub>2</sub>O, 5.6 mM <span class="smallcaps smallerCapital">d</span>-glucose, 5 mM HEPES, 0.1% BSA, 0.1 U/mL ADA and 10 μM rolipram, pH = 7.45). Cells were then stimulated for 30 min with 500 nM NECA in the absence or presence of increasing concentrations of compound in a final volume of 100 μL. Buffer was then removed and cells lysed with 50 μL of 100% ethanol. Following ethanol evaporation, 50 μL of detection buffer was added (0.1% BSA, 0.3% Tween-20, and 5 mM HEPES, pH = 7.45) and plates agitated for 10 min. Lysate (10 μL) was transferred to a 384-well Optiplate and 1 Unit/well of AlphaScreen acceptor beads, AlphaScreen donor beads and biotinylated cAMP were added. AlphaScreen donor beads and biotinylated cAMP were equilibrated for 30 min prior to addition. Plates were incubated overnight in the dark at room temperature, followed by measurement of fluorescence by an EnVision plate reader (PerkinElmer) using AlphaScreen settings.</div></div><div id="sec5_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> Data Analysis</h4><div class="NLM_p last">All data obtained were analyzed in GraphPad Prism 6.0 (GraphPad Software Inc., San Diego, CA). Results in the text are shown as means ± SEM, along with the number of experiments.</div></div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> Dopamine D<sub>2</sub> Assay</h3><div id="sec5_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> Cell Culture</h4><div class="NLM_p last">Chinese hamster ovary (CHO) cells stably expressing human D<sub>2L</sub> dopamine receptors (Wilson et al., 2001) were grown in Dulbecco’s Modified Eagle’s Medium containing 5% fetal bovine serum and 400 mg/mL active Geneticin (to maintain selection pressure). Cells were grown at 37 °C in a humidified atmosphere of 5% CO<sub>2</sub>.</div></div><div id="sec5_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> Membrane Preparation</h4><div class="NLM_p last">Membranes were prepared from CHO cells expressing D<sub>2L</sub> dopamine receptors as described previously (Castro and Strange, 1993). Briefly, confluent 175 cm<sup>2</sup> flasks of cells were washed once with 10 mL of 4-(2-hydroxyethyl)-1-piperazineethyl-sulfonic acid (HEPES) buffer (11.9 g/L HEPES, 2 mL/L ethylenediaminetetraacetic acid ((EDTA), 47 mg/L leupeptin, 25 mg/mL bacitracin; pH 7.4 using KOH). The cell pellet was resuspended in 10 volumes of buffer. Pepstatin (2 × 10<sup>–6</sup> M) and PMSF (1 mM) were added to Waring blender and homogenized for 15 s (full speed). Homogenate was left to stand on ice for 5 min and homogensized for further 15 s and let stand for another 30 min (500 mL blender for volumes up to 200 mL, 1 L blender for volumes 200–500 mL. Volumes larger than 500 mL were split and processed in smaller aliquots). The liquid had settled after 30 min and was transferred to 500 mL centrifuge tubes and centrifuged at 1200 rpm, 4 °C for 10 min. Supernatant was transferred to Beckman 70 mL ultracentrifuge tubes and centrifuged at 24800 rpm for 36 min. Supernatant was discarded and pellet was resuspended in approx 4 volumes of buffer using a 20 mL syringe. Once the membrane pellet was an even suspension, it was passed through a 0.6 mm × 25 mm needle and dispensed into 1 mL aliquots and stored at −80 °C until use. Protein concentration was determined using a BCA assay (determined by the method of Lowry et al., 1951).</div></div><div id="sec5_4_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> [<sup>35</sup>S]GTPγS Binding Assays</h4><div class="NLM_p last">Cell membranes (20 μg/mL) were preincubated for 30 min at room temperature in 20 mM HEPES buffer containing 1 μM GDP, 5 mM NaCl, 95 mM NMDG, and 10 mM MgCl<sub>2</sub>, pH 7.4. Also 30 μg/mL saponin, 0.01% Pluronic F-127, and 5 mg/mL of PS-WGA beads were also added before the incubation. After the addition of ligands (in duplicated, 1/3 dilution serial response), the assay was initiated by adding [<sup>35</sup>S]GTPγS to give a final concentration of 500 pM. The assay was incubated for 1 h, and then plates were centrifuged at 1200 rpm for 2 min before reading them in a ViewLux reader from PerkinElmer.</div></div><div id="sec5_4_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> Data Analysis</h4><div class="NLM_p last">Results in the text are shown as means ± SEM, along with the number of experiments. Quinelorane was used as pharmaceutical standard compound as well as dopamine and preclamol in order to check the assay robustness and variability and validate the data arisen. Data from [<sup>35</sup>S]GTPγS binding experiments were fitted to a sigmoidal concentration/response curve with a Hill coefficient of one which provided the best fit to the data in all cases (<i>P</i> < 0.05). Time course data were fitted well by monoexponential equations from which the apparent first-order rate constant (<i>k</i>, min<sup>–1</sup>) and maximal binding (<i>B</i><sub>max</sub>, fmol mg<sup>–1</sup>) values could be extracted. The initial rate of [<sup>35</sup>S]GTPγS binding was calculated as <i>k·B</i><sub>max</sub> in fmol mg<sup>–1</sup> min<sup>–1</sup>. The maximum response values were referenced to quinelorane at 100 μM.</div></div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> <i>K</i><sub>bb</sub> Assay</h3><div class="NLM_p">The testing has been done by WuXi, Shanghai.</div><div id="sec5_5_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> Preparation of Solutions</h4><div class="NLM_p last">The stock solutions in dimethyl sulfoxide were prepared to 10 mM stock concentration and 1 mM working solution and stored at 4 °C. The dialysis buffer (PBS, pH 7.4) was prepared by dissolving 1.42 g of Na<sub>2</sub>HPO<sub>4</sub>, 0.27 g of KH<sub>2</sub>PO<sub>4</sub>, 8.01 g of NaCl, and 0.20 g of KCl into a final volume of 1000 mL of ultra pure water, mixed, and the resulting solution adjusted with 1% phosphoric acid to pH 7.4 ± 0.1. The final solutions were stored at +2–8 °C in the refrigerator within an expiration of a month after preparation.</div></div><div id="sec5_5_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> Test System</h4><div class="NLM_p last">The fresh blood and brain tissue was from a male Wistar Han Rat (WuXi 20130520). Control blood was collected fresh, diluted 1:1 (v/v) with dialysis buffer and stored at +2–8 °C refrigerator. EDTA-K<sub>2</sub> was used as anticoagulant in the fresh blood sample. Brains were collected and homogenized 1:2 with dialysis buffer and stored at ≤ −70 °C in the freezer. The diluted blood and brain homogenates were equilibrated to room temperature before used on the day of the experiment. HT-Dialysis plate (Model HTD 96 b, catalogue no. 1006), and the dialysis membrane (molecular weight cut off 12–14 kDa, catalogue no. 1101) were purchased from HT Dialysis LLC (Gales Ferry, CT).</div></div><div id="sec5_5_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> Methods</h4><div class="NLM_p last">The dialysis membrane was pretreated according to the manufacturer’s instructions: therefore, the dialysis membrane was soaked in ultra pure water for 60 min and each strip was separated, then the membrane was soaked in 20% ethanol for 20 min and finally in ultra pure water for 20 min. The dialysis instrument was assembled following the manufacturer’s instructions. A 12-channel pipettor was used to add 150 μL of PBS to the appropriate compartment of all wells being used. The 1 mM working solutions were made by diluting stock solutions with appropriate volume of neat dimethyl sulfoxide. The final 5 μM solutions were made by diluting 3 μL of the working solutions with 597 μL of control diluted blood/brain homogenates. Each cell was loaded with 150 μL of spiked diluted blood or brain homogenates (in triplicate) to the other compartment of each well against dialysis buffer. The dialysis plate were sealed with adhesive sealing strip to the top of the block to avoid evaporation and placed it in an incubator at 37 °C for 4 h with rotating at 130 rpm (model VXR B, IKA). After incubation, the samples were removed from the blood or brain homogenates (5 μL) as well as the buffer (50 μL) sides to the sample collection plates. The blood or brain homogenate aliquots (5 μL) were diluted with 45 μL of diluted control blood (blood:PBS = 1:1 in v:v) or control brain homogenates (brain tissue: PBS = 1:2 in g:mL) and 50 μL of blank buffer to generate donor samples; buffer samples (50 μL) were diluted with 50 μL of diluted control blood or control brain homogenates to generate receiver samples. The diluted samples were mixed with 3 volumes of precipitation solvent (50% acetonitrile/CH<sub>3</sub>OH with internal standards of 200 ng/mL Labetalol plus 10 ng/mL Buspirone). The sample collection plates were shaken at 800 rpm for 10 min to mix samples, and then the plate was centrifuged at 3220 RCF for 15 min. An aliquot of supernatant (100 μL for Loperamide and test compounds, 200 μL for Naproxen) was transferred in each well of the sample analytic plates, mixed with solution (200 μL of ultra pure water:50% acetonitrile/CH<sub>3</sub>OH = 1:2 for test compounds; 500 μL for Loperamide), and replaced on the plate shaker for at least 5 min before subjecting to LC- MS/MS analysis.</div></div><div id="sec5_5_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> Data Analysis</h4><div class="NLM_p last">MS response ratio of test compound in matrix and buffer samples was expressed using peak area ratios of analyte/internal standard. The fraction of unbound (apparent <i>f</i><sub>u</sub>) and undiluted unbound were calculated by the following equations: apparent <i>f</i><sub>u</sub> = MS corrected response [buffer]/MS corrected response [blood/brain]; MS corrected response = MS response ratio/correction factor; correction factor = volume of aliquot/total volume. Blood: 5 μL, dilution 20-fold (correction factor = 0.05). Brain: 5 μL, dilution 20-fold (correction factor = 0.05). Buffer: 50 μL, dilution 2-fold (correction factor = 0.5). Calculation of undiluted <i>f</i><sub>u</sub> with correction for “dilution factor (<i>D</i>)”; % undiluted unbound = (1/<i>D</i>)/[(1/<i>f</i><sub>u</sub>(apparent) – 1) + 1/<i>D</i>] × 100; blood, <i>D</i> = 2; brain, <i>D</i> = 3.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i80"><a href="/doi/suppl/10.1021/jm501254d">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27286" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27286" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The provided document comprises the synthesis and characterization of the important intermediates ZM 241385 (<b>1</b>), TCAC (<b>3</b>), OAC (<b>5</b>), sTCAC (<b>16</b>), and sulfone <b>29</b>.  This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm501254d/suppl_file/jm501254d_si_001.pdf">jm501254d_si_001.pdf (511.07 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm501254d" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_42205" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_42205" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Peter J. Scammells</span> - <span class="hlFld-Affiliation affiliation">†Medicinal Chemistry and ‡Drug Discovery
Biology, Monash Institute of Pharmaceutical
Sciences, 381 Royal Parade, Parkville, Victoria 3052, Australia</span>; 
    <span class="hlFld-Affiliation affiliation">Neural
Pathways DPU, Neurosciences TAU, GSK R&D, 11 Biopolis Way, Helios Bldg #03-01/02, Singapore 138667, Singapore</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#7525100110075b26161418181019190635181a1b14061d5b101100"><span class="__cf_email__" data-cfemail="2c7c4958495e027f4f4d41414940405f6c4143424d5f4402494859">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ben Capuano</span> - <span class="hlFld-Affiliation affiliation">†Medicinal Chemistry and ‡Drug Discovery
Biology, Monash Institute of Pharmaceutical
Sciences, 381 Royal Parade, Parkville, Victoria 3052, Australia</span>; 
    <span class="hlFld-Affiliation affiliation">Neural
Pathways DPU, Neurosciences TAU, GSK R&D, 11 Biopolis Way, Helios Bldg #03-01/02, Singapore 138667, Singapore</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#1250777c3c51736267737c7d527f7d7c73617a3c777667"><span class="__cf_email__" data-cfemail="1456717a3a57756461757a7b54797b7a75677c3a717061">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Manuela Jörg</span> - <span class="hlFld-Affiliation affiliation">†Medicinal Chemistry and ‡Drug Discovery
Biology, Monash Institute of Pharmaceutical
Sciences, 381 Royal Parade, Parkville, Victoria 3052, Australia</span>; 
    <span class="hlFld-Affiliation affiliation">Neural
Pathways DPU, Neurosciences TAU, GSK R&D, 11 Biopolis Way, Helios Bldg #03-01/02, Singapore 138667, Singapore</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lauren T. May</span> - <span class="hlFld-Affiliation affiliation">†Medicinal Chemistry and ‡Drug Discovery
Biology, Monash Institute of Pharmaceutical
Sciences, 381 Royal Parade, Parkville, Victoria 3052, Australia</span>; 
    <span class="hlFld-Affiliation affiliation">Neural
Pathways DPU, Neurosciences TAU, GSK R&D, 11 Biopolis Way, Helios Bldg #03-01/02, Singapore 138667, Singapore</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Frankie S. Mak</span> - <span class="hlFld-Affiliation affiliation">Neural
Pathways DPU, Neurosciences TAU, GSK R&D, 11 Biopolis Way, Helios Bldg #03-01/02, Singapore 138667, Singapore</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kiew Ching K. Lee</span> - <span class="hlFld-Affiliation affiliation">Neural
Pathways DPU, Neurosciences TAU, GSK R&D, 11 Biopolis Way, Helios Bldg #03-01/02, Singapore 138667, Singapore</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Neil D. Miller</span> - <span class="hlFld-Affiliation affiliation">Neural
Pathways DPU, Neurosciences TAU, GSK R&D, 11 Biopolis Way, Helios Bldg #03-01/02, Singapore 138667, Singapore</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d1020e8239-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i81">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46405" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46405" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">M. J. is a recipient of the Australian Postgraduate Award Industry (APAI) and Monash University Postgraduate Publication Award. L.T.M. is an Australian Research Council DECRA Fellow. We thank GSK R&D, Singapore, for financial support. Thank you to Francisco Javie Colilla-Rodriguez (GSK R&D Tres Cantos, Spain) for the dopamine D<sub>2</sub> receptor testing of our compounds. We thank Dr Joseph A. Nicolazzo (Monash University) for his valuable support with analyzing the in vitro permeability data.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i82" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i82"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i83" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i83"> Abbreviations Used</h2><tr><td class="NLM_term">D<sub>2</sub>R</td><td class="NLM_def"><p class="first last">dopamine D<sub>2</sub> receptor</p></td></tr><tr><td class="NLM_term">A<sub>2A</sub>R</td><td class="NLM_def"><p class="first last">adenosine A<sub>2A</sub> receptor</p></td></tr><tr><td class="NLM_term">LC–MS</td><td class="NLM_def"><p class="first last">liquid chromatography–mass spectrometry</p></td></tr><tr><td class="NLM_term">BOP</td><td class="NLM_def"><p class="first last">(benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate</p></td></tr><tr><td class="NLM_term">cAMP</td><td class="NLM_def"><p class="first last">cyclic adenosine monophosphate</p></td></tr><tr><td class="NLM_term">CNS</td><td class="NLM_def"><p class="first last">central nervous system</p></td></tr><tr><td class="NLM_term">COMU</td><td class="NLM_def"><p class="first last">(1-cyano-2-ethoxy-2-oxoethylidenaminooxy)dimethylamino-morpholino-carbenium hexafluorophosphate</p></td></tr><tr><td class="NLM_term">DBU</td><td class="NLM_def"><p class="first last">1,8-diazabicycloundec-7-ene</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last">diisopropyl ethylamine</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last">dimethylformamide</p></td></tr><tr><td class="NLM_term">HCTU</td><td class="NLM_def"><p class="first last">2-(6-chloro-1<i>H</i>-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate</p></td></tr><tr><td class="NLM_term">NECA</td><td class="NLM_def"><p class="first last">5′-<i>N</i>-ethylcarboxamidoadenosine or alternatively 1-(6-amino-9<i>H</i>-purin-9-yl)-1-deoxy-<i>N</i>-ethyl-β-<span class="smallcaps smallerCapital">d</span>-ribofuranuronamide</p></td></tr><tr><td class="NLM_term">PPHT-NH<sub>2</sub></td><td class="NLM_def"><p class="first last">6-((4-aminophenethyl)(propyl)amino)-5,6,7,8- tetrahydronaphthalen-1-ol</p></td></tr><tr><td class="NLM_term">TEA</td><td class="NLM_def"><p class="first last">triethylamine</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">rt</td><td class="NLM_def"><p class="first last">room temperature</p></td></tr><tr><td class="NLM_term">XCC</td><td class="NLM_def"><p class="first last">2-(4-(2,6-dioxo-1,3-dipropyl-2,3,4,5,6,7-hexahydro-1<i>H</i>-purin-8-yl)phenoxy)acetic acid</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i84">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76002" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76002" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 51 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Nussbaum, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, C. E.</span><span> </span><span class="NLM_article-title">Alzheimer’s disease and Parkinson’s disease</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">348</span><span class="NLM_x">, </span> <span class="NLM_fpage">1356</span><span class="NLM_x">–</span> <span class="NLM_lpage">1364</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm501254d&amp;key=10.1056%2FNEJM2003ra020003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm501254d&amp;key=12672864" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm501254d&amp;key=1%3ACAS%3A528%3ADC%252BD3sXis1egt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2003&pages=1356-1364&author=R.+L.+Nussbaumauthor=C.+E.+Ellis&title=Alzheimer%E2%80%99s+disease+and+Parkinson%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Alzheimer's disease and Parkinson's disease</span></div><div class="casAuthors">Nussbaum, Robert L.; Ellis, Christopher E.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">348</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1356-1364</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review discusses the current understanding on the pathogenesis of Alzheimer's disease (AD) and Parkinson's disease (PD) based on genetic studies.  The emergence of a consensus hypothesis that aggregates of Aβ42 and α-synuclein are neurotoxic in AD and PD, resp., may explain the pathogenesis not only of the inherited forms of these diseases but also of the idiopathic variety.  Such insights into causation and pathogenesis are helping to identify new treatment targets for these debilitating disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrg4V6nJZUmELVg90H21EOLACvtfcHk0li9K9FFBUQDTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXis1egt7c%253D&md5=1be9cf3a17cccd2beb16a94779e64180</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1056%2FNEJM2003ra020003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM2003ra020003%26sid%3Dliteratum%253Aachs%26aulast%3DNussbaum%26aufirst%3DR.%2BL.%26aulast%3DEllis%26aufirst%3DC.%2BE.%26atitle%3DAlzheimer%25E2%2580%2599s%2520disease%2520and%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2003%26volume%3D348%26spage%3D1356%26epage%3D1364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Samii, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nutt, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ransom, B. R.</span><span> </span><span class="NLM_article-title">Parkinson’s disease</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">363</span><span class="NLM_x">, </span> <span class="NLM_fpage">1783</span><span class="NLM_x">–</span> <span class="NLM_lpage">1793</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2004&pages=1783-1793&author=A.+Samiiauthor=J.+G.+Nuttauthor=B.+R.+Ransom&title=Parkinson%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSamii%26aufirst%3DA.%26aulast%3DNutt%26aufirst%3DJ.%2BG.%26aulast%3DRansom%26aufirst%3DB.%2BR.%26atitle%3DParkinson%25E2%2580%2599s%2520disease%26jtitle%3DLancet%26date%3D2004%26volume%3D363%26spage%3D1783%26epage%3D1793" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Hickey, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stacy, M.</span><span> </span><span class="NLM_article-title">Available and emerging treatments for Parkinson’s disease: a review</span> <span class="citation_source-journal">Drug Des. Dev. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">241</span><span class="NLM_x">–</span> <span class="NLM_lpage">254</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm501254d&amp;key=1%3ACAS%3A280%3ADC%252BC3MrksFeltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2011&pages=241-254&author=P.+Hickeyauthor=M.+Stacy&title=Available+and+emerging+treatments+for+Parkinson%E2%80%99s+disease%3A+a+review"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Available and emerging treatments for Parkinson's disease: a review</span></div><div class="casAuthors">Hickey Patrick; Stacy Mark</div><div class="citationInfo"><span class="NLM_cas:title">Drug design, development and therapy</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">241-54</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Parkinson's disease is a commonly encountered neurodegenerative disorder primarily found in aged populations.  A number of medications are available to control symptoms, although these are less effective in advanced disease.  Deep brain stimulation provides a practicable alternative at this stage, although a minority of patients meet the strict criteria for surgery.  Novel medications that provide enhanced symptomatic control remain in developmental demand.  Both gene and cell-based therapies have shown promise in early clinical studies.  A major unmet need is a treatment that slows or stops disease progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSS--Rf7YUny9TiMd2aNQVUfW6udTcc2ebsmxNSVRm3hbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MrksFeltw%253D%253D&md5=52769e248a130309aa98cb930f8d8ea3</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHickey%26aufirst%3DP.%26aulast%3DStacy%26aufirst%3DM.%26atitle%3DAvailable%2520and%2520emerging%2520treatments%2520for%2520Parkinson%25E2%2580%2599s%2520disease%253A%2520a%2520review%26jtitle%3DDrug%2520Des.%2520Dev.%2520Ther.%26date%3D2011%26volume%3D5%26spage%3D241%26epage%3D254" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Poewe, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahlknecht, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jankovic, J.</span><span> </span><span class="NLM_article-title">Emerging therapies for Parkinson’s disease</span> <span class="citation_source-journal">Curr. Opin. Neurol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">448</span><span class="NLM_x">–</span> <span class="NLM_lpage">459</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm501254d&amp;key=10.1097%2FWCO.0b013e3283542fde" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm501254d&amp;key=22772874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm501254d&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVWjs7zM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2012&pages=448-459&author=W.+Poeweauthor=P.+Mahlknechtauthor=J.+Jankovic&title=Emerging+therapies+for+Parkinson%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging therapies for Parkinson's disease</span></div><div class="casAuthors">Poewe, Werner; Mahlknecht, Philipp; Jankovic, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Neurology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">448-459</span>CODEN:
                <span class="NLM_cas:coden">CONEEX</span>;
        ISSN:<span class="NLM_cas:issn">1350-7540</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose of review: The exptl. therapeutics of Parkinson's disease are reviewed, highlighting the current pipeline of emerging therapeutic approaches.  Recent findings: This review includes novel approaches to dopaminergic drug delivery such as intraintestinal infusions or new extended-release formulations of levodopa and also intrapulmonary delivery of apomorphine as well as novel dopaminergic agents like the monoamine oxidase-B inhibitor safinamide or novel catechol-O-Me transferase inhibitors.  An even greater no. of ongoing clin. trials assess the efficacy and safety of nondopaminergic approaches to enhance motor control or reduce motor complications like fluctuations and dyskinesias.  These include adenosine A2A antagonists, α-adrenergic and serotonergic agonists as well as drugs acting on the glutamatergic system.  Gene-based or cell-based intrastriatal delivery of therapeutic principles that enhance striatal dopaminergic transmission directly or via the stimulation of trophic activity has also reached phase II clin. development with encouraging results in some studies.  Finally, a wide spectrum of agents with a potential for slowing disease progression is currently tested.  Summary: A variety of medical and nonmedical interventions in different phases of clin. development provide an interesting and promising portfolio of emerging therapies for Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomNZpxzJjBtrVg90H21EOLACvtfcHk0lg6T9qK8JTI3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVWjs7zM&md5=421b6b0b289da7fcc8e817ae1808c15a</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1097%2FWCO.0b013e3283542fde&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FWCO.0b013e3283542fde%26sid%3Dliteratum%253Aachs%26aulast%3DPoewe%26aufirst%3DW.%26aulast%3DMahlknecht%26aufirst%3DP.%26aulast%3DJankovic%26aufirst%3DJ.%26atitle%3DEmerging%2520therapies%2520for%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DCurr.%2520Opin.%2520Neurol.%26date%3D2012%26volume%3D25%26spage%3D448%26epage%3D459" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Hornykiewicz, O.</span><span> </span><span class="NLM_article-title">Dopamine miracle: from brain homogenate to dopamine replacement</span> <span class="citation_source-journal">Movement Disord.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">501</span><span class="NLM_x">–</span> <span class="NLM_lpage">508</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm501254d&amp;key=10.1002%2Fmds.10115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm501254d&amp;key=12112197" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm501254d&amp;key=1%3ACAS%3A280%3ADC%252BD38zmtFWgtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2002&pages=501-508&author=O.+Hornykiewicz&title=Dopamine+miracle%3A+from+brain+homogenate+to+dopamine+replacement"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine miracle: from brain homogenate to dopamine replacement</span></div><div class="casAuthors">Hornykiewicz Oleh</div><div class="citationInfo"><span class="NLM_cas:title">Movement disorders : official journal of the Movement Disorder Society</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">501-8</span>
        ISSN:<span class="NLM_cas:issn">0885-3185</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ86vK8nfFu0Gx8TEN9K18QfW6udTcc2ebsmxNSVRm3hbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38zmtFWgtA%253D%253D&md5=50f4fdbab9ac5aab71703e0c7d77c363</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1002%2Fmds.10115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmds.10115%26sid%3Dliteratum%253Aachs%26aulast%3DHornykiewicz%26aufirst%3DO.%26atitle%3DDopamine%2520miracle%253A%2520from%2520brain%2520homogenate%2520to%2520dopamine%2520replacement%26jtitle%3DMovement%2520Disord.%26date%3D2002%26volume%3D17%26spage%3D501%26epage%3D508" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Fahn, S.</span><span> </span><span class="NLM_article-title">The history of dopamine and levodopa in the treatment of Parkinson’s disease</span> <span class="citation_source-journal">Movement Disord.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">497</span><span class="NLM_x">–</span> <span class="NLM_lpage">508</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm501254d&amp;key=10.1002%2Fmds.22028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm501254d&amp;key=18781671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm501254d&amp;key=1%3ACAS%3A280%3ADC%252BD1cnjt1elsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2008&pages=497-508&author=S.+Fahn&title=The+history+of+dopamine+and+levodopa+in+the+treatment+of+Parkinson%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The history of dopamine and levodopa in the treatment of Parkinson's disease</span></div><div class="casAuthors">Fahn Stanley</div><div class="citationInfo"><span class="NLM_cas:title">Movement disorders : official journal of the Movement Disorder Society</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">23 Suppl 3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">S497-508</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The discoveries of dopamine as a neurotransmitter in the brain, its depletion in patients with Parkinson disease, and its replacement with levodopa therapy were major revolutionary events in the rise to effective therapy for patients with this disorder.  This review describes these events and the persons who carried out these accomplishments.  Their impact went beyond a single clinical entity of parkinsonism, for it opened up the beginning of a much better understanding of the role of dopamine in other neurologic movement disorders and also in many psychiatric diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTvbCPehkebW0EgZCMqtRBifW6udTcc2ebsmxNSVRm3hbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cnjt1elsQ%253D%253D&md5=066bfc5127027e09bbbd2f40261955e7</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1002%2Fmds.22028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmds.22028%26sid%3Dliteratum%253Aachs%26aulast%3DFahn%26aufirst%3DS.%26atitle%3DThe%2520history%2520of%2520dopamine%2520and%2520levodopa%2520in%2520the%2520treatment%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DMovement%2520Disord.%26date%3D2008%26volume%3D23%26spage%3D497%26epage%3D508" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Hauser, R. A.</span><span> </span><span class="NLM_article-title">Levodopa: past, present, and future</span> <span class="citation_source-journal">Eur. Neurol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">8</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm501254d&amp;key=10.1159%2F000215875" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm501254d&amp;key=19407449" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm501254d&amp;key=1%3ACAS%3A528%3ADC%252BD1MXntFaqtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2009&pages=1-8&author=R.+A.+Hauser&title=Levodopa%3A+past%2C+present%2C+and+future"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Levodopa: Past, Present, and Future</span></div><div class="casAuthors">Hauser, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">European Neurology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-8</span>CODEN:
                <span class="NLM_cas:coden">EUNEAP</span>;
        ISSN:<span class="NLM_cas:issn">0014-3022</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">A review.  Levodopa has been the mainstay of treatment for Parkinson's disease (PD) for more than 40 years.  During this time, researchers have strived to optimize levodopa formulations to minimize side effects, enhance central nervous system (CNS) bioavailability, and achieve stable therapeutic plasma levels.  Current strategies include concomitant treatment with inhibitors of dopa decarboxylase (DDC) and catechol-O-methyltransferase (COMT) to prolong the peripheral levodopa half-life and increase CNS bioavailability.  Levodopa combined with DDC inhibition is the current std. method of delivering levodopa for symptomatic treatment of PD.  Recent research suggests that continuous dopaminergic stimulation that more closely approximates physiol. stimulation may delay or prevent the development of motor fluctuations ( wearing off') and dyskinesias.  Strategies currently being used to achieve more continuous dopaminergic stimulation include the combination of an oral levodopa/DDC inhibitor with a COMT inhibitor and the enteral infusion of a levodopa gel formulation.  Attempts are underway to develop oral and transdermal very long-acting levodopa prepns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtDAZQ96ayLrVg90H21EOLACvtfcHk0ljVeeRDCNFfBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXntFaqtbg%253D&md5=fdc604da9d201fa25b633602274fe0f4</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1159%2F000215875&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000215875%26sid%3Dliteratum%253Aachs%26aulast%3DHauser%26aufirst%3DR.%2BA.%26atitle%3DLevodopa%253A%2520past%252C%2520present%252C%2520and%2520future%26jtitle%3DEur.%2520Neurol.%26date%3D2009%26volume%3D62%26spage%3D1%26epage%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Tan, E.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jankovic, J.</span><span> </span><span class="NLM_article-title">Choosing dopamine agonists in Parkinson’s disease</span> <span class="citation_source-journal">Clin. Neuropharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">247</span><span class="NLM_x">–</span> <span class="NLM_lpage">253</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2001&pages=247-253&author=E.-K.+Tanauthor=J.+Jankovic&title=Choosing+dopamine+agonists+in+Parkinson%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DE.-K.%26aulast%3DJankovic%26aufirst%3DJ.%26atitle%3DChoosing%2520dopamine%2520agonists%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DClin.%2520Neuropharmacol.%26date%3D2001%26volume%3D24%26spage%3D247%26epage%3D253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Simola, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morelli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinna, A.</span><span> </span><span class="NLM_article-title">Adenosine A<sub>2A</sub> receptor antagonists and Parkinson’s disease: state of the art and future directions</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1475</span><span class="NLM_x">–</span> <span class="NLM_lpage">1489</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm501254d&amp;key=10.2174%2F138161208784480072" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm501254d&amp;key=18537671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm501254d&amp;key=1%3ACAS%3A528%3ADC%252BD1cXns1ymsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=1475-1489&author=N.+Simolaauthor=M.+Morelliauthor=A.+Pinna&title=Adenosine+A2A+receptor+antagonists+and+Parkinson%E2%80%99s+disease%3A+state+of+the+art+and+future+directions"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine A2A receptor antagonists and Parkinson's disease: state of the art and future directions</span></div><div class="casAuthors">Simola, N.; Morelli, M.; Pinna, A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1475-1489</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Adenosine A2A receptors present in the central nervous system have been implicated in the modulation of motor functions.  Accordingly, adenosine A2A receptor antagonists currently constitute an attractive non-dopaminergic option for use in the treatment of Parkinson's disease (PD).  The highly enriched distributions of adenosine A2A receptors in striatopallidal neurons, and their ability to form functional heteromeric complexes with dopamine D2 and metabotropic glutamate mGlu5 receptors, render A2A receptor antagonists of particular interest in the modulation of motor behavior, while at the same time displaying a low predisposition to inducing non-motor side effects.  Furthermore, adenosine A2A receptor antagonists appear to exert a marked efficacy on PD tremor and in reducing the progress of underlying neurodegeneration and maladaptive neuroplasticity that complicates std. dopamine replacement treatments in PD.  Finally, recent evidence has illustrated an improvement of cognitive function as well as enhancement of attention in rodents following administration of A2A receptor antagonists.  This article is aimed at examg. preclin. studies describing these findings as well as reports from clin. trials, in order to provide a comprehensive review of the evidence suggesting that this class of drugs may represent an advance in the treatment of PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_H3uAbCpz3bVg90H21EOLACvtfcHk0ljVeeRDCNFfBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXns1ymsr0%253D&md5=1760d409edbb456ee19636a893cbdf6b</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.2174%2F138161208784480072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161208784480072%26sid%3Dliteratum%253Aachs%26aulast%3DSimola%26aufirst%3DN.%26aulast%3DMorelli%26aufirst%3DM.%26aulast%3DPinna%26aufirst%3DA.%26atitle%3DAdenosine%2520A2A%2520receptor%2520antagonists%2520and%2520Parkinson%25E2%2580%2599s%2520disease%253A%2520state%2520of%2520the%2520art%2520and%2520future%2520directions%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2008%26volume%3D14%26spage%3D1475%26epage%3D1489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Morelli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blandini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simola, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hauser, R. A.</span><span> </span><span class="NLM_article-title">A<sub>2A</sub> receptor antagonism and dyskinesia in Parkinson’s disease</span> <span class="citation_source-journal">Parkinson’s Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_fpage">489853</span><span class="NLM_x">–</span> <span class="NLM_lpage">489861</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm501254d&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVemsr%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=489853-489861&author=M.+Morelliauthor=F.+Blandiniauthor=N.+Simolaauthor=R.+A.+Hauser&title=A2A+receptor+antagonism+and+dyskinesia+in+Parkinson%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">A2A receptor antagonism and dyskinesia in Parkinson's disease</span></div><div class="casAuthors">Morelli, Micaela; Blandini, Fabio; Simola, Nicola; Hauser, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Parkinson's Disease</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">489853, 8 pp.</span>CODEN:
                <span class="NLM_cas:coden">PDAIB9</span>;
        ISSN:<span class="NLM_cas:issn">2042-0080</span>.
    
            (<span class="NLM_cas:orgname">Hindawi Publishing Corp.</span>)
        </div><div class="casAbstract">A review.  Dyskinesia, a major complication of treatment of Parkinson's disease (PD), involves two phases: induction, which is responsible for dyskinesia onset, and expression, which underlies its clin. manifestation.  The unique cellular and regional distribution of adenosine A2A receptors in basal ganglia areas that are richly innervated by dopamine, and their antagonistic role towards dopamine receptor stimulation, have positioned A2A receptor antagonists as an attractive nondopaminergic target to improve the motor deficits that characterize PD.  In this paper, we describe the biochem. characteristics of A2A receptors and the effects of adenosine A2A antagonists in rodent and primate models of PD on -DOPA-induced dyskinesia, together with relevant biomarker studies.  We also review clin. trials of A2A antagonists as adjuncts to l-DOPA in PD patients with motor fluctuations.  These studies have generally demonstrated that the addn. of an A2A antagonist to a stable -DOPA regimen reduces OFF time and mildly increases dyskinesia.  However, limited clin. data suggest that the addn. of an A2A antagonist along with a redn. of -DOPA mightmaintain anti-Parkinsonian benefit and reduce dyskinesia.  Whether A2A antagonists might reduce the development of dyskinesia has not yet been tested clin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpW3s40ZMidP7Vg90H21EOLACvtfcHk0ljVeeRDCNFfBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVemsr%252FM&md5=8362dcfb95d89a3a2c0475d80bf4ccfb</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMorelli%26aufirst%3DM.%26aulast%3DBlandini%26aufirst%3DF.%26aulast%3DSimola%26aufirst%3DN.%26aulast%3DHauser%26aufirst%3DR.%2BA.%26atitle%3DA2A%2520receptor%2520antagonism%2520and%2520dyskinesia%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DParkinson%25E2%2580%2599s%2520Dis.%26date%3D2012%26spage%3D489853%26epage%3D489861" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Pinna, A.</span><span> </span><span class="NLM_article-title">Novel investigational adenosine A<sub>2A</sub> receptor antagonists for Parkinson’s disease</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1619</span><span class="NLM_x">–</span> <span class="NLM_lpage">1631</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2009&pages=1619-1631&author=A.+Pinna&title=Novel+investigational+adenosine+A2A+receptor+antagonists+for+Parkinson%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPinna%26aufirst%3DA.%26atitle%3DNovel%2520investigational%2520adenosine%2520A2A%2520receptor%2520antagonists%2520for%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2009%26volume%3D18%26spage%3D1619%26epage%3D1631" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Armentero, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinna, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferre, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lanciego, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mueller, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franco, R.</span><span> </span><span class="NLM_article-title">Past, present and future of A<sub>2A</sub> adenosine receptor antagonists in the therapy of Parkinson’s disease</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">132</span><span class="NLM_x">, </span> <span class="NLM_fpage">280</span><span class="NLM_x">–</span> <span class="NLM_lpage">299</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm501254d&amp;key=10.1016%2Fj.pharmthera.2011.07.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm501254d&amp;key=21810444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm501254d&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtl2ntrzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2011&pages=280-299&author=M.+T.+Armenteroauthor=A.+Pinnaauthor=S.+Ferreauthor=J.+L.+Lanciegoauthor=C.+E.+Muellerauthor=R.+Franco&title=Past%2C+present+and+future+of+A2A+adenosine+receptor+antagonists+in+the+therapy+of+Parkinson%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Past, present and future of A2A adenosine receptor antagonists in the therapy of Parkinson's disease</span></div><div class="casAuthors">Armentero, Marie Therese; Pinna, Annalisa; Ferre, Sergi; Lanciego, Jose Luis; Mueller, Christa E.; Franco, Rafael</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">280-299</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Several selective antagonists for adenosine A2A receptors (A2AR) are currently under evaluation in clin. trials (phases I to III) to treat Parkinson's disease, and they will probably soon reach the market.  The usefulness of these antagonists has been deduced from studies demonstrating functional interactions between dopamine D2 and adenosine A2A receptors in the basal ganglia.  At present it is believed that A2AR antagonists can be used in combination with the dopamine precursor L-DOPA to minimize the motor symptoms of Parkinson's patients.  However, a considerable body of data indicates that in addn. to ameliorating motor symptoms, adenosine A2AR antagonists may also prevent neurodegeneration.  Despite these promising indications, one further issue must be considered in order to develop fully optimized antiparkinsonian drug therapy, namely the existence of (hetero)dimers/oligomers of G protein-coupled receptors, a topic that is currently the focus of intense debate within the scientific community.  Dopamine D2 receptors (D2Rs) expressed in the striatum are known to form heteromers with A2A adenosine receptors.  Thus, the development of heteromer-specific A2A receptor antagonists represents a promising strategy for the identification of more selective and safer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2pOYdmdfQMLVg90H21EOLACvtfcHk0lgJ1EHOSVc2lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtl2ntrzP&md5=39fa871338516f7574deb7845029e624</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2011.07.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2011.07.004%26sid%3Dliteratum%253Aachs%26aulast%3DArmentero%26aufirst%3DM.%2BT.%26aulast%3DPinna%26aufirst%3DA.%26aulast%3DFerre%26aufirst%3DS.%26aulast%3DLanciego%26aufirst%3DJ.%2BL.%26aulast%3DMueller%26aufirst%3DC.%2BE.%26aulast%3DFranco%26aufirst%3DR.%26atitle%3DPast%252C%2520present%2520and%2520future%2520of%2520A2A%2520adenosine%2520receptor%2520antagonists%2520in%2520the%2520therapy%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DPharmacol.%2520Ther.%26date%3D2011%26volume%3D132%26spage%3D280%26epage%3D299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Morelli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardas, J.</span><span> </span><span class="NLM_article-title">Adenosine A<sub>2A</sub> receptor antagonists: potential therapeutic and neuroprotective effects in Parkinson’s disease</span> <span class="citation_source-journal">Neurotoxic. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">545</span><span class="NLM_x">–</span> <span class="NLM_lpage">556</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm501254d&amp;key=10.1007%2FBF03033210" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm501254d&amp;key=15111244" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm501254d&amp;key=1%3ACAS%3A528%3ADC%252BD38XpsVc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2001&pages=545-556&author=M.+Morelliauthor=J.+Wardas&title=Adenosine+A2A+receptor+antagonists%3A+potential+therapeutic+and+neuroprotective+effects+in+Parkinson%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine A2A receptor antagonists: Potential therapeutic and neuroprotective effects in Parkinson's disease</span></div><div class="casAuthors">Morelli, M.; Wardas, J.</div><div class="citationInfo"><span class="NLM_cas:title">Neurotoxicity Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">545-556</span>CODEN:
                <span class="NLM_cas:coden">NURRFI</span>;
        ISSN:<span class="NLM_cas:issn">1029-8428</span>.
    
            (<span class="NLM_cas:orgname">Harwood Academic Publishers</span>)
        </div><div class="casAbstract">The most effective treatment of Parkinson's disease (PD) is, at present, the dopamine precursor L-3,4-dihydroxyphenyl-alanine (L-DOPA), however a no. of disadvantages such as a loss of drug efficacy and severe side-effects (psychoses, dyskinesias and on-off phenomena) limit long-term, effective utilization of this drug.  Recent exptl. studies in which selective antagonists of adenosine A2A receptors were used, have shown an improvement in motor disabilities in animal models of PD.  The A2A antagonist [7-(2-phenylethyl)-5-amino-2-(2-furyl)-pyrazolo-(4,3-e)-1,2,4-triazolo(1,5--c)pyrimidine] (SCH 58261) potentiated the contralateral turning behavior induced by a threshold dose of L-DOPA or direct dopamine receptor agonists in unilaterally 6-hydroxydopamine (6-OHDA) lesioned rats, an effect accompanied by an increase in Foslike-immunoreactivity in neurons of the lesioned striatum.  Likewise, other A2A receptor antagonists such as (3,7-dimethyl-1-propargylxanthine) (DMPX), [E-8-(3,4-dimethoxystyryl)-1,3-dipropyl-7-methylxanthine] (KF 17837) and [E-1,3-diethyl-8-(3,4-dimethoxystyryl)-7-methyl-3,7-dihydro-1H-purine-2, 6-dione] (KW 6002) antagonized catalepsy induced by haloperidol or reserpine in the rat, whereas in non-human primate models of PD, KW 6002 reduced the rigidity and improved the disability score of MPTP-treated marmosets and cynomolgus monkeys.  Moreover, in contrast to L-DOPA, selective A2A receptor antagonists administered chronically did not produce dyskinesias and did not evoke tolerance in 6-OHDA and MPTP models of PD.  An addnl. therapeutic potential of adenosine A2A antagonists emerged from studies showing neuroprotective properties of these compds. in animal models of cerebral ischemia and excitotoxicity, as well as in the (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) (MPTP) model of PD.  Adenosine A2A receptor antagonists by reversing motor impairments in animal models of PD and by contrasting cell degeneration are some of the most promising compds. for the treatment of PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcszaghZSO_rVg90H21EOLACvtfcHk0lgJ1EHOSVc2lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XpsVc%253D&md5=cda23d435af01aa1ffa6b2bff156d653</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1007%2FBF03033210&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF03033210%26sid%3Dliteratum%253Aachs%26aulast%3DMorelli%26aufirst%3DM.%26aulast%3DWardas%26aufirst%3DJ.%26atitle%3DAdenosine%2520A2A%2520receptor%2520antagonists%253A%2520potential%2520therapeutic%2520and%2520neuroprotective%2520effects%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DNeurotoxic.%2520Res.%26date%3D2001%26volume%3D3%26spage%3D545%26epage%3D556" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Xu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bastia, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwarzschild, M.</span><span> </span><span class="NLM_article-title">Therapeutic potential of adenosine A<sub>2A</sub> receptor antagonists in Parkinson’s disease</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">267</span><span class="NLM_x">–</span> <span class="NLM_lpage">310</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm501254d&amp;key=10.1016%2Fj.pharmthera.2004.10.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm501254d&amp;key=15737407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm501254d&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhvVCjt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2005&pages=267-310&author=K.+Xuauthor=E.+Bastiaauthor=M.+Schwarzschild&title=Therapeutic+potential+of+adenosine+A2A+receptor+antagonists+in+Parkinson%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic potential of adenosine A2A receptor antagonists in Parkinson's disease</span></div><div class="casAuthors">Xu, Kui; Bastia, Elena; Schwarzschild, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">267-310</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  In the pursuit of improved treatments for Parkinson's disease (PD), the adenosine A2A receptor has emerged as an attractive nondopaminergic target.  Based on the compelling behavioral pharmacol. and selective basal ganglia expression of this G-protein-coupled receptor, its antagonists are now crossing the threshold of clin. development as adjunctive symptomatic treatment for relatively advanced PD.  The antiparkinsonian potential of A2A antagonism has been boosted further by recent preclin. evidence that A2A antagonists might favorably alter the course as well as the symptoms of the disease.  Convergent epidemiol. and lab. data have suggested that A2A blockade may confer neuroprotection against the underlying dopaminergic neuron degeneration.  In addn., rodent and nonhuman primate studies have raised the possibility that A2A receptor activation contributes to the pathophysiol. of dyskinesias-problematic motor complications of std. PD therapy-and that A2A antagonism might help prevent them.  Realistically, despite being targeted to basal ganglia pathophysiol., A2A antagonists may be expected to have other beneficial and adverse effects elsewhere in the central nervous system (e.g., on mood and sleep) and in the periphery (e.g., on immune and inflammatory processes).  The thoughtful design of new clin. trials of A2A antagonists should take into consideration these counterbalancing hopes and concerns and may do well to shift toward a broader set of disease-modifying as well as symptomatic indications in early PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3HbF9ZxHP3bVg90H21EOLACvtfcHk0lgJ1EHOSVc2lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhvVCjt7s%253D&md5=ca493d29bdda09382108c0566a3a0877</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2004.10.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2004.10.007%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DK.%26aulast%3DBastia%26aufirst%3DE.%26aulast%3DSchwarzschild%26aufirst%3DM.%26atitle%3DTherapeutic%2520potential%2520of%2520adenosine%2520A2A%2520receptor%2520antagonists%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DPharmacol.%2520Ther.%26date%3D2005%26volume%3D105%26spage%3D267%26epage%3D310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Berque-Bestel, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lezoulac’h, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jockers, R.</span><span> </span><span class="NLM_article-title">Bivalent ligands as specific pharmacological tools for G-protein coupled receptor dimers</span> <span class="citation_source-journal">Curr. Drug Discovery Technol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">312</span><span class="NLM_x">–</span> <span class="NLM_lpage">318</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2008&pages=312-318&author=I.+Berque-Bestelauthor=F.+Lezoulac%E2%80%99hauthor=R.+Jockers&title=Bivalent+ligands+as+specific+pharmacological+tools+for+G-protein+coupled+receptor+dimers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBerque-Bestel%26aufirst%3DI.%26aulast%3DLezoulac%25E2%2580%2599h%26aufirst%3DF.%26aulast%3DJockers%26aufirst%3DR.%26atitle%3DBivalent%2520ligands%2520as%2520specific%2520pharmacological%2520tools%2520for%2520G-protein%2520coupled%2520receptor%2520dimers%26jtitle%3DCurr.%2520Drug%2520Discovery%2520Technol.%26date%3D2008%26volume%3D5%26spage%3D312%26epage%3D318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Shonberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scammells, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capuano, B.</span><span> </span><span class="NLM_article-title">Design strategies for bivalent ligands targeting GPCRs</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">963</span><span class="NLM_x">–</span> <span class="NLM_lpage">974</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Fjm501254d&amp;key=10.1002%2Fcmdc.201100101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm501254d&amp;key=21520422" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm501254d&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmsFGjsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=963-974&author=J.+Shonbergauthor=P.+J.+Scammellsauthor=B.+Capuano&title=Design+strategies+for+bivalent+ligands+targeting+GPCRs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Design Strategies for Bivalent Ligands Targeting GPCRs</span></div><div class="casAuthors">Shonberg, Jeremy; Scammells, Peter J.; Capuano, Ben</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">963-974</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Specifically designed bivalent ligands targeting G protein-coupled receptor (GPCR) dimeric structures have become increasingly popular in recent literature.  The advantages of the bivalent approach are numerous, including enhanced potency and receptor subtype specificity.  However, the use of bivalent ligands as potential pharmacotherapeutics is limited by problematic mol. properties, such as high mol. wt. and lipophilicity.  This Minireview focuses on the design of bivalent ligands recently described in the literature; discussing the choice of lead pharmacophore, the position and nature of the attachment point for linking the two pharmacophore units, and the length and compn. of the spacer group.  Furthermore, this Minireview distills the mol. descriptors of the bivalent ligands that exhibit in vivo activity, as well as highlights their ability to access the central nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7uDrMXq0sprVg90H21EOLACvtfcHk0lilzhoMLagOcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmsFGjsL0%253D&md5=569a8a988cdd9d2daf8f492211303934</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201100101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201100101%26sid%3Dliteratum%253Aachs%26aulast%3DShonberg%26aufirst%3DJ.%26aulast%3DScammells%26aufirst%3DP.%2BJ.%26aulast%3DCapuano%26aufirst%3DB.%26atitle%3DDesign%2520strategies%2520for%2520bivalent%2520ligands%2520targeting%2520GPCRs%26jtitle%3DChemMedChem%26date%3D2011%26volume%3D6%26spage%3D963%26epage%3D974" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Soriano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ventura, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molero, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casadó, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortés, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fanelli, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albericio, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lluís, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franco, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Royo, M.</span><span> </span><span class="NLM_article-title">Adenosine A<sub>2A</sub> receptor-antagonist/dopamine D<sub>2</sub> receptor-agonist bivalent ligands as pharmacological tools to detect A<sub>2A</sub>–D<sub>2</sub> receptor heteromers</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">5590</span><span class="NLM_x">–</span> <span class="NLM_lpage">5602</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm900298c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=5590-5602&author=A.+Sorianoauthor=R.+Venturaauthor=A.+Moleroauthor=R.+Hoenauthor=V.+Casad%C3%B3author=A.+Cort%C3%A9sauthor=F.+Fanelliauthor=F.+Albericioauthor=C.+Llu%C3%ADsauthor=R.+Francoauthor=M.+Royo&title=Adenosine+A2A+receptor-antagonist%2Fdopamine+D2+receptor-agonist+bivalent+ligands+as+pharmacological+tools+to+detect+A2A%E2%80%93D2+receptor+heteromers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm900298c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900298c%26sid%3Dliteratum%253Aachs%26aulast%3DSoriano%26aufirst%3DA.%26aulast%3DVentura%26aufirst%3DR.%26aulast%3DMolero%26aufirst%3DA.%26aulast%3DHoen%26aufirst%3DR.%26aulast%3DCasad%25C3%25B3%26aufirst%3DV.%26aulast%3DCort%25C3%25A9s%26aufirst%3DA.%26aulast%3DFanelli%26aufirst%3DF.%26aulast%3DAlbericio%26aufirst%3DF.%26aulast%3DLlu%25C3%25ADs%26aufirst%3DC.%26aulast%3DFranco%26aufirst%3DR.%26aulast%3DRoyo%26aufirst%3DM.%26atitle%3DAdenosine%2520A2A%2520receptor-antagonist%252Fdopamine%2520D2%2520receptor-agonist%2520bivalent%2520ligands%2520as%2520pharmacological%2520tools%2520to%2520detect%2520A2A%25E2%2580%2593D2%2520receptor%2520heteromers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D5590%26epage%3D5602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Morphy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kay, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rankovic, Z.</span><span> </span><span class="NLM_article-title">From magic bullets to designed multiple ligands</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">641</span><span class="NLM_x">–</span> <span class="NLM_lpage">651</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm501254d&amp;key=10.1016%2FS1359-6446%2804%2903163-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm501254d&amp;key=15279847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm501254d&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtVSktb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=641-651&author=R.+Morphyauthor=C.+Kayauthor=Z.+Rankovic&title=From+magic+bullets+to+designed+multiple+ligands"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">From magic bullets to designed multiple ligands</span></div><div class="casAuthors">Morphy, Richard; Kay, Corinne; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">641-651</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  A major trend in medicinal chem. in the coming years will be the rational design of ligands that are capable of modulating multiple disease-relevant targets in a specific manner.  Increasingly, it is being recognized that a balanced modulation of several targets can provide a superior therapeutic effect and side effect profile compared to the action of a selective ligand.  Rational approaches in which structural features from selective ligands are combined have produced designed multiple ligands that span a wide variety of targets and target classes.  A key challenge in the design of multiple ligands is attaining a balanced activity at each target of interest while simultaneously achieving a wider selectivity and a suitable pharmacokinetic profile.  An anal. of literature examples reveals trends and insights that might help medicinal chemists discover the next generation of these types of compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcsGpfzZok5rVg90H21EOLACvtfcHk0lgfZnwRitZ_ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtVSktb8%253D&md5=cd2491baad707043dbee4f59ccad9e1d</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2804%2903163-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252804%252903163-0%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DKay%26aufirst%3DC.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DFrom%2520magic%2520bullets%2520to%2520designed%2520multiple%2520ligands%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2004%26volume%3D9%26spage%3D641%26epage%3D651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Petzer, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steyn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castagnoli, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwarzschild, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van der Schyf, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castagnoli, N.</span><span> </span><span class="NLM_article-title">Inhibition of monoamine oxidase B by selective adenosine A<sub>2A</sub> receptor antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1299</span><span class="NLM_x">–</span> <span class="NLM_lpage">1310</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2003&pages=1299-1310&author=J.+P.+Petzerauthor=S.+Steynauthor=K.+P.+Castagnoliauthor=J.-F.+Chenauthor=M.+A.+Schwarzschildauthor=C.+J.+Van+der+Schyfauthor=N.+Castagnoli&title=Inhibition+of+monoamine+oxidase+B+by+selective+adenosine+A2A+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPetzer%26aufirst%3DJ.%2BP.%26aulast%3DSteyn%26aufirst%3DS.%26aulast%3DCastagnoli%26aufirst%3DK.%2BP.%26aulast%3DChen%26aufirst%3DJ.-F.%26aulast%3DSchwarzschild%26aufirst%3DM.%2BA.%26aulast%3DVan%2Bder%2BSchyf%26aufirst%3DC.%2BJ.%26aulast%3DCastagnoli%26aufirst%3DN.%26atitle%3DInhibition%2520of%2520monoamine%2520oxidase%2520B%2520by%2520selective%2520adenosine%2520A2A%2520receptor%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2003%26volume%3D11%26spage%3D1299%26epage%3D1310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Stößel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Küppers, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gütschow, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, C. E.</span><span> </span><span class="NLM_article-title">Dual targeting of the adenosine A<sub>2A</sub> receptors and monoamine oxidase B by 4<i>H</i>-3,1-benzothiazin-4-ones</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">4580</span><span class="NLM_x">–</span> <span class="NLM_lpage">4596</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm400336x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=4580-4596&author=A.+St%C3%B6%C3%9Felauthor=S.+Hinzauthor=P.+K%C3%BCppersauthor=J.+Heerauthor=M.+G%C3%BCtschowauthor=C.+E.+M%C3%BCller&title=Dual+targeting+of+the+adenosine+A2A+receptors+and+monoamine+oxidase+B+by+4H-3%2C1-benzothiazin-4-ones"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm400336x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400336x%26sid%3Dliteratum%253Aachs%26aulast%3DSt%25C3%25B6%25C3%259Fel%26aufirst%3DA.%26aulast%3DHinz%26aufirst%3DS.%26aulast%3DK%25C3%25BCppers%26aufirst%3DP.%26aulast%3DHeer%26aufirst%3DJ.%26aulast%3DG%25C3%25BCtschow%26aufirst%3DM.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26atitle%3DDual%2520targeting%2520of%2520the%2520adenosine%2520A2A%2520receptors%2520and%2520monoamine%2520oxidase%2520B%2520by%25204H-3%252C1-benzothiazin-4-ones%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D4580%26epage%3D4596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Gogoi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biswas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antonio, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reith, M. E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dutta, A. K.</span><span> </span><span class="NLM_article-title">Novel bivalent ligands for D<sub>2</sub>/D<sub>3</sub> dopamine receptors: significant cooperative gain in D<sub>2</sub> affinity and potency</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">991</span><span class="NLM_x">–</span> <span class="NLM_lpage">996</span></span><div class="citationLinks">[<a href="/doi/10.1021/ml3002117" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=991-996&author=S.+Gogoiauthor=S.+Biswasauthor=G.+Modiauthor=T.+Antonioauthor=M.+E.+A.+Reithauthor=A.+K.+Dutta&title=Novel+bivalent+ligands+for+D2%2FD3+dopamine+receptors%3A+significant+cooperative+gain+in+D2+affinity+and+potency"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fml3002117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml3002117%26sid%3Dliteratum%253Aachs%26aulast%3DGogoi%26aufirst%3DS.%26aulast%3DBiswas%26aufirst%3DS.%26aulast%3DModi%26aufirst%3DG.%26aulast%3DAntonio%26aufirst%3DT.%26aulast%3DReith%26aufirst%3DM.%2BE.%2BA.%26aulast%3DDutta%26aufirst%3DA.%2BK.%26atitle%3DNovel%2520bivalent%2520ligands%2520for%2520D2%252FD3%2520dopamine%2520receptors%253A%2520significant%2520cooperative%2520gain%2520in%2520D2%2520affinity%2520and%2520potency%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D991%26epage%3D996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Caulkett, P. W. R.; Jones, G.; Collis, M. G.; Poucher, S. M.</span><span> </span><span class="NLM_article-title">Preparation of (amino)heteroaryl[1,2,4]triazolo[1,5-<i>a</i>]triazines and related compounds as adenosine A<sub>2</sub> receptor antagonists</span> EP 459702, <span class="NLM_month">May</span><span class="NLM_day">23</span>,<span class="NLM_x"> </span><span class="NLM_year">1991</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1991&author=P.+W.+R.+Caulkett&author=G.+Jones&author=M.+G.+Collis&author=S.+M.+Poucher&title=Preparation+of+%28amino%29heteroaryl%5B1%2C2%2C4%5Dtriazolo%5B1%2C5-a%5Dtriazines+and+related+compounds+as+adenosine+A2+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCaulkett%26aufirst%3DP.%2BW.%2BR.%26atitle%3DPreparation%2520of%2520%2528amino%2529heteroaryl%255B1%252C2%252C4%255Dtriazolo%255B1%252C5-a%255Dtriazines%2520and%2520related%2520compounds%2520as%2520adenosine%2520A2%2520receptor%2520antagonists%26date%3D1991" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Jörg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agostino, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuriev, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mak, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scammells, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capuano, B.</span><span> </span><span class="NLM_article-title">Synthesis, molecular structure, NMR spectroscopic and computational analysis of a selective adenosine A<sub>2A</sub> antagonist, ZM 241385</span> <span class="citation_source-journal">Struct. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">1241</span><span class="NLM_x">–</span> <span class="NLM_lpage">1251</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Fjm501254d&amp;key=10.1007%2Fs11224-012-0151-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm501254d&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFeltL7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2013&pages=1241-1251&author=M.+J%C3%B6rgauthor=M.+Agostinoauthor=E.+Yurievauthor=F.+Makauthor=N.+Millerauthor=J.+Whiteauthor=P.+Scammellsauthor=B.+Capuano&title=Synthesis%2C+molecular+structure%2C+NMR+spectroscopic+and+computational+analysis+of+a+selective+adenosine+A2A+antagonist%2C+ZM+241385"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, molecular structure, NMR spectroscopic and computational analysis of a selective adenosine A2A antagonist, ZM 241385</span></div><div class="casAuthors">Jorg, Manuela; Agostino, Mark; Yuriev, Elizabeth; Mak, Frankie S.; Miller, Neil D.; White, Jonathan M.; Scammells, Peter J.; Capuano, Ben</div><div class="citationInfo"><span class="NLM_cas:title">Structural Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1241-1251</span>CODEN:
                <span class="NLM_cas:coden">STCHES</span>;
        ISSN:<span class="NLM_cas:issn">1040-0400</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Herein, we describe the synthesis of the adenosine A2A antagonist ZM 241385 (9) starting from com. available 2-furanhydrazide (1) and including a comprehensive structural characterization of all the intermediates and the final product.  In addn., extensive NMR anal., including temp. and concn.-dependent expts., are reported as well as the first single-crystal structure of the compd. ZM 241385 (9) as the trihydrate.  Furthermore, an extensive structural comparison of the single-crystal structure with the published protein bound X-ray structures is reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoY8hfprg36XbVg90H21EOLACvtfcHk0ljKjdzSU9-gyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFeltL7J&md5=c396ef41105a98f343b00cfd240587a7</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1007%2Fs11224-012-0151-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11224-012-0151-7%26sid%3Dliteratum%253Aachs%26aulast%3DJ%25C3%25B6rg%26aufirst%3DM.%26aulast%3DAgostino%26aufirst%3DM.%26aulast%3DYuriev%26aufirst%3DE.%26aulast%3DMak%26aufirst%3DF.%26aulast%3DMiller%26aufirst%3DN.%26aulast%3DWhite%26aufirst%3DJ.%26aulast%3DScammells%26aufirst%3DP.%26aulast%3DCapuano%26aufirst%3DB.%26atitle%3DSynthesis%252C%2520molecular%2520structure%252C%2520NMR%2520spectroscopic%2520and%2520computational%2520analysis%2520of%2520a%2520selective%2520adenosine%2520A2A%2520antagonist%252C%2520ZM%2520241385%26jtitle%3DStruct.%2520Chem.%26date%3D2013%26volume%3D24%26spage%3D1241%26epage%3D1251" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Jaakola, V.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffith, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanson, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherezov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chien, E. Y. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">IJzerman, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, R. C.</span><span> </span><span class="NLM_article-title">The 2.6 angstrom crystal structure of a human A<sub>2A</sub> adenosine receptor bound to an antagonist</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">322</span><span class="NLM_x">, </span> <span class="NLM_fpage">1211</span><span class="NLM_x">–</span> <span class="NLM_lpage">1217</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm501254d&amp;key=10.1126%2Fscience.1164772" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm501254d&amp;key=18832607" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm501254d&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlyqtbfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=322&publication_year=2008&pages=1211-1217&author=V.-P.+Jaakolaauthor=M.+T.+Griffithauthor=M.+A.+Hansonauthor=V.+Cherezovauthor=E.+Y.+T.+Chienauthor=J.+R.+Laneauthor=A.+P.+IJzermanauthor=R.+C.+Stevens&title=The+2.6+angstrom+crystal+structure+of+a+human+A2A+adenosine+receptor+bound+to+an+antagonist"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The 2.6 Angstrom Crystal Structure of a Human A2A Adenosine Receptor Bound to an Antagonist</span></div><div class="casAuthors">Jaakola, Veli-Pekka; Griffith, Mark T.; Hanson, Michael A.; Cherezov, Vadim; Chien, Ellen Y. T.; Lane, J. Robert; IJzerman, Adriaan P.; Stevens, Raymond C.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">322</span>
        (<span class="NLM_cas:issue">5905</span>),
    <span class="NLM_cas:pages">1211-1217</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The adenosine class of heterotrimeric guanine nucleotide-binding protein (G protein)-coupled receptors (GPCRs) mediates the important role of extracellular adenosine in many physiol. processes and is antagonized by caffeine.  The authors have detd. the crystal structure of the human A2A adenosine receptor, in complex with a high-affinity subtype-selective antagonist, ZM241385, to 2.6 angstrom resoln.  Four disulfide bridges in the extracellular domain, combined with a subtle repacking of the transmembrane helixes relative to the adrenergic and rhodopsin receptor structures, define a pocket distinct from that of other structurally detd. GPCRs.  The arrangement allows for the binding of the antagonist in an extended conformation, perpendicular to the membrane plane.  The binding site highlights an integral role for the extracellular loops, together with the helical core, in ligand recognition by this class of GPCRs and suggests a role for ZM241385 in restricting the movement of a tryptophan residue important in the activation mechanism of the class A receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7QL4wN4TdhrVg90H21EOLACvtfcHk0ljKjdzSU9-gyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlyqtbfN&md5=5bdb862b41f345c244f3c162e058206b</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1126%2Fscience.1164772&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1164772%26sid%3Dliteratum%253Aachs%26aulast%3DJaakola%26aufirst%3DV.-P.%26aulast%3DGriffith%26aufirst%3DM.%2BT.%26aulast%3DHanson%26aufirst%3DM.%2BA.%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DChien%26aufirst%3DE.%2BY.%2BT.%26aulast%3DLane%26aufirst%3DJ.%2BR.%26aulast%3DIJzerman%26aufirst%3DA.%2BP.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26atitle%3DThe%25202.6%2520angstrom%2520crystal%2520structure%2520of%2520a%2520human%2520A2A%2520adenosine%2520receptor%2520bound%2520to%2520an%2520antagonist%26jtitle%3DScience%26date%3D2008%26volume%3D322%26spage%3D1211%26epage%3D1217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Gallagher, G.,  Jr.</span><span> </span><span class="NLM_article-title">4-Aminoalkyl-2(3<i>H</i>)-indolones</span>. US4452808A,<span class="NLM_x"> </span><span class="NLM_year">1984</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1984&author=G.+Gallagher&title=4-Aminoalkyl-2%283H%29-indolones"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGallagher%26aufirst%3DG.%26atitle%3D4-Aminoalkyl-2%25283H%2529-indolones%26date%3D1984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">De, M. C.; Sree, H. N.</span><span> </span><span class="NLM_article-title">Ropinirole and domperidone for use in the treatment of Parkinson’s disease</span>. WO9200735A1,<span class="NLM_x"> </span><span class="NLM_year">1992</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1992&author=M.+C.+De&author=H.+N.+Sree&title=Ropinirole+and+domperidone+for+use+in+the+treatment+of+Parkinson%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDe%26aufirst%3DM.%2BC.%26atitle%3DRopinirole%2520and%2520domperidone%2520for%2520use%2520in%2520the%2520treatment%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26date%3D1992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Horvath, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fross, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kleiner-Fisman, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lerch, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stalder, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liaudat, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raskoff, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flachsbart, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rakowski, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pache, J.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burkhard, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lang, A. E.</span><span> </span><span class="NLM_article-title">Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists</span> <span class="citation_source-journal">Movement Disord.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">656</span><span class="NLM_x">–</span> <span class="NLM_lpage">662</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm501254d&amp;key=10.1002%2Fmds.20201" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Fjm501254d&amp;key=15197703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm501254d&amp;key=1%3ACAS%3A280%3ADC%252BD2c3ps1Cntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2004&pages=656-662&author=J.+Horvathauthor=R.+D.+Frossauthor=G.+Kleiner-Fismanauthor=R.+Lerchauthor=H.+Stalderauthor=S.+Liaudatauthor=W.+J.+Raskoffauthor=K.+D.+Flachsbartauthor=H.+Rakowskiauthor=J.-C.+Pacheauthor=P.+R.+Burkhardauthor=A.+E.+Lang&title=Severe+multivalvular+heart+disease%3A+a+new+complication+of+the+ergot+derivative+dopamine+agonists"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists</span></div><div class="casAuthors">Horvath Judit; Fross Robin D; Kleiner-Fisman Galit; Lerch Rene; Stalder Hans; Liaudat Suzanne; Raskoff William J; Flachsbart Keith D; Rakowski Harry; Pache Jean-Claude; Burkhard Pierre R; Lang Anthony E</div><div class="citationInfo"><span class="NLM_cas:title">Movement disorders : official journal of the Movement Disorder Society</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">656-62</span>
        ISSN:<span class="NLM_cas:issn">0885-3185</span>.
    </div><div class="casAbstract">We report on 4 new cases of valvular heart disease in Parkinson's disease patients treated with the ergot derivative dopamine agonists pergolide and cabergoline.  Noninflammatory fibrotic degeneration of cardiac valves has been reported to occur in patients with carcinoid syndrome and to occasionally complicate therapies with the anti-migraine ergot alkaloid ergotamine and methysergide and with the appetite suppressants fenfluramine and dexfenfluramine.  In these cases, the pathogenesis is suspected to involve serotonin-mediated abnormal fibrogenesis by means of the 5-HT2B receptors, which are expressed in the fibroblasts of heart valves.  Based on strikingly similar echocardiographic and histopathological features, we strongly suspect that ergot-derived dopamine agonists may cause a valvular heart disease nearly identical to that seen in those conditions.  These cases add to a rapidly growing and worrying list of similar published reports, suggesting that we may well be facing a novel, yet unrecognized, complication of this class of agents, which are widely used not only in Parkinson's disease but also in restless legs syndrome and various common endocrine dysfunctions.  Therefore, until more is known about the true prevalence of this side effect, we propose that an assessment of cardiac function be performed before and in the course of a long-term therapy with ergot derivative dopamine agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSxQF9MCY-7EI2y4bB4mnvYfW6udTcc2eZ4w4hNS9d15rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c3ps1Cntg%253D%253D&md5=95f8237633e64358628bea9fdb40c34a</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1002%2Fmds.20201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmds.20201%26sid%3Dliteratum%253Aachs%26aulast%3DHorvath%26aufirst%3DJ.%26aulast%3DFross%26aufirst%3DR.%2BD.%26aulast%3DKleiner-Fisman%26aufirst%3DG.%26aulast%3DLerch%26aufirst%3DR.%26aulast%3DStalder%26aufirst%3DH.%26aulast%3DLiaudat%26aufirst%3DS.%26aulast%3DRaskoff%26aufirst%3DW.%2BJ.%26aulast%3DFlachsbart%26aufirst%3DK.%2BD.%26aulast%3DRakowski%26aufirst%3DH.%26aulast%3DPache%26aufirst%3DJ.-C.%26aulast%3DBurkhard%26aufirst%3DP.%2BR.%26aulast%3DLang%26aufirst%3DA.%2BE.%26atitle%3DSevere%2520multivalvular%2520heart%2520disease%253A%2520a%2520new%2520complication%2520of%2520the%2520ergot%2520derivative%2520dopamine%2520agonists%26jtitle%3DMovement%2520Disord.%26date%3D2004%26volume%3D19%26spage%3D656%26epage%3D662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Müller, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fritze, J.</span><span> </span><span class="NLM_article-title">Fibrosis associated with dopamine agonist therapy in Parkinson’s disease</span> <span class="citation_source-journal">Clin. Neuropharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">109</span><span class="NLM_x">–</span> <span class="NLM_lpage">111</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2003&pages=109-111&author=T.+M%C3%BCllerauthor=J.+Fritze&title=Fibrosis+associated+with+dopamine+agonist+therapy+in+Parkinson%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25BCller%26aufirst%3DT.%26aulast%3DFritze%26aufirst%3DJ.%26atitle%3DFibrosis%2520associated%2520with%2520dopamine%2520agonist%2520therapy%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DClin.%2520Neuropharmacol.%26date%3D2003%26volume%3D26%26spage%3D109%26epage%3D111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Jörg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kazcor, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poso, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mak, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K. C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, N. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scammells, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capuano, B.</span><span> </span><span class="NLM_article-title">Investigation of novel ropinirole analogues: synthesis, pharmacological evaluation and computational analysis of dopamine D<sub>2</sub> receptor functionalized congeners and homobivalent ligands</span> <span class="citation_source-journal">Med. Chem. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">891</span><span class="NLM_x">–</span> <span class="NLM_lpage">898</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Fjm501254d&amp;key=10.1039%2Fc4md00066h" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=891-898&author=M.+J%C3%B6rgauthor=A.+Kazcorauthor=A.+Posoauthor=F.+S.+Makauthor=K.+C.+K.+Leeauthor=N.+D.+Millerauthor=P.+J.+Scammellsauthor=B.+Capuano&title=Investigation+of+novel+ropinirole+analogues%3A+synthesis%2C+pharmacological+evaluation+and+computational+analysis+of+dopamine+D2+receptor+functionalized+congeners+and+homobivalent+ligands"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1039%2Fc4md00066h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc4md00066h%26sid%3Dliteratum%253Aachs%26aulast%3DJ%25C3%25B6rg%26aufirst%3DM.%26aulast%3DKazcor%26aufirst%3DA.%26aulast%3DPoso%26aufirst%3DA.%26aulast%3DMak%26aufirst%3DF.%2BS.%26aulast%3DLee%26aufirst%3DK.%2BC.%2BK.%26aulast%3DMiller%26aufirst%3DN.%2BD.%26aulast%3DScammells%26aufirst%3DP.%2BJ.%26aulast%3DCapuano%26aufirst%3DB.%26atitle%3DInvestigation%2520of%2520novel%2520ropinirole%2520analogues%253A%2520synthesis%252C%2520pharmacological%2520evaluation%2520and%2520computational%2520analysis%2520of%2520dopamine%2520D2%2520receptor%2520functionalized%2520congeners%2520and%2520homobivalent%2520ligands%26jtitle%3DMed.%2520Chem.%2520Commun.%26date%3D2014%26volume%3D5%26spage%3D891%26epage%3D898" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Jörg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Headey, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scammells, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capuano, B.</span><span> </span><span class="NLM_article-title">NMR case study of ropinirole: concentration-dependent effects of nonexchangeable proton resonances</span> <span class="citation_source-journal">Magn. Reson. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">715</span><span class="NLM_x">–</span> <span class="NLM_lpage">718</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Fjm501254d&amp;key=10.1002%2Fmrc.4114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Fjm501254d&amp;key=25104507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm501254d&amp;key=1%3ACAS%3A280%3ADC%252BC2M%252FgtFWhuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2014&pages=715-718&author=M.+J%C3%B6rgauthor=S.+Headeyauthor=P.+J.+Scammellsauthor=B.+Capuano&title=NMR+case+study+of+ropinirole%3A+concentration-dependent+effects+of+nonexchangeable+proton+resonances"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">NMR case study of ropinirole: concentration-dependent effects of nonexchangeable proton resonances</span></div><div class="casAuthors">Jorg Manuela; Headey Stephen; Scammells Peter J; Capuano Ben</div><div class="citationInfo"><span class="NLM_cas:title">Magnetic resonance in chemistry : MRC</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">715-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRDrVxS3o7BkzdblLE_E9PWfW6udTcc2eZ4w4hNS9d15rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M%252FgtFWhuw%253D%253D&md5=0771b4b0a64befe905297fd4171a0cb6</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1002%2Fmrc.4114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmrc.4114%26sid%3Dliteratum%253Aachs%26aulast%3DJ%25C3%25B6rg%26aufirst%3DM.%26aulast%3DHeadey%26aufirst%3DS.%26aulast%3DScammells%26aufirst%3DP.%2BJ.%26aulast%3DCapuano%26aufirst%3DB.%26atitle%3DNMR%2520case%2520study%2520of%2520ropinirole%253A%2520concentration-dependent%2520effects%2520of%2520nonexchangeable%2520proton%2520resonances%26jtitle%3DMagn.%2520Reson.%2520Chem.%26date%3D2014%26volume%3D52%26spage%3D715%26epage%3D718" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Jörg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shonberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mak, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, N. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuriev, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scammells, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capuano, B.</span><span> </span><span class="NLM_article-title">Novel adenosine A<sub>2A</sub> receptor ligands: a synthetic, functional and computational investigation of selected literature adenosine A<sub>2A</sub> receptor antagonists for extending into extracellular space</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">3427</span><span class="NLM_x">–</span> <span class="NLM_lpage">3433</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=3427-3433&author=M.+J%C3%B6rgauthor=J.+Shonbergauthor=F.+S.+Makauthor=N.+D.+Millerauthor=E.+Yurievauthor=P.+J.+Scammellsauthor=B.+Capuano&title=Novel+adenosine+A2A+receptor+ligands%3A+a+synthetic%2C+functional+and+computational+investigation+of+selected+literature+adenosine+A2A+receptor+antagonists+for+extending+into+extracellular+space"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJ%25C3%25B6rg%26aufirst%3DM.%26aulast%3DShonberg%26aufirst%3DJ.%26aulast%3DMak%26aufirst%3DF.%2BS.%26aulast%3DMiller%26aufirst%3DN.%2BD.%26aulast%3DYuriev%26aufirst%3DE.%26aulast%3DScammells%26aufirst%3DP.%2BJ.%26aulast%3DCapuano%26aufirst%3DB.%26atitle%3DNovel%2520adenosine%2520A2A%2520receptor%2520ligands%253A%2520a%2520synthetic%252C%2520functional%2520and%2520computational%2520investigation%2520of%2520selected%2520literature%2520adenosine%2520A2A%2520receptor%2520antagonists%2520for%2520extending%2520into%2520extracellular%2520space%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D3427%26epage%3D3433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Federico, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paoletta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheong, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pastorin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cacciari, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stragliotto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klotz, K. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Z.-G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moro, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spalluto, G.</span><span> </span><span class="NLM_article-title">Synthesis and biological evaluation of a new series of 1,2,4-triazolo[1,5-<i>a</i>]-1,3,5-triazines as human A<sub>2A</sub> adenosine receptor antagonists with improved water solubility</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">877</span><span class="NLM_x">–</span> <span class="NLM_lpage">889</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm101349u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=877-889&author=S.+Federicoauthor=S.+Paolettaauthor=S.+L.+Cheongauthor=G.+Pastorinauthor=B.+Cacciariauthor=S.+Stragliottoauthor=K.+N.+Klotzauthor=J.+Siegelauthor=Z.-G.+Gaoauthor=K.+A.+Jacobsonauthor=S.+Moroauthor=G.+Spalluto&title=Synthesis+and+biological+evaluation+of+a+new+series+of+1%2C2%2C4-triazolo%5B1%2C5-a%5D-1%2C3%2C5-triazines+as+human+A2A+adenosine+receptor+antagonists+with+improved+water+solubility"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm101349u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101349u%26sid%3Dliteratum%253Aachs%26aulast%3DFederico%26aufirst%3DS.%26aulast%3DPaoletta%26aufirst%3DS.%26aulast%3DCheong%26aufirst%3DS.%2BL.%26aulast%3DPastorin%26aufirst%3DG.%26aulast%3DCacciari%26aufirst%3DB.%26aulast%3DStragliotto%26aufirst%3DS.%26aulast%3DKlotz%26aufirst%3DK.%2BN.%26aulast%3DSiegel%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DZ.-G.%26aulast%3DJacobson%26aufirst%3DK.%2BA.%26aulast%3DMoro%26aufirst%3DS.%26aulast%3DSpalluto%26aufirst%3DG.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520a%2520new%2520series%2520of%25201%252C2%252C4-triazolo%255B1%252C5-a%255D-1%252C3%252C5-triazines%2520as%2520human%2520A2A%2520adenosine%2520receptor%2520antagonists%2520with%2520improved%2520water%2520solubility%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D877%26epage%3D889" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Lee, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, M.-R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, Y.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, L.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, K.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, K.-L.</span><span> </span><span class="NLM_article-title">Preparation of unconventional dendrimers that contain rigid NH-triazine linkages and peripheral <i>tert</i>-butyl moieties for CO<sub>2</sub>-selective adsorption</span> <span class="citation_source-journal">Chem.—Eur. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">10573</span><span class="NLM_x">–</span> <span class="NLM_lpage">10579</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Fjm501254d&amp;key=10.1002%2Fchem.201202161" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Fjm501254d&amp;key=23794529" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm501254d&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpvVegtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=10573-10579&author=C.-H.+Leeauthor=M.-R.+Tsaiauthor=Y.-T.+Changauthor=L.-L.+Laiauthor=K.-L.+Luauthor=K.-L.+Cheng&title=Preparation+of+unconventional+dendrimers+that+contain+rigid+NH-triazine+linkages+and+peripheral+tert-butyl+moieties+for+CO2-selective+adsorption"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Preparation of Unconventional Dendrimers that Contain Rigid NH-Triazine Linkages and Peripheral tert-Butyl Moieties for CO2-Selective Adsorption</span></div><div class="casAuthors">Lee, Cheng-Hua; Tsai, Meng-Rong; Chang, Yen-Tzu; Lai, Long-Li; Lu, Kuang-Lieh; Cheng, Kung-Lung</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">10573-10579</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Three unconventional dendrimers that contained rigid NH-triazine linkages and peripheral tert-butoxycarbonyl moieties were prepd. by using a convergent approach and characterized by 1H and 13C NMR spectroscopy, mass spectrometry, and elemental anal.  Based on a thermogravimetric anal. study, these dendrimers were obsd. to display thermal stability at about 300°C.  The NH-triazine moiety, which possessed protonated and proton-free nitrogen sites (like the imidazole unit), displayed the capture of polarizable CO2 mols. through hydrogen-bond and/or dipole-quadrupole interactions.  In addn., the adsorption of various amts. of CO2 and N2 at different pressures suggests that the dendritic pores, which arise from the stacking of the middle co-planar and rim protuberant dendrimers, GnN-NGn (n = 1-3), either swell or shrink at high pressure, thus indicating that these dendrimers may have a breathing ability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYqhoBmwk_gLVg90H21EOLACvtfcHk0lgZi9dhc_8V_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpvVegtLg%253D&md5=ee772d70895dce09ebccfb06134c8bd0</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1002%2Fchem.201202161&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.201202161%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DC.-H.%26aulast%3DTsai%26aufirst%3DM.-R.%26aulast%3DChang%26aufirst%3DY.-T.%26aulast%3DLai%26aufirst%3DL.-L.%26aulast%3DLu%26aufirst%3DK.-L.%26aulast%3DCheng%26aufirst%3DK.-L.%26atitle%3DPreparation%2520of%2520unconventional%2520dendrimers%2520that%2520contain%2520rigid%2520NH-triazine%2520linkages%2520and%2520peripheral%2520tert-butyl%2520moieties%2520for%2520CO2-selective%2520adsorption%26jtitle%3DChem.%25E2%2580%2594Eur.%2520J.%26date%3D2013%26volume%3D19%26spage%3D10573%26epage%3D10579" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Castelar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbera, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcos, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romero, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serrano, J.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golemme, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Termine, R.</span><span> </span><span class="NLM_article-title">Supramolecular dendrimers based on the self-assembly of carbazole-derived dendrons and triazine rings: liquid crystal, photophysical and electrochemical properties</span> <span class="citation_source-journal">J. Mater. Chem. C</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">7321</span><span class="NLM_x">–</span> <span class="NLM_lpage">7332</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Fjm501254d&amp;key=10.1039%2Fc3tc31390e" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm501254d&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1KkurrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2013&pages=7321-7332&author=S.+Castelarauthor=J.+Barberaauthor=M.+Marcosauthor=P.+Romeroauthor=J.-L.+Serranoauthor=A.+Golemmeauthor=R.+Termine&title=Supramolecular+dendrimers+based+on+the+self-assembly+of+carbazole-derived+dendrons+and+triazine+rings%3A+liquid+crystal%2C+photophysical+and+electrochemical+properties"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Supramolecular dendrimers based on the self-assembly of carbazole-derived dendrons and triazine rings: liquid crystal, photophysical and electrochemical properties</span></div><div class="casAuthors">Castelar, Susana; Barbera, Joaquin; Marcos, Mercedes; Romero, Pilar; Serrano, Jose-Luis; Golemme, Attilio; Termine, Roberto</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Materials Chemistry C: Materials for Optical and Electronic Devices</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">7321-7332</span>CODEN:
                <span class="NLM_cas:coden">JMCCCX</span>;
        ISSN:<span class="NLM_cas:issn">2050-7534</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Two novel families of dendrimers have been synthesized by hydrogen bonding between a triazine moiety (M), as an electron-transporting central core, and three peripheral dendrons of generations 1 and 2 derived from bis(hydroxymethyl)propionic acid (bis-MPA).  The dendrons contain both carbazole-based groups as hole-transporting moieties and promesogenic units derived from 5-[4-(4-butoxybenzoyloxy)phenyloxy]pentanoic acid (family A) or cholesteryl hemisuccinate (family B) (in a 1 : 3 ratio).  The formation of the complexes was confirmed by IR and NMR data.  All synthesized complexes displayed mesogenic properties and their liq. cryst. properties have been investigated by means of differential scanning calorimetry (DSC), polarized optical microscopy (POM) and X-ray diffractometry (XRD).  Complexes derived from CzAn dendrons (family A) exhibit nematic mesomorphism whereas complexes derived from CzBn dendrons (family B) exhibit a smectic A phase.  The electrochem. behavior of the dendritic complexes was investigated by cyclic voltammetry (CV) and the dendrimers show irreversible or quasi-reversible electrochem. behavior in the range 0.0-2.0 V at a scan rate of 100 mV s-1.  The UV-vis absorption and emission properties of the compds. and the photoconductive properties of the dendrons and dendrimers have also been investigated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKJPShy7MEkbVg90H21EOLACvtfcHk0lgZi9dhc_8V_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1KkurrI&md5=a9c449684eb231aaaf0454e600e87718</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1039%2Fc3tc31390e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc3tc31390e%26sid%3Dliteratum%253Aachs%26aulast%3DCastelar%26aufirst%3DS.%26aulast%3DBarbera%26aufirst%3DJ.%26aulast%3DMarcos%26aufirst%3DM.%26aulast%3DRomero%26aufirst%3DP.%26aulast%3DSerrano%26aufirst%3DJ.-L.%26aulast%3DGolemme%26aufirst%3DA.%26aulast%3DTermine%26aufirst%3DR.%26atitle%3DSupramolecular%2520dendrimers%2520based%2520on%2520the%2520self-assembly%2520of%2520carbazole-derived%2520dendrons%2520and%2520triazine%2520rings%253A%2520liquid%2520crystal%252C%2520photophysical%2520and%2520electrochemical%2520properties%26jtitle%3DJ.%2520Mater.%2520Chem.%2520C%26date%3D2013%26volume%3D1%26spage%3D7321%26epage%3D7332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Pal, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mandal, M.</span><span> </span><span class="NLM_article-title">PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes</span> <span class="citation_source-journal">Acta Pharmacol. Sin.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">1441</span><span class="NLM_x">–</span> <span class="NLM_lpage">1458</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Fjm501254d&amp;key=10.1038%2Faps.2012.72" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Fjm501254d&amp;key=22983389" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm501254d&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslKqur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2012&pages=1441-1458&author=I.+Palauthor=M.+Mandal&title=PI3K+and+Akt+as+molecular+targets+for+cancer+therapy%3A+current+clinical+outcomes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes</span></div><div class="casAuthors">Pal, Ipsita; Mandal, Mahitosh</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmacologica Sinica</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1441-1458</span>CODEN:
                <span class="NLM_cas:coden">APSCG5</span>;
        ISSN:<span class="NLM_cas:issn">1671-4083</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The PI3K-Akt pathway is a vital regulator of cell proliferation and survival.  Alterations in the PIK3CA gene that lead to enhanced PI3K kinase activity were reported in many human cancer types, including cancers of the colon, breast, brain, liver, stomach and lung.  Deregulation of PI3K causes aberrant Akt activity.  Therefore targeting this pathway could have implications for cancer treatment.  The 1st generation PI3K-Akt inhibitors were proven to be highly effective with a low IC50, but later, they were shown to have toxic side effects and poor pharmacol. properties and selectivity.  Thus, these inhibitors were only effective in preclin. models.  However, derivs. of these 1st generation inhibitors are much more selective and are quite effective in targeting the PI3K-Akt pathway, either alone or in combination.  These 2nd-generation inhibitors are essentially a specific chem. moiety that helps to form a strong hydrogen bond interaction with the PI3K/Akt mol.  The goal of this review is to delineate the current efforts that were undertaken to inhibit the various components of the PI3K and Akt pathway in different types of cancer both in vitro and in vivo.  Our focus here is on these novel therapies and their inhibitory effects that depend upon their chem. nature, as well as their development towards clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGre6N5ImyVnMLVg90H21EOLACvtfcHk0lj0599ERLPqCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslKqur%252FP&md5=33f1ffb53abf0d9ba6518c18e10b3330</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1038%2Faps.2012.72&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Faps.2012.72%26sid%3Dliteratum%253Aachs%26aulast%3DPal%26aufirst%3DI.%26aulast%3DMandal%26aufirst%3DM.%26atitle%3DPI3K%2520and%2520Akt%2520as%2520molecular%2520targets%2520for%2520cancer%2520therapy%253A%2520current%2520clinical%2520outcomes%26jtitle%3DActa%2520Pharmacol.%2520Sin.%26date%3D2012%26volume%3D33%26spage%3D1441%26epage%3D1458" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Wu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Y.</span><span> </span><span class="NLM_article-title">Small molecules targeting phosphoinositide 3-kinases</span> <span class="citation_source-journal">MedChemComm</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1337</span><span class="NLM_x">–</span> <span class="NLM_lpage">1355</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=1337-1355&author=P.+Wuauthor=Y.+Hu&title=Small+molecules+targeting+phosphoinositide+3-kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DP.%26aulast%3DHu%26aufirst%3DY.%26atitle%3DSmall%2520molecules%2520targeting%2520phosphoinositide%25203-kinases%26jtitle%3DMedChemComm%26date%3D2012%26volume%3D3%26spage%3D1337%26epage%3D1355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Doan, K. M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humphreys, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webster, L. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wring, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shampine, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serabjit-Singh, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adkison, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polli, J. W.</span><span> </span><span class="NLM_article-title">Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">303</span><span class="NLM_x">, </span> <span class="NLM_fpage">1029</span><span class="NLM_x">–</span> <span class="NLM_lpage">1037</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Fjm501254d&amp;key=10.1124%2Fjpet.102.039255" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Fjm501254d&amp;key=12438524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Fjm501254d&amp;key=1%3ACAS%3A528%3ADC%252BD38XptlamtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=303&publication_year=2002&pages=1029-1037&author=K.+M.+M.+Doanauthor=J.+E.+Humphreysauthor=L.+O.+Websterauthor=S.+A.+Wringauthor=L.+J.+Shampineauthor=C.+J.+Serabjit-Singhauthor=K.+K.+Adkisonauthor=J.+W.+Polli&title=Passive+permeability+and+P-glycoprotein-mediated+efflux+differentiate+central+nervous+system+%28CNS%29+and+non-CNS+marketed+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs</span></div><div class="casAuthors">Doan, Kelly M. Mahar; Humphreys, Joan E.; Webster, Lindsey O.; Wring, Stephen A.; Shampine, Larry J.; Serabjit-Singh, Cosette J.; Adkison, Kimberly K.; Polli, Joseph W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">303</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1029-1037</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Membrane permeability and P-glycoprotein (Pgp) can be limiting factors for blood-brain barrier penetration.  The objectives of this study were to det. whether there are differences in the in vitro permeability, Pgp substrate profiles, and physicochem. properties of drugs for central nervous system (CNS) and non-CNS indications, and whether these differences are useful criteria in selecting compds. for drug development.  Apparent permeability (Papp) and Pgp substrate profiles for 93 CNS and non-CNS drugs were detd. by monolayer efflux.  Calcein-AM inhibition assays were used to supplement the efflux results.  The CNS set (2 of 48, 4.2%) had a 7-fold lower incidence of passive permeability values <150 nm/s compared with the non-CNS set (13 of 45, 28.9%).  The majority of drugs (72.0%, 67 of 93) were not Pgp substrates; however, 49.5% (46 of 93) were pos. in the calcein-AM assay when tested at 100 μM.  The CNS drug set (of 48, 14.6%) had a 3-fold lower incidence of Pgp-mediated efflux than the non-CNS drug set (of 45, 42.2%).  Anal. of 18 physicochem. properties revealed that the CNS drug set had fewer hydrogen bond donors, fewer pos. charges, greater lipophilicity, lower polar surface area, and reduced flexibility compared with the non-CNS group, properties that enhance membrane permeability.  This study on a large, diverse set of marketed compds. clearly demonstrates that permeability, Pgp-mediated efflux, and certain physicochem. properties are factors that differentiate CNS and non-CNS drugs.  For CNS delivery, a drug should ideally have an in vitro passive permeability >150 nm/s and not be a good (B → A/A → B ratio <2.5) Pgp substrate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2qUc-kS0MC7Vg90H21EOLACvtfcHk0lj0599ERLPqCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XptlamtLg%253D&md5=bcac11a02278360d6d6ad48718f0d5be</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1124%2Fjpet.102.039255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.102.039255%26sid%3Dliteratum%253Aachs%26aulast%3DDoan%26aufirst%3DK.%2BM.%2BM.%26aulast%3DHumphreys%26aufirst%3DJ.%2BE.%26aulast%3DWebster%26aufirst%3DL.%2BO.%26aulast%3DWring%26aufirst%3DS.%2BA.%26aulast%3DShampine%26aufirst%3DL.%2BJ.%26aulast%3DSerabjit-Singh%26aufirst%3DC.%2BJ.%26aulast%3DAdkison%26aufirst%3DK.%2BK.%26aulast%3DPolli%26aufirst%3DJ.%2BW.%26atitle%3DPassive%2520permeability%2520and%2520P-glycoprotein-mediated%2520efflux%2520differentiate%2520central%2520nervous%2520system%2520%2528CNS%2529%2520and%2520non-CNS%2520marketed%2520drugs%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2002%26volume%3D303%26spage%3D1029%26epage%3D1037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Begley, D. J.</span><span> </span><span class="NLM_article-title">Delivery of therapeutic agents to the central nervous system: the problems and the possibilities</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">29</span><span class="NLM_x">–</span> <span class="NLM_lpage">45</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Fjm501254d&amp;key=10.1016%2Fj.pharmthera.2004.08.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Fjm501254d&amp;key=15500907" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm501254d&amp;key=1%3ACAS%3A528%3ADC%252BD2cXovVKqsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2004&pages=29-45&author=D.+J.+Begley&title=Delivery+of+therapeutic+agents+to+the+central+nervous+system%3A+the+problems+and+the+possibilities"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Delivery of therapeutic agents to the central nervous system: the problems and the possibilities</span></div><div class="casAuthors">Begley, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29-45</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The presence of a blood-brain barrier (BBB) and a blood-cerebrospinal fluid barrier presents a huge challenge for effective delivery of therapeutics to the central nervous system (CNS).  Many potential drugs, which are effective at their site of action, have failed and have been discarded during their development for clin. use due to a failure to deliver them in sufficient quantity to the CNS.  In consequence, many diseases of the CNS are undertreated.  In recent years, it has become clear that the blood-CNS barriers are not only anatomical barriers to the free movement of solutes between blood and brain but also transport and metabolic barriers.  The cell assocn., sometimes called the neurovascular unit, constitutes the BBB and is now appreciated to be a complex group of interacting cells, which in combination induce the formation of a BBB.  The various strategies available and under development for enhancing drug delivery to the CNS are reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSEcyTMlnGXrVg90H21EOLACvtfcHk0lj0599ERLPqCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXovVKqsrc%253D&md5=2667522bbe2ce0501a9d6d442db40d5a</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2004.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2004.08.001%26sid%3Dliteratum%253Aachs%26aulast%3DBegley%26aufirst%3DD.%2BJ.%26atitle%3DDelivery%2520of%2520therapeutic%2520agents%2520to%2520the%2520central%2520nervous%2520system%253A%2520the%2520problems%2520and%2520the%2520possibilities%26jtitle%3DPharmacol.%2520Ther.%26date%3D2004%26volume%3D104%26spage%3D29%26epage%3D45" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Ghosh, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antonio, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reith, M. E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dutta, A. K.</span><span> </span><span class="NLM_article-title">Discovery of 4-(4-(2-((5-hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)(propyl)amino)ethyl)piperazin-1-yl)quinolin-8-ol and its analogues as highly potent dopamine D<sub>2</sub>/D<sub>3</sub> agonists and as iron chelator: in vivo activity indicates potential application in symptomatic and neuroprotective therapy for Parkinson’s disease</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">2114</span><span class="NLM_x">–</span> <span class="NLM_lpage">2125</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm901618d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2114-2125&author=B.+Ghoshauthor=T.+Antonioauthor=M.+E.+A.+Reithauthor=A.+K.+Dutta&title=Discovery+of+4-%284-%282-%28%285-hydroxy-1%2C2%2C3%2C4-tetrahydronaphthalen-2-yl%29%28propyl%29amino%29ethyl%29piperazin-1-yl%29quinolin-8-ol+and+its+analogues+as+highly+potent+dopamine+D2%2FD3+agonists+and+as+iron+chelator%3A+in+vivo+activity+indicates+potential+application+in+symptomatic+and+neuroprotective+therapy+for+Parkinson%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fjm901618d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901618d%26sid%3Dliteratum%253Aachs%26aulast%3DGhosh%26aufirst%3DB.%26aulast%3DAntonio%26aufirst%3DT.%26aulast%3DReith%26aufirst%3DM.%2BE.%2BA.%26aulast%3DDutta%26aufirst%3DA.%2BK.%26atitle%3DDiscovery%2520of%25204-%25284-%25282-%2528%25285-hydroxy-1%252C2%252C3%252C4-tetrahydronaphthalen-2-yl%2529%2528propyl%2529amino%2529ethyl%2529piperazin-1-yl%2529quinolin-8-ol%2520and%2520its%2520analogues%2520as%2520highly%2520potent%2520dopamine%2520D2%252FD3%2520agonists%2520and%2520as%2520iron%2520chelator%253A%2520in%2520vivo%2520activity%2520indicates%2520potential%2520application%2520in%2520symptomatic%2520and%2520neuroprotective%2520therapy%2520for%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2114%26epage%3D2125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Doll, M. K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nichols, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kilts, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prioleau, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawler, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mailman, R. B.</span><span> </span><span class="NLM_article-title">Synthesis and dopaminergic properties of benzo-fused analogs of quinpirole and quinelorane</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">935</span><span class="NLM_x">–</span> <span class="NLM_lpage">940</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm9804533" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1999&pages=935-940&author=M.+K.+H.+Dollauthor=D.+E.+Nicholsauthor=J.+D.+Kiltsauthor=C.+Prioleauauthor=C.+P.+Lawlerauthor=M.+M.+Lewisauthor=R.+B.+Mailman&title=Synthesis+and+dopaminergic+properties+of+benzo-fused+analogs+of+quinpirole+and+quinelorane"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm9804533&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9804533%26sid%3Dliteratum%253Aachs%26aulast%3DDoll%26aufirst%3DM.%2BK.%2BH.%26aulast%3DNichols%26aufirst%3DD.%2BE.%26aulast%3DKilts%26aufirst%3DJ.%2BD.%26aulast%3DPrioleau%26aufirst%3DC.%26aulast%3DLawler%26aufirst%3DC.%2BP.%26aulast%3DLewis%26aufirst%3DM.%2BM.%26aulast%3DMailman%26aufirst%3DR.%2BB.%26atitle%3DSynthesis%2520and%2520dopaminergic%2520properties%2520of%2520benzo-fused%2520analogs%2520of%2520quinpirole%2520and%2520quinelorane%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1999%26volume%3D42%26spage%3D935%26epage%3D940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Wilcox, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, W.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brusniak, M.-Y. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilcox, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearlman, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teeter, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DuRand, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiens, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neve, K. A.</span><span> </span><span class="NLM_article-title">CoMFA-based prediction of agonist affinities at recombinant wild type versus serine to alanine point mutated D<sub>2</sub> dopamine receptors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">3005</span><span class="NLM_x">–</span> <span class="NLM_lpage">3019</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm990526y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=3005-3019&author=R.+E.+Wilcoxauthor=W.-H.+Huangauthor=M.-Y.+K.+Brusniakauthor=D.+M.+Wilcoxauthor=R.+S.+Pearlmanauthor=M.+M.+Teeterauthor=C.+J.+DuRandauthor=B.+L.+Wiensauthor=K.+A.+Neve&title=CoMFA-based+prediction+of+agonist+affinities+at+recombinant+wild+type+versus+serine+to+alanine+point+mutated+D2+dopamine+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Fjm990526y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm990526y%26sid%3Dliteratum%253Aachs%26aulast%3DWilcox%26aufirst%3DR.%2BE.%26aulast%3DHuang%26aufirst%3DW.-H.%26aulast%3DBrusniak%26aufirst%3DM.-Y.%2BK.%26aulast%3DWilcox%26aufirst%3DD.%2BM.%26aulast%3DPearlman%26aufirst%3DR.%2BS.%26aulast%3DTeeter%26aufirst%3DM.%2BM.%26aulast%3DDuRand%26aufirst%3DC.%2BJ.%26aulast%3DWiens%26aufirst%3DB.%2BL.%26aulast%3DNeve%26aufirst%3DK.%2BA.%26atitle%3DCoMFA-based%2520prediction%2520of%2520agonist%2520affinities%2520at%2520recombinant%2520wild%2520type%2520versus%2520serine%2520to%2520alanine%2520point%2520mutated%2520D2%2520dopamine%2520receptors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D3005%26epage%3D3019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Brewster, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nichols, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riggs, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mottola, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovenberg, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mailman, R. B.</span><span> </span><span class="NLM_article-title"><i>trans</i>-10,11-Dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[<i>a</i>]phenanthridine: a highly potent selective dopamine D<sub>1</sub> full agonist</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">1756</span><span class="NLM_x">–</span> <span class="NLM_lpage">1764</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00168a034" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=1990&pages=1756-1764&author=W.+K.+Brewsterauthor=D.+E.+Nicholsauthor=R.+M.+Riggsauthor=D.+M.+Mottolaauthor=T.+W.+Lovenbergauthor=M.+H.+Lewisauthor=R.+B.+Mailman&title=trans-10%2C11-Dihydroxy-5%2C6%2C6a%2C7%2C8%2C12b-hexahydrobenzo%5Ba%5Dphenanthridine%3A+a+highly+potent+selective+dopamine+D1+full+agonist"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fjm00168a034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00168a034%26sid%3Dliteratum%253Aachs%26aulast%3DBrewster%26aufirst%3DW.%2BK.%26aulast%3DNichols%26aufirst%3DD.%2BE.%26aulast%3DRiggs%26aufirst%3DR.%2BM.%26aulast%3DMottola%26aufirst%3DD.%2BM.%26aulast%3DLovenberg%26aufirst%3DT.%2BW.%26aulast%3DLewis%26aufirst%3DM.%2BH.%26aulast%3DMailman%26aufirst%3DR.%2BB.%26atitle%3Dtrans-10%252C11-Dihydroxy-5%252C6%252C6a%252C7%252C8%252C12b-hexahydrobenzo%255Ba%255Dphenanthridine%253A%2520a%2520highly%2520potent%2520selective%2520dopamine%2520D1%2520full%2520agonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1990%26volume%3D33%26spage%3D1756%26epage%3D1764" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Smith, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nichols, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mailman, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawler, C. P.</span><span> </span><span class="NLM_article-title">Locomotor inhibition, yawning and vacuous chewing induced by a novel dopamine D<sub>2</sub> post-synaptic receptor agonist</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">323</span><span class="NLM_x">, </span> <span class="NLM_fpage">27</span><span class="NLM_x">–</span> <span class="NLM_lpage">36</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Fjm501254d&amp;key=10.1016%2FS0014-2999%2897%2900026-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Fjm501254d&amp;key=9105873" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Fjm501254d&amp;key=1%3ACAS%3A528%3ADyaK2sXhslOltbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=323&publication_year=1997&pages=27-36&author=H.+P.+Smithauthor=D.+E.+Nicholsauthor=R.+B.+Mailmanauthor=C.+P.+Lawler&title=Locomotor+inhibition%2C+yawning+and+vacuous+chewing+induced+by+a+novel+dopamine+D2+post-synaptic+receptor+agonist"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Locomotor inhibition, yawning and vacuous chewing induced by a novel dopamine D2 post-synaptic receptor agonist</span></div><div class="casAuthors">Smith, Hilary P.; Nichols, David E.; Mailman, Richard B.; Lawler, Cindy P.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">323</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-36</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The N-Pr analog of dihydrexidine ((±)-trans-10,11-dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine) is a dopamine receptor agonist with high affinity for dopamine D2 and D3 receptors (K0.5 = 26 and 5 nM, resp.).  Members of the hexahydrobenzo[a]phenanthridine structural class are atypical because they display high intrinsic activity at post-synaptic dopamine D2 receptors, but low intrinsic activity at dopamine D2 autoreceptors.  The present study examd. the effects of (±)-N-n-propyl-dihydrexidine on unconditioned behaviors in rats.  The most striking results obsd. were large, dose-dependent decreases in locomotor activity (e.g., locomotor inhibition), and increases in vacuous chewing; yawning was also increased at the highest dose of (±)-N-n-propyl-dihydrexidine.  The locomotor inhibition and yawning induced by (±)-N-n-propyl-dihydrexidine were blocked by pre-treatment with (-)-remoxipride (S(-)-3-bromo-N-((1-ethyl-2-pyrrolidinyl)-methyl)-2,6-dimethoxybenzamide), a dopamine D2 receptor antagonist, but not by the dopamine D1 receptor antagonist (+)-SCH23390 (R(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine).  Vacuous chewing was decreased by both (-)-remoxipride and (+)-SCH23390.  These data support the hypothesis that a subpopulation of post-synaptic dopamine D2 receptors has a crit. role in decreases in locomotor activity and induction of vacuous chewing and yawning.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJVedYkLwAbLVg90H21EOLACvtfcHk0liDt3IhZro27Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXhslOltbs%253D&md5=ab93c276c6116f67e970be5113c45ea7</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2FS0014-2999%2897%2900026-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-2999%252897%252900026-5%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DH.%2BP.%26aulast%3DNichols%26aufirst%3DD.%2BE.%26aulast%3DMailman%26aufirst%3DR.%2BB.%26aulast%3DLawler%26aufirst%3DC.%2BP.%26atitle%3DLocomotor%2520inhibition%252C%2520yawning%2520and%2520vacuous%2520chewing%2520induced%2520by%2520a%2520novel%2520dopamine%2520D2%2520post-synaptic%2520receptor%2520agonist%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1997%26volume%3D323%26spage%3D27%26epage%3D36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Gobert, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dekeyne, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Millan, M. J.</span><span> </span><span class="NLM_article-title">The ability of WAY100,635 to potentiate the neurochemical and functional actions of fluoxetine is enhanced by co-administration of SB224,289, but not BRL15572</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">1608</span><span class="NLM_x">–</span> <span class="NLM_lpage">1616</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2000&pages=1608-1616&author=A.+Gobertauthor=A.+Dekeyneauthor=M.+J.+Millan&title=The+ability+of+WAY100%2C635+to+potentiate+the+neurochemical+and+functional+actions+of+fluoxetine+is+enhanced+by+co-administration+of+SB224%2C289%2C+but+not+BRL15572"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGobert%26aufirst%3DA.%26aulast%3DDekeyne%26aufirst%3DA.%26aulast%3DMillan%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520ability%2520of%2520WAY100%252C635%2520to%2520potentiate%2520the%2520neurochemical%2520and%2520functional%2520actions%2520of%2520fluoxetine%2520is%2520enhanced%2520by%2520co-administration%2520of%2520SB224%252C289%252C%2520but%2520not%2520BRL15572%26jtitle%3DNeuropharmacology%26date%3D2000%26volume%3D39%26spage%3D1608%26epage%3D1616" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Hitchcock, S. A.</span><span> </span><span class="NLM_article-title">Blood-brain barrier permeability considerations for CNS-targeted compound library design</span> <span class="citation_source-journal">Curr. Opin. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">318</span><span class="NLM_x">–</span> <span class="NLM_lpage">323</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Fjm501254d&amp;key=10.1016%2Fj.cbpa.2008.03.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Fjm501254d&amp;key=18435937" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Fjm501254d&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnt1ers74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2008&pages=318-323&author=S.+A.+Hitchcock&title=Blood-brain+barrier+permeability+considerations+for+CNS-targeted+compound+library+design"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Blood-brain barrier permeability considerations for CNS-targeted compound library design</span></div><div class="casAuthors">Hitchcock, Stephen A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">318-323</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  A further refinement of the concept of drug-likeness is required for compd. libraries intended for central nervous system (CNS) targets to account for the limitations imposed by blood-brain barrier permeability.  This review describes criteria and processes that can be applied in the de novo design and assembly of libraries to increase the odds of compds. residing within CNS-accessible chem. space.  A no. of published examples where CNS activity and/or penetration characteristics have been a factor in library design are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorhMoAmlVhlrVg90H21EOLACvtfcHk0lio4Y4od0P8gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnt1ers74%253D&md5=7b6962e237bc80c1d44053b54c5f3f40</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2008.03.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2008.03.019%26sid%3Dliteratum%253Aachs%26aulast%3DHitchcock%26aufirst%3DS.%2BA.%26atitle%3DBlood-brain%2520barrier%2520permeability%2520considerations%2520for%2520CNS-targeted%2520compound%2520library%2520design%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2008%26volume%3D12%26spage%3D318%26epage%3D323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Summerfield, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cutler, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osuna, M. d. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hammond, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, S.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hersey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spalding, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeffrey, P.</span><span> </span><span class="NLM_article-title">Improving the in vitro prediction of in vivo central nervous system penetration: integrating permeability, P-glycoprotein efflux, and free fractions in blood and brain</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">316</span><span class="NLM_x">, </span> <span class="NLM_fpage">1282</span><span class="NLM_x">–</span> <span class="NLM_lpage">1290</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Fjm501254d&amp;key=10.1124%2Fjpet.105.092916" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Fjm501254d&amp;key=16330496" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Fjm501254d&amp;key=1%3ACAS%3A528%3ADC%252BD28Xit1SgsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=316&publication_year=2006&pages=1282-1290&author=S.+G.+Summerfieldauthor=A.+J.+Stevensauthor=L.+Cutlerauthor=M.+d.+C.+Osunaauthor=B.+Hammondauthor=S.-P.+Tangauthor=A.+Herseyauthor=D.+J.+Spaldingauthor=P.+Jeffrey&title=Improving+the+in+vitro+prediction+of+in+vivo+central+nervous+system+penetration%3A+integrating+permeability%2C+P-glycoprotein+efflux%2C+and+free+fractions+in+blood+and+brain"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Improving the in vitro prediction of in vivo central nervous system penetration: integrating permeability, P-glycoprotein efflux, and free fractions in blood and brain</span></div><div class="casAuthors">Summerfield, Scott G.; Stevens, Alexander J.; Cutler, Leanne; Osuna, Maria del Carmen; Hammond, Beverley; Tang, Sac-Pham; Hersey, Ann; Spalding, David J.; Jeffrey, Phil</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">316</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1282-1290</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">This work examines the inter-relationship between the unbound drug fractions in blood and brain homogenate, passive membrane permeability, P-glycoprotein (Pgp) efflux ratio, and log octanol/water partition coeffs. (cLogP) in detg. the extent of central nervous system (CNS) penetration obsd. in vivo.  The present results demonstrate that compds. often considered to be Pgp substrates in rodents (efflux ratio greater than 5 in multidrug resistant Madin-Darby canine kidney cells) with poor passive permeability may still exhibit reasonable CNS penetration in vivo; i.e., where the unbound fractions and non-specific tissue binding act as a compensating force.  In these instances, the efflux ratio and in vitro blood-brain partition ratio may be used to predict the in vivo blood-brain ratio.  This relationship may be extended to account for the differences in CNS penetration obsd. in vivo between mdr1a/b wild type and knockout mice.  In some instances, cross-species differences that might initially seem to be related to differing transporter expression can be rationalized from knowledge of unbound fractions alone.  The results presented in this article suggest that the information exists to provide a coherent picture of the nature of CNS penetration in the drug discovery setting, allowing the focus to be shifted away from understanding CNS penetration toward the more important aspect of understanding CNS efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZMb2mL7xQC7Vg90H21EOLACvtfcHk0lio4Y4od0P8gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xit1SgsL0%253D&md5=02b6cbbcde6738e7f6802d223b889261</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1124%2Fjpet.105.092916&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.105.092916%26sid%3Dliteratum%253Aachs%26aulast%3DSummerfield%26aufirst%3DS.%2BG.%26aulast%3DStevens%26aufirst%3DA.%2BJ.%26aulast%3DCutler%26aufirst%3DL.%26aulast%3DOsuna%26aufirst%3DM.%2Bd.%2BC.%26aulast%3DHammond%26aufirst%3DB.%26aulast%3DTang%26aufirst%3DS.-P.%26aulast%3DHersey%26aufirst%3DA.%26aulast%3DSpalding%26aufirst%3DD.%2BJ.%26aulast%3DJeffrey%26aufirst%3DP.%26atitle%3DImproving%2520the%2520in%2520vitro%2520prediction%2520of%2520in%2520vivo%2520central%2520nervous%2520system%2520penetration%253A%2520integrating%2520permeability%252C%2520P-glycoprotein%2520efflux%252C%2520and%2520free%2520fractions%2520in%2520blood%2520and%2520brain%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2006%26volume%3D316%26spage%3D1282%26epage%3D1290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Veber, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, H.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kopple, K. D.</span><span> </span><span class="NLM_article-title">Molecular properties that influence the oral bioavailability of drug candidates</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">2615</span><span class="NLM_x">–</span> <span class="NLM_lpage">2623</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm020017n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Fjm501254d&amp;key=1%3ACAS%3A528%3ADC%252BD38XjsFCmt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=2615-2623&author=D.+F.+Veberauthor=S.+R.+Johnsonauthor=H.-Y.+Chengauthor=B.+R.+Smithauthor=K.+W.+Wardauthor=K.+D.+Kopple&title=Molecular+properties+that+influence+the+oral+bioavailability+of+drug+candidates"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Properties That Influence the Oral Bioavailability of Drug Candidates</span></div><div class="casAuthors">Veber, Daniel F.; Johnson, Stephen R.; Cheng, Hung-Yuan; Smith, Brian R.; Ward, Keith W.; Kopple, Kenneth D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2615-2623</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Oral bioavailability measurements in rats for over 1100 drug candidates studied at Smith-Kline Beecham Pharmaceuticals (now Glaxo Smith-Kline) have allowed us to analyze the relative importance of mol. properties considered to influence that drug property.  Reduced mol. flexibility, as measured by the no. of rotatable bonds, and low polar surface area or total hydrogen bond count (sum of donors and acceptors) are found to be important predictors of good oral bioavailability, independent of mol. wt.  That on av. both the no. of rotatable bonds and polar surface area or hydrogen bond count tend to increase with mol. wt. may in part explain the success of the mol. wt. parameter in predicting oral bioavailability.  The commonly applied mol. wt. cutoff at 500 does not itself significantly sep. compds. with poor oral bioavailability from those with acceptable values in this extensive data set.  Our observations suggest that compds. which meet only the 2 criteria of (1) 10 or fewer rotatable bonds and (2) polar surface area ≤140 Å2 (or 12 or fewer H-bond donors and acceptors) will have a high probability of good oral bioavailability in the rat.  Data sets for the artificial membrane permeation rate and for clearance in the rat were also examd.  Reduced polar surface area correlates better with increased permeation rate than does lipophilicity (C log P), and increased rotatable bond count has a neg. effect on the permeation rate.  A threshold permeation rate is a prerequisite of oral bioavailability.  The rotatable bond count does not correlate with the data examd. here for the in vivo clearance rate in the rat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3JtJEkO7yVLVg90H21EOLACvtfcHk0lgBVNDdxcaJDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjsFCmt7g%253D&md5=eaad26ed6a259de82ad65a8834fc397d</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fjm020017n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020017n%26sid%3Dliteratum%253Aachs%26aulast%3DVeber%26aufirst%3DD.%2BF.%26aulast%3DJohnson%26aufirst%3DS.%2BR.%26aulast%3DCheng%26aufirst%3DH.-Y.%26aulast%3DSmith%26aufirst%3DB.%2BR.%26aulast%3DWard%26aufirst%3DK.%2BW.%26aulast%3DKopple%26aufirst%3DK.%2BD.%26atitle%3DMolecular%2520properties%2520that%2520influence%2520the%2520oral%2520bioavailability%2520of%2520drug%2520candidates%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D2615%26epage%3D2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Bergström, C. A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charman, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicolazzo, J. A.</span><span> </span><span class="NLM_article-title">Computational prediction of CNS drug exposure based on a novel in vivo dataset</span> <span class="citation_source-journal">Pharm. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">3131</span><span class="NLM_x">–</span> <span class="NLM_lpage">3142</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2012&pages=3131-3142&author=C.+A.+S.+Bergstr%C3%B6mauthor=S.+A.+Charmanauthor=J.+A.+Nicolazzo&title=Computational+prediction+of+CNS+drug+exposure+based+on+a+novel+in+vivo+dataset"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBergstr%25C3%25B6m%26aufirst%3DC.%2BA.%2BS.%26aulast%3DCharman%26aufirst%3DS.%2BA.%26aulast%3DNicolazzo%26aufirst%3DJ.%2BA.%26atitle%3DComputational%2520prediction%2520of%2520CNS%2520drug%2520exposure%2520based%2520on%2520a%2520novel%2520in%2520vivo%2520dataset%26jtitle%3DPharm.%2520Res.%26date%3D2012%26volume%3D29%26spage%3D3131%26epage%3D3142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Ghose, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herbertz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudkins, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorsey, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallamo, J. P.</span><span> </span><span class="NLM_article-title">Knowledge-based, central nervous system (CNS) lead selection and lead optimization for CNS drug discovery</span> <span class="citation_source-journal">ACS Chem. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">50</span><span class="NLM_x">–</span> <span class="NLM_lpage">68</span></span><div class="citationLinks">[<a href="/doi/10.1021/cn200100h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Fjm501254d&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVSit7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=50-68&author=A.+K.+Ghoseauthor=T.+Herbertzauthor=R.+L.+Hudkinsauthor=B.+D.+Dorseyauthor=J.+P.+Mallamo&title=Knowledge-based%2C+central+nervous+system+%28CNS%29+lead+selection+and+lead+optimization+for+CNS+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Knowledge-Based, Central Nervous System (CNS) Lead Selection and Lead Optimization for CNS Drug Discovery</span></div><div class="casAuthors">Ghose, Arup K.; Herbertz, Torsten; Hudkins, Robert L.; Dorsey, Bruce D.; Mallamo, John P.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">50-68</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The central nervous system (CNS) is the major area that is affected by aging.  Alzheimer's disease (AD), Parkinson's disease (PD), brain cancer, and stroke are the CNS diseases that will cost trillions of dollars for their treatment.  Achievement of appropriate blood-brain barrier (BBB) penetration is often considered a significant hurdle in the CNS drug discovery process.  On the other hand, BBB penetration may be a liability for many of the non-CNS drug targets, and a clear understanding of the physicochem. and structural differences between CNS and non-CNS drugs may assist both research areas.  Because of the numerous and challenging issues in CNS drug discovery and the low success rates, pharmaceutical companies are beginning to deprioritize their drug discovery efforts in the CNS arena.  Prompted by these challenges and to aid in the design of high-quality, efficacious CNS compds., we analyzed the physicochem. property and the chem. structural profiles of 317 CNS and 626 non-CNS oral drugs.  The conclusions derived provide an ideal property profile for lead selection and the property modification strategy during the lead optimization process.  A list of substructural units that may be useful for CNS drug design was also provided here.  A classification tree was also developed to differentiate between CNS drugs and non-CNS oral drugs.  The combined anal. provided the following guidelines for designing high-quality CNS drugs: (i) topol. mol. polar surface area of <76 Å2 (25-60 Å2), (ii) at least one (one or two, including one aliph. amine) nitrogen, (iii) fewer than seven (two to four) linear chains outside of rings, (iv) fewer than three (zero or one) polar hydrogen atoms, (v) vol. of 740-970 Å3, (vi) solvent accessible surface area of 460-580 Å2, and (vii) pos. QikProp parameter CNS.  The ranges within parentheses may be used during lead optimization.  One violation to this proposed profile may be acceptable.  The chemoinformatics approaches for graphically analyzing multiple properties efficiently are presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozqfO0vq2i5bVg90H21EOLACvtfcHk0lgBVNDdxcaJDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVSit7rO&md5=4c20ba34c3d5397170b50242975ce25d</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fcn200100h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn200100h%26sid%3Dliteratum%253Aachs%26aulast%3DGhose%26aufirst%3DA.%2BK.%26aulast%3DHerbertz%26aufirst%3DT.%26aulast%3DHudkins%26aufirst%3DR.%2BL.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26aulast%3DMallamo%26aufirst%3DJ.%2BP.%26atitle%3DKnowledge-based%252C%2520central%2520nervous%2520system%2520%2528CNS%2529%2520lead%2520selection%2520and%2520lead%2520optimization%2520for%2520CNS%2520drug%2520discovery%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2012%26volume%3D3%26spage%3D50%26epage%3D68" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Jörg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scammells, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capuano, B.</span><span> </span><span class="NLM_article-title">The dopamine D<sub>2</sub> and adenosine A<sub>2A</sub> receptors: past, present and future trends for the treatment of Parkinson’s disease</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">2188</span><span class="NLM_x">–</span> <span class="NLM_lpage">2210</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Fjm501254d&amp;key=10.2174%2F1389200215666140217110716" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2014&pages=2188-2210&author=M.+J%C3%B6rgauthor=P.+J.+Scammellsauthor=B.+Capuano&title=The+dopamine+D2+and+adenosine+A2A+receptors%3A+past%2C+present+and+future+trends+for+the+treatment+of+Parkinson%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.2174%2F1389200215666140217110716&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389200215666140217110716%26sid%3Dliteratum%253Aachs%26aulast%3DJ%25C3%25B6rg%26aufirst%3DM.%26aulast%3DScammells%26aufirst%3DP.%2BJ.%26aulast%3DCapuano%26aufirst%3DB.%26atitle%3DThe%2520dopamine%2520D2%2520and%2520adenosine%2520A2A%2520receptors%253A%2520past%252C%2520present%2520and%2520future%2520trends%2520for%2520the%2520treatment%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2014%26volume%3D21%26spage%3D2188%26epage%3D2210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Hayler, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howie, S. L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giles, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Negus, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oxley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walsgrove, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walsh, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dagger, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fortunak, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mastrocola, A.</span><span> </span><span class="NLM_article-title">Some synthetic approaches to ropinirole (SK&F 101468-A): a potent dopamine receptor agonist</span> <span class="citation_source-journal">J. Heterocycl. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">875</span><span class="NLM_x">–</span> <span class="NLM_lpage">882</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1995&pages=875-882&author=J.+D.+Haylerauthor=S.+L.+B.+Howieauthor=R.+G.+Gilesauthor=A.+Negusauthor=P.+W.+Oxleyauthor=T.+C.+Walsgroveauthor=S.+E.+Walshauthor=R.+E.+Daggerauthor=J.+M.+Fortunakauthor=A.+Mastrocola&title=Some+synthetic+approaches+to+ropinirole+%28SK%26F+101468-A%29%3A+a+potent+dopamine+receptor+agonist"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHayler%26aufirst%3DJ.%2BD.%26aulast%3DHowie%26aufirst%3DS.%2BL.%2BB.%26aulast%3DGiles%26aufirst%3DR.%2BG.%26aulast%3DNegus%26aufirst%3DA.%26aulast%3DOxley%26aufirst%3DP.%2BW.%26aulast%3DWalsgrove%26aufirst%3DT.%2BC.%26aulast%3DWalsh%26aufirst%3DS.%2BE.%26aulast%3DDagger%26aufirst%3DR.%2BE.%26aulast%3DFortunak%26aufirst%3DJ.%2BM.%26aulast%3DMastrocola%26aufirst%3DA.%26atitle%3DSome%2520synthetic%2520approaches%2520to%2520ropinirole%2520%2528SK%2526F%2520101468-A%2529%253A%2520a%2520potent%2520dopamine%2520receptor%2520agonist%26jtitle%3DJ.%2520Heterocycl.%2520Chem.%26date%3D1995%26volume%3D32%26spage%3D875%26epage%3D882" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 32 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Amy Hauck Newman, Francisco O. Battiti, <span class="NLM_string-name hlFld-ContribAuthor">Alessandro Bonifazi</span>. </span><span class="cited-content_cbyCitation_article-title">2016 Philip S. Portoghese Medicinal Chemistry Lectureship: Designing Bivalent or Bitopic Molecules for G-Protein Coupled Receptors. The Whole Is Greater Than the Sum of Its Parts. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (5)
                                     , 1779-1797. <a href="https://doi.org/10.1021/acs.jmedchem.9b01105" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01105</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01105%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3D2016%252BPhilip%252BS.%252BPortoghese%252BMedicinal%252BChemistry%252BLectureship%25253A%252BDesigning%252BBivalent%252Bor%252BBitopic%252BMolecules%252Bfor%252BG-Protein%252BCoupled%252BReceptors.%252BThe%252BWhole%252BIs%252BGreater%252BThan%252Bthe%252BSum%252Bof%252BIts%252BParts%26aulast%3DNewman%26aufirst%3DAmy%2BHauck%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D09072019%26date%3D24092019%26date%3D09092019%26volume%3D63%26issue%3D5%26spage%3D1779%26epage%3D1797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Daniel Pulido, Verònica Casadó-Anguera, Laura Pérez-Benito, Estefanía Moreno, Arnau Cordomí, Laura López, Antoni Cortés, Sergi Ferré, Leonardo Pardo, Vicent Casadó, <span class="NLM_string-name hlFld-ContribAuthor">Miriam Royo</span>. </span><span class="cited-content_cbyCitation_article-title">Design of a True Bivalent Ligand with Picomolar Binding Affinity for a G Protein-Coupled Receptor Homodimer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (20)
                                     , 9335-9346. <a href="https://doi.org/10.1021/acs.jmedchem.8b01249" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01249</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01249&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01249%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Bof%252Ba%252BTrue%252BBivalent%252BLigand%252Bwith%252BPicomolar%252BBinding%252BAffinity%252Bfor%252Ba%252BG%252BProtein-Coupled%252BReceptor%252BHomodimer%26aulast%3DPulido%26aufirst%3DDaniel%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D07082018%26date%3D11102018%26date%3D26092018%26volume%3D61%26issue%3D20%26spage%3D9335%26epage%3D9346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Mariama Jaiteh, Alexey Zeifman, Marcus Saarinen, Per Svenningsson, Jose Bréa, Maria Isabel Loza, <span class="NLM_string-name hlFld-ContribAuthor">Jens Carlsson</span>. </span><span class="cited-content_cbyCitation_article-title">Docking Screens for Dual Inhibitors of Disparate Drug Targets for Parkinson’s Disease. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (12)
                                     , 5269-5278. <a href="https://doi.org/10.1021/acs.jmedchem.8b00204" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00204</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00204&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00204%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDocking%252BScreens%252Bfor%252BDual%252BInhibitors%252Bof%252BDisparate%252BDrug%252BTargets%252Bfor%252BParkinson%2525E2%252580%252599s%252BDisease%26aulast%3DJaiteh%26aufirst%3DMariama%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D06022018%26date%3D15062018%26date%3D24052018%26volume%3D61%26issue%3D12%26spage%3D5269%26epage%3D5278" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Subhadip Senapati, Sudipta Biswas, Saikat Manna, Robert Ros, Stuart Lindsay, <span class="NLM_string-name hlFld-ContribAuthor">Peiming Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">A Y-Shaped Three-Arm Structure for Probing Bivalent Interactions between Protein Receptor–Ligand Using AFM and SPR. </span><span class="cited-content_cbyCitation_journal-name">Langmuir</span><span> <strong>2018,</strong> <em>34 </em>
                                    (23)
                                     , 6930-6940. <a href="https://doi.org/10.1021/acs.langmuir.8b00735" title="DOI URL">https://doi.org/10.1021/acs.langmuir.8b00735</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.langmuir.8b00735&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.langmuir.8b00735%26sid%3Dliteratum%253Aachs%26jtitle%3DLangmuir%26atitle%3DA%252BY-Shaped%252BThree-Arm%252BStructure%252Bfor%252BProbing%252BBivalent%252BInteractions%252Bbetween%252BProtein%252BReceptor%2525E2%252580%252593Ligand%252BUsing%252BAFM%252Band%252BSPR%26aulast%3DSenapati%26aufirst%3DSubhadip%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D06032018%26date%3D17052018%26date%3D04062018%26date%3D21052018%26volume%3D34%26issue%3D23%26spage%3D6930%26epage%3D6940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cody J.  Lensing</span>, <span class="hlFld-ContribAuthor ">Katie T.  Freeman</span>, <span class="hlFld-ContribAuthor ">Sathya M.  Schnell</span>, <span class="hlFld-ContribAuthor ">Danielle N.  Adank</span>, <span class="hlFld-ContribAuthor ">Robert C.  Speth</span>, and <span class="hlFld-ContribAuthor ">Carrie  Haskell-Luevano</span>  . </span><span class="cited-content_cbyCitation_article-title">An in Vitro and in Vivo Investigation of Bivalent Ligands That Display Preferential Binding and Functional Activity for Different Melanocortin Receptor Homodimers. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (7)
                                     , 3112-3128. <a href="https://doi.org/10.1021/acs.jmedchem.5b01894" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01894</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01894&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b01894%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DAn%252Bin%252BVitro%252Band%252Bin%252BVivo%252BInvestigation%252Bof%252BBivalent%252BLigands%252BThat%252BDisplay%252BPreferential%252BBinding%252Band%252BFunctional%252BActivity%252Bfor%252BDifferent%252BMelanocortin%252BReceptor%252BHomodimers%26aulast%3DLensing%26aufirst%3DCody%2BJ.%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D07122015%26date%3D29032016%26date%3D14042016%26date%3D09032016%26volume%3D59%26issue%3D7%26spage%3D3112%26epage%3D3128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiao  Sun</span>, <span class="hlFld-ContribAuthor ">Lei  Li</span>, <span class="hlFld-ContribAuthor ">Hu-Yun-Long  Zhang</span>, <span class="hlFld-ContribAuthor ">Wei  He</span>, <span class="hlFld-ContribAuthor ">Dian-Ru  Wang</span>, <span class="hlFld-ContribAuthor ">Zhi-Li  Huang</span>, <span class="hlFld-ContribAuthor ">Yi-Qun  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Adenosine A2A Receptor Neurons in the Olfactory Bulb Mediate Odor-Guided Behaviors in Miceg. </span><span class="cited-content_cbyCitation_journal-name">Brain Research</span><span> <strong>2021,</strong> <em>7 </em>, 147590. <a href="https://doi.org/10.1016/j.brainres.2021.147590" title="DOI URL">https://doi.org/10.1016/j.brainres.2021.147590</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.brainres.2021.147590&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.brainres.2021.147590%26sid%3Dliteratum%253Aachs%26jtitle%3DBrain%2520Research%26atitle%3DAdenosine%252BA2A%252BReceptor%252BNeurons%252Bin%252Bthe%252BOlfactory%252BBulb%252BMediate%252BOdor-Guided%252BBehaviors%252Bin%252BMiceg%26aulast%3DSun%26aufirst%3DXiao%26date%3D2021%26volume%3D7%26spage%3D147590" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kavya  Prasad</span>, <span class="hlFld-ContribAuthor ">Erik F. J.  de Vries</span>, <span class="hlFld-ContribAuthor ">Philip H.  Elsinga</span>, <span class="hlFld-ContribAuthor ">Rudi A. J. O.  Dierckx</span>, <span class="hlFld-ContribAuthor ">Aren  van Waarde</span>. </span><span class="cited-content_cbyCitation_article-title">Allosteric Interactions between Adenosine A2A and Dopamine D2 Receptors in Heteromeric Complexes: Biochemical and Pharmacological Characteristics, and Opportunities for PET Imaging. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2021,</strong> <em>22 </em>
                                    (4)
                                     , 1719. <a href="https://doi.org/10.3390/ijms22041719" title="DOI URL">https://doi.org/10.3390/ijms22041719</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms22041719&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms22041719%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DAllosteric%252BInteractions%252Bbetween%252BAdenosine%252BA2A%252Band%252BDopamine%252BD2%252BReceptors%252Bin%252BHeteromeric%252BComplexes%25253A%252BBiochemical%252Band%252BPharmacological%252BCharacteristics%25252C%252Band%252BOpportunities%252Bfor%252BPET%252BImaging%26aulast%3DPrasad%26aufirst%3DKavya%26date%3D2021%26date%3D2021%26volume%3D22%26issue%3D4%26spage%3D1719" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aurélie  Claraz</span>. </span><span class="cited-content_cbyCitation_article-title">Bicyclic 5-6 Systems With One Bridgehead (Ring Junction) Nitrogen Atom: Four Extra Heteroatoms 2: 2. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,<a href="https://doi.org/10.1016/B978-0-12-818655-8.00086-X" title="DOI URL">https://doi.org/10.1016/B978-0-12-818655-8.00086-X</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-818655-8.00086-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-818655-8.00086-X%26sid%3Dliteratum%253Aachs%26atitle%3DBicyclic%252B5-6%252BSystems%252BWith%252BOne%252BBridgehead%252B%252528Ring%252BJunction%252529%252BNitrogen%252BAtom%25253A%252BFour%252BExtra%252BHeteroatoms%252B2%25253A%252B2%26aulast%3DClaraz%26aufirst%3DAur%25C3%25A9lie%26date%3D2021%26pub%3DElsevier%26atitle%3DReference%252BModule%252Bin%252BChemistry%25252C%252BMolecular%252BSciences%252Band%252BChemical%252BEngineering%26date%3D2021%26volume%3D3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yan Fang  Cheng</span>, <span class="hlFld-ContribAuthor ">Dicky  Pranantyo</span>, <span class="hlFld-ContribAuthor ">Gopinath  Kasi</span>, <span class="hlFld-ContribAuthor ">Zhi Song  Lu</span>, <span class="hlFld-ContribAuthor ">Chang Ming  Li</span>, <span class="hlFld-ContribAuthor ">Li Qun  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Amino-containing tannic acid derivative-mediated universal coatings for multifunctional surface modification. </span><span class="cited-content_cbyCitation_journal-name">Biomaterials Science</span><span> <strong>2020,</strong> <em>8 </em>
                                    (8)
                                     , 2120-2128. <a href="https://doi.org/10.1039/D0BM00242A" title="DOI URL">https://doi.org/10.1039/D0BM00242A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0BM00242A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0BM00242A%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomaterials%2520Science%26atitle%3DAmino-containing%252Btannic%252Bacid%252Bderivative-mediated%252Buniversal%252Bcoatings%252Bfor%252Bmultifunctional%252Bsurface%252Bmodification%26aulast%3DCheng%26aufirst%3DYan%2BFang%26date%3D2020%26date%3D2020%26volume%3D8%26issue%3D8%26spage%3D2120%26epage%3D2128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiangyi  Jiang</span>, <span class="hlFld-ContribAuthor ">Ji  Yu</span>, <span class="hlFld-ContribAuthor ">Zhongxia  Zhou</span>, <span class="hlFld-ContribAuthor ">Jacob  Kongsted</span>, <span class="hlFld-ContribAuthor ">Yuning  Song</span>, <span class="hlFld-ContribAuthor ">Christophe  Pannecouque</span>, <span class="hlFld-ContribAuthor ">Erik  De Clercq</span>, <span class="hlFld-ContribAuthor ">Dongwei  Kang</span>, <span class="hlFld-ContribAuthor ">Vasanthanathan  Poongavanam</span>, <span class="hlFld-ContribAuthor ">Xinyong  Liu</span>, <span class="hlFld-ContribAuthor ">Peng  Zhan</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular design opportunities presented by solvent‐exposed regions of target proteins. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2019,</strong> <em>39 </em>
                                    (6)
                                     , 2194-2238. <a href="https://doi.org/10.1002/med.21581" title="DOI URL">https://doi.org/10.1002/med.21581</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21581%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DMolecular%252Bdesign%252Bopportunities%252Bpresented%252Bby%252Bsolvent%2525E2%252580%252590exposed%252Bregions%252Bof%252Btarget%252Bproteins%26aulast%3DJiang%26aufirst%3DXiangyi%26date%3D2019%26date%3D2019%26volume%3D39%26issue%3D6%26spage%3D2194%26epage%3D2238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lyes  Derouiche</span>, <span class="hlFld-ContribAuthor ">Dominique  Massotte</span>. </span><span class="cited-content_cbyCitation_article-title">G protein-coupled receptor heteromers are key players in substance use disorder. </span><span class="cited-content_cbyCitation_journal-name">Neuroscience & Biobehavioral Reviews</span><span> <strong>2019,</strong> <em>106 </em>, 73-90. <a href="https://doi.org/10.1016/j.neubiorev.2018.09.026" title="DOI URL">https://doi.org/10.1016/j.neubiorev.2018.09.026</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.neubiorev.2018.09.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.neubiorev.2018.09.026%26sid%3Dliteratum%253Aachs%26jtitle%3DNeuroscience%2520%2526%2520Biobehavioral%2520Reviews%26atitle%3DG%252Bprotein-coupled%252Breceptor%252Bheteromers%252Bare%252Bkey%252Bplayers%252Bin%252Bsubstance%252Buse%252Bdisorder%26aulast%3DDerouiche%26aufirst%3DLyes%26date%3D2019%26volume%3D106%26spage%3D73%26epage%3D90" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Omar H.A.  Al-Attraqchi</span>, <span class="hlFld-ContribAuthor ">Mahesh  Attimarad</span>, <span class="hlFld-ContribAuthor ">Katharigatta N.  Venugopala</span>, <span class="hlFld-ContribAuthor ">Anroop  Nair</span>, <span class="hlFld-ContribAuthor ">Noor H.A.  Al-Attraqchi</span>. </span><span class="cited-content_cbyCitation_article-title">Adenosine A2A Receptor as a Potential Drug Target - Current Status and Future Perspectives. </span><span class="cited-content_cbyCitation_journal-name">Current Pharmaceutical Design</span><span> <strong>2019,</strong> <em>25 </em>
                                    (25)
                                     , 2716-2740. <a href="https://doi.org/10.2174/1381612825666190716113444" title="DOI URL">https://doi.org/10.2174/1381612825666190716113444</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1381612825666190716113444&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1381612825666190716113444%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Pharmaceutical%2520Design%26atitle%3DAdenosine%252BA2A%252BReceptor%252Bas%252Ba%252BPotential%252BDrug%252BTarget%252B-%252BCurrent%252BStatus%252Band%252BFuture%252BPerspectives%26aulast%3DAl-Attraqchi%26aufirst%3DOmar%2BH.A.%26date%3D2019%26volume%3D25%26issue%3D25%26spage%3D2716%26epage%3D2740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nizar A.  Al-Shar'i</span>, <span class="hlFld-ContribAuthor ">Qosay A.  Al-Balas</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular Dynamics Simulations of Adenosine Receptors: Advances, Applications and Trends. </span><span class="cited-content_cbyCitation_journal-name">Current Pharmaceutical Design</span><span> <strong>2019,</strong> <em>25 </em>
                                    (7)
                                     , 783-816. <a href="https://doi.org/10.2174/1381612825666190304123414" title="DOI URL">https://doi.org/10.2174/1381612825666190304123414</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1381612825666190304123414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1381612825666190304123414%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Pharmaceutical%2520Design%26atitle%3DMolecular%252BDynamics%252BSimulations%252Bof%252BAdenosine%252BReceptors%25253A%252BAdvances%25252C%252BApplications%252Band%252BTrends%26aulast%3DAl-Shar%2527i%26aufirst%3DNizar%2BA.%26date%3D2019%26volume%3D25%26issue%3D7%26spage%3D783%26epage%3D816" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Simone  Pelassa</span>, <span class="hlFld-ContribAuthor ">Diego  Guidolin</span>, <span class="hlFld-ContribAuthor ">Arianna  Venturini</span>, <span class="hlFld-ContribAuthor ">Monica  Averna</span>, <span class="hlFld-ContribAuthor ">Giulia  Frumento</span>, <span class="hlFld-ContribAuthor ">Letizia  Campanini</span>, <span class="hlFld-ContribAuthor ">Rosa  Bernardi</span>, <span class="hlFld-ContribAuthor ">Pietro  Cortelli</span>, <span class="hlFld-ContribAuthor ">Giovanna  Calandra Buonaura</span>, <span class="hlFld-ContribAuthor ">Guido  Maura</span>, <span class="hlFld-ContribAuthor ">Luigi F.  Agnati</span>, <span class="hlFld-ContribAuthor ">Chiara  Cervetto</span>, <span class="hlFld-ContribAuthor ">Manuela  Marcoli</span>. </span><span class="cited-content_cbyCitation_article-title">A2A-D2 Heteromers on Striatal Astrocytes: Biochemical and Biophysical Evidence. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2019,</strong> <em>20 </em>
                                    (10)
                                     , 2457. <a href="https://doi.org/10.3390/ijms20102457" title="DOI URL">https://doi.org/10.3390/ijms20102457</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms20102457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms20102457%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DA2A-D2%252BHeteromers%252Bon%252BStriatal%252BAstrocytes%25253A%252BBiochemical%252Band%252BBiophysical%252BEvidence%26aulast%3DPelassa%26aufirst%3DSimone%26date%3D2019%26date%3D2019%26volume%3D20%26issue%3D10%26spage%3D2457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Carlo  Matera</span>, <span class="hlFld-ContribAuthor ">Federica  Bono</span>, <span class="hlFld-ContribAuthor ">Silvia  Pelucchi</span>, <span class="hlFld-ContribAuthor ">Ginetta  Collo</span>, <span class="hlFld-ContribAuthor ">Leonardo  Bontempi</span>, <span class="hlFld-ContribAuthor ">Cecilia  Gotti</span>, <span class="hlFld-ContribAuthor ">Michele  Zoli</span>, <span class="hlFld-ContribAuthor ">Marco  De Amici</span>, <span class="hlFld-ContribAuthor ">Cristina  Missale</span>, <span class="hlFld-ContribAuthor ">Chiara  Fiorentini</span>, <span class="hlFld-ContribAuthor ">Clelia  Dallanoce</span>. </span><span class="cited-content_cbyCitation_article-title">The novel hybrid agonist HyNDA-1 targets the D3R-nAChR heteromeric complex in dopaminergic neurons. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Pharmacology</span><span> <strong>2019,</strong> <em>163 </em>, 154-168. <a href="https://doi.org/10.1016/j.bcp.2019.02.019" title="DOI URL">https://doi.org/10.1016/j.bcp.2019.02.019</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bcp.2019.02.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bcp.2019.02.019%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Pharmacology%26atitle%3DThe%252Bnovel%252Bhybrid%252Bagonist%252BHyNDA-1%252Btargets%252Bthe%252BD3R-nAChR%252Bheteromeric%252Bcomplex%252Bin%252Bdopaminergic%252Bneurons%26aulast%3DMatera%26aufirst%3DCarlo%26date%3D2019%26volume%3D163%26spage%3D154%26epage%3D168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ian D.  Tomlinson</span>, <span class="hlFld-ContribAuthor ">Oleg  Kovtun</span>, <span class="hlFld-ContribAuthor ">Tiffany M.  Crescentini</span>, <span class="hlFld-ContribAuthor ">Sandra J.  Rosenthal</span>. </span><span class="cited-content_cbyCitation_article-title">Biotinylated-spiperone ligands for quantum dot labeling of the dopamine D2 receptor in live cell cultures. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (8)
                                     , 959-964. <a href="https://doi.org/10.1016/j.bmcl.2019.02.024" title="DOI URL">https://doi.org/10.1016/j.bmcl.2019.02.024</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2019.02.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2019.02.024%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DBiotinylated-spiperone%252Bligands%252Bfor%252Bquantum%252Bdot%252Blabeling%252Bof%252Bthe%252Bdopamine%252BD2%252Breceptor%252Bin%252Blive%252Bcell%252Bcultures%26aulast%3DTomlinson%26aufirst%3DIan%2BD.%26date%3D2019%26volume%3D29%26issue%3D8%26spage%3D959%26epage%3D964" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Muzeyyen  Ugur</span>, <span class="hlFld-ContribAuthor ">Lyes  Derouiche</span>, <span class="hlFld-ContribAuthor ">Dominique  Massotte</span>. </span><span class="cited-content_cbyCitation_article-title">Heteromerization Modulates mu Opioid Receptor Functional Properties in vivo. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Pharmacology</span><span> <strong>2018,</strong> <em>9 </em><a href="https://doi.org/10.3389/fphar.2018.01240" title="DOI URL">https://doi.org/10.3389/fphar.2018.01240</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fphar.2018.01240&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffphar.2018.01240%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Pharmacology%26atitle%3DHeteromerization%252BModulates%252Bmu%252BOpioid%252BReceptor%252BFunctional%252BProperties%252Bin%252Bvivo%26aulast%3DUgur%26aufirst%3DMuzeyyen%26date%3D2018%26date%3D2018%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Elizabeth A  Vecchio</span>, <span class="hlFld-ContribAuthor ">Jo‐Anne  Baltos</span>, <span class="hlFld-ContribAuthor ">Anh T N  Nguyen</span>, <span class="hlFld-ContribAuthor ">Arthur  Christopoulos</span>, <span class="hlFld-ContribAuthor ">Paul J  White</span>, <span class="hlFld-ContribAuthor ">Lauren T  May</span>. </span><span class="cited-content_cbyCitation_article-title">New paradigms in adenosine receptor pharmacology: allostery, oligomerization and biased agonism. </span><span class="cited-content_cbyCitation_journal-name">British Journal of Pharmacology</span><span> <strong>2018,</strong> <em>175 </em>
                                    (21)
                                     , 4036-4046. <a href="https://doi.org/10.1111/bph.14337" title="DOI URL">https://doi.org/10.1111/bph.14337</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/bph.14337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fbph.14337%26sid%3Dliteratum%253Aachs%26jtitle%3DBritish%2520Journal%2520of%2520Pharmacology%26atitle%3DNew%252Bparadigms%252Bin%252Badenosine%252Breceptor%252Bpharmacology%25253A%252Ballostery%25252C%252Boligomerization%252Band%252Bbiased%252Bagonism%26aulast%3DVecchio%26aufirst%3DElizabeth%2BA%26date%3D2018%26date%3D2018%26volume%3D175%26issue%3D21%26spage%3D4036%26epage%3D4046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chiara  Cervetto</span>, <span class="hlFld-ContribAuthor ">Arianna  Venturini</span>, <span class="hlFld-ContribAuthor ">Diego  Guidolin</span>, <span class="hlFld-ContribAuthor ">Guido  Maura</span>, <span class="hlFld-ContribAuthor ">Mario  Passalacqua</span>, <span class="hlFld-ContribAuthor ">Carlo  Tacchetti</span>, <span class="hlFld-ContribAuthor ">Pietro  Cortelli</span>, <span class="hlFld-ContribAuthor ">Susanna  Genedani</span>, <span class="hlFld-ContribAuthor ">Simona  Candiani</span>, <span class="hlFld-ContribAuthor ">Paola  Ramoino</span>, <span class="hlFld-ContribAuthor ">Simone  Pelassa</span>, <span class="hlFld-ContribAuthor ">Manuela  Marcoli</span>, <span class="hlFld-ContribAuthor ">Luigi F.  Agnati</span>. </span><span class="cited-content_cbyCitation_article-title">Homocysteine and A2A-D2 Receptor-Receptor Interaction at Striatal Astrocyte Processes. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Neuroscience</span><span> <strong>2018,</strong> <em>65 </em>
                                    (4)
                                     , 456-466. <a href="https://doi.org/10.1007/s12031-018-1120-4" title="DOI URL">https://doi.org/10.1007/s12031-018-1120-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s12031-018-1120-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs12031-018-1120-4%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Neuroscience%26atitle%3DHomocysteine%252Band%252BA2A-D2%252BReceptor-Receptor%252BInteraction%252Bat%252BStriatal%252BAstrocyte%252BProcesses%26aulast%3DCervetto%26aufirst%3DChiara%26date%3D2018%26date%3D2018%26volume%3D65%26issue%3D4%26spage%3D456%26epage%3D466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cheng  Zhang</span>, <span class="hlFld-ContribAuthor ">Yi-Ming  Shao</span>, <span class="hlFld-ContribAuthor ">Xiaohua  Ma</span>, <span class="hlFld-ContribAuthor ">Siew Lee  Cheong</span>, <span class="hlFld-ContribAuthor ">Chu  Qin</span>, <span class="hlFld-ContribAuthor ">Lin  Tao</span>, <span class="hlFld-ContribAuthor ">Peng  Zhang</span>, <span class="hlFld-ContribAuthor ">Shangying  Chen</span>, <span class="hlFld-ContribAuthor ">Xian  Zeng</span>, <span class="hlFld-ContribAuthor ">Hongxia  Liu</span>, <span class="hlFld-ContribAuthor ">Giorgia  Pastorin</span>, <span class="hlFld-ContribAuthor ">Yuyang  Jiang</span>, <span class="hlFld-ContribAuthor ">Yu Zong  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacological relationships and ligand discovery of G protein-coupled receptors revealed by simultaneous ligand and receptor clustering. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Graphics and Modelling</span><span> <strong>2017,</strong> <em>76 </em>, 136-142. <a href="https://doi.org/10.1016/j.jmgm.2017.06.014" title="DOI URL">https://doi.org/10.1016/j.jmgm.2017.06.014</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jmgm.2017.06.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jmgm.2017.06.014%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Graphics%2520and%2520Modelling%26atitle%3DPharmacological%252Brelationships%252Band%252Bligand%252Bdiscovery%252Bof%252BG%252Bprotein-coupled%252Breceptors%252Brevealed%252Bby%252Bsimultaneous%252Bligand%252Band%252Breceptor%252Bclustering%26aulast%3DZhang%26aufirst%3DCheng%26date%3D2017%26volume%3D76%26spage%3D136%26epage%3D142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pier Andrea  Borea</span>, <span class="hlFld-ContribAuthor ">Stefania  Gessi</span>, <span class="hlFld-ContribAuthor ">Stefania  Merighi</span>, <span class="hlFld-ContribAuthor ">Fabrizio  Vincenzi</span>, <span class="hlFld-ContribAuthor ">Katia  Varani</span>. </span><span class="cited-content_cbyCitation_article-title">Pathological overproduction: the bad side of adenosine. </span><span class="cited-content_cbyCitation_journal-name">British Journal of Pharmacology</span><span> <strong>2017,</strong> <em>174 </em>
                                    (13)
                                     , 1945-1960. <a href="https://doi.org/10.1111/bph.13763" title="DOI URL">https://doi.org/10.1111/bph.13763</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/bph.13763&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fbph.13763%26sid%3Dliteratum%253Aachs%26jtitle%3DBritish%2520Journal%2520of%2520Pharmacology%26atitle%3DPathological%252Boverproduction%25253A%252Bthe%252Bbad%252Bside%252Bof%252Badenosine%26aulast%3DBorea%26aufirst%3DPier%2BAndrea%26date%3D2017%26date%3D2017%26volume%3D174%26issue%3D13%26spage%3D1945%26epage%3D1960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jan  Schmidt</span>, <span class="hlFld-ContribAuthor ">Polonca  Ferk</span>. </span><span class="cited-content_cbyCitation_article-title">Safety issues of compounds acting on adenosinergic signalling. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmacy and Pharmacology</span><span> <strong>2017,</strong> <em>69 </em>
                                    (7)
                                     , 790-806. <a href="https://doi.org/10.1111/jphp.12720" title="DOI URL">https://doi.org/10.1111/jphp.12720</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/jphp.12720&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fjphp.12720%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmacy%2520and%2520Pharmacology%26atitle%3DSafety%252Bissues%252Bof%252Bcompounds%252Bacting%252Bon%252Badenosinergic%252Bsignalling%26aulast%3DSchmidt%26aufirst%3DJan%26date%3D2017%26date%3D2017%26volume%3D69%26issue%3D7%26spage%3D790%26epage%3D806" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Batoul  Farran</span>. </span><span class="cited-content_cbyCitation_article-title">An update on the physiological and therapeutic relevance of GPCR oligomers. </span><span class="cited-content_cbyCitation_journal-name">Pharmacological Research</span><span> <strong>2017,</strong> <em>117 </em>, 303-327. <a href="https://doi.org/10.1016/j.phrs.2017.01.008" title="DOI URL">https://doi.org/10.1016/j.phrs.2017.01.008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.phrs.2017.01.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.phrs.2017.01.008%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacological%2520Research%26atitle%3DAn%252Bupdate%252Bon%252Bthe%252Bphysiological%252Band%252Btherapeutic%252Brelevance%252Bof%252BGPCR%252Boligomers%26aulast%3DFarran%26aufirst%3DBatoul%26date%3D2017%26volume%3D117%26spage%3D303%26epage%3D327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mudumala  Veeranarayana Reddy</span>, <span class="hlFld-ContribAuthor ">Gangireddy  Chandra Sekhar Reddy</span>, <span class="hlFld-ContribAuthor ">Nguyen  Thi Kim Lien</span>, <span class="hlFld-ContribAuthor ">Dong Wook  Kim</span>, <span class="hlFld-ContribAuthor ">Yeon Tae  Jeong</span>. </span><span class="cited-content_cbyCitation_article-title">An efficient and green synthesis of benzo[4,5]imidazo[1,2-a]pyrimidines using highly active and stable poly acrylic acid-supported layered double hydroxides. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2017,</strong> <em>73 </em>
                                    (10)
                                     , 1317-1323. <a href="https://doi.org/10.1016/j.tet.2017.01.037" title="DOI URL">https://doi.org/10.1016/j.tet.2017.01.037</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2017.01.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2017.01.037%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DAn%252Befficient%252Band%252Bgreen%252Bsynthesis%252Bof%252Bbenzo%25255B4%25252C5%25255Dimidazo%25255B1%25252C2-a%25255Dpyrimidines%252Busing%252Bhighly%252Bactive%252Band%252Bstable%252Bpoly%252Bacrylic%252Bacid-supported%252Blayered%252Bdouble%252Bhydroxides%26aulast%3DVeeranarayana%2BReddy%26aufirst%3DMudumala%26date%3D2017%26volume%3D73%26issue%3D10%26spage%3D1317%26epage%3D1323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chenyi  Liao</span>, <span class="hlFld-ContribAuthor ">Xiaochuan  Zhao</span>, <span class="hlFld-ContribAuthor ">Jiyuan  Liu</span>, <span class="hlFld-ContribAuthor ">Severin T.  Schneebeli</span>, <span class="hlFld-ContribAuthor ">John C.  Shelley</span>, <span class="hlFld-ContribAuthor ">Jianing  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Capturing the multiscale dynamics of membrane protein complexes with all-atom, mixed-resolution, and coarse-grained models. </span><span class="cited-content_cbyCitation_journal-name">Physical Chemistry Chemical Physics</span><span> <strong>2017,</strong> <em>19 </em>
                                    (13)
                                     , 9181-9188. <a href="https://doi.org/10.1039/C7CP00200A" title="DOI URL">https://doi.org/10.1039/C7CP00200A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C7CP00200A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC7CP00200A%26sid%3Dliteratum%253Aachs%26jtitle%3DPhysical%2520Chemistry%2520Chemical%2520Physics%26atitle%3DCapturing%252Bthe%252Bmultiscale%252Bdynamics%252Bof%252Bmembrane%252Bprotein%252Bcomplexes%252Bwith%252Ball-atom%25252C%252Bmixed-resolution%25252C%252Band%252Bcoarse-grained%252Bmodels%26aulast%3DLiao%26aufirst%3DChenyi%26date%3D2017%26date%3D2017%26volume%3D19%26issue%3D13%26spage%3D9181%26epage%3D9188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">S.  Butini</span>, <span class="hlFld-ContribAuthor ">K.  Nikolic</span>, <span class="hlFld-ContribAuthor ">S.  Kassel</span>, <span class="hlFld-ContribAuthor ">H.  Brückmann</span>, <span class="hlFld-ContribAuthor ">S.  Filipic</span>, <span class="hlFld-ContribAuthor ">D.  Agbaba</span>, <span class="hlFld-ContribAuthor ">S.  Gemma</span>, <span class="hlFld-ContribAuthor ">S.  Brogi</span>, <span class="hlFld-ContribAuthor ">M.  Brindisi</span>, <span class="hlFld-ContribAuthor ">G.  Campiani</span>, <span class="hlFld-ContribAuthor ">H.  Stark</span>. </span><span class="cited-content_cbyCitation_article-title">Polypharmacology of dopamine receptor ligands. </span><span class="cited-content_cbyCitation_journal-name">Progress in Neurobiology</span><span> <strong>2016,</strong> <em>142 </em>, 68-103. <a href="https://doi.org/10.1016/j.pneurobio.2016.03.011" title="DOI URL">https://doi.org/10.1016/j.pneurobio.2016.03.011</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.pneurobio.2016.03.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.pneurobio.2016.03.011%26sid%3Dliteratum%253Aachs%26jtitle%3DProgress%2520in%2520Neurobiology%26atitle%3DPolypharmacology%252Bof%252Bdopamine%252Breceptor%252Bligands%26aulast%3DButini%26aufirst%3DS.%26date%3D2016%26volume%3D142%26spage%3D68%26epage%3D103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anitha  Kopinathan</span>, <span class="hlFld-ContribAuthor ">Peter J  Scammells</span>, <span class="hlFld-ContribAuthor ">J Robert  Lane</span>, <span class="hlFld-ContribAuthor ">Ben  Capuano</span>. </span><span class="cited-content_cbyCitation_article-title">Multivalent approaches and beyond: novel tools for the investigation of dopamine D
              2
              receptor pharmacology. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2016,</strong> <em>8 </em>
                                    (11)
                                     , 1349-1372. <a href="https://doi.org/10.4155/fmc-2016-0010" title="DOI URL">https://doi.org/10.4155/fmc-2016-0010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2016-0010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2016-0010%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DMultivalent%252Bapproaches%252Band%252Bbeyond%25253A%252Bnovel%252Btools%252Bfor%252Bthe%252Binvestigation%252Bof%252Bdopamine%252BD%252B2%252Breceptor%252Bpharmacology%26aulast%3DKopinathan%26aufirst%3DAnitha%26date%3D2016%26volume%3D8%26issue%3D11%26spage%3D1349%26epage%3D1372" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michelle  Glass</span>, <span class="hlFld-ContribAuthor ">Karan  Govindpani</span>, <span class="hlFld-ContribAuthor ">Daniel P.  Furkert</span>, <span class="hlFld-ContribAuthor ">Dow P.  Hurst</span>, <span class="hlFld-ContribAuthor ">Patricia H.  Reggio</span>, <span class="hlFld-ContribAuthor ">Jack U.  Flanagan</span>. </span><span class="cited-content_cbyCitation_article-title">One for the Price of Two…Are Bivalent Ligands Targeting Cannabinoid Receptor Dimers Capable of Simultaneously Binding to both Receptors?. </span><span class="cited-content_cbyCitation_journal-name">Trends in Pharmacological Sciences</span><span> <strong>2016,</strong> <em>37 </em>
                                    (5)
                                     , 353-363. <a href="https://doi.org/10.1016/j.tips.2016.01.010" title="DOI URL">https://doi.org/10.1016/j.tips.2016.01.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tips.2016.01.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tips.2016.01.010%26sid%3Dliteratum%253Aachs%26jtitle%3DTrends%2520in%2520Pharmacological%2520Sciences%26atitle%3DOne%252Bfor%252Bthe%252BPrice%252Bof%252BTwo%2525E2%252580%2525A6Are%252BBivalent%252BLigands%252BTargeting%252BCannabinoid%252BReceptor%252BDimers%252BCapable%252Bof%252BSimultaneously%252BBinding%252Bto%252Bboth%252BReceptors%25253F%26aulast%3DGlass%26aufirst%3DMichelle%26date%3D2016%26volume%3D37%26issue%3D5%26spage%3D353%26epage%3D363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ramon  Guixà-González</span>, <span class="hlFld-ContribAuthor ">Matti  Javanainen</span>, <span class="hlFld-ContribAuthor ">Maricel  Gómez-Soler</span>, <span class="hlFld-ContribAuthor ">Begoña  Cordobilla</span>, <span class="hlFld-ContribAuthor ">Joan Carles  Domingo</span>, <span class="hlFld-ContribAuthor ">Ferran  Sanz</span>, <span class="hlFld-ContribAuthor ">Manuel  Pastor</span>, <span class="hlFld-ContribAuthor ">Francisco  Ciruela</span>, <span class="hlFld-ContribAuthor ">Hector  Martinez-Seara</span>, <span class="hlFld-ContribAuthor ">Jana  Selent</span>. </span><span class="cited-content_cbyCitation_article-title">Membrane omega-3 fatty acids modulate the oligomerisation kinetics of adenosine A2A and dopamine D2 receptors. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2016,</strong> <em>6 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/srep19839" title="DOI URL">https://doi.org/10.1038/srep19839</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/srep19839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fsrep19839%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DMembrane%252Bomega-3%252Bfatty%252Bacids%252Bmodulate%252Bthe%252Boligomerisation%252Bkinetics%252Bof%252Badenosine%252BA2A%252Band%252Bdopamine%252BD2%252Breceptors%26aulast%3DGuix%25C3%25A0-Gonz%25C3%25A1lez%26aufirst%3DRamon%26date%3D2016%26date%3D2016%26volume%3D6%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mudumala Veeranarayana  Reddy</span>, <span class="hlFld-ContribAuthor ">Nguyen Thi Kim  Lien</span>, <span class="hlFld-ContribAuthor ">Gangireddy Chandra Sekhar  Reddy</span>, <span class="hlFld-ContribAuthor ">Kwon Taek  Lim</span>, <span class="hlFld-ContribAuthor ">Yeon Tae  Jeong</span>. </span><span class="cited-content_cbyCitation_article-title">Polymer grafted layered double hydroxides (LDHs-g-POEGMA): a highly efficient reusable solid catalyst for the synthesis of chromene incorporated dihydroquinoline derivatives under solvent-free conditions. </span><span class="cited-content_cbyCitation_journal-name">Green Chemistry</span><span> <strong>2016,</strong> <em>18 </em>
                                    (15)
                                     , 4228-4239. <a href="https://doi.org/10.1039/C6GC00339G" title="DOI URL">https://doi.org/10.1039/C6GC00339G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C6GC00339G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC6GC00339G%26sid%3Dliteratum%253Aachs%26jtitle%3DGreen%2520Chemistry%26atitle%3DPolymer%252Bgrafted%252Blayered%252Bdouble%252Bhydroxides%252B%252528LDHs-g-POEGMA%252529%25253A%252Ba%252Bhighly%252Befficient%252Breusable%252Bsolid%252Bcatalyst%252Bfor%252Bthe%252Bsynthesis%252Bof%252Bchromene%252Bincorporated%252Bdihydroquinoline%252Bderivatives%252Bunder%252Bsolvent-free%252Bconditions%26aulast%3DReddy%26aufirst%3DMudumala%2BVeeranarayana%26date%3D2016%26date%3D2016%26volume%3D18%26issue%3D15%26spage%3D4228%26epage%3D4239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Delia  Preti</span>, <span class="hlFld-ContribAuthor ">Pier Giovanni  Baraldi</span>, <span class="hlFld-ContribAuthor ">Allan R.  Moorman</span>, <span class="hlFld-ContribAuthor ">Pier Andrea  Borea</span>, <span class="hlFld-ContribAuthor ">Katia  Varani</span>. </span><span class="cited-content_cbyCitation_article-title">History and Perspectives of A
              2A
              Adenosine Receptor Antagonists as Potential Therapeutic Agents. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2015,</strong> <em>35 </em>
                                    (4)
                                     , 790-848. <a href="https://doi.org/10.1002/med.21344" title="DOI URL">https://doi.org/10.1002/med.21344</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21344&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21344%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DHistory%252Band%252BPerspectives%252Bof%252BA%252B2A%252BAdenosine%252BReceptor%252BAntagonists%252Bas%252BPotential%252BTherapeutic%252BAgents%26aulast%3DPreti%26aufirst%3DDelia%26date%3D2015%26date%3D2015%26volume%3D35%26issue%3D4%26spage%3D790%26epage%3D848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christa E.  Müller</span>. </span><span class="cited-content_cbyCitation_article-title">Adenosine A2A Receptor Antagonists in Drug Development. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2015,</strong>,, 39-56. <a href="https://doi.org/10.1007/978-3-319-20273-0_3" title="DOI URL">https://doi.org/10.1007/978-3-319-20273-0_3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-319-20273-0_3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-319-20273-0_3%26sid%3Dliteratum%253Aachs%26atitle%3DAdenosine%252BA2A%252BReceptor%252BAntagonists%252Bin%252BDrug%252BDevelopment%26aulast%3DM%25C3%25BCller%26aufirst%3DChrista%2BE.%26date%3D2015%26date%3D2015%26spage%3D39%26epage%3D56%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DThe%252BAdenosinergic%252BSystem%26aulast%3DMorelli%26aufirst%3DMicaela%26date%3D2015%26volume%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-2/jm501254d/20150115/images/medium/jm-2014-01254d_0011.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-2/jm501254d/20150115/images/large/jm-2014-01254d_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501254d&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-2/jm501254d/20150115/images/medium/jm-2014-01254d_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-2/jm501254d/20150115/images/large/jm-2014-01254d_0002.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (left) Schematic representation of a heterobivalent ligand and integrated dual acting ligand consisting of a D<sub>2</sub>R agonist and an A<sub>2A</sub>R antagonist. (right) Schematic examples of a heterobivalent ligand binding to a heterodimer and an integrated dual acting ligand acting at the two orthosteric sites of two different types of receptor monomers.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-2/jm501254d/20150115/images/large/jm-2014-01254d_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501254d&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-2/jm501254d/20150115/images/medium/jm-2014-01254d_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-2/jm501254d/20150115/images/large/jm-2014-01254d_0003.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Chemical structures of the A<sub>2A</sub>R antagonist ZM 241385 (<b>1</b>) and D<sub>2</sub>R agonist ropinirole (<b>2</b>) and their respective functionalized carboxylic acid congeners TCAC (<b>3</b>) and OCAC (<b>4</b>), as well as the functionalized amine congener OAC (<b>5</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-2/jm501254d/20150115/images/large/jm-2014-01254d_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501254d&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-2/jm501254d/20150115/images/medium/jm-2014-01254d_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-2/jm501254d/20150115/images/large/jm-2014-01254d_0004.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. An example of the design principle of the “classical” heterobivalent ligands incorporating the fully furnished pharmacophores ZM 241385 (<b>1</b>) and ropinirole (<b>2</b>) and the integrated dual acting ligands without the tyramine moiety of the A<sub>2A</sub>R antagonist ZM 241385 (<b>1</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-2/jm501254d/20150115/images/large/jm-2014-01254d_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501254d&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-2/jm501254d/20150115/images/medium/jm-2014-01254d_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-2/jm501254d/20150115/images/large/jm-2014-01254d_0006.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of the Ester-Linked Heterobivalent Ligand <b>11</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-2/jm501254d/20150115/images/large/jm-2014-01254d_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501254d&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) toluene, 24 h, reflux, 13% (<b>7a</b>); (b) TEA, toluene, 29 h, rt, no product observed (<b>8</b>), 28% (<b>10</b>); (c) DIPEA, HCTU, DMF, 3 h, rt, 10%.</p></p></figure><figure data-id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-2/jm501254d/20150115/images/medium/jm-2014-01254d_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-2/jm501254d/20150115/images/large/jm-2014-01254d_0007.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Heterobivalent Ligands <b>17a</b>, <b>17b</b>, and <b>18a</b>–<b>c</b> Incorporating Amide Bonds and the Chemical Structure of the Triazolotriazine Monovalent Ligand <b>19</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-2/jm501254d/20150115/images/large/jm-2014-01254d_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501254d&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Boc anhydride, 1 M NaOH, THF, 3 h, rt, 66% (<b>13a</b>), Boc anhydride, TEA, methanol, 2 h, 60 °C, 81% (<b>13b</b>) and 68% (<b>13c</b>); (b) COMU, DIPEA, DMF, 1 h, 0 °C followed by 2 h, rt, 31% (<b>14a</b>), 23% (<b>14b</b>), and 41% (<b>14c</b>); (c) TFA, DCM, 2.5–9 h, rt, 69% (<b>15a</b>), 99% (<b>15b</b>), and 39% (<b>15c</b>); (d) BOP, DIPEA, DMF, 5 h, rt, 7% (<b>17a</b>), HCTU, DIPEA, DMF, 3 h, rt, 24% (<b>17b</b>); (e) COMU, DIPEA, DMF, 1 h, 0 °C followed by 2–9 h, rt, 17% (<b>18a</b>), 17% (<b>18b</b>), and 8% (<b>18c</b>).</p></p></figure><figure data-id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-2/jm501254d/20150115/images/medium/jm-2014-01254d_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-2/jm501254d/20150115/images/large/jm-2014-01254d_0008.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Triazine Spacer Containing Heterobivalent Ligand <b>24</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-2/jm501254d/20150115/images/large/jm-2014-01254d_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501254d&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) TEA, acetone, 15 min, −20 °C, 75%; (b) NaH 60%, THF, 2 days, rt, 53%; (c) K<sub>2</sub>CO<sub>3</sub>, DMF, microwave, 15 min, 100 °C, 67%.</p></p></figure><figure data-id="sch4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-2/jm501254d/20150115/images/medium/jm-2014-01254d_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-2/jm501254d/20150115/images/large/jm-2014-01254d_0009.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Integrated Dual Acting Ligands Based on ZM 241385 (<b>1</b>) and Ropinirole (<b>2</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-2/jm501254d/20150115/images/large/jm-2014-01254d_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501254d&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <i>p</i>-toluenesulfonyl chloride, DCM, pyridine, 5–10 °C, 4 h, 80%; (b) 40% aq methylamine solution or neat <i>n</i>-propylamine, reflux, 1.5 h, 57% and 74%, respectively; (c) 1 M NaOH, ethyl acetate or DCM, rt, 15–20 min, 54% (<b>27a</b>) and 92% (<b>27b</b>); (d) <b>28</b>, acetonitrile, rt, 2.5 days, 8%; (e) Br(CH<sub>2</sub>)<sub>n+2</sub>NHBoc, K<sub>2</sub>CO<sub>3</sub>, acetonitrile, reflux, 3–19 h, 46% (<b>30a</b>), 38% (<b>30b</b>), and 48% (<b>30c</b>); (f) TFA, DCM, rt, 1 h, 43% (<b>31a</b>), 84% (<b>5</b>), and 87% (<b>31c</b>); (g) <b>28</b>, acetonitrile, toluene, rt, 5–60 h, 23% (<b>32a</b>), 65% (<b>32b</b>), and 63% (<b>32c</b>).</p></p></figure><figure data-id="sch5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-2/jm501254d/20150115/images/medium/jm-2014-01254d_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-2/jm501254d/20150115/images/large/jm-2014-01254d_0010.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Cyclic Integrated Dual Acting Ligands Based on ZM 241385 (<b>1</b>) and Ropinirole (<b>2</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-2/jm501254d/20150115/images/large/jm-2014-01254d_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501254d&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <i>tert</i>-butyl 4-aminopiperidine-1-carboxylate, acetonitrile, rt, 3 h, 63%; (b) TFA, DCM, rt, 3.5 h; (c) <b>26</b>, DIPEA, DBU, acetonitrile, 85 °C, 2 days, no product; (d) <i>tert</i>-butyl piperidin-4-ylcarbamate, DIPEA, acetonitrile, reflux 6 h, 34%; (e) TFA, DCM, rt, 2 h, 46%; (f) <b>28</b>, acetonitrile, DMF, rt, 22 h, 49%; (g) Boc-piperazine, DIPEA, acetonitrile, reflux, 22 h, 75% (<b>38a</b>), <b>26</b>, Boc-homopiperazine, DIPEA, acetonitrile, 23 h, reflux, 74% (<b>38b</b>); (h) TFA, DCM, rt, 5 h, followed 1 M NaOH, 71% (<b>39a</b>), TFA, DCM, rt, 3.5 h (<b>39b</b>); (i) <b>28</b>, acetonitrile, toluene, rt, 18 h, 66% (<b>40a</b>); DBU, acetonitrile, rt, 23 h, 5% (<b>40b</b>).</p></p></figure><figure data-id="fig4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-2/jm501254d/20150115/images/medium/jm-2014-01254d_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-2/jm501254d/20150115/images/large/jm-2014-01254d_0005.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Overview of some of the most promising dual acting ligands including chemical structures, physical structures as well as the inhibitory and functional potencies at the adenosine A<sub>2A</sub> and dopamine D<sub>2</sub> receptors, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-2/jm501254d/20150115/images/large/jm-2014-01254d_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501254d&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i84">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27567" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27567" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 51 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Nussbaum, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, C. E.</span><span> </span><span class="NLM_article-title">Alzheimer’s disease and Parkinson’s disease</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">348</span><span class="NLM_x">, </span> <span class="NLM_fpage">1356</span><span class="NLM_x">–</span> <span class="NLM_lpage">1364</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm501254d&amp;key=10.1056%2FNEJM2003ra020003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm501254d&amp;key=12672864" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm501254d&amp;key=1%3ACAS%3A528%3ADC%252BD3sXis1egt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2003&pages=1356-1364&author=R.+L.+Nussbaumauthor=C.+E.+Ellis&title=Alzheimer%E2%80%99s+disease+and+Parkinson%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Alzheimer's disease and Parkinson's disease</span></div><div class="casAuthors">Nussbaum, Robert L.; Ellis, Christopher E.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">348</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1356-1364</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review discusses the current understanding on the pathogenesis of Alzheimer's disease (AD) and Parkinson's disease (PD) based on genetic studies.  The emergence of a consensus hypothesis that aggregates of Aβ42 and α-synuclein are neurotoxic in AD and PD, resp., may explain the pathogenesis not only of the inherited forms of these diseases but also of the idiopathic variety.  Such insights into causation and pathogenesis are helping to identify new treatment targets for these debilitating disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrg4V6nJZUmELVg90H21EOLACvtfcHk0likXD1WwwtiAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXis1egt7c%253D&md5=1be9cf3a17cccd2beb16a94779e64180</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1056%2FNEJM2003ra020003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM2003ra020003%26sid%3Dliteratum%253Aachs%26aulast%3DNussbaum%26aufirst%3DR.%2BL.%26aulast%3DEllis%26aufirst%3DC.%2BE.%26atitle%3DAlzheimer%25E2%2580%2599s%2520disease%2520and%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2003%26volume%3D348%26spage%3D1356%26epage%3D1364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Samii, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nutt, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ransom, B. R.</span><span> </span><span class="NLM_article-title">Parkinson’s disease</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">363</span><span class="NLM_x">, </span> <span class="NLM_fpage">1783</span><span class="NLM_x">–</span> <span class="NLM_lpage">1793</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2004&pages=1783-1793&author=A.+Samiiauthor=J.+G.+Nuttauthor=B.+R.+Ransom&title=Parkinson%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSamii%26aufirst%3DA.%26aulast%3DNutt%26aufirst%3DJ.%2BG.%26aulast%3DRansom%26aufirst%3DB.%2BR.%26atitle%3DParkinson%25E2%2580%2599s%2520disease%26jtitle%3DLancet%26date%3D2004%26volume%3D363%26spage%3D1783%26epage%3D1793" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Hickey, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stacy, M.</span><span> </span><span class="NLM_article-title">Available and emerging treatments for Parkinson’s disease: a review</span> <span class="citation_source-journal">Drug Des. Dev. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">241</span><span class="NLM_x">–</span> <span class="NLM_lpage">254</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm501254d&amp;key=1%3ACAS%3A280%3ADC%252BC3MrksFeltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2011&pages=241-254&author=P.+Hickeyauthor=M.+Stacy&title=Available+and+emerging+treatments+for+Parkinson%E2%80%99s+disease%3A+a+review"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Available and emerging treatments for Parkinson's disease: a review</span></div><div class="casAuthors">Hickey Patrick; Stacy Mark</div><div class="citationInfo"><span class="NLM_cas:title">Drug design, development and therapy</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">241-54</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Parkinson's disease is a commonly encountered neurodegenerative disorder primarily found in aged populations.  A number of medications are available to control symptoms, although these are less effective in advanced disease.  Deep brain stimulation provides a practicable alternative at this stage, although a minority of patients meet the strict criteria for surgery.  Novel medications that provide enhanced symptomatic control remain in developmental demand.  Both gene and cell-based therapies have shown promise in early clinical studies.  A major unmet need is a treatment that slows or stops disease progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSS--Rf7YUny9TiMd2aNQVUfW6udTcc2eZ9uyb9XKjH87ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MrksFeltw%253D%253D&md5=52769e248a130309aa98cb930f8d8ea3</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHickey%26aufirst%3DP.%26aulast%3DStacy%26aufirst%3DM.%26atitle%3DAvailable%2520and%2520emerging%2520treatments%2520for%2520Parkinson%25E2%2580%2599s%2520disease%253A%2520a%2520review%26jtitle%3DDrug%2520Des.%2520Dev.%2520Ther.%26date%3D2011%26volume%3D5%26spage%3D241%26epage%3D254" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Poewe, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahlknecht, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jankovic, J.</span><span> </span><span class="NLM_article-title">Emerging therapies for Parkinson’s disease</span> <span class="citation_source-journal">Curr. Opin. Neurol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">448</span><span class="NLM_x">–</span> <span class="NLM_lpage">459</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm501254d&amp;key=10.1097%2FWCO.0b013e3283542fde" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm501254d&amp;key=22772874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm501254d&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVWjs7zM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2012&pages=448-459&author=W.+Poeweauthor=P.+Mahlknechtauthor=J.+Jankovic&title=Emerging+therapies+for+Parkinson%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging therapies for Parkinson's disease</span></div><div class="casAuthors">Poewe, Werner; Mahlknecht, Philipp; Jankovic, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Neurology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">448-459</span>CODEN:
                <span class="NLM_cas:coden">CONEEX</span>;
        ISSN:<span class="NLM_cas:issn">1350-7540</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose of review: The exptl. therapeutics of Parkinson's disease are reviewed, highlighting the current pipeline of emerging therapeutic approaches.  Recent findings: This review includes novel approaches to dopaminergic drug delivery such as intraintestinal infusions or new extended-release formulations of levodopa and also intrapulmonary delivery of apomorphine as well as novel dopaminergic agents like the monoamine oxidase-B inhibitor safinamide or novel catechol-O-Me transferase inhibitors.  An even greater no. of ongoing clin. trials assess the efficacy and safety of nondopaminergic approaches to enhance motor control or reduce motor complications like fluctuations and dyskinesias.  These include adenosine A2A antagonists, α-adrenergic and serotonergic agonists as well as drugs acting on the glutamatergic system.  Gene-based or cell-based intrastriatal delivery of therapeutic principles that enhance striatal dopaminergic transmission directly or via the stimulation of trophic activity has also reached phase II clin. development with encouraging results in some studies.  Finally, a wide spectrum of agents with a potential for slowing disease progression is currently tested.  Summary: A variety of medical and nonmedical interventions in different phases of clin. development provide an interesting and promising portfolio of emerging therapies for Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomNZpxzJjBtrVg90H21EOLACvtfcHk0likXD1WwwtiAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVWjs7zM&md5=421b6b0b289da7fcc8e817ae1808c15a</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1097%2FWCO.0b013e3283542fde&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FWCO.0b013e3283542fde%26sid%3Dliteratum%253Aachs%26aulast%3DPoewe%26aufirst%3DW.%26aulast%3DMahlknecht%26aufirst%3DP.%26aulast%3DJankovic%26aufirst%3DJ.%26atitle%3DEmerging%2520therapies%2520for%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DCurr.%2520Opin.%2520Neurol.%26date%3D2012%26volume%3D25%26spage%3D448%26epage%3D459" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Hornykiewicz, O.</span><span> </span><span class="NLM_article-title">Dopamine miracle: from brain homogenate to dopamine replacement</span> <span class="citation_source-journal">Movement Disord.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">501</span><span class="NLM_x">–</span> <span class="NLM_lpage">508</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm501254d&amp;key=10.1002%2Fmds.10115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm501254d&amp;key=12112197" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm501254d&amp;key=1%3ACAS%3A280%3ADC%252BD38zmtFWgtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2002&pages=501-508&author=O.+Hornykiewicz&title=Dopamine+miracle%3A+from+brain+homogenate+to+dopamine+replacement"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine miracle: from brain homogenate to dopamine replacement</span></div><div class="casAuthors">Hornykiewicz Oleh</div><div class="citationInfo"><span class="NLM_cas:title">Movement disorders : official journal of the Movement Disorder Society</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">501-8</span>
        ISSN:<span class="NLM_cas:issn">0885-3185</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ86vK8nfFu0Gx8TEN9K18QfW6udTcc2ebpXuKhaa_ZPLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38zmtFWgtA%253D%253D&md5=50f4fdbab9ac5aab71703e0c7d77c363</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1002%2Fmds.10115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmds.10115%26sid%3Dliteratum%253Aachs%26aulast%3DHornykiewicz%26aufirst%3DO.%26atitle%3DDopamine%2520miracle%253A%2520from%2520brain%2520homogenate%2520to%2520dopamine%2520replacement%26jtitle%3DMovement%2520Disord.%26date%3D2002%26volume%3D17%26spage%3D501%26epage%3D508" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Fahn, S.</span><span> </span><span class="NLM_article-title">The history of dopamine and levodopa in the treatment of Parkinson’s disease</span> <span class="citation_source-journal">Movement Disord.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">497</span><span class="NLM_x">–</span> <span class="NLM_lpage">508</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm501254d&amp;key=10.1002%2Fmds.22028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm501254d&amp;key=18781671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm501254d&amp;key=1%3ACAS%3A280%3ADC%252BD1cnjt1elsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2008&pages=497-508&author=S.+Fahn&title=The+history+of+dopamine+and+levodopa+in+the+treatment+of+Parkinson%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The history of dopamine and levodopa in the treatment of Parkinson's disease</span></div><div class="casAuthors">Fahn Stanley</div><div class="citationInfo"><span class="NLM_cas:title">Movement disorders : official journal of the Movement Disorder Society</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">23 Suppl 3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">S497-508</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The discoveries of dopamine as a neurotransmitter in the brain, its depletion in patients with Parkinson disease, and its replacement with levodopa therapy were major revolutionary events in the rise to effective therapy for patients with this disorder.  This review describes these events and the persons who carried out these accomplishments.  Their impact went beyond a single clinical entity of parkinsonism, for it opened up the beginning of a much better understanding of the role of dopamine in other neurologic movement disorders and also in many psychiatric diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTvbCPehkebW0EgZCMqtRBifW6udTcc2ebpXuKhaa_ZPLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cnjt1elsQ%253D%253D&md5=066bfc5127027e09bbbd2f40261955e7</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1002%2Fmds.22028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmds.22028%26sid%3Dliteratum%253Aachs%26aulast%3DFahn%26aufirst%3DS.%26atitle%3DThe%2520history%2520of%2520dopamine%2520and%2520levodopa%2520in%2520the%2520treatment%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DMovement%2520Disord.%26date%3D2008%26volume%3D23%26spage%3D497%26epage%3D508" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Hauser, R. A.</span><span> </span><span class="NLM_article-title">Levodopa: past, present, and future</span> <span class="citation_source-journal">Eur. Neurol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">8</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm501254d&amp;key=10.1159%2F000215875" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm501254d&amp;key=19407449" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm501254d&amp;key=1%3ACAS%3A528%3ADC%252BD1MXntFaqtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2009&pages=1-8&author=R.+A.+Hauser&title=Levodopa%3A+past%2C+present%2C+and+future"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Levodopa: Past, Present, and Future</span></div><div class="casAuthors">Hauser, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">European Neurology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-8</span>CODEN:
                <span class="NLM_cas:coden">EUNEAP</span>;
        ISSN:<span class="NLM_cas:issn">0014-3022</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">A review.  Levodopa has been the mainstay of treatment for Parkinson's disease (PD) for more than 40 years.  During this time, researchers have strived to optimize levodopa formulations to minimize side effects, enhance central nervous system (CNS) bioavailability, and achieve stable therapeutic plasma levels.  Current strategies include concomitant treatment with inhibitors of dopa decarboxylase (DDC) and catechol-O-methyltransferase (COMT) to prolong the peripheral levodopa half-life and increase CNS bioavailability.  Levodopa combined with DDC inhibition is the current std. method of delivering levodopa for symptomatic treatment of PD.  Recent research suggests that continuous dopaminergic stimulation that more closely approximates physiol. stimulation may delay or prevent the development of motor fluctuations ( wearing off') and dyskinesias.  Strategies currently being used to achieve more continuous dopaminergic stimulation include the combination of an oral levodopa/DDC inhibitor with a COMT inhibitor and the enteral infusion of a levodopa gel formulation.  Attempts are underway to develop oral and transdermal very long-acting levodopa prepns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtDAZQ96ayLrVg90H21EOLACvtfcHk0ljekt2oe5sFvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXntFaqtbg%253D&md5=fdc604da9d201fa25b633602274fe0f4</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1159%2F000215875&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000215875%26sid%3Dliteratum%253Aachs%26aulast%3DHauser%26aufirst%3DR.%2BA.%26atitle%3DLevodopa%253A%2520past%252C%2520present%252C%2520and%2520future%26jtitle%3DEur.%2520Neurol.%26date%3D2009%26volume%3D62%26spage%3D1%26epage%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Tan, E.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jankovic, J.</span><span> </span><span class="NLM_article-title">Choosing dopamine agonists in Parkinson’s disease</span> <span class="citation_source-journal">Clin. Neuropharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">247</span><span class="NLM_x">–</span> <span class="NLM_lpage">253</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2001&pages=247-253&author=E.-K.+Tanauthor=J.+Jankovic&title=Choosing+dopamine+agonists+in+Parkinson%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DE.-K.%26aulast%3DJankovic%26aufirst%3DJ.%26atitle%3DChoosing%2520dopamine%2520agonists%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DClin.%2520Neuropharmacol.%26date%3D2001%26volume%3D24%26spage%3D247%26epage%3D253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Simola, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morelli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinna, A.</span><span> </span><span class="NLM_article-title">Adenosine A<sub>2A</sub> receptor antagonists and Parkinson’s disease: state of the art and future directions</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1475</span><span class="NLM_x">–</span> <span class="NLM_lpage">1489</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm501254d&amp;key=10.2174%2F138161208784480072" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm501254d&amp;key=18537671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm501254d&amp;key=1%3ACAS%3A528%3ADC%252BD1cXns1ymsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=1475-1489&author=N.+Simolaauthor=M.+Morelliauthor=A.+Pinna&title=Adenosine+A2A+receptor+antagonists+and+Parkinson%E2%80%99s+disease%3A+state+of+the+art+and+future+directions"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine A2A receptor antagonists and Parkinson's disease: state of the art and future directions</span></div><div class="casAuthors">Simola, N.; Morelli, M.; Pinna, A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1475-1489</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Adenosine A2A receptors present in the central nervous system have been implicated in the modulation of motor functions.  Accordingly, adenosine A2A receptor antagonists currently constitute an attractive non-dopaminergic option for use in the treatment of Parkinson's disease (PD).  The highly enriched distributions of adenosine A2A receptors in striatopallidal neurons, and their ability to form functional heteromeric complexes with dopamine D2 and metabotropic glutamate mGlu5 receptors, render A2A receptor antagonists of particular interest in the modulation of motor behavior, while at the same time displaying a low predisposition to inducing non-motor side effects.  Furthermore, adenosine A2A receptor antagonists appear to exert a marked efficacy on PD tremor and in reducing the progress of underlying neurodegeneration and maladaptive neuroplasticity that complicates std. dopamine replacement treatments in PD.  Finally, recent evidence has illustrated an improvement of cognitive function as well as enhancement of attention in rodents following administration of A2A receptor antagonists.  This article is aimed at examg. preclin. studies describing these findings as well as reports from clin. trials, in order to provide a comprehensive review of the evidence suggesting that this class of drugs may represent an advance in the treatment of PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_H3uAbCpz3bVg90H21EOLACvtfcHk0lhfAmmxosOdpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXns1ymsr0%253D&md5=1760d409edbb456ee19636a893cbdf6b</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.2174%2F138161208784480072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161208784480072%26sid%3Dliteratum%253Aachs%26aulast%3DSimola%26aufirst%3DN.%26aulast%3DMorelli%26aufirst%3DM.%26aulast%3DPinna%26aufirst%3DA.%26atitle%3DAdenosine%2520A2A%2520receptor%2520antagonists%2520and%2520Parkinson%25E2%2580%2599s%2520disease%253A%2520state%2520of%2520the%2520art%2520and%2520future%2520directions%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2008%26volume%3D14%26spage%3D1475%26epage%3D1489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Morelli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blandini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simola, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hauser, R. A.</span><span> </span><span class="NLM_article-title">A<sub>2A</sub> receptor antagonism and dyskinesia in Parkinson’s disease</span> <span class="citation_source-journal">Parkinson’s Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_fpage">489853</span><span class="NLM_x">–</span> <span class="NLM_lpage">489861</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm501254d&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVemsr%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=489853-489861&author=M.+Morelliauthor=F.+Blandiniauthor=N.+Simolaauthor=R.+A.+Hauser&title=A2A+receptor+antagonism+and+dyskinesia+in+Parkinson%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">A2A receptor antagonism and dyskinesia in Parkinson's disease</span></div><div class="casAuthors">Morelli, Micaela; Blandini, Fabio; Simola, Nicola; Hauser, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Parkinson's Disease</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">489853, 8 pp.</span>CODEN:
                <span class="NLM_cas:coden">PDAIB9</span>;
        ISSN:<span class="NLM_cas:issn">2042-0080</span>.
    
            (<span class="NLM_cas:orgname">Hindawi Publishing Corp.</span>)
        </div><div class="casAbstract">A review.  Dyskinesia, a major complication of treatment of Parkinson's disease (PD), involves two phases: induction, which is responsible for dyskinesia onset, and expression, which underlies its clin. manifestation.  The unique cellular and regional distribution of adenosine A2A receptors in basal ganglia areas that are richly innervated by dopamine, and their antagonistic role towards dopamine receptor stimulation, have positioned A2A receptor antagonists as an attractive nondopaminergic target to improve the motor deficits that characterize PD.  In this paper, we describe the biochem. characteristics of A2A receptors and the effects of adenosine A2A antagonists in rodent and primate models of PD on -DOPA-induced dyskinesia, together with relevant biomarker studies.  We also review clin. trials of A2A antagonists as adjuncts to l-DOPA in PD patients with motor fluctuations.  These studies have generally demonstrated that the addn. of an A2A antagonist to a stable -DOPA regimen reduces OFF time and mildly increases dyskinesia.  However, limited clin. data suggest that the addn. of an A2A antagonist along with a redn. of -DOPA mightmaintain anti-Parkinsonian benefit and reduce dyskinesia.  Whether A2A antagonists might reduce the development of dyskinesia has not yet been tested clin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpW3s40ZMidP7Vg90H21EOLACvtfcHk0lhfAmmxosOdpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVemsr%252FM&md5=8362dcfb95d89a3a2c0475d80bf4ccfb</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMorelli%26aufirst%3DM.%26aulast%3DBlandini%26aufirst%3DF.%26aulast%3DSimola%26aufirst%3DN.%26aulast%3DHauser%26aufirst%3DR.%2BA.%26atitle%3DA2A%2520receptor%2520antagonism%2520and%2520dyskinesia%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DParkinson%25E2%2580%2599s%2520Dis.%26date%3D2012%26spage%3D489853%26epage%3D489861" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Pinna, A.</span><span> </span><span class="NLM_article-title">Novel investigational adenosine A<sub>2A</sub> receptor antagonists for Parkinson’s disease</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1619</span><span class="NLM_x">–</span> <span class="NLM_lpage">1631</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2009&pages=1619-1631&author=A.+Pinna&title=Novel+investigational+adenosine+A2A+receptor+antagonists+for+Parkinson%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPinna%26aufirst%3DA.%26atitle%3DNovel%2520investigational%2520adenosine%2520A2A%2520receptor%2520antagonists%2520for%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2009%26volume%3D18%26spage%3D1619%26epage%3D1631" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Armentero, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinna, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferre, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lanciego, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mueller, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franco, R.</span><span> </span><span class="NLM_article-title">Past, present and future of A<sub>2A</sub> adenosine receptor antagonists in the therapy of Parkinson’s disease</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">132</span><span class="NLM_x">, </span> <span class="NLM_fpage">280</span><span class="NLM_x">–</span> <span class="NLM_lpage">299</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm501254d&amp;key=10.1016%2Fj.pharmthera.2011.07.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm501254d&amp;key=21810444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm501254d&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtl2ntrzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2011&pages=280-299&author=M.+T.+Armenteroauthor=A.+Pinnaauthor=S.+Ferreauthor=J.+L.+Lanciegoauthor=C.+E.+Muellerauthor=R.+Franco&title=Past%2C+present+and+future+of+A2A+adenosine+receptor+antagonists+in+the+therapy+of+Parkinson%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Past, present and future of A2A adenosine receptor antagonists in the therapy of Parkinson's disease</span></div><div class="casAuthors">Armentero, Marie Therese; Pinna, Annalisa; Ferre, Sergi; Lanciego, Jose Luis; Mueller, Christa E.; Franco, Rafael</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">280-299</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Several selective antagonists for adenosine A2A receptors (A2AR) are currently under evaluation in clin. trials (phases I to III) to treat Parkinson's disease, and they will probably soon reach the market.  The usefulness of these antagonists has been deduced from studies demonstrating functional interactions between dopamine D2 and adenosine A2A receptors in the basal ganglia.  At present it is believed that A2AR antagonists can be used in combination with the dopamine precursor L-DOPA to minimize the motor symptoms of Parkinson's patients.  However, a considerable body of data indicates that in addn. to ameliorating motor symptoms, adenosine A2AR antagonists may also prevent neurodegeneration.  Despite these promising indications, one further issue must be considered in order to develop fully optimized antiparkinsonian drug therapy, namely the existence of (hetero)dimers/oligomers of G protein-coupled receptors, a topic that is currently the focus of intense debate within the scientific community.  Dopamine D2 receptors (D2Rs) expressed in the striatum are known to form heteromers with A2A adenosine receptors.  Thus, the development of heteromer-specific A2A receptor antagonists represents a promising strategy for the identification of more selective and safer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2pOYdmdfQMLVg90H21EOLACvtfcHk0lhfAmmxosOdpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtl2ntrzP&md5=39fa871338516f7574deb7845029e624</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2011.07.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2011.07.004%26sid%3Dliteratum%253Aachs%26aulast%3DArmentero%26aufirst%3DM.%2BT.%26aulast%3DPinna%26aufirst%3DA.%26aulast%3DFerre%26aufirst%3DS.%26aulast%3DLanciego%26aufirst%3DJ.%2BL.%26aulast%3DMueller%26aufirst%3DC.%2BE.%26aulast%3DFranco%26aufirst%3DR.%26atitle%3DPast%252C%2520present%2520and%2520future%2520of%2520A2A%2520adenosine%2520receptor%2520antagonists%2520in%2520the%2520therapy%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DPharmacol.%2520Ther.%26date%3D2011%26volume%3D132%26spage%3D280%26epage%3D299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Morelli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardas, J.</span><span> </span><span class="NLM_article-title">Adenosine A<sub>2A</sub> receptor antagonists: potential therapeutic and neuroprotective effects in Parkinson’s disease</span> <span class="citation_source-journal">Neurotoxic. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">545</span><span class="NLM_x">–</span> <span class="NLM_lpage">556</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm501254d&amp;key=10.1007%2FBF03033210" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm501254d&amp;key=15111244" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm501254d&amp;key=1%3ACAS%3A528%3ADC%252BD38XpsVc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2001&pages=545-556&author=M.+Morelliauthor=J.+Wardas&title=Adenosine+A2A+receptor+antagonists%3A+potential+therapeutic+and+neuroprotective+effects+in+Parkinson%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine A2A receptor antagonists: Potential therapeutic and neuroprotective effects in Parkinson's disease</span></div><div class="casAuthors">Morelli, M.; Wardas, J.</div><div class="citationInfo"><span class="NLM_cas:title">Neurotoxicity Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">545-556</span>CODEN:
                <span class="NLM_cas:coden">NURRFI</span>;
        ISSN:<span class="NLM_cas:issn">1029-8428</span>.
    
            (<span class="NLM_cas:orgname">Harwood Academic Publishers</span>)
        </div><div class="casAbstract">The most effective treatment of Parkinson's disease (PD) is, at present, the dopamine precursor L-3,4-dihydroxyphenyl-alanine (L-DOPA), however a no. of disadvantages such as a loss of drug efficacy and severe side-effects (psychoses, dyskinesias and on-off phenomena) limit long-term, effective utilization of this drug.  Recent exptl. studies in which selective antagonists of adenosine A2A receptors were used, have shown an improvement in motor disabilities in animal models of PD.  The A2A antagonist [7-(2-phenylethyl)-5-amino-2-(2-furyl)-pyrazolo-(4,3-e)-1,2,4-triazolo(1,5--c)pyrimidine] (SCH 58261) potentiated the contralateral turning behavior induced by a threshold dose of L-DOPA or direct dopamine receptor agonists in unilaterally 6-hydroxydopamine (6-OHDA) lesioned rats, an effect accompanied by an increase in Foslike-immunoreactivity in neurons of the lesioned striatum.  Likewise, other A2A receptor antagonists such as (3,7-dimethyl-1-propargylxanthine) (DMPX), [E-8-(3,4-dimethoxystyryl)-1,3-dipropyl-7-methylxanthine] (KF 17837) and [E-1,3-diethyl-8-(3,4-dimethoxystyryl)-7-methyl-3,7-dihydro-1H-purine-2, 6-dione] (KW 6002) antagonized catalepsy induced by haloperidol or reserpine in the rat, whereas in non-human primate models of PD, KW 6002 reduced the rigidity and improved the disability score of MPTP-treated marmosets and cynomolgus monkeys.  Moreover, in contrast to L-DOPA, selective A2A receptor antagonists administered chronically did not produce dyskinesias and did not evoke tolerance in 6-OHDA and MPTP models of PD.  An addnl. therapeutic potential of adenosine A2A antagonists emerged from studies showing neuroprotective properties of these compds. in animal models of cerebral ischemia and excitotoxicity, as well as in the (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) (MPTP) model of PD.  Adenosine A2A receptor antagonists by reversing motor impairments in animal models of PD and by contrasting cell degeneration are some of the most promising compds. for the treatment of PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcszaghZSO_rVg90H21EOLACvtfcHk0lgnv264FqJFLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XpsVc%253D&md5=cda23d435af01aa1ffa6b2bff156d653</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1007%2FBF03033210&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF03033210%26sid%3Dliteratum%253Aachs%26aulast%3DMorelli%26aufirst%3DM.%26aulast%3DWardas%26aufirst%3DJ.%26atitle%3DAdenosine%2520A2A%2520receptor%2520antagonists%253A%2520potential%2520therapeutic%2520and%2520neuroprotective%2520effects%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DNeurotoxic.%2520Res.%26date%3D2001%26volume%3D3%26spage%3D545%26epage%3D556" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Xu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bastia, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwarzschild, M.</span><span> </span><span class="NLM_article-title">Therapeutic potential of adenosine A<sub>2A</sub> receptor antagonists in Parkinson’s disease</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">267</span><span class="NLM_x">–</span> <span class="NLM_lpage">310</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm501254d&amp;key=10.1016%2Fj.pharmthera.2004.10.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm501254d&amp;key=15737407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm501254d&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhvVCjt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2005&pages=267-310&author=K.+Xuauthor=E.+Bastiaauthor=M.+Schwarzschild&title=Therapeutic+potential+of+adenosine+A2A+receptor+antagonists+in+Parkinson%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic potential of adenosine A2A receptor antagonists in Parkinson's disease</span></div><div class="casAuthors">Xu, Kui; Bastia, Elena; Schwarzschild, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">267-310</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  In the pursuit of improved treatments for Parkinson's disease (PD), the adenosine A2A receptor has emerged as an attractive nondopaminergic target.  Based on the compelling behavioral pharmacol. and selective basal ganglia expression of this G-protein-coupled receptor, its antagonists are now crossing the threshold of clin. development as adjunctive symptomatic treatment for relatively advanced PD.  The antiparkinsonian potential of A2A antagonism has been boosted further by recent preclin. evidence that A2A antagonists might favorably alter the course as well as the symptoms of the disease.  Convergent epidemiol. and lab. data have suggested that A2A blockade may confer neuroprotection against the underlying dopaminergic neuron degeneration.  In addn., rodent and nonhuman primate studies have raised the possibility that A2A receptor activation contributes to the pathophysiol. of dyskinesias-problematic motor complications of std. PD therapy-and that A2A antagonism might help prevent them.  Realistically, despite being targeted to basal ganglia pathophysiol., A2A antagonists may be expected to have other beneficial and adverse effects elsewhere in the central nervous system (e.g., on mood and sleep) and in the periphery (e.g., on immune and inflammatory processes).  The thoughtful design of new clin. trials of A2A antagonists should take into consideration these counterbalancing hopes and concerns and may do well to shift toward a broader set of disease-modifying as well as symptomatic indications in early PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3HbF9ZxHP3bVg90H21EOLACvtfcHk0lgnv264FqJFLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhvVCjt7s%253D&md5=ca493d29bdda09382108c0566a3a0877</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2004.10.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2004.10.007%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DK.%26aulast%3DBastia%26aufirst%3DE.%26aulast%3DSchwarzschild%26aufirst%3DM.%26atitle%3DTherapeutic%2520potential%2520of%2520adenosine%2520A2A%2520receptor%2520antagonists%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DPharmacol.%2520Ther.%26date%3D2005%26volume%3D105%26spage%3D267%26epage%3D310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Berque-Bestel, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lezoulac’h, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jockers, R.</span><span> </span><span class="NLM_article-title">Bivalent ligands as specific pharmacological tools for G-protein coupled receptor dimers</span> <span class="citation_source-journal">Curr. Drug Discovery Technol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">312</span><span class="NLM_x">–</span> <span class="NLM_lpage">318</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2008&pages=312-318&author=I.+Berque-Bestelauthor=F.+Lezoulac%E2%80%99hauthor=R.+Jockers&title=Bivalent+ligands+as+specific+pharmacological+tools+for+G-protein+coupled+receptor+dimers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBerque-Bestel%26aufirst%3DI.%26aulast%3DLezoulac%25E2%2580%2599h%26aufirst%3DF.%26aulast%3DJockers%26aufirst%3DR.%26atitle%3DBivalent%2520ligands%2520as%2520specific%2520pharmacological%2520tools%2520for%2520G-protein%2520coupled%2520receptor%2520dimers%26jtitle%3DCurr.%2520Drug%2520Discovery%2520Technol.%26date%3D2008%26volume%3D5%26spage%3D312%26epage%3D318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Shonberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scammells, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capuano, B.</span><span> </span><span class="NLM_article-title">Design strategies for bivalent ligands targeting GPCRs</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">963</span><span class="NLM_x">–</span> <span class="NLM_lpage">974</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Fjm501254d&amp;key=10.1002%2Fcmdc.201100101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm501254d&amp;key=21520422" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm501254d&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmsFGjsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=963-974&author=J.+Shonbergauthor=P.+J.+Scammellsauthor=B.+Capuano&title=Design+strategies+for+bivalent+ligands+targeting+GPCRs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Design Strategies for Bivalent Ligands Targeting GPCRs</span></div><div class="casAuthors">Shonberg, Jeremy; Scammells, Peter J.; Capuano, Ben</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">963-974</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Specifically designed bivalent ligands targeting G protein-coupled receptor (GPCR) dimeric structures have become increasingly popular in recent literature.  The advantages of the bivalent approach are numerous, including enhanced potency and receptor subtype specificity.  However, the use of bivalent ligands as potential pharmacotherapeutics is limited by problematic mol. properties, such as high mol. wt. and lipophilicity.  This Minireview focuses on the design of bivalent ligands recently described in the literature; discussing the choice of lead pharmacophore, the position and nature of the attachment point for linking the two pharmacophore units, and the length and compn. of the spacer group.  Furthermore, this Minireview distills the mol. descriptors of the bivalent ligands that exhibit in vivo activity, as well as highlights their ability to access the central nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7uDrMXq0sprVg90H21EOLACvtfcHk0liHhzzbHmYyGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmsFGjsL0%253D&md5=569a8a988cdd9d2daf8f492211303934</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201100101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201100101%26sid%3Dliteratum%253Aachs%26aulast%3DShonberg%26aufirst%3DJ.%26aulast%3DScammells%26aufirst%3DP.%2BJ.%26aulast%3DCapuano%26aufirst%3DB.%26atitle%3DDesign%2520strategies%2520for%2520bivalent%2520ligands%2520targeting%2520GPCRs%26jtitle%3DChemMedChem%26date%3D2011%26volume%3D6%26spage%3D963%26epage%3D974" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Soriano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ventura, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molero, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casadó, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortés, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fanelli, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albericio, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lluís, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franco, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Royo, M.</span><span> </span><span class="NLM_article-title">Adenosine A<sub>2A</sub> receptor-antagonist/dopamine D<sub>2</sub> receptor-agonist bivalent ligands as pharmacological tools to detect A<sub>2A</sub>–D<sub>2</sub> receptor heteromers</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">5590</span><span class="NLM_x">–</span> <span class="NLM_lpage">5602</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm900298c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=5590-5602&author=A.+Sorianoauthor=R.+Venturaauthor=A.+Moleroauthor=R.+Hoenauthor=V.+Casad%C3%B3author=A.+Cort%C3%A9sauthor=F.+Fanelliauthor=F.+Albericioauthor=C.+Llu%C3%ADsauthor=R.+Francoauthor=M.+Royo&title=Adenosine+A2A+receptor-antagonist%2Fdopamine+D2+receptor-agonist+bivalent+ligands+as+pharmacological+tools+to+detect+A2A%E2%80%93D2+receptor+heteromers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm900298c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900298c%26sid%3Dliteratum%253Aachs%26aulast%3DSoriano%26aufirst%3DA.%26aulast%3DVentura%26aufirst%3DR.%26aulast%3DMolero%26aufirst%3DA.%26aulast%3DHoen%26aufirst%3DR.%26aulast%3DCasad%25C3%25B3%26aufirst%3DV.%26aulast%3DCort%25C3%25A9s%26aufirst%3DA.%26aulast%3DFanelli%26aufirst%3DF.%26aulast%3DAlbericio%26aufirst%3DF.%26aulast%3DLlu%25C3%25ADs%26aufirst%3DC.%26aulast%3DFranco%26aufirst%3DR.%26aulast%3DRoyo%26aufirst%3DM.%26atitle%3DAdenosine%2520A2A%2520receptor-antagonist%252Fdopamine%2520D2%2520receptor-agonist%2520bivalent%2520ligands%2520as%2520pharmacological%2520tools%2520to%2520detect%2520A2A%25E2%2580%2593D2%2520receptor%2520heteromers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D5590%26epage%3D5602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Morphy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kay, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rankovic, Z.</span><span> </span><span class="NLM_article-title">From magic bullets to designed multiple ligands</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">641</span><span class="NLM_x">–</span> <span class="NLM_lpage">651</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm501254d&amp;key=10.1016%2FS1359-6446%2804%2903163-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm501254d&amp;key=15279847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm501254d&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtVSktb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=641-651&author=R.+Morphyauthor=C.+Kayauthor=Z.+Rankovic&title=From+magic+bullets+to+designed+multiple+ligands"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">From magic bullets to designed multiple ligands</span></div><div class="casAuthors">Morphy, Richard; Kay, Corinne; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">641-651</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  A major trend in medicinal chem. in the coming years will be the rational design of ligands that are capable of modulating multiple disease-relevant targets in a specific manner.  Increasingly, it is being recognized that a balanced modulation of several targets can provide a superior therapeutic effect and side effect profile compared to the action of a selective ligand.  Rational approaches in which structural features from selective ligands are combined have produced designed multiple ligands that span a wide variety of targets and target classes.  A key challenge in the design of multiple ligands is attaining a balanced activity at each target of interest while simultaneously achieving a wider selectivity and a suitable pharmacokinetic profile.  An anal. of literature examples reveals trends and insights that might help medicinal chemists discover the next generation of these types of compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcsGpfzZok5rVg90H21EOLACvtfcHk0lgp2wn1ibLHuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtVSktb8%253D&md5=cd2491baad707043dbee4f59ccad9e1d</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2804%2903163-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252804%252903163-0%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DKay%26aufirst%3DC.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DFrom%2520magic%2520bullets%2520to%2520designed%2520multiple%2520ligands%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2004%26volume%3D9%26spage%3D641%26epage%3D651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Petzer, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steyn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castagnoli, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwarzschild, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van der Schyf, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castagnoli, N.</span><span> </span><span class="NLM_article-title">Inhibition of monoamine oxidase B by selective adenosine A<sub>2A</sub> receptor antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1299</span><span class="NLM_x">–</span> <span class="NLM_lpage">1310</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2003&pages=1299-1310&author=J.+P.+Petzerauthor=S.+Steynauthor=K.+P.+Castagnoliauthor=J.-F.+Chenauthor=M.+A.+Schwarzschildauthor=C.+J.+Van+der+Schyfauthor=N.+Castagnoli&title=Inhibition+of+monoamine+oxidase+B+by+selective+adenosine+A2A+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPetzer%26aufirst%3DJ.%2BP.%26aulast%3DSteyn%26aufirst%3DS.%26aulast%3DCastagnoli%26aufirst%3DK.%2BP.%26aulast%3DChen%26aufirst%3DJ.-F.%26aulast%3DSchwarzschild%26aufirst%3DM.%2BA.%26aulast%3DVan%2Bder%2BSchyf%26aufirst%3DC.%2BJ.%26aulast%3DCastagnoli%26aufirst%3DN.%26atitle%3DInhibition%2520of%2520monoamine%2520oxidase%2520B%2520by%2520selective%2520adenosine%2520A2A%2520receptor%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2003%26volume%3D11%26spage%3D1299%26epage%3D1310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Stößel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Küppers, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gütschow, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, C. E.</span><span> </span><span class="NLM_article-title">Dual targeting of the adenosine A<sub>2A</sub> receptors and monoamine oxidase B by 4<i>H</i>-3,1-benzothiazin-4-ones</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">4580</span><span class="NLM_x">–</span> <span class="NLM_lpage">4596</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm400336x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=4580-4596&author=A.+St%C3%B6%C3%9Felauthor=S.+Hinzauthor=P.+K%C3%BCppersauthor=J.+Heerauthor=M.+G%C3%BCtschowauthor=C.+E.+M%C3%BCller&title=Dual+targeting+of+the+adenosine+A2A+receptors+and+monoamine+oxidase+B+by+4H-3%2C1-benzothiazin-4-ones"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm400336x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400336x%26sid%3Dliteratum%253Aachs%26aulast%3DSt%25C3%25B6%25C3%259Fel%26aufirst%3DA.%26aulast%3DHinz%26aufirst%3DS.%26aulast%3DK%25C3%25BCppers%26aufirst%3DP.%26aulast%3DHeer%26aufirst%3DJ.%26aulast%3DG%25C3%25BCtschow%26aufirst%3DM.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26atitle%3DDual%2520targeting%2520of%2520the%2520adenosine%2520A2A%2520receptors%2520and%2520monoamine%2520oxidase%2520B%2520by%25204H-3%252C1-benzothiazin-4-ones%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D4580%26epage%3D4596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Gogoi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biswas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antonio, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reith, M. E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dutta, A. K.</span><span> </span><span class="NLM_article-title">Novel bivalent ligands for D<sub>2</sub>/D<sub>3</sub> dopamine receptors: significant cooperative gain in D<sub>2</sub> affinity and potency</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">991</span><span class="NLM_x">–</span> <span class="NLM_lpage">996</span></span><div class="citationLinks">[<a href="/doi/10.1021/ml3002117" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=991-996&author=S.+Gogoiauthor=S.+Biswasauthor=G.+Modiauthor=T.+Antonioauthor=M.+E.+A.+Reithauthor=A.+K.+Dutta&title=Novel+bivalent+ligands+for+D2%2FD3+dopamine+receptors%3A+significant+cooperative+gain+in+D2+affinity+and+potency"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fml3002117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml3002117%26sid%3Dliteratum%253Aachs%26aulast%3DGogoi%26aufirst%3DS.%26aulast%3DBiswas%26aufirst%3DS.%26aulast%3DModi%26aufirst%3DG.%26aulast%3DAntonio%26aufirst%3DT.%26aulast%3DReith%26aufirst%3DM.%2BE.%2BA.%26aulast%3DDutta%26aufirst%3DA.%2BK.%26atitle%3DNovel%2520bivalent%2520ligands%2520for%2520D2%252FD3%2520dopamine%2520receptors%253A%2520significant%2520cooperative%2520gain%2520in%2520D2%2520affinity%2520and%2520potency%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D991%26epage%3D996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Caulkett, P. W. R.; Jones, G.; Collis, M. G.; Poucher, S. M.</span><span> </span><span class="NLM_article-title">Preparation of (amino)heteroaryl[1,2,4]triazolo[1,5-<i>a</i>]triazines and related compounds as adenosine A<sub>2</sub> receptor antagonists</span> EP 459702, <span class="NLM_month">May</span><span class="NLM_day">23</span>,<span class="NLM_x"> </span><span class="NLM_year">1991</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1991&author=P.+W.+R.+Caulkett&author=G.+Jones&author=M.+G.+Collis&author=S.+M.+Poucher&title=Preparation+of+%28amino%29heteroaryl%5B1%2C2%2C4%5Dtriazolo%5B1%2C5-a%5Dtriazines+and+related+compounds+as+adenosine+A2+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCaulkett%26aufirst%3DP.%2BW.%2BR.%26atitle%3DPreparation%2520of%2520%2528amino%2529heteroaryl%255B1%252C2%252C4%255Dtriazolo%255B1%252C5-a%255Dtriazines%2520and%2520related%2520compounds%2520as%2520adenosine%2520A2%2520receptor%2520antagonists%26date%3D1991" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Jörg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agostino, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuriev, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mak, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scammells, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capuano, B.</span><span> </span><span class="NLM_article-title">Synthesis, molecular structure, NMR spectroscopic and computational analysis of a selective adenosine A<sub>2A</sub> antagonist, ZM 241385</span> <span class="citation_source-journal">Struct. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">1241</span><span class="NLM_x">–</span> <span class="NLM_lpage">1251</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Fjm501254d&amp;key=10.1007%2Fs11224-012-0151-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm501254d&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFeltL7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2013&pages=1241-1251&author=M.+J%C3%B6rgauthor=M.+Agostinoauthor=E.+Yurievauthor=F.+Makauthor=N.+Millerauthor=J.+Whiteauthor=P.+Scammellsauthor=B.+Capuano&title=Synthesis%2C+molecular+structure%2C+NMR+spectroscopic+and+computational+analysis+of+a+selective+adenosine+A2A+antagonist%2C+ZM+241385"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, molecular structure, NMR spectroscopic and computational analysis of a selective adenosine A2A antagonist, ZM 241385</span></div><div class="casAuthors">Jorg, Manuela; Agostino, Mark; Yuriev, Elizabeth; Mak, Frankie S.; Miller, Neil D.; White, Jonathan M.; Scammells, Peter J.; Capuano, Ben</div><div class="citationInfo"><span class="NLM_cas:title">Structural Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1241-1251</span>CODEN:
                <span class="NLM_cas:coden">STCHES</span>;
        ISSN:<span class="NLM_cas:issn">1040-0400</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Herein, we describe the synthesis of the adenosine A2A antagonist ZM 241385 (9) starting from com. available 2-furanhydrazide (1) and including a comprehensive structural characterization of all the intermediates and the final product.  In addn., extensive NMR anal., including temp. and concn.-dependent expts., are reported as well as the first single-crystal structure of the compd. ZM 241385 (9) as the trihydrate.  Furthermore, an extensive structural comparison of the single-crystal structure with the published protein bound X-ray structures is reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoY8hfprg36XbVg90H21EOLACvtfcHk0livNGm2_qG25w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFeltL7J&md5=c396ef41105a98f343b00cfd240587a7</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1007%2Fs11224-012-0151-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11224-012-0151-7%26sid%3Dliteratum%253Aachs%26aulast%3DJ%25C3%25B6rg%26aufirst%3DM.%26aulast%3DAgostino%26aufirst%3DM.%26aulast%3DYuriev%26aufirst%3DE.%26aulast%3DMak%26aufirst%3DF.%26aulast%3DMiller%26aufirst%3DN.%26aulast%3DWhite%26aufirst%3DJ.%26aulast%3DScammells%26aufirst%3DP.%26aulast%3DCapuano%26aufirst%3DB.%26atitle%3DSynthesis%252C%2520molecular%2520structure%252C%2520NMR%2520spectroscopic%2520and%2520computational%2520analysis%2520of%2520a%2520selective%2520adenosine%2520A2A%2520antagonist%252C%2520ZM%2520241385%26jtitle%3DStruct.%2520Chem.%26date%3D2013%26volume%3D24%26spage%3D1241%26epage%3D1251" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Jaakola, V.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffith, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanson, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherezov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chien, E. Y. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">IJzerman, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, R. C.</span><span> </span><span class="NLM_article-title">The 2.6 angstrom crystal structure of a human A<sub>2A</sub> adenosine receptor bound to an antagonist</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">322</span><span class="NLM_x">, </span> <span class="NLM_fpage">1211</span><span class="NLM_x">–</span> <span class="NLM_lpage">1217</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm501254d&amp;key=10.1126%2Fscience.1164772" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm501254d&amp;key=18832607" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm501254d&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlyqtbfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=322&publication_year=2008&pages=1211-1217&author=V.-P.+Jaakolaauthor=M.+T.+Griffithauthor=M.+A.+Hansonauthor=V.+Cherezovauthor=E.+Y.+T.+Chienauthor=J.+R.+Laneauthor=A.+P.+IJzermanauthor=R.+C.+Stevens&title=The+2.6+angstrom+crystal+structure+of+a+human+A2A+adenosine+receptor+bound+to+an+antagonist"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The 2.6 Angstrom Crystal Structure of a Human A2A Adenosine Receptor Bound to an Antagonist</span></div><div class="casAuthors">Jaakola, Veli-Pekka; Griffith, Mark T.; Hanson, Michael A.; Cherezov, Vadim; Chien, Ellen Y. T.; Lane, J. Robert; IJzerman, Adriaan P.; Stevens, Raymond C.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">322</span>
        (<span class="NLM_cas:issue">5905</span>),
    <span class="NLM_cas:pages">1211-1217</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The adenosine class of heterotrimeric guanine nucleotide-binding protein (G protein)-coupled receptors (GPCRs) mediates the important role of extracellular adenosine in many physiol. processes and is antagonized by caffeine.  The authors have detd. the crystal structure of the human A2A adenosine receptor, in complex with a high-affinity subtype-selective antagonist, ZM241385, to 2.6 angstrom resoln.  Four disulfide bridges in the extracellular domain, combined with a subtle repacking of the transmembrane helixes relative to the adrenergic and rhodopsin receptor structures, define a pocket distinct from that of other structurally detd. GPCRs.  The arrangement allows for the binding of the antagonist in an extended conformation, perpendicular to the membrane plane.  The binding site highlights an integral role for the extracellular loops, together with the helical core, in ligand recognition by this class of GPCRs and suggests a role for ZM241385 in restricting the movement of a tryptophan residue important in the activation mechanism of the class A receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7QL4wN4TdhrVg90H21EOLACvtfcHk0livNGm2_qG25w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlyqtbfN&md5=5bdb862b41f345c244f3c162e058206b</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1126%2Fscience.1164772&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1164772%26sid%3Dliteratum%253Aachs%26aulast%3DJaakola%26aufirst%3DV.-P.%26aulast%3DGriffith%26aufirst%3DM.%2BT.%26aulast%3DHanson%26aufirst%3DM.%2BA.%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DChien%26aufirst%3DE.%2BY.%2BT.%26aulast%3DLane%26aufirst%3DJ.%2BR.%26aulast%3DIJzerman%26aufirst%3DA.%2BP.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26atitle%3DThe%25202.6%2520angstrom%2520crystal%2520structure%2520of%2520a%2520human%2520A2A%2520adenosine%2520receptor%2520bound%2520to%2520an%2520antagonist%26jtitle%3DScience%26date%3D2008%26volume%3D322%26spage%3D1211%26epage%3D1217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Gallagher, G.,  Jr.</span><span> </span><span class="NLM_article-title">4-Aminoalkyl-2(3<i>H</i>)-indolones</span>. US4452808A,<span class="NLM_x"> </span><span class="NLM_year">1984</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1984&author=G.+Gallagher&title=4-Aminoalkyl-2%283H%29-indolones"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGallagher%26aufirst%3DG.%26atitle%3D4-Aminoalkyl-2%25283H%2529-indolones%26date%3D1984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">De, M. C.; Sree, H. N.</span><span> </span><span class="NLM_article-title">Ropinirole and domperidone for use in the treatment of Parkinson’s disease</span>. WO9200735A1,<span class="NLM_x"> </span><span class="NLM_year">1992</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1992&author=M.+C.+De&author=H.+N.+Sree&title=Ropinirole+and+domperidone+for+use+in+the+treatment+of+Parkinson%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDe%26aufirst%3DM.%2BC.%26atitle%3DRopinirole%2520and%2520domperidone%2520for%2520use%2520in%2520the%2520treatment%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26date%3D1992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Horvath, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fross, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kleiner-Fisman, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lerch, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stalder, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liaudat, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raskoff, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flachsbart, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rakowski, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pache, J.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burkhard, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lang, A. E.</span><span> </span><span class="NLM_article-title">Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists</span> <span class="citation_source-journal">Movement Disord.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">656</span><span class="NLM_x">–</span> <span class="NLM_lpage">662</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm501254d&amp;key=10.1002%2Fmds.20201" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Fjm501254d&amp;key=15197703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm501254d&amp;key=1%3ACAS%3A280%3ADC%252BD2c3ps1Cntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2004&pages=656-662&author=J.+Horvathauthor=R.+D.+Frossauthor=G.+Kleiner-Fismanauthor=R.+Lerchauthor=H.+Stalderauthor=S.+Liaudatauthor=W.+J.+Raskoffauthor=K.+D.+Flachsbartauthor=H.+Rakowskiauthor=J.-C.+Pacheauthor=P.+R.+Burkhardauthor=A.+E.+Lang&title=Severe+multivalvular+heart+disease%3A+a+new+complication+of+the+ergot+derivative+dopamine+agonists"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists</span></div><div class="casAuthors">Horvath Judit; Fross Robin D; Kleiner-Fisman Galit; Lerch Rene; Stalder Hans; Liaudat Suzanne; Raskoff William J; Flachsbart Keith D; Rakowski Harry; Pache Jean-Claude; Burkhard Pierre R; Lang Anthony E</div><div class="citationInfo"><span class="NLM_cas:title">Movement disorders : official journal of the Movement Disorder Society</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">656-62</span>
        ISSN:<span class="NLM_cas:issn">0885-3185</span>.
    </div><div class="casAbstract">We report on 4 new cases of valvular heart disease in Parkinson's disease patients treated with the ergot derivative dopamine agonists pergolide and cabergoline.  Noninflammatory fibrotic degeneration of cardiac valves has been reported to occur in patients with carcinoid syndrome and to occasionally complicate therapies with the anti-migraine ergot alkaloid ergotamine and methysergide and with the appetite suppressants fenfluramine and dexfenfluramine.  In these cases, the pathogenesis is suspected to involve serotonin-mediated abnormal fibrogenesis by means of the 5-HT2B receptors, which are expressed in the fibroblasts of heart valves.  Based on strikingly similar echocardiographic and histopathological features, we strongly suspect that ergot-derived dopamine agonists may cause a valvular heart disease nearly identical to that seen in those conditions.  These cases add to a rapidly growing and worrying list of similar published reports, suggesting that we may well be facing a novel, yet unrecognized, complication of this class of agents, which are widely used not only in Parkinson's disease but also in restless legs syndrome and various common endocrine dysfunctions.  Therefore, until more is known about the true prevalence of this side effect, we propose that an assessment of cardiac function be performed before and in the course of a long-term therapy with ergot derivative dopamine agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSxQF9MCY-7EI2y4bB4mnvYfW6udTcc2eas_Pw-A111A7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c3ps1Cntg%253D%253D&md5=95f8237633e64358628bea9fdb40c34a</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1002%2Fmds.20201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmds.20201%26sid%3Dliteratum%253Aachs%26aulast%3DHorvath%26aufirst%3DJ.%26aulast%3DFross%26aufirst%3DR.%2BD.%26aulast%3DKleiner-Fisman%26aufirst%3DG.%26aulast%3DLerch%26aufirst%3DR.%26aulast%3DStalder%26aufirst%3DH.%26aulast%3DLiaudat%26aufirst%3DS.%26aulast%3DRaskoff%26aufirst%3DW.%2BJ.%26aulast%3DFlachsbart%26aufirst%3DK.%2BD.%26aulast%3DRakowski%26aufirst%3DH.%26aulast%3DPache%26aufirst%3DJ.-C.%26aulast%3DBurkhard%26aufirst%3DP.%2BR.%26aulast%3DLang%26aufirst%3DA.%2BE.%26atitle%3DSevere%2520multivalvular%2520heart%2520disease%253A%2520a%2520new%2520complication%2520of%2520the%2520ergot%2520derivative%2520dopamine%2520agonists%26jtitle%3DMovement%2520Disord.%26date%3D2004%26volume%3D19%26spage%3D656%26epage%3D662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Müller, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fritze, J.</span><span> </span><span class="NLM_article-title">Fibrosis associated with dopamine agonist therapy in Parkinson’s disease</span> <span class="citation_source-journal">Clin. Neuropharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">109</span><span class="NLM_x">–</span> <span class="NLM_lpage">111</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2003&pages=109-111&author=T.+M%C3%BCllerauthor=J.+Fritze&title=Fibrosis+associated+with+dopamine+agonist+therapy+in+Parkinson%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25BCller%26aufirst%3DT.%26aulast%3DFritze%26aufirst%3DJ.%26atitle%3DFibrosis%2520associated%2520with%2520dopamine%2520agonist%2520therapy%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DClin.%2520Neuropharmacol.%26date%3D2003%26volume%3D26%26spage%3D109%26epage%3D111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Jörg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kazcor, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poso, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mak, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K. C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, N. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scammells, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capuano, B.</span><span> </span><span class="NLM_article-title">Investigation of novel ropinirole analogues: synthesis, pharmacological evaluation and computational analysis of dopamine D<sub>2</sub> receptor functionalized congeners and homobivalent ligands</span> <span class="citation_source-journal">Med. Chem. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">891</span><span class="NLM_x">–</span> <span class="NLM_lpage">898</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Fjm501254d&amp;key=10.1039%2Fc4md00066h" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=891-898&author=M.+J%C3%B6rgauthor=A.+Kazcorauthor=A.+Posoauthor=F.+S.+Makauthor=K.+C.+K.+Leeauthor=N.+D.+Millerauthor=P.+J.+Scammellsauthor=B.+Capuano&title=Investigation+of+novel+ropinirole+analogues%3A+synthesis%2C+pharmacological+evaluation+and+computational+analysis+of+dopamine+D2+receptor+functionalized+congeners+and+homobivalent+ligands"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1039%2Fc4md00066h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc4md00066h%26sid%3Dliteratum%253Aachs%26aulast%3DJ%25C3%25B6rg%26aufirst%3DM.%26aulast%3DKazcor%26aufirst%3DA.%26aulast%3DPoso%26aufirst%3DA.%26aulast%3DMak%26aufirst%3DF.%2BS.%26aulast%3DLee%26aufirst%3DK.%2BC.%2BK.%26aulast%3DMiller%26aufirst%3DN.%2BD.%26aulast%3DScammells%26aufirst%3DP.%2BJ.%26aulast%3DCapuano%26aufirst%3DB.%26atitle%3DInvestigation%2520of%2520novel%2520ropinirole%2520analogues%253A%2520synthesis%252C%2520pharmacological%2520evaluation%2520and%2520computational%2520analysis%2520of%2520dopamine%2520D2%2520receptor%2520functionalized%2520congeners%2520and%2520homobivalent%2520ligands%26jtitle%3DMed.%2520Chem.%2520Commun.%26date%3D2014%26volume%3D5%26spage%3D891%26epage%3D898" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Jörg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Headey, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scammells, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capuano, B.</span><span> </span><span class="NLM_article-title">NMR case study of ropinirole: concentration-dependent effects of nonexchangeable proton resonances</span> <span class="citation_source-journal">Magn. Reson. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">715</span><span class="NLM_x">–</span> <span class="NLM_lpage">718</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Fjm501254d&amp;key=10.1002%2Fmrc.4114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Fjm501254d&amp;key=25104507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm501254d&amp;key=1%3ACAS%3A280%3ADC%252BC2M%252FgtFWhuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2014&pages=715-718&author=M.+J%C3%B6rgauthor=S.+Headeyauthor=P.+J.+Scammellsauthor=B.+Capuano&title=NMR+case+study+of+ropinirole%3A+concentration-dependent+effects+of+nonexchangeable+proton+resonances"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">NMR case study of ropinirole: concentration-dependent effects of nonexchangeable proton resonances</span></div><div class="casAuthors">Jorg Manuela; Headey Stephen; Scammells Peter J; Capuano Ben</div><div class="citationInfo"><span class="NLM_cas:title">Magnetic resonance in chemistry : MRC</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">715-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRDrVxS3o7BkzdblLE_E9PWfW6udTcc2eas_Pw-A111A7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M%252FgtFWhuw%253D%253D&md5=0771b4b0a64befe905297fd4171a0cb6</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1002%2Fmrc.4114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmrc.4114%26sid%3Dliteratum%253Aachs%26aulast%3DJ%25C3%25B6rg%26aufirst%3DM.%26aulast%3DHeadey%26aufirst%3DS.%26aulast%3DScammells%26aufirst%3DP.%2BJ.%26aulast%3DCapuano%26aufirst%3DB.%26atitle%3DNMR%2520case%2520study%2520of%2520ropinirole%253A%2520concentration-dependent%2520effects%2520of%2520nonexchangeable%2520proton%2520resonances%26jtitle%3DMagn.%2520Reson.%2520Chem.%26date%3D2014%26volume%3D52%26spage%3D715%26epage%3D718" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Jörg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shonberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mak, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, N. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuriev, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scammells, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capuano, B.</span><span> </span><span class="NLM_article-title">Novel adenosine A<sub>2A</sub> receptor ligands: a synthetic, functional and computational investigation of selected literature adenosine A<sub>2A</sub> receptor antagonists for extending into extracellular space</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">3427</span><span class="NLM_x">–</span> <span class="NLM_lpage">3433</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=3427-3433&author=M.+J%C3%B6rgauthor=J.+Shonbergauthor=F.+S.+Makauthor=N.+D.+Millerauthor=E.+Yurievauthor=P.+J.+Scammellsauthor=B.+Capuano&title=Novel+adenosine+A2A+receptor+ligands%3A+a+synthetic%2C+functional+and+computational+investigation+of+selected+literature+adenosine+A2A+receptor+antagonists+for+extending+into+extracellular+space"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJ%25C3%25B6rg%26aufirst%3DM.%26aulast%3DShonberg%26aufirst%3DJ.%26aulast%3DMak%26aufirst%3DF.%2BS.%26aulast%3DMiller%26aufirst%3DN.%2BD.%26aulast%3DYuriev%26aufirst%3DE.%26aulast%3DScammells%26aufirst%3DP.%2BJ.%26aulast%3DCapuano%26aufirst%3DB.%26atitle%3DNovel%2520adenosine%2520A2A%2520receptor%2520ligands%253A%2520a%2520synthetic%252C%2520functional%2520and%2520computational%2520investigation%2520of%2520selected%2520literature%2520adenosine%2520A2A%2520receptor%2520antagonists%2520for%2520extending%2520into%2520extracellular%2520space%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D3427%26epage%3D3433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Federico, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paoletta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheong, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pastorin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cacciari, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stragliotto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klotz, K. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Z.-G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moro, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spalluto, G.</span><span> </span><span class="NLM_article-title">Synthesis and biological evaluation of a new series of 1,2,4-triazolo[1,5-<i>a</i>]-1,3,5-triazines as human A<sub>2A</sub> adenosine receptor antagonists with improved water solubility</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">877</span><span class="NLM_x">–</span> <span class="NLM_lpage">889</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm101349u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=877-889&author=S.+Federicoauthor=S.+Paolettaauthor=S.+L.+Cheongauthor=G.+Pastorinauthor=B.+Cacciariauthor=S.+Stragliottoauthor=K.+N.+Klotzauthor=J.+Siegelauthor=Z.-G.+Gaoauthor=K.+A.+Jacobsonauthor=S.+Moroauthor=G.+Spalluto&title=Synthesis+and+biological+evaluation+of+a+new+series+of+1%2C2%2C4-triazolo%5B1%2C5-a%5D-1%2C3%2C5-triazines+as+human+A2A+adenosine+receptor+antagonists+with+improved+water+solubility"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm101349u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101349u%26sid%3Dliteratum%253Aachs%26aulast%3DFederico%26aufirst%3DS.%26aulast%3DPaoletta%26aufirst%3DS.%26aulast%3DCheong%26aufirst%3DS.%2BL.%26aulast%3DPastorin%26aufirst%3DG.%26aulast%3DCacciari%26aufirst%3DB.%26aulast%3DStragliotto%26aufirst%3DS.%26aulast%3DKlotz%26aufirst%3DK.%2BN.%26aulast%3DSiegel%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DZ.-G.%26aulast%3DJacobson%26aufirst%3DK.%2BA.%26aulast%3DMoro%26aufirst%3DS.%26aulast%3DSpalluto%26aufirst%3DG.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520a%2520new%2520series%2520of%25201%252C2%252C4-triazolo%255B1%252C5-a%255D-1%252C3%252C5-triazines%2520as%2520human%2520A2A%2520adenosine%2520receptor%2520antagonists%2520with%2520improved%2520water%2520solubility%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D877%26epage%3D889" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Lee, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, M.-R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, Y.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, L.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, K.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, K.-L.</span><span> </span><span class="NLM_article-title">Preparation of unconventional dendrimers that contain rigid NH-triazine linkages and peripheral <i>tert</i>-butyl moieties for CO<sub>2</sub>-selective adsorption</span> <span class="citation_source-journal">Chem.—Eur. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">10573</span><span class="NLM_x">–</span> <span class="NLM_lpage">10579</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Fjm501254d&amp;key=10.1002%2Fchem.201202161" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Fjm501254d&amp;key=23794529" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm501254d&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpvVegtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=10573-10579&author=C.-H.+Leeauthor=M.-R.+Tsaiauthor=Y.-T.+Changauthor=L.-L.+Laiauthor=K.-L.+Luauthor=K.-L.+Cheng&title=Preparation+of+unconventional+dendrimers+that+contain+rigid+NH-triazine+linkages+and+peripheral+tert-butyl+moieties+for+CO2-selective+adsorption"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Preparation of Unconventional Dendrimers that Contain Rigid NH-Triazine Linkages and Peripheral tert-Butyl Moieties for CO2-Selective Adsorption</span></div><div class="casAuthors">Lee, Cheng-Hua; Tsai, Meng-Rong; Chang, Yen-Tzu; Lai, Long-Li; Lu, Kuang-Lieh; Cheng, Kung-Lung</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">10573-10579</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Three unconventional dendrimers that contained rigid NH-triazine linkages and peripheral tert-butoxycarbonyl moieties were prepd. by using a convergent approach and characterized by 1H and 13C NMR spectroscopy, mass spectrometry, and elemental anal.  Based on a thermogravimetric anal. study, these dendrimers were obsd. to display thermal stability at about 300°C.  The NH-triazine moiety, which possessed protonated and proton-free nitrogen sites (like the imidazole unit), displayed the capture of polarizable CO2 mols. through hydrogen-bond and/or dipole-quadrupole interactions.  In addn., the adsorption of various amts. of CO2 and N2 at different pressures suggests that the dendritic pores, which arise from the stacking of the middle co-planar and rim protuberant dendrimers, GnN-NGn (n = 1-3), either swell or shrink at high pressure, thus indicating that these dendrimers may have a breathing ability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYqhoBmwk_gLVg90H21EOLACvtfcHk0ljTxCtymbfXnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpvVegtLg%253D&md5=ee772d70895dce09ebccfb06134c8bd0</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1002%2Fchem.201202161&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.201202161%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DC.-H.%26aulast%3DTsai%26aufirst%3DM.-R.%26aulast%3DChang%26aufirst%3DY.-T.%26aulast%3DLai%26aufirst%3DL.-L.%26aulast%3DLu%26aufirst%3DK.-L.%26aulast%3DCheng%26aufirst%3DK.-L.%26atitle%3DPreparation%2520of%2520unconventional%2520dendrimers%2520that%2520contain%2520rigid%2520NH-triazine%2520linkages%2520and%2520peripheral%2520tert-butyl%2520moieties%2520for%2520CO2-selective%2520adsorption%26jtitle%3DChem.%25E2%2580%2594Eur.%2520J.%26date%3D2013%26volume%3D19%26spage%3D10573%26epage%3D10579" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Castelar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbera, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcos, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romero, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serrano, J.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golemme, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Termine, R.</span><span> </span><span class="NLM_article-title">Supramolecular dendrimers based on the self-assembly of carbazole-derived dendrons and triazine rings: liquid crystal, photophysical and electrochemical properties</span> <span class="citation_source-journal">J. Mater. Chem. C</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">7321</span><span class="NLM_x">–</span> <span class="NLM_lpage">7332</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Fjm501254d&amp;key=10.1039%2Fc3tc31390e" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm501254d&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1KkurrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2013&pages=7321-7332&author=S.+Castelarauthor=J.+Barberaauthor=M.+Marcosauthor=P.+Romeroauthor=J.-L.+Serranoauthor=A.+Golemmeauthor=R.+Termine&title=Supramolecular+dendrimers+based+on+the+self-assembly+of+carbazole-derived+dendrons+and+triazine+rings%3A+liquid+crystal%2C+photophysical+and+electrochemical+properties"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Supramolecular dendrimers based on the self-assembly of carbazole-derived dendrons and triazine rings: liquid crystal, photophysical and electrochemical properties</span></div><div class="casAuthors">Castelar, Susana; Barbera, Joaquin; Marcos, Mercedes; Romero, Pilar; Serrano, Jose-Luis; Golemme, Attilio; Termine, Roberto</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Materials Chemistry C: Materials for Optical and Electronic Devices</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">7321-7332</span>CODEN:
                <span class="NLM_cas:coden">JMCCCX</span>;
        ISSN:<span class="NLM_cas:issn">2050-7534</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Two novel families of dendrimers have been synthesized by hydrogen bonding between a triazine moiety (M), as an electron-transporting central core, and three peripheral dendrons of generations 1 and 2 derived from bis(hydroxymethyl)propionic acid (bis-MPA).  The dendrons contain both carbazole-based groups as hole-transporting moieties and promesogenic units derived from 5-[4-(4-butoxybenzoyloxy)phenyloxy]pentanoic acid (family A) or cholesteryl hemisuccinate (family B) (in a 1 : 3 ratio).  The formation of the complexes was confirmed by IR and NMR data.  All synthesized complexes displayed mesogenic properties and their liq. cryst. properties have been investigated by means of differential scanning calorimetry (DSC), polarized optical microscopy (POM) and X-ray diffractometry (XRD).  Complexes derived from CzAn dendrons (family A) exhibit nematic mesomorphism whereas complexes derived from CzBn dendrons (family B) exhibit a smectic A phase.  The electrochem. behavior of the dendritic complexes was investigated by cyclic voltammetry (CV) and the dendrimers show irreversible or quasi-reversible electrochem. behavior in the range 0.0-2.0 V at a scan rate of 100 mV s-1.  The UV-vis absorption and emission properties of the compds. and the photoconductive properties of the dendrons and dendrimers have also been investigated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKJPShy7MEkbVg90H21EOLACvtfcHk0ljTxCtymbfXnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1KkurrI&md5=a9c449684eb231aaaf0454e600e87718</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1039%2Fc3tc31390e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc3tc31390e%26sid%3Dliteratum%253Aachs%26aulast%3DCastelar%26aufirst%3DS.%26aulast%3DBarbera%26aufirst%3DJ.%26aulast%3DMarcos%26aufirst%3DM.%26aulast%3DRomero%26aufirst%3DP.%26aulast%3DSerrano%26aufirst%3DJ.-L.%26aulast%3DGolemme%26aufirst%3DA.%26aulast%3DTermine%26aufirst%3DR.%26atitle%3DSupramolecular%2520dendrimers%2520based%2520on%2520the%2520self-assembly%2520of%2520carbazole-derived%2520dendrons%2520and%2520triazine%2520rings%253A%2520liquid%2520crystal%252C%2520photophysical%2520and%2520electrochemical%2520properties%26jtitle%3DJ.%2520Mater.%2520Chem.%2520C%26date%3D2013%26volume%3D1%26spage%3D7321%26epage%3D7332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Pal, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mandal, M.</span><span> </span><span class="NLM_article-title">PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes</span> <span class="citation_source-journal">Acta Pharmacol. Sin.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">1441</span><span class="NLM_x">–</span> <span class="NLM_lpage">1458</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Fjm501254d&amp;key=10.1038%2Faps.2012.72" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Fjm501254d&amp;key=22983389" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm501254d&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslKqur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2012&pages=1441-1458&author=I.+Palauthor=M.+Mandal&title=PI3K+and+Akt+as+molecular+targets+for+cancer+therapy%3A+current+clinical+outcomes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes</span></div><div class="casAuthors">Pal, Ipsita; Mandal, Mahitosh</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmacologica Sinica</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1441-1458</span>CODEN:
                <span class="NLM_cas:coden">APSCG5</span>;
        ISSN:<span class="NLM_cas:issn">1671-4083</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The PI3K-Akt pathway is a vital regulator of cell proliferation and survival.  Alterations in the PIK3CA gene that lead to enhanced PI3K kinase activity were reported in many human cancer types, including cancers of the colon, breast, brain, liver, stomach and lung.  Deregulation of PI3K causes aberrant Akt activity.  Therefore targeting this pathway could have implications for cancer treatment.  The 1st generation PI3K-Akt inhibitors were proven to be highly effective with a low IC50, but later, they were shown to have toxic side effects and poor pharmacol. properties and selectivity.  Thus, these inhibitors were only effective in preclin. models.  However, derivs. of these 1st generation inhibitors are much more selective and are quite effective in targeting the PI3K-Akt pathway, either alone or in combination.  These 2nd-generation inhibitors are essentially a specific chem. moiety that helps to form a strong hydrogen bond interaction with the PI3K/Akt mol.  The goal of this review is to delineate the current efforts that were undertaken to inhibit the various components of the PI3K and Akt pathway in different types of cancer both in vitro and in vivo.  Our focus here is on these novel therapies and their inhibitory effects that depend upon their chem. nature, as well as their development towards clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGre6N5ImyVnMLVg90H21EOLACvtfcHk0ljGdGhCVvq3UQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslKqur%252FP&md5=33f1ffb53abf0d9ba6518c18e10b3330</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1038%2Faps.2012.72&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Faps.2012.72%26sid%3Dliteratum%253Aachs%26aulast%3DPal%26aufirst%3DI.%26aulast%3DMandal%26aufirst%3DM.%26atitle%3DPI3K%2520and%2520Akt%2520as%2520molecular%2520targets%2520for%2520cancer%2520therapy%253A%2520current%2520clinical%2520outcomes%26jtitle%3DActa%2520Pharmacol.%2520Sin.%26date%3D2012%26volume%3D33%26spage%3D1441%26epage%3D1458" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Wu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Y.</span><span> </span><span class="NLM_article-title">Small molecules targeting phosphoinositide 3-kinases</span> <span class="citation_source-journal">MedChemComm</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1337</span><span class="NLM_x">–</span> <span class="NLM_lpage">1355</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=1337-1355&author=P.+Wuauthor=Y.+Hu&title=Small+molecules+targeting+phosphoinositide+3-kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DP.%26aulast%3DHu%26aufirst%3DY.%26atitle%3DSmall%2520molecules%2520targeting%2520phosphoinositide%25203-kinases%26jtitle%3DMedChemComm%26date%3D2012%26volume%3D3%26spage%3D1337%26epage%3D1355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Doan, K. M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humphreys, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webster, L. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wring, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shampine, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serabjit-Singh, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adkison, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polli, J. W.</span><span> </span><span class="NLM_article-title">Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">303</span><span class="NLM_x">, </span> <span class="NLM_fpage">1029</span><span class="NLM_x">–</span> <span class="NLM_lpage">1037</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Fjm501254d&amp;key=10.1124%2Fjpet.102.039255" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Fjm501254d&amp;key=12438524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Fjm501254d&amp;key=1%3ACAS%3A528%3ADC%252BD38XptlamtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=303&publication_year=2002&pages=1029-1037&author=K.+M.+M.+Doanauthor=J.+E.+Humphreysauthor=L.+O.+Websterauthor=S.+A.+Wringauthor=L.+J.+Shampineauthor=C.+J.+Serabjit-Singhauthor=K.+K.+Adkisonauthor=J.+W.+Polli&title=Passive+permeability+and+P-glycoprotein-mediated+efflux+differentiate+central+nervous+system+%28CNS%29+and+non-CNS+marketed+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs</span></div><div class="casAuthors">Doan, Kelly M. Mahar; Humphreys, Joan E.; Webster, Lindsey O.; Wring, Stephen A.; Shampine, Larry J.; Serabjit-Singh, Cosette J.; Adkison, Kimberly K.; Polli, Joseph W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">303</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1029-1037</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Membrane permeability and P-glycoprotein (Pgp) can be limiting factors for blood-brain barrier penetration.  The objectives of this study were to det. whether there are differences in the in vitro permeability, Pgp substrate profiles, and physicochem. properties of drugs for central nervous system (CNS) and non-CNS indications, and whether these differences are useful criteria in selecting compds. for drug development.  Apparent permeability (Papp) and Pgp substrate profiles for 93 CNS and non-CNS drugs were detd. by monolayer efflux.  Calcein-AM inhibition assays were used to supplement the efflux results.  The CNS set (2 of 48, 4.2%) had a 7-fold lower incidence of passive permeability values <150 nm/s compared with the non-CNS set (13 of 45, 28.9%).  The majority of drugs (72.0%, 67 of 93) were not Pgp substrates; however, 49.5% (46 of 93) were pos. in the calcein-AM assay when tested at 100 μM.  The CNS drug set (of 48, 14.6%) had a 3-fold lower incidence of Pgp-mediated efflux than the non-CNS drug set (of 45, 42.2%).  Anal. of 18 physicochem. properties revealed that the CNS drug set had fewer hydrogen bond donors, fewer pos. charges, greater lipophilicity, lower polar surface area, and reduced flexibility compared with the non-CNS group, properties that enhance membrane permeability.  This study on a large, diverse set of marketed compds. clearly demonstrates that permeability, Pgp-mediated efflux, and certain physicochem. properties are factors that differentiate CNS and non-CNS drugs.  For CNS delivery, a drug should ideally have an in vitro passive permeability >150 nm/s and not be a good (B → A/A → B ratio <2.5) Pgp substrate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2qUc-kS0MC7Vg90H21EOLACvtfcHk0ljGdGhCVvq3UQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XptlamtLg%253D&md5=bcac11a02278360d6d6ad48718f0d5be</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1124%2Fjpet.102.039255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.102.039255%26sid%3Dliteratum%253Aachs%26aulast%3DDoan%26aufirst%3DK.%2BM.%2BM.%26aulast%3DHumphreys%26aufirst%3DJ.%2BE.%26aulast%3DWebster%26aufirst%3DL.%2BO.%26aulast%3DWring%26aufirst%3DS.%2BA.%26aulast%3DShampine%26aufirst%3DL.%2BJ.%26aulast%3DSerabjit-Singh%26aufirst%3DC.%2BJ.%26aulast%3DAdkison%26aufirst%3DK.%2BK.%26aulast%3DPolli%26aufirst%3DJ.%2BW.%26atitle%3DPassive%2520permeability%2520and%2520P-glycoprotein-mediated%2520efflux%2520differentiate%2520central%2520nervous%2520system%2520%2528CNS%2529%2520and%2520non-CNS%2520marketed%2520drugs%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2002%26volume%3D303%26spage%3D1029%26epage%3D1037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Begley, D. J.</span><span> </span><span class="NLM_article-title">Delivery of therapeutic agents to the central nervous system: the problems and the possibilities</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">29</span><span class="NLM_x">–</span> <span class="NLM_lpage">45</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Fjm501254d&amp;key=10.1016%2Fj.pharmthera.2004.08.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Fjm501254d&amp;key=15500907" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm501254d&amp;key=1%3ACAS%3A528%3ADC%252BD2cXovVKqsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2004&pages=29-45&author=D.+J.+Begley&title=Delivery+of+therapeutic+agents+to+the+central+nervous+system%3A+the+problems+and+the+possibilities"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Delivery of therapeutic agents to the central nervous system: the problems and the possibilities</span></div><div class="casAuthors">Begley, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29-45</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The presence of a blood-brain barrier (BBB) and a blood-cerebrospinal fluid barrier presents a huge challenge for effective delivery of therapeutics to the central nervous system (CNS).  Many potential drugs, which are effective at their site of action, have failed and have been discarded during their development for clin. use due to a failure to deliver them in sufficient quantity to the CNS.  In consequence, many diseases of the CNS are undertreated.  In recent years, it has become clear that the blood-CNS barriers are not only anatomical barriers to the free movement of solutes between blood and brain but also transport and metabolic barriers.  The cell assocn., sometimes called the neurovascular unit, constitutes the BBB and is now appreciated to be a complex group of interacting cells, which in combination induce the formation of a BBB.  The various strategies available and under development for enhancing drug delivery to the CNS are reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSEcyTMlnGXrVg90H21EOLACvtfcHk0lhuP_BZAw63wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXovVKqsrc%253D&md5=2667522bbe2ce0501a9d6d442db40d5a</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2004.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2004.08.001%26sid%3Dliteratum%253Aachs%26aulast%3DBegley%26aufirst%3DD.%2BJ.%26atitle%3DDelivery%2520of%2520therapeutic%2520agents%2520to%2520the%2520central%2520nervous%2520system%253A%2520the%2520problems%2520and%2520the%2520possibilities%26jtitle%3DPharmacol.%2520Ther.%26date%3D2004%26volume%3D104%26spage%3D29%26epage%3D45" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Ghosh, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antonio, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reith, M. E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dutta, A. K.</span><span> </span><span class="NLM_article-title">Discovery of 4-(4-(2-((5-hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)(propyl)amino)ethyl)piperazin-1-yl)quinolin-8-ol and its analogues as highly potent dopamine D<sub>2</sub>/D<sub>3</sub> agonists and as iron chelator: in vivo activity indicates potential application in symptomatic and neuroprotective therapy for Parkinson’s disease</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">2114</span><span class="NLM_x">–</span> <span class="NLM_lpage">2125</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm901618d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2114-2125&author=B.+Ghoshauthor=T.+Antonioauthor=M.+E.+A.+Reithauthor=A.+K.+Dutta&title=Discovery+of+4-%284-%282-%28%285-hydroxy-1%2C2%2C3%2C4-tetrahydronaphthalen-2-yl%29%28propyl%29amino%29ethyl%29piperazin-1-yl%29quinolin-8-ol+and+its+analogues+as+highly+potent+dopamine+D2%2FD3+agonists+and+as+iron+chelator%3A+in+vivo+activity+indicates+potential+application+in+symptomatic+and+neuroprotective+therapy+for+Parkinson%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fjm901618d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901618d%26sid%3Dliteratum%253Aachs%26aulast%3DGhosh%26aufirst%3DB.%26aulast%3DAntonio%26aufirst%3DT.%26aulast%3DReith%26aufirst%3DM.%2BE.%2BA.%26aulast%3DDutta%26aufirst%3DA.%2BK.%26atitle%3DDiscovery%2520of%25204-%25284-%25282-%2528%25285-hydroxy-1%252C2%252C3%252C4-tetrahydronaphthalen-2-yl%2529%2528propyl%2529amino%2529ethyl%2529piperazin-1-yl%2529quinolin-8-ol%2520and%2520its%2520analogues%2520as%2520highly%2520potent%2520dopamine%2520D2%252FD3%2520agonists%2520and%2520as%2520iron%2520chelator%253A%2520in%2520vivo%2520activity%2520indicates%2520potential%2520application%2520in%2520symptomatic%2520and%2520neuroprotective%2520therapy%2520for%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2114%26epage%3D2125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Doll, M. K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nichols, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kilts, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prioleau, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawler, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mailman, R. B.</span><span> </span><span class="NLM_article-title">Synthesis and dopaminergic properties of benzo-fused analogs of quinpirole and quinelorane</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">935</span><span class="NLM_x">–</span> <span class="NLM_lpage">940</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm9804533" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1999&pages=935-940&author=M.+K.+H.+Dollauthor=D.+E.+Nicholsauthor=J.+D.+Kiltsauthor=C.+Prioleauauthor=C.+P.+Lawlerauthor=M.+M.+Lewisauthor=R.+B.+Mailman&title=Synthesis+and+dopaminergic+properties+of+benzo-fused+analogs+of+quinpirole+and+quinelorane"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm9804533&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9804533%26sid%3Dliteratum%253Aachs%26aulast%3DDoll%26aufirst%3DM.%2BK.%2BH.%26aulast%3DNichols%26aufirst%3DD.%2BE.%26aulast%3DKilts%26aufirst%3DJ.%2BD.%26aulast%3DPrioleau%26aufirst%3DC.%26aulast%3DLawler%26aufirst%3DC.%2BP.%26aulast%3DLewis%26aufirst%3DM.%2BM.%26aulast%3DMailman%26aufirst%3DR.%2BB.%26atitle%3DSynthesis%2520and%2520dopaminergic%2520properties%2520of%2520benzo-fused%2520analogs%2520of%2520quinpirole%2520and%2520quinelorane%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1999%26volume%3D42%26spage%3D935%26epage%3D940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Wilcox, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, W.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brusniak, M.-Y. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilcox, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearlman, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teeter, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DuRand, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiens, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neve, K. A.</span><span> </span><span class="NLM_article-title">CoMFA-based prediction of agonist affinities at recombinant wild type versus serine to alanine point mutated D<sub>2</sub> dopamine receptors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">3005</span><span class="NLM_x">–</span> <span class="NLM_lpage">3019</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm990526y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=3005-3019&author=R.+E.+Wilcoxauthor=W.-H.+Huangauthor=M.-Y.+K.+Brusniakauthor=D.+M.+Wilcoxauthor=R.+S.+Pearlmanauthor=M.+M.+Teeterauthor=C.+J.+DuRandauthor=B.+L.+Wiensauthor=K.+A.+Neve&title=CoMFA-based+prediction+of+agonist+affinities+at+recombinant+wild+type+versus+serine+to+alanine+point+mutated+D2+dopamine+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Fjm990526y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm990526y%26sid%3Dliteratum%253Aachs%26aulast%3DWilcox%26aufirst%3DR.%2BE.%26aulast%3DHuang%26aufirst%3DW.-H.%26aulast%3DBrusniak%26aufirst%3DM.-Y.%2BK.%26aulast%3DWilcox%26aufirst%3DD.%2BM.%26aulast%3DPearlman%26aufirst%3DR.%2BS.%26aulast%3DTeeter%26aufirst%3DM.%2BM.%26aulast%3DDuRand%26aufirst%3DC.%2BJ.%26aulast%3DWiens%26aufirst%3DB.%2BL.%26aulast%3DNeve%26aufirst%3DK.%2BA.%26atitle%3DCoMFA-based%2520prediction%2520of%2520agonist%2520affinities%2520at%2520recombinant%2520wild%2520type%2520versus%2520serine%2520to%2520alanine%2520point%2520mutated%2520D2%2520dopamine%2520receptors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D3005%26epage%3D3019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Brewster, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nichols, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riggs, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mottola, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovenberg, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mailman, R. B.</span><span> </span><span class="NLM_article-title"><i>trans</i>-10,11-Dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[<i>a</i>]phenanthridine: a highly potent selective dopamine D<sub>1</sub> full agonist</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">1756</span><span class="NLM_x">–</span> <span class="NLM_lpage">1764</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00168a034" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=1990&pages=1756-1764&author=W.+K.+Brewsterauthor=D.+E.+Nicholsauthor=R.+M.+Riggsauthor=D.+M.+Mottolaauthor=T.+W.+Lovenbergauthor=M.+H.+Lewisauthor=R.+B.+Mailman&title=trans-10%2C11-Dihydroxy-5%2C6%2C6a%2C7%2C8%2C12b-hexahydrobenzo%5Ba%5Dphenanthridine%3A+a+highly+potent+selective+dopamine+D1+full+agonist"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fjm00168a034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00168a034%26sid%3Dliteratum%253Aachs%26aulast%3DBrewster%26aufirst%3DW.%2BK.%26aulast%3DNichols%26aufirst%3DD.%2BE.%26aulast%3DRiggs%26aufirst%3DR.%2BM.%26aulast%3DMottola%26aufirst%3DD.%2BM.%26aulast%3DLovenberg%26aufirst%3DT.%2BW.%26aulast%3DLewis%26aufirst%3DM.%2BH.%26aulast%3DMailman%26aufirst%3DR.%2BB.%26atitle%3Dtrans-10%252C11-Dihydroxy-5%252C6%252C6a%252C7%252C8%252C12b-hexahydrobenzo%255Ba%255Dphenanthridine%253A%2520a%2520highly%2520potent%2520selective%2520dopamine%2520D1%2520full%2520agonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1990%26volume%3D33%26spage%3D1756%26epage%3D1764" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Smith, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nichols, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mailman, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawler, C. P.</span><span> </span><span class="NLM_article-title">Locomotor inhibition, yawning and vacuous chewing induced by a novel dopamine D<sub>2</sub> post-synaptic receptor agonist</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">323</span><span class="NLM_x">, </span> <span class="NLM_fpage">27</span><span class="NLM_x">–</span> <span class="NLM_lpage">36</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Fjm501254d&amp;key=10.1016%2FS0014-2999%2897%2900026-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Fjm501254d&amp;key=9105873" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Fjm501254d&amp;key=1%3ACAS%3A528%3ADyaK2sXhslOltbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=323&publication_year=1997&pages=27-36&author=H.+P.+Smithauthor=D.+E.+Nicholsauthor=R.+B.+Mailmanauthor=C.+P.+Lawler&title=Locomotor+inhibition%2C+yawning+and+vacuous+chewing+induced+by+a+novel+dopamine+D2+post-synaptic+receptor+agonist"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Locomotor inhibition, yawning and vacuous chewing induced by a novel dopamine D2 post-synaptic receptor agonist</span></div><div class="casAuthors">Smith, Hilary P.; Nichols, David E.; Mailman, Richard B.; Lawler, Cindy P.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">323</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-36</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The N-Pr analog of dihydrexidine ((±)-trans-10,11-dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine) is a dopamine receptor agonist with high affinity for dopamine D2 and D3 receptors (K0.5 = 26 and 5 nM, resp.).  Members of the hexahydrobenzo[a]phenanthridine structural class are atypical because they display high intrinsic activity at post-synaptic dopamine D2 receptors, but low intrinsic activity at dopamine D2 autoreceptors.  The present study examd. the effects of (±)-N-n-propyl-dihydrexidine on unconditioned behaviors in rats.  The most striking results obsd. were large, dose-dependent decreases in locomotor activity (e.g., locomotor inhibition), and increases in vacuous chewing; yawning was also increased at the highest dose of (±)-N-n-propyl-dihydrexidine.  The locomotor inhibition and yawning induced by (±)-N-n-propyl-dihydrexidine were blocked by pre-treatment with (-)-remoxipride (S(-)-3-bromo-N-((1-ethyl-2-pyrrolidinyl)-methyl)-2,6-dimethoxybenzamide), a dopamine D2 receptor antagonist, but not by the dopamine D1 receptor antagonist (+)-SCH23390 (R(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine).  Vacuous chewing was decreased by both (-)-remoxipride and (+)-SCH23390.  These data support the hypothesis that a subpopulation of post-synaptic dopamine D2 receptors has a crit. role in decreases in locomotor activity and induction of vacuous chewing and yawning.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJVedYkLwAbLVg90H21EOLACvtfcHk0lii4RbE_RjYjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXhslOltbs%253D&md5=ab93c276c6116f67e970be5113c45ea7</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2FS0014-2999%2897%2900026-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-2999%252897%252900026-5%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DH.%2BP.%26aulast%3DNichols%26aufirst%3DD.%2BE.%26aulast%3DMailman%26aufirst%3DR.%2BB.%26aulast%3DLawler%26aufirst%3DC.%2BP.%26atitle%3DLocomotor%2520inhibition%252C%2520yawning%2520and%2520vacuous%2520chewing%2520induced%2520by%2520a%2520novel%2520dopamine%2520D2%2520post-synaptic%2520receptor%2520agonist%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1997%26volume%3D323%26spage%3D27%26epage%3D36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Gobert, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dekeyne, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Millan, M. J.</span><span> </span><span class="NLM_article-title">The ability of WAY100,635 to potentiate the neurochemical and functional actions of fluoxetine is enhanced by co-administration of SB224,289, but not BRL15572</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">1608</span><span class="NLM_x">–</span> <span class="NLM_lpage">1616</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2000&pages=1608-1616&author=A.+Gobertauthor=A.+Dekeyneauthor=M.+J.+Millan&title=The+ability+of+WAY100%2C635+to+potentiate+the+neurochemical+and+functional+actions+of+fluoxetine+is+enhanced+by+co-administration+of+SB224%2C289%2C+but+not+BRL15572"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGobert%26aufirst%3DA.%26aulast%3DDekeyne%26aufirst%3DA.%26aulast%3DMillan%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520ability%2520of%2520WAY100%252C635%2520to%2520potentiate%2520the%2520neurochemical%2520and%2520functional%2520actions%2520of%2520fluoxetine%2520is%2520enhanced%2520by%2520co-administration%2520of%2520SB224%252C289%252C%2520but%2520not%2520BRL15572%26jtitle%3DNeuropharmacology%26date%3D2000%26volume%3D39%26spage%3D1608%26epage%3D1616" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Hitchcock, S. A.</span><span> </span><span class="NLM_article-title">Blood-brain barrier permeability considerations for CNS-targeted compound library design</span> <span class="citation_source-journal">Curr. Opin. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">318</span><span class="NLM_x">–</span> <span class="NLM_lpage">323</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Fjm501254d&amp;key=10.1016%2Fj.cbpa.2008.03.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Fjm501254d&amp;key=18435937" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Fjm501254d&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnt1ers74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2008&pages=318-323&author=S.+A.+Hitchcock&title=Blood-brain+barrier+permeability+considerations+for+CNS-targeted+compound+library+design"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Blood-brain barrier permeability considerations for CNS-targeted compound library design</span></div><div class="casAuthors">Hitchcock, Stephen A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">318-323</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  A further refinement of the concept of drug-likeness is required for compd. libraries intended for central nervous system (CNS) targets to account for the limitations imposed by blood-brain barrier permeability.  This review describes criteria and processes that can be applied in the de novo design and assembly of libraries to increase the odds of compds. residing within CNS-accessible chem. space.  A no. of published examples where CNS activity and/or penetration characteristics have been a factor in library design are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorhMoAmlVhlrVg90H21EOLACvtfcHk0lii4RbE_RjYjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnt1ers74%253D&md5=7b6962e237bc80c1d44053b54c5f3f40</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2008.03.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2008.03.019%26sid%3Dliteratum%253Aachs%26aulast%3DHitchcock%26aufirst%3DS.%2BA.%26atitle%3DBlood-brain%2520barrier%2520permeability%2520considerations%2520for%2520CNS-targeted%2520compound%2520library%2520design%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2008%26volume%3D12%26spage%3D318%26epage%3D323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Summerfield, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cutler, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osuna, M. d. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hammond, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, S.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hersey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spalding, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeffrey, P.</span><span> </span><span class="NLM_article-title">Improving the in vitro prediction of in vivo central nervous system penetration: integrating permeability, P-glycoprotein efflux, and free fractions in blood and brain</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">316</span><span class="NLM_x">, </span> <span class="NLM_fpage">1282</span><span class="NLM_x">–</span> <span class="NLM_lpage">1290</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Fjm501254d&amp;key=10.1124%2Fjpet.105.092916" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Fjm501254d&amp;key=16330496" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Fjm501254d&amp;key=1%3ACAS%3A528%3ADC%252BD28Xit1SgsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=316&publication_year=2006&pages=1282-1290&author=S.+G.+Summerfieldauthor=A.+J.+Stevensauthor=L.+Cutlerauthor=M.+d.+C.+Osunaauthor=B.+Hammondauthor=S.-P.+Tangauthor=A.+Herseyauthor=D.+J.+Spaldingauthor=P.+Jeffrey&title=Improving+the+in+vitro+prediction+of+in+vivo+central+nervous+system+penetration%3A+integrating+permeability%2C+P-glycoprotein+efflux%2C+and+free+fractions+in+blood+and+brain"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Improving the in vitro prediction of in vivo central nervous system penetration: integrating permeability, P-glycoprotein efflux, and free fractions in blood and brain</span></div><div class="casAuthors">Summerfield, Scott G.; Stevens, Alexander J.; Cutler, Leanne; Osuna, Maria del Carmen; Hammond, Beverley; Tang, Sac-Pham; Hersey, Ann; Spalding, David J.; Jeffrey, Phil</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">316</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1282-1290</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">This work examines the inter-relationship between the unbound drug fractions in blood and brain homogenate, passive membrane permeability, P-glycoprotein (Pgp) efflux ratio, and log octanol/water partition coeffs. (cLogP) in detg. the extent of central nervous system (CNS) penetration obsd. in vivo.  The present results demonstrate that compds. often considered to be Pgp substrates in rodents (efflux ratio greater than 5 in multidrug resistant Madin-Darby canine kidney cells) with poor passive permeability may still exhibit reasonable CNS penetration in vivo; i.e., where the unbound fractions and non-specific tissue binding act as a compensating force.  In these instances, the efflux ratio and in vitro blood-brain partition ratio may be used to predict the in vivo blood-brain ratio.  This relationship may be extended to account for the differences in CNS penetration obsd. in vivo between mdr1a/b wild type and knockout mice.  In some instances, cross-species differences that might initially seem to be related to differing transporter expression can be rationalized from knowledge of unbound fractions alone.  The results presented in this article suggest that the information exists to provide a coherent picture of the nature of CNS penetration in the drug discovery setting, allowing the focus to be shifted away from understanding CNS penetration toward the more important aspect of understanding CNS efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZMb2mL7xQC7Vg90H21EOLACvtfcHk0ljDd40vhA4Tng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xit1SgsL0%253D&md5=02b6cbbcde6738e7f6802d223b889261</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1124%2Fjpet.105.092916&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.105.092916%26sid%3Dliteratum%253Aachs%26aulast%3DSummerfield%26aufirst%3DS.%2BG.%26aulast%3DStevens%26aufirst%3DA.%2BJ.%26aulast%3DCutler%26aufirst%3DL.%26aulast%3DOsuna%26aufirst%3DM.%2Bd.%2BC.%26aulast%3DHammond%26aufirst%3DB.%26aulast%3DTang%26aufirst%3DS.-P.%26aulast%3DHersey%26aufirst%3DA.%26aulast%3DSpalding%26aufirst%3DD.%2BJ.%26aulast%3DJeffrey%26aufirst%3DP.%26atitle%3DImproving%2520the%2520in%2520vitro%2520prediction%2520of%2520in%2520vivo%2520central%2520nervous%2520system%2520penetration%253A%2520integrating%2520permeability%252C%2520P-glycoprotein%2520efflux%252C%2520and%2520free%2520fractions%2520in%2520blood%2520and%2520brain%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2006%26volume%3D316%26spage%3D1282%26epage%3D1290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Veber, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, H.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kopple, K. D.</span><span> </span><span class="NLM_article-title">Molecular properties that influence the oral bioavailability of drug candidates</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">2615</span><span class="NLM_x">–</span> <span class="NLM_lpage">2623</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm020017n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Fjm501254d&amp;key=1%3ACAS%3A528%3ADC%252BD38XjsFCmt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=2615-2623&author=D.+F.+Veberauthor=S.+R.+Johnsonauthor=H.-Y.+Chengauthor=B.+R.+Smithauthor=K.+W.+Wardauthor=K.+D.+Kopple&title=Molecular+properties+that+influence+the+oral+bioavailability+of+drug+candidates"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Properties That Influence the Oral Bioavailability of Drug Candidates</span></div><div class="casAuthors">Veber, Daniel F.; Johnson, Stephen R.; Cheng, Hung-Yuan; Smith, Brian R.; Ward, Keith W.; Kopple, Kenneth D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2615-2623</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Oral bioavailability measurements in rats for over 1100 drug candidates studied at Smith-Kline Beecham Pharmaceuticals (now Glaxo Smith-Kline) have allowed us to analyze the relative importance of mol. properties considered to influence that drug property.  Reduced mol. flexibility, as measured by the no. of rotatable bonds, and low polar surface area or total hydrogen bond count (sum of donors and acceptors) are found to be important predictors of good oral bioavailability, independent of mol. wt.  That on av. both the no. of rotatable bonds and polar surface area or hydrogen bond count tend to increase with mol. wt. may in part explain the success of the mol. wt. parameter in predicting oral bioavailability.  The commonly applied mol. wt. cutoff at 500 does not itself significantly sep. compds. with poor oral bioavailability from those with acceptable values in this extensive data set.  Our observations suggest that compds. which meet only the 2 criteria of (1) 10 or fewer rotatable bonds and (2) polar surface area ≤140 Å2 (or 12 or fewer H-bond donors and acceptors) will have a high probability of good oral bioavailability in the rat.  Data sets for the artificial membrane permeation rate and for clearance in the rat were also examd.  Reduced polar surface area correlates better with increased permeation rate than does lipophilicity (C log P), and increased rotatable bond count has a neg. effect on the permeation rate.  A threshold permeation rate is a prerequisite of oral bioavailability.  The rotatable bond count does not correlate with the data examd. here for the in vivo clearance rate in the rat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3JtJEkO7yVLVg90H21EOLACvtfcHk0ljDd40vhA4Tng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjsFCmt7g%253D&md5=eaad26ed6a259de82ad65a8834fc397d</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fjm020017n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020017n%26sid%3Dliteratum%253Aachs%26aulast%3DVeber%26aufirst%3DD.%2BF.%26aulast%3DJohnson%26aufirst%3DS.%2BR.%26aulast%3DCheng%26aufirst%3DH.-Y.%26aulast%3DSmith%26aufirst%3DB.%2BR.%26aulast%3DWard%26aufirst%3DK.%2BW.%26aulast%3DKopple%26aufirst%3DK.%2BD.%26atitle%3DMolecular%2520properties%2520that%2520influence%2520the%2520oral%2520bioavailability%2520of%2520drug%2520candidates%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D2615%26epage%3D2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Bergström, C. A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charman, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicolazzo, J. A.</span><span> </span><span class="NLM_article-title">Computational prediction of CNS drug exposure based on a novel in vivo dataset</span> <span class="citation_source-journal">Pharm. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">3131</span><span class="NLM_x">–</span> <span class="NLM_lpage">3142</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2012&pages=3131-3142&author=C.+A.+S.+Bergstr%C3%B6mauthor=S.+A.+Charmanauthor=J.+A.+Nicolazzo&title=Computational+prediction+of+CNS+drug+exposure+based+on+a+novel+in+vivo+dataset"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBergstr%25C3%25B6m%26aufirst%3DC.%2BA.%2BS.%26aulast%3DCharman%26aufirst%3DS.%2BA.%26aulast%3DNicolazzo%26aufirst%3DJ.%2BA.%26atitle%3DComputational%2520prediction%2520of%2520CNS%2520drug%2520exposure%2520based%2520on%2520a%2520novel%2520in%2520vivo%2520dataset%26jtitle%3DPharm.%2520Res.%26date%3D2012%26volume%3D29%26spage%3D3131%26epage%3D3142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Ghose, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herbertz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudkins, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorsey, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallamo, J. P.</span><span> </span><span class="NLM_article-title">Knowledge-based, central nervous system (CNS) lead selection and lead optimization for CNS drug discovery</span> <span class="citation_source-journal">ACS Chem. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">50</span><span class="NLM_x">–</span> <span class="NLM_lpage">68</span></span><div class="citationLinks">[<a href="/doi/10.1021/cn200100h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Fjm501254d&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVSit7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=50-68&author=A.+K.+Ghoseauthor=T.+Herbertzauthor=R.+L.+Hudkinsauthor=B.+D.+Dorseyauthor=J.+P.+Mallamo&title=Knowledge-based%2C+central+nervous+system+%28CNS%29+lead+selection+and+lead+optimization+for+CNS+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Knowledge-Based, Central Nervous System (CNS) Lead Selection and Lead Optimization for CNS Drug Discovery</span></div><div class="casAuthors">Ghose, Arup K.; Herbertz, Torsten; Hudkins, Robert L.; Dorsey, Bruce D.; Mallamo, John P.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">50-68</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The central nervous system (CNS) is the major area that is affected by aging.  Alzheimer's disease (AD), Parkinson's disease (PD), brain cancer, and stroke are the CNS diseases that will cost trillions of dollars for their treatment.  Achievement of appropriate blood-brain barrier (BBB) penetration is often considered a significant hurdle in the CNS drug discovery process.  On the other hand, BBB penetration may be a liability for many of the non-CNS drug targets, and a clear understanding of the physicochem. and structural differences between CNS and non-CNS drugs may assist both research areas.  Because of the numerous and challenging issues in CNS drug discovery and the low success rates, pharmaceutical companies are beginning to deprioritize their drug discovery efforts in the CNS arena.  Prompted by these challenges and to aid in the design of high-quality, efficacious CNS compds., we analyzed the physicochem. property and the chem. structural profiles of 317 CNS and 626 non-CNS oral drugs.  The conclusions derived provide an ideal property profile for lead selection and the property modification strategy during the lead optimization process.  A list of substructural units that may be useful for CNS drug design was also provided here.  A classification tree was also developed to differentiate between CNS drugs and non-CNS oral drugs.  The combined anal. provided the following guidelines for designing high-quality CNS drugs: (i) topol. mol. polar surface area of <76 Å2 (25-60 Å2), (ii) at least one (one or two, including one aliph. amine) nitrogen, (iii) fewer than seven (two to four) linear chains outside of rings, (iv) fewer than three (zero or one) polar hydrogen atoms, (v) vol. of 740-970 Å3, (vi) solvent accessible surface area of 460-580 Å2, and (vii) pos. QikProp parameter CNS.  The ranges within parentheses may be used during lead optimization.  One violation to this proposed profile may be acceptable.  The chemoinformatics approaches for graphically analyzing multiple properties efficiently are presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozqfO0vq2i5bVg90H21EOLACvtfcHk0ljBBMJf0Tpsfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVSit7rO&md5=4c20ba34c3d5397170b50242975ce25d</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fcn200100h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn200100h%26sid%3Dliteratum%253Aachs%26aulast%3DGhose%26aufirst%3DA.%2BK.%26aulast%3DHerbertz%26aufirst%3DT.%26aulast%3DHudkins%26aufirst%3DR.%2BL.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26aulast%3DMallamo%26aufirst%3DJ.%2BP.%26atitle%3DKnowledge-based%252C%2520central%2520nervous%2520system%2520%2528CNS%2529%2520lead%2520selection%2520and%2520lead%2520optimization%2520for%2520CNS%2520drug%2520discovery%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2012%26volume%3D3%26spage%3D50%26epage%3D68" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Jörg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scammells, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capuano, B.</span><span> </span><span class="NLM_article-title">The dopamine D<sub>2</sub> and adenosine A<sub>2A</sub> receptors: past, present and future trends for the treatment of Parkinson’s disease</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">2188</span><span class="NLM_x">–</span> <span class="NLM_lpage">2210</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Fjm501254d&amp;key=10.2174%2F1389200215666140217110716" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2014&pages=2188-2210&author=M.+J%C3%B6rgauthor=P.+J.+Scammellsauthor=B.+Capuano&title=The+dopamine+D2+and+adenosine+A2A+receptors%3A+past%2C+present+and+future+trends+for+the+treatment+of+Parkinson%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.2174%2F1389200215666140217110716&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389200215666140217110716%26sid%3Dliteratum%253Aachs%26aulast%3DJ%25C3%25B6rg%26aufirst%3DM.%26aulast%3DScammells%26aufirst%3DP.%2BJ.%26aulast%3DCapuano%26aufirst%3DB.%26atitle%3DThe%2520dopamine%2520D2%2520and%2520adenosine%2520A2A%2520receptors%253A%2520past%252C%2520present%2520and%2520future%2520trends%2520for%2520the%2520treatment%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2014%26volume%3D21%26spage%3D2188%26epage%3D2210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Hayler, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howie, S. L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giles, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Negus, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oxley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walsgrove, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walsh, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dagger, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fortunak, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mastrocola, A.</span><span> </span><span class="NLM_article-title">Some synthetic approaches to ropinirole (SK&F 101468-A): a potent dopamine receptor agonist</span> <span class="citation_source-journal">J. Heterocycl. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">875</span><span class="NLM_x">–</span> <span class="NLM_lpage">882</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1995&pages=875-882&author=J.+D.+Haylerauthor=S.+L.+B.+Howieauthor=R.+G.+Gilesauthor=A.+Negusauthor=P.+W.+Oxleyauthor=T.+C.+Walsgroveauthor=S.+E.+Walshauthor=R.+E.+Daggerauthor=J.+M.+Fortunakauthor=A.+Mastrocola&title=Some+synthetic+approaches+to+ropinirole+%28SK%26F+101468-A%29%3A+a+potent+dopamine+receptor+agonist"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHayler%26aufirst%3DJ.%2BD.%26aulast%3DHowie%26aufirst%3DS.%2BL.%2BB.%26aulast%3DGiles%26aufirst%3DR.%2BG.%26aulast%3DNegus%26aufirst%3DA.%26aulast%3DOxley%26aufirst%3DP.%2BW.%26aulast%3DWalsgrove%26aufirst%3DT.%2BC.%26aulast%3DWalsh%26aufirst%3DS.%2BE.%26aulast%3DDagger%26aufirst%3DR.%2BE.%26aulast%3DFortunak%26aufirst%3DJ.%2BM.%26aulast%3DMastrocola%26aufirst%3DA.%26atitle%3DSome%2520synthetic%2520approaches%2520to%2520ropinirole%2520%2528SK%2526F%2520101468-A%2529%253A%2520a%2520potent%2520dopamine%2520receptor%2520agonist%26jtitle%3DJ.%2520Heterocycl.%2520Chem.%26date%3D1995%26volume%3D32%26spage%3D875%26epage%3D882" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i80"><a href="/doi/suppl/10.1021/jm501254d">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_00780"></div></div></div></div></div><hr /></hr><p class="last">The provided document comprises the synthesis and characterization of the important intermediates ZM 241385 (<b>1</b>), TCAC (<b>3</b>), OAC (<b>5</b>), sTCAC (<b>16</b>), and sulfone <b>29</b>.  This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm501254d/suppl_file/jm501254d_si_001.pdf">jm501254d_si_001.pdf (511.07 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm501254d&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Barticle%3Aarticle%3A10.1021%2Fjm501254d%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2015.58.issue-2%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm501254d" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                1MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799c3aa3add124c","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
